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   ABSTRACT	  	  Chemosensitivity	   testing	   and	   molecular	   biomarkers	   are	   commonly	   used	  methods	   during	   the	   management	   of	   several	   types	   of	   malignant	   tumours	   in	  routine	  clinical	  practice.	  The	  present	  work	  attempts	  to	  transfer	  the	  use	  of	  these	  two	  concepts	  to	  the	  management	  of	  malignant	  gliomas.	  	  	  Chemosensitivity	   testing	  was	   performed	   on	   twelve	   primary	  malignant	   glioma	  cultures	   at	   passage	   0.	   The	   drugs	   tested	   were	   Temozolomide,	   Cisplatin	   and	  Carmustine,	   which	   are	   commonly	   administered	   chemotherapeutic	   agents	   in	  clinical	   practice	   in	   our	   institution.	   The	   results	   revealed	   that	   cultures	   derived	  from	  females	  or	  from	  patients	  under	  65	  years	  of	  age	  were	  more	  sensitive	  to	  the	  drugs	   used.	   More	   importantly,	   the	   chemosensitivity	   in	   vitro	   results	   were	  predictive	  of	  the	  clinical	  outcome	  of	  the	  donor	  patient.	  During	  chemosensitivity	  testing,	   Temozolomide	   was	   found	   to	   have	   poor	   in	   vitro	   effect.	   Increased	  frequency	  of	  application	  as	  well	  as	  cell	  cycle	  synchronisation	  of	  glioma	  cell	  lines	  were	  found	  to	  improve	  the	  kill	  efficiency	  of	  Temozolomide.	  	  	  Six	  molecules	  were	  considered	  as	  potential	  biomarkers.	  All	  of	  them	  were	  found	  to	   be	   effective	   at	   predicting	   the	   presence	   of	   malignant	   gliomas.	   With	   the	  exception	  of	  VEGF	  and	  PDGF-­‐BB,	  this	  is	  the	  first	  report	  of	  Follistatin,	  IL-­‐6,	  IL-­‐8	  and	   IL-­‐10	   as	   biomarkers	   for	   malignant	   gliomas.	   Overall	   age	   and	   gender	   of	  patients	  did	  not	  affect	  the	  biomarker	  results.	  	  	  Brain	   tumours	   represent	   2%	   of	   all	   cancers	   in	   the	   UK.	   Early	   detection	   and	  treatment	  of	   glioblastoma	   is	   challenging	  and	   little	  progress	  has	  been	  made	   so	  far.	  This	  imposes	  a	  clear	  need	  for	  improving	  the	  diagnosis	  and	  management	  of	  malignant	   gliomas.	   This	   study	   aims	   to	   address	   both	   challenges	   and	   proposed	  ways	  of	  improvement.	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1 GENERAL	  INTRODUCTION	  
	  
1.1 Glioma	  incidence	  and	  epidemiology	  	  Gliomas	  are	  the	  commonest	  primary	  brain	  tumours	  accounting	  for	  almost	  2%	  of	  all	  newly	  diagnosed	  malignancies	  every	  year	  in	  the	  UK	  [1].	  Amongst	  the	  gliomas,	  malignant	  gliomas	  represent	  approximately	  60%	  of	  the	  primary	  brain	  tumours,	  making	   them	   the	   commonest	   histological	   type	   of	   primary	   brain	   tumours	  diagnosed	   every	   year.	   Their	   incidence	   almost	   compares	   with	   the	   yearly	  incidence	  of	  leukaemia,	  being	  7	  per	  100,000	  population.	  They	  account	  for	  7%	  of	  the	   years	   of	   life	   lost	   from	   cancer	   before	   the	   age	   of	   70	   [1].	   The	   incidence	   for	  males	   is	  8.8	  and	   females	  6.2	  per	  100,000	  population.	  There	  were	  3674	  deaths	  occurring	   from	   brain	   tumour	   malignancies	   in	   the	   UK	   in	   2008,	   with	   the	   peak	  mortality	  during	  the	  7th	  decade	  of	  life	  for	  both	  sexes.	  The	  overall	  1-­‐year	  survival	  of	   patients	   with	   all	   histological	   types	   of	   brain	   malignancies	   is	   approximately	  50%,	  but	  drops	  to	  23%	  at	  5	  years.	  The	  5-­‐year	  survival	  of	  young	  adults	  (age	  15-­‐39	  years)	  is	  32%,	  nine	  times	  the	  one	  of	  the	  older	  population	  (age	  60-­‐79	  years)	  [1].	  	  	  The	   incidence	   of	   malignant	   gliomas	   varies	   by	   age,	   with	   a	   gross	   difference	  between	   childhood	   and	   adulthood.	   In	   childhood,	   malignant	   brain	   tumours	  represent	   the	   commonest	   solid	   tumour.	   The	   incidence	   peak	   drops	   in	   teenage	  years	  and	  steadily	  increases	  to	  a	  second	  peak	  in	  the	  7th	  decade	  of	  life	  [2].	  	  	  Tumour	  location	  is	  also	  different	  between	  these	  age	  groups.	  Malignant	  gliomas	  in	   the	  childhood	  are	  most	  often	   found	   in	   the	   infratentorial	   compartment	  or	   in	  the	   midline,	   while	   in	   the	   adult	   population,	   the	   commonest	   site	   of	   these	  malignancies	  is	  the	  supratentorial	  compartment.	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1.2 Glioma	  classification	  	  Gliomas	  are	  classified	  according	  to	  the	  phenotype	  of	  the	  cell	  type	  they	  mimic	  as	  astrocytoma,	   oligodendroglioma	   and	   ependymoma.	   The	   cell	   of	   origin	   of	   the	  gliomas	   on	   the	   other	   hand,	   remains	   uncertain.	   The	   theory	   that	   seems	   to	   be	  gaining	  acceptance	  is	  the	  cancer	  stem	  cell	  theory.	  Stem	  cells	  have	  the	  ability	  to	  divide	  and	  differentiate	  into	  diverse	  and	  specialised	  cell	  types.	  The	  two	  cardinal	  features	  that	  define	  stem	  cells	  are	  the	  ability	  to	  self	  renew	  and	  the	  totipotency.	  Self-­‐renewal	  is	  the	  capacity	  that	  these	  cells	  have	  to	  divide	  while	  they	  maintain	  an	  undifferentiated	  state.	  There	  are	  two	  theories	  of	  the	  self-­‐renewal	  mechanism.	  The	  first	  one	  is	  the	  obligatory	  asymmetric	  replication,	  where	  a	  stem	  cell	  divides	  into	  one	  daughter	   cell	   identical	   to	   the	  one	  of	  origin	  and	  another	  daughter	   cell	  that	  differentiates	  to	  a	  specialised	  cell.	  The	  second	  mechanism	  is	  the	  stochastic	  differentiation,	  where	  one	   stem	  cell	  develops	   into	   two	  differentiated	  daughter	  cells,	  while	  another	   stem	  cell	  divides	   into	   to	   stem	  cells	   identical	   to	   the	  parent	  cell.	  	  	  The	  potency	  of	  these	  cells	  makes	  them	  able	  to	  differentiate	  into	  specialised	  cell	  types.	  Totipotent	  are	   stem	  cells	  able	   to	  differentiate	   into	  embryonic	  and	  extra	  embryonic	  cells,	  which	  are	  able	  to	  give	  rise	  to	  a	  complete	  organism.	  These	  cells	  are	  typically	  produced	  after	  the	  fusion	  of	  an	  egg	  to	  a	  sperm	  cell.	  	  	  It	  is	  becoming	  increasingly	  evident	  that	  many,	  if	  not	  all,	  tumours	  originate	  from	  cancer	  stem	  cells.	  These	  cells	  are	  cancer	  cells	  that	  share	  common	  characteristics	  with	   normal	   stem	   cells,	   namely	   the	   ability	   to	   self-­‐renew	   and	   to	   give	   rise	   to	   a	  particular	  cancer	  cell	  type.	  	  There	  is	  growing	  evidence	  that	  in	  the	  case	  of	  brain	  tumours,	  the	  cell	  of	  origin	  is	  a	  cancer	  stem	  cell	  [3].	  	  Malignant	   gliomas	   grow	   rapidly,	   invade	   and	   destroy	   surrounding	   brain	   tissue	  but	  rarely	  metastasize.	  Classification	  is	  the	  major	  factor	  that	  clinicians	  take	  into	  account	  to	  decide	  on	  treatment.	  In	  Neuro-­‐oncology	  histological	  classification	  is	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an	  important	  factor	  in	  determining	  prognosis	  and	  the	  type	  of	  treatment	  offered	  to	   the	  patient.	   It	   is	   therefore	   imperative	   that	   the	  classification	  system	  of	  brain	  tumours	   is	   as	   accurate	   as	   possible.	   It	   is	   clear	   on	   the	   other	   hand	   that	   brain	  tumours	  that	  fall	  into	  the	  same	  histological	  type,	  respond	  very	  differently	  to	  the	  same	  treatment.	  It	  is	  to	  date	  impossible	  to	  distinguish	  between	  the	  responding	  and	  non-­‐responding	  tumours	  just	  on	  the	  basis	  of	  the	  histological	  classification.	  This	   is	   one	   of	   the	   limitations	   of	   the	   current	   classification	   system.	   There	   is,	  though,	   a	   continuous	   re-­‐evaluation	   of	   the	   existing	   classification	   of	   brain	  tumours,	  which	   is	   updated	   on	   a	   regular	   basis.	   The	   updates	   take	   into	   account	  advances	   into	   the	   molecular	   studies	   of	   gliomas	   in	   an	   attempt	   to	   classify	   the	  disease	  in	  a	  way,	  which	  will	  precisely	  guide	  therapy.	  	  	  The	   most	   widely	   used	   classification	   of	   brain	   tumours	   is	   the	   World	   Health	  Organisation	   (WHO),	   which	   was	   revised	   in	   2000.	   This	   classification	  differentiates	  malignant	  gliomas	   into	   four	  grades,	  according	   to	   the	  histological	  hallmarks	  present	  (see	  Table	  1-­‐1).	  Astrocytomas	  represent	  25	  –	  30%	  of	  all	  adult	  gliomas.	  	  	  Pilocytic	  astrocytomas	  are	   classified	  as	  Grade	   I	   tumours.	  They	  are	   common	   in	  children,	   located	   in	   the	   cerebellum	   and	   are	   characterized	   by	   the	   presence	   of	  Rosenthal	   fibers.	  Diffuse	  astrocytomas,	  or	  Grade	   II	   tumours,	   are	   characterized	  by	   the	   presence	   of	   hypercellularity	   with	   pleomorphism	   and	   nuclear	   atypia,	  while	   Grade	   III	   or	   anaplastic	   astrocytomas	   show	  mitotic	   activity	   and	   cellular	  anaplasia.	  Presence	  of	  vascular	  endothelial	  proliferation	  and	  or	  necrosis	  makes	  the	   tumour	   the	  highest	   grade,	  Grade	   IV	  also	  known	  as	  Glioblastoma	   (formally	  suffixed	   “Multiforme”).	   The	  Kernohan	  grading	   system	  of	   gliomas	   classifies	   the	  disease	  according	  to	  progressive	  malignancy,	  and	  groups	  Grade	  I	  and	  Grade	  II	  to	  make	  the	  Low	  Grade	  Glioma	  group	  and	  Grade	  III	  and	  Grade	  IV	  tumours	  to	  form	  the	   High	   Grade	   Gliomas.	   The	   prognosis,	   survival	   and	   treatment	   of	   these	   two	  groups	   is	   different	   [4].	   Table	   1-­‐1	   summarizes	   the	   WHO	   Grading	   of	  Astrocytomas.	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Table	  1-­‐1	  WHO	  Grading	  of	  Astrocytomas	  WHO	  grade	   Classification	   Histological	  features	  I	   Pilocytic	  Astrocytoma	   Rosenthal	  fibres	  +	  piloid	  cells	  II	   Diffuse	  Astrocytoma	   Nuclear	  atypia	  III	   Anaplastic	  Astrocytoma	   Cellular	  anaplasia	  and	  mitoses	  IV	   Glioblastoma	  multiforme	   Anaplasia,	   mitoses,	   vascular	   endothelial	  proliferation	  ,	  necrosis	  	  	  Recent	   studies	   of	   molecular	   genetics	   have	   suggested	   that	   glioblastomas	   may	  arise	  by	  two	  separate	  pathways,	  primary	  or	  de	  novo	  glioblastoma	  and	  secondary	  glioblastoma.	   Secondary	   glioblastomas	   arise	   by	  malignant	   progression	   from	   a	  low	  grade	   glioma	  whereas	  de	   novo	   glioblastomas	   arise	  without	   a	   lower	   grade	  precursor.	   The	   two	   subtypes	   of	   glioblastoma	   are	   characterized	   by	   different	  genetic	   alterations.	   The	   de	   novo	   glioblastomas	   frequently	   have	   EGFR	   gene	  amplification,	   overexpression	   of	   Mouse	   Double	   Minute	   2	   (MDM2)	   and	   PTEN	  mutations	   whilst	   the	   secondary	   tumours	   show	   TP53	   gene	   mutations	   and	  
PDGFR-­‐α	   overexpression	   [5,	   6].	   The	   oligodendrogliomas	   as	   well	   as	   the	  ependymomas	   are	   less	   common	   and	   are	   classified	   according	   to	   three	   grades.	  Table	  1-­‐2	  summarizes	  the	  grades	  and	  the	  histological	  hallmarks	  of	  each	  group	  [4].	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I	   	   	  II	   Oligodendroglioma	   Round	   nuclei,	   fine	   reticular	   capillary	  network	   and	   microcalcification,	   perinuclear	  halo	  III	   Anaplastic	  Oligodendroglioma	   Mitotic	  activity	  
WHO	  
grade	  
Classification	  of	  Mixed	  
Gliomas	  
Histological	  features	  






I	   Subependymoma	   Low	   cellularity,	   low	   proliferation,	  isomorphic	  tumour	  cell	  nuclei	  	  I	   Myxopapillary	  Ependymoma	   Perivascular	  rosettes,	  ependymal	  rosettes	  II	   Ependymoma	   Perivascular	  pseudorosettes,	  mitotic	  activity,	  vascular	  proliferation	  III	   Anaplastic	  Ependymoma	   Mitoses,	   perivascular	   pseudo	   rosettes,	  vascular	  proliferation,	  necrosis	  	  	  
1.3 Molecular	  Markers	  in	  Gliomas	  	  Neuropathology	   has	   evolved	   in	   using	   several	   molecular	   markers,	   which	  highlight	  the	  tumour	  biology.	  These	  are	  useful	  in	  demonstrating	  the	  neoplastic	  changes	   at	   a	   molecular	   level;	   facilitate	   diagnosis	   as	   well	   as	   contribute	   to	   the	  prognosis	   of	   the	   tumour.	   The	  molecular	  markers	   used	   in	   neuropathology	   are	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markers	   of	   proliferation,	   immunohistochemical	   markers	   and	   genetic	   markers	  [7].	  	  	  Recently,	  there	  has	  been	  an	  increasing	  focus	  on	  molecular	  markers	  in	  malignant	  gliomas	   that	   may	   provide	   prognostic	   information	   or	   predict	   response	   to	  treatment.	  The	  goal	  of	  molecular	  genetics	   is	   to	   individualize	  patient	   treatment	  regimens	  and	  to	  allow	  monitoring	  of	  treatment	  response.	  	  
1.3.1 Markers	  of	  proliferation	  	  Counting	   the	  mitotic	   figures	   in	   the	   tumour	   has	   been	   currently	   superseded	   by	  the	  Ki-­‐67	  and	  the	  bromodeoxyuridine	  (BRU)	  labelling	  indices,	  although	  BRU	  is	  not	   used	   frequently	   nowadays.	   The	   frequency	   of	   immunostaining	   for	  Ki-­‐67	   (a	  marker	   of	   cycling	   cells)	   or	   the	   frequency	   of	   the	   incorporation	   of	   the	   bromine	  analogue	  of	  deoxyuridine	  (a	  marker	  for	  cells	  in	  the	  S	  phase	  of	  the	  cell	  cycle)	  in	  tumour	  cell	  DNA,	  gives	  an	  estimate	  of	  cells	  that	  are	  actively	  dividing.	  This	  index	  generally	   correlates	   with	   increasingly	   malignant	   behaviour	   such	   as	   tumour	  necrosis,	  vascular	  proliferation,	  high	   invasiveness	  and	  dedifferentiation.	  These	  indexes	  are	  important	  in	  evaluation	  of	  tumour	  growth	  rate	  and	  clinical	  outcome	  and	  add	  a	  valuable	  tool	  in	  predicting	  outcome	  to	  tumour	  histopathology	  [8,	  9].	  	  
1.3.2 Immunophenotypic	  markers	  	  Immunohistochemistry	   is	   the	  process	  of	  detecting	   antigens	   in	   cells	   of	   a	   tissue	  section.	  It	  uses	  antibodies	  and	  their	  affinity	  to	  specific	  antigens	  found	  on	  the	  cell	  that	   requires	   identification.	   The	   antibody-­‐antigen	   interaction	   is	   visualised	   by	  tagging	  the	  antibody	  to	  a	  fluorophore	  or	  to	  an	  enzyme	  such	  as	  peroxidase	  that	  catalyses	  a	  colour-­‐producing	  reaction.	  Histochemical	  markers	  are	  proteins	  and	  glycolipids	   and	   are	   used	   to	   classify	   tumours	   by	   their	   cell	   type	   and	   degree	   of	  differentiation.	   Glial	   fibrillary	   acidic	   protein	   (GFAP)	   is	   a	   protein	   produced	   by	  normal	   astrocytes	   as	   well	   as	   by	   glial,	   intraepithelial	   and	   some	   ependymal	  tumours,	  and	  is	  widely	  used	  for	  this	  purpose.	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Another	   type	   of	   immunohistochemical	   marker	   used	   currently	   is	   monoclonal	  antibodies	  against	  tumour	  specific	  antigens.	  They	  are	  used	  to	  study	  the	  pattern	  of	   expression	  of	   these	  antigens	  on	   the	   tumours.	  They	  may	  guide	   in	   the	   future	  selecting	  specific	  therapies	  for	  the	  tumours	  that	  express	  them	  [10].	  	  	  
1.3.3 Genetic	  markers	  	  Genetic	  markers	  are	  small	  sequences	  of	  DNA	  specific	  to	  chromosomal	  locations	  and	   are	   associated	   with	   particular	   traits.	   They	   are	   usually	   used	   to	   trace	  inheritance	   of	   disease,	   guide	   diagnosis	   and	   treatment	   of	   disease.	   In	  neuropathology	   they	   are	   vital	   for	   the	  diagnosis	   as	  well	   as	   the	   classification	  of	  brain	   tumours.	   Examples	   of	   genetic	   aberrations	   are	   degree	   of	   aneuploidy,	  chromosome	  deletions,	  translocations	  and	  amplifications.	  Those	  may	  signal	  the	  loss	  of	  a	  tumour	  suppressor	  gene	  or	  the	  amplification	  of	  oncogenes.	  	  	  
1.4 Glioma	  biology	  	  The	  aetiology	  of	  gliomas	  to	  date	  has	  been	  debated	  extensively.	  Although	  there	  is	  much	   that	   is	   unknown,	   a	   picture	   is	   emerging	   about	   the	  molecular	   events	   that	  lead	   to	   tumour	   initiation	  and	  progression.	   	  The	  WHO	  classification	  of	   the	  CNS	  tumours	   mentions	   studies	   undertaken	   in	   1992	   and	   1997	   of	   tumours	   arising	  from	   the	   malignant	   transformation	   of	   bipotential	   precursors	   cells	   or	   neural	  stem	   cells,	   respectively.	   The	   presence	   of	   Brain	   Tumour	   Stem	   Cells	   is	   widely	  accepted	   although	   debate	   still	   exists	   with	   regards	   to	   the	   efficiency	   of	   the	  enrichment	  markers	  used	  to	  demonstrate	  the	  entire	  stem	  cell	  population.	  In	  fact	  the	  previously	   thought	  most	   important	   stem	  cell	  marker	  CD133	  may	  not	  be	  a	  stem	   cell	   marker	   but	   rather	   an	   epi-­‐marker	   of	   proliferation	   [11].	   Son	   and	  coworkers	  in	  2009	  have	  reported	  another	  enrichment	  stem	  cell	  marker,	  which	  seems	  to	  be	  more	  efficient.	  This	  marker	  is	  the	  stage-­‐specific	  embryonic	  antigen	  1	  SSEA-­‐1/LeX	  [12].	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Currently	   the	   debate	   is	   about	   the	   origin	   of	   the	   stem	   cells	   and	   the	  mechanism	  which	   gives	   rise	   to	   a	   malignant	   tumour.	   There	   have	   been	   three	   theories	  postulated:	   the	   first	  holds	   that	  mature	  glial	  cells	  have	  acquired	  mutations	   that	  render	  their	  behaviour	  as	  “stem-­‐cell	  like”;	  the	  second	  theory	  is	  that	  committed	  neural	   progenitors	   that	   have	   gone	   through	   a	   limited	   number	   of	   cell	   divisions	  and	   otherwise	   would	   terminally	   differentiate,	   acquire	   mutations	   that	   render	  their	   behaviour	   “stem-­‐cell	   like”.	   The	   third	   theory	   proposes	   that	   adult	   neural	  stem	   cells	   normally	   regulated,	   acquire	   mutations	   that	   render	   them	   able	   to	  create	  a	  tumour	  [13].	  The	  last	  theory	  has	  been	  the	  basis	  of	  a	  study	  by	  Wang	  and	  his	  coworkers	  in	  2009	  [14]	  on	  a	  murine	  model	  featuring	  a	  mutant	  form	  of	  p53	  in	  a	   small	   population	   of	   neural	   stem	   cells	   located	   in	   the	   sub	   ventricular	   zone.	  These	  gave	  rise	  to	  mutated	  and	  fast	  dividing	  cells,	  suggesting	  that	  glioblastomas	  may	  originate	  by	  neural	  stem	  cells.	  	  	  Glioblastomas	  are	  heterogeneous	  tumours	  at	  the	  cellular	  level.	  These	  cells	  have	  different	   proliferative	   potentials	   and	   their	   behaviour	   depends	   on	   their	  microenvironment	  as	  well	  as	  cell-­‐to-­‐cell	  interactions	  and	  genetic	  characteristics.	  The	   important	   genetic	   factors	   include	   the	   group	   of	   tumour	   suppressor	   genes	  and	  oncogenes	   that	  play	  an	   important	  role	   in	   the	  development	  of	  gliomas	  and	  their	  progression	   to	  higher	  grades.	  The	  capacity	   to	  proliferate	  depends	  on	   the	  cell	  cycle	  time,	  growth	  fraction,	  tumour	  doubling	  time	  and	  cell	  death.	  Cell	  death	  happens	   either	   by	   apoptosis	   (programmed	   cell	   death)	   or	   by	   necrosis,	   due	   to	  outgrowth	  of	  the	  tumour	  volume	  in	  relation	  to	  its	  vascular	  supply	  and	  by	  default	  to	  its	  nutrient	  and	  oxygen	  supply.	  	  	  	  
1.4.1 Tumour	  suppressor	  genes	  in	  Gliomas	  	  Tumour	  suppressor	  genes	  are	  genes	  that	  regulate	  normal	  cell	  cycle	  progression	  and	  other	   aspects	   of	   cellular	  metabolism.	  During	   gene	   transcription	   they	   stop	  the	  cell	  cycle	  either	  by	  inducing	  apoptosis	  or	  by	  initiating	  DNA	  repair.	  The	  loss	  or	   inactivation	   of	   those	   genes	   leads	   to	   tumourigenesis.	   Although	   at	   a	   cellular	  level	   both	   alleles	   of	   the	   gene	   have	   to	   be	   lost	   or	   inactivated	   before	   this	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contributes	  to	  tumourigenesis,	  at	  an	  organism	  level	  the	  number	  of	  cells	  at	  risk	  and	  the	  frequency	  of	  acquired	  loss	  or	  inactivation	  of	  the	  gene	  are	  high	  enough	  to	  greatly	   increase	   the	   chance	  of	   a	   tumour	  developing	   [15].	   Examples	  of	   tumour	  suppressor	   genes	   are	   Rb	   (transcriptional	   co-­‐repression),	   TP53	   (transcription	  factor),	   PTEN	   (phosphatase	   and	   tensin	   homolog	   deleted	   on	   chromosome	   10)	  and	  ARF	  (MDM2	  antagonist)	  [16].	  	  
Retinoblastoma	  Rb	  	  Knudson	  first	  suggested	  the	  existence	  of	  tumour	  suppressor	  genes	  after	  analysis	  of	   the	   incidence	   of	   familial	   retinoblastomas.	   This	   is	   a	   paediatric	   tumour	  syndrome	   often	   associated	   with	   pineoblastoma,	   meningioma,	   glioma	   or	  osteosarcoma.	  He	  reported	  that	  in	  order	  to	  develop	  retinoblastomas	  there	  is	  the	  need	   for	   two	  somatic	  mutations	  –	   the	   two	  hit	  hypothesis.	   In	   the	   familial	   form,	  however,	   those	   individuals	   who	   have	   inherited	   one	   mutant	   allele	   are	  predisposed	   to	  developing	   these	   tumours	   [17].	  The	  RB	   locus	   is	   located	  on	   the	  long	   arm	   of	   chromosome	   13	   (13q14)	   [18].	   Cyclin	   Dependent	   Kinase	   CDK	  inhibitors	   of	   the	   INK4	   family,	   with	   D-­‐type	   cyclins	   control	   this	   pathway.	   The	  protein	   pRb	   acts	   as	   a	   negative	   regulator	   of	   cell	   proliferation	   at	   the	   G1/S	  checkpoint.	   The	   downstream	   targets	   of	   the	   Rb	   pathway	   are	   the	   E2F	  transcription	  factors.	  Most	  human	  malignant	  tumours	  contain	  alterations	  of	  the	  genes	  in	  the	  Rb	  pathway	  either	  through	  inactivating	  mutations	  of	  the	  Rb1	  gene	  or	   activating	   mutations	   and	   amplification	   of	   the	   D-­‐type	   cyclins	   and	   CDK4	   or	  CDK6.	  13%	  of	  glioblastomas	  have	  been	  reported	  as	  having	  deletions	  of	  the	  Rb1	  gene	  [19].	   It	  has	  also	  been	  found	  that	   tumours	  displaying	  abnormalities	  of	   the	  Rb	  pathway	  commonly	  have	  TP53	  abnormalities	  [20].	  These	  two	  pathways	  are	  intrinsically	  linked	  to	  each	  other	  and	  to	  cell	  proliferation.	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TP53	  	  The	  TP53	   tumour	  suppressor	  gene	  is	  located	  on	  the	  short	  arm	  of	  chromosome	  17.	  Its	  loss	  or	  inactivation	  contributes	  to	  the	  development	  of	  colon,	  breast,	  lung	  carcinomas	   as	   well	   as	   gliomas	   [21].	   It	   encodes	   for	   a	   53	   kDa	   nuclear	  phosphoprotein,	  which	  contributes	   in	  regulating	  cell	  division.	  The	  p53	  protein	  is	   produced	   in	   response	   to	   cellular	   stress,	   hypoxia,	   irradiation,	   drug-­‐induced	  genotoxic	   damage	   and	   oncogenic	   activation	   [22].	   This	   protein	   binds	   tumour	  promoting	  viral	  proteins	  and	  suppresses	  transformation	  of	  cells	  by	  myc	  and	  ras	  oncogenes.	   It	   binds	   and	   activates	   specific	   genes	   that	   promote	   apoptosis	   or	  programmed	  cell	  death.	  Up	  to	  date	  there	  have	  been	  three	  apoptotic	  promoting	  pathways	  that	  have	  been	  linked	  to	  its	  DNA	  binding	  domain:	  1)	  binding	  to	  Bcl2	  family	   proteins	   at	   mitochondrial	   level;	   2)	   binding	   to	   genes	   that	   promote	  apoptosis	   (microDNA,	  miR-­‐34	   gene	   family);	   3)	   binding	   to	   Drosha	   complex	   to	  promote	   formation	   of	   microRNAs	   that	   suppress	   proliferation	   (miR-­‐16-­‐1	   and	  miR-­‐143)	  [23].	  	  Point	  mutations	   of	   this	   gene	   are	   the	  most	   frequent	   genetic	   changes	   found	   in	  human	  malignancies.	  These	  almost	  always	  occur	  in	  the	  area	  occupied	  by	  exons	  5	  through	  exon	  8.	  These	  point	  mutations	  occur	  in	  highly	  conserved	  sequences	  of	  the	  gene,	   suggesting	   that	   these	  sequences	  are	  vital	   for	   the	   function	  of	   the	  p53	  protein.	   Point	  mutations	   involving	   exons	  5,	   7	   and	  8	   that	   inactivate	  TP53	   have	  been	  found	  in	  astrocytomas	  [24].	  The	  incidence	  of	  TP53	  mutations	  reported	  in	  secondary	  glioblastomas	  reaches	  65%	  and	  is	  significantly	  more	  frequently	  seen	  than	  primary	  glioblastomas	  (10%)	  [25].	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TP53,	  p14ARF	  and	  MDM2	  	  P14	  protein	  binds	  to	  the	  TP53/MDM2	  complex	   inhibiting	  the	  MDM2	  mediated	  p53	   degradation.	   This	   indicates	   that	   p14	   is	   an	   upstream	   regulator	   of	   the	   p53	  protein.	   [26]	   P14	   also	   acts	   as	   an	   inhibitor	   of	   MDM2.	   The	   result	   of	   the	  p53/MDM2/p14	  interactions	  is	  a	  reduction	  of	  p53	  concentration,	  which	  finally	  leads	  to	  tumour	  growth.	  	  	  
PTEN	  	  
PTEN	  was	  identified	  in	  1997	  by	  Li	  and	  coworkers	  [27],	  and	  has	  been	  located	  on	  10q23	   [28].	   It	   encodes	   for	   a	   protein	   called	   phosphatidylinositol-­‐3,4,5-­‐triphosphate	  3-­‐phosphatase	  and	  was	  the	  first	  lipid	  phosphatase	  to	  be	  identified	  as	  a	  tumour	  suppressor	  [29].	  It	  negatively	  regulates	  the	  Akt	  signalling	  pathway	  that	   is	   important	   for	   several	   cellular	   functions	   (nutrient	   metabolism,	   cell	  growth,	  apoptosis	  and	  survival)	  [30].	  This	  mutation	  has	  been	  identified	  in	  45%	  of	  glioblastomas	  [31].	  	  	  
1.4.2 Oncogenes	  in	  gliomas	  	  Oncogenes	   are	   genes	   that	   act	   in	   tension	   with	   tumour	   suppressor	   genes	   to	  regulate	  many	   aspects	   of	   cell	   metabolism.	   In	   general	   they	   promote	   cell	   cycle	  progression	  and	  nuclear	  division	  as	  well	  as	  stimulate	  other	  metabolic	  pathways	  leading	  to	  cell	  growth.	  When	  overexpressed	  they	  lead	  to	  tumour	  development.	  They	  are	  involved	  in	  the	  control	  of	  the	  cell	  growth	  and	  can	  be	  classified	  into	  five	  groups	   as	   growth	   factors,	   growth	   factor	   receptors,	   signalling	   intermediates,	  transcription	  factors	  and	  modifiers	  of	  apoptotic	  pathways.	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Growth	  factors	  and	  Growth	  factor	  receptors	  	  Growth	   factors	   are	   molecules	   that	   occur	   naturally	   and	   stimulate	   growth,	  proliferation	  and	  cell	  differentiation.	  They	  act	  as	  signalling	  molecules	  between	  cells.	  They	  usually	  bind	  to	  cell	  surface	  receptors	  of	  their	  target	  cells	  and	  activate	  a	  signalling	  pathway,	  which	  leads	  to	  the	  specific	  effect	  of	  the	  growth	  factor.	  	  	  The	   growth	   factors	   commonly	   found	   in	   brain	   tumours	   are	   members	   of	   the	  tyrosine	   kinase	   pathway.	   They	   bind	   to	   their	   receptors,	   initiating	   a	   signalling	  cascade	  that	  leads	  to	  proliferation.	  The	  growth	  factors	  and	  their	  receptors	  may	  be	   produced	   by	   the	   same	   cell	   resulting	   in	   autostimulation	   (autocrine	  production),	  or	  may	  be	  produced	  by	  adjacent	  cells	  (paracrine	  production)	  even	  of	  a	  different	  cell	  type	  (juxtacrine	  production)	  [32].	  Finally,	  growth	  factors	  can	  also	  stimulate	   the	  production	  of	  other	  growth	   factors.	  The	  growth	   factors	   that	  have	   been	   reported	   to	   act	   as	   oncogenes	   in	   gliomas	   are	   the	  Epidermal	   growth	  factor	  (EGF),	   the	  Vascular	  Endothelial	  growth	  factor	  (VEGF),	   the	  Transforming	  growth	   factor-­‐α	   (TGF-­‐α),	   the	   Fibroblast	   growth	   factor	   (FGF),	   the	   basic	  Fibroblast	  growth	  factor	  (bFGF)	  and	  the	  Platelet	  Derived	  growth	  factor-­‐α	  and	  –β	  (PDGFR-­‐α	  and	  PDGFR-­‐β)	  [33].	  	  Growth	   factor	   receptors	   are	   cell	   surface	   receptors	   with	   three	   domains:	   an	  external	   domain	   which	   binds	   the	   growth	   factor,	   a	   second	   transmembrane	  domain	  which	  enhances	  enzymatic	  activity	  and	  the	  cytoplasmic	  domain	  which	  is	   part	   of	   the	   tyrosine	   kinase	   pathway	   and	   activates	   secondary	   signalling	  molecules	   by	   phosphorylating	   their	   tyrosine	   residues.	   The	   growth	   factor	  receptors	   themselves	   can	   be	   activated	   by	   a	   sequence	   mutation	   causing	  constitutive	   activation	   or	   over	   expression	   causing	   loss	   of	   growth	   control.	  Currently	   the	   most	   promising	   targets	   for	   therapeutic	   interventions	   in	   CNS	  tumours	  are	  the	  tyrosine	  kinase	  PDGFR	  and	  the	  VEGFR	  [34].	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Epidermal	  Growth	  Factor	  (EGF)	  and	  EGFR	  	  EGFR	  is	  a	  member	  of	  the	  Tyrosine	  kinase	  family	  and	  was	  the	  first	  of	  the	  human	  EGF	   receptor	   to	   be	   discovered.	   The	   erb-­‐B	   gene	   encodes	   for	   EGFR.	  Wong	   and	  coworkers	   have	   demonstrated	   that	   over	   80%	   of	   astrocytic	   tumours	   and	   all	  established	   astrocytic	   cell	   lines	   have	  higher	   levels	   of	   EGFR	   than	  normal	   brain	  [35].	  The	  cascade	  activated	  by	  the	  ligand	  binding	  the	  receptor	  can	  be	  produced	  by	  four	  different	  mechanisms:	  i)	  increased	  expression	  of	  ligands,	  ii)	  EGFR	  gene	  amplification,	  iii)	  over	  expression	  of	  EGFR	  wild-­‐type	  or	  mutant	  family	  members	  or	   iv)	  by	  EGFR	   independent	  mechanisms.	  The	  receptor	  has	  also	  been	  reported	  to	  undergo	  deletion	  mutations	  [36].	  One	  deletion	  mutation	  removes	  sequences	  for	   down-­‐regulation	   leading	   to	   the	   constitutive	   activation	   of	   the	   receptor.	   A	  second	   frequently	   observed	   deletion	  mutation	   results	   in	   the	   formation	   of	   the	  receptor	  with	  increased	  auto-­‐phosphorylating	  activity.	  The	  third	  most	  common	  deletion	   mutation	   shortens	   the	   extracellular	   domain	   of	   the	   receptor.	   Mutant	  proteins	   which	   result	   from	   these	   deletions	   may	   be	   abnormally	   active	   and	  stimulate	  cell	  proliferation	  [37].	  Gene	  amplification	  of	  EGFR	  has	  been	  found	  to	  be	   higher	   in	   primary	   (40%)	   rather	   than	   secondary	   (8%)	   glioblastoma.	   The	  presence	  of	  EGFRvIII	  in	  primary	  malignant	  gliomas	  is	  an	  independent	  predictor	  of	  poor	  survival	  [37,	  38].	  	  Platelet-­‐	  derived	  Growth	  Factor	  (PDGF)	  and	  PDGF	  Receptor	  (PDGFR)	  	  PDGF	   and	   PDGFR	   are	   also	   members	   of	   the	   Tyrosine	   kinase	   family.	   The	  processes	   regulated	   by	   them	   include	   cell	   proliferation,	   differentiation	   and	  migration	   [39].	   Uhrbom	   and	   coworkers	   have	   shown	   that	   PDGF	   is	   involved	   in	  early	   tumourigenesis	   [40].	   Other	   studies	   have	   shown	   that	   75%	   of	   malignant	  gliomas	  have	  an	  over	  expression	  of	  PDGF	  [41].	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Vascular	  Endothelial	  Growth	  Factor	  (VEGF)	  	  VEGF	  is	  part	  of	  the	  Tyrosine	  Kinase	  family.	  It	  has	  specific	  action	  on	  endothelial	  cells,	   mediating	   vascular	   permeability,	   inducing	   angiogenesis	   and	  vasculogenesis.	  It	  promotes	  endothelial	  cell	  growth,	  cell	  migration	  and	  inhibits	  apoptosis.	  VEGF	  and	  VEGFR	  are	  over	  expressed	  in	  malignant	  gliomas	  and	  their	  levels	   have	   been	  positively	   correlated	  with	   increasing	  malignancy,	   vascularity	  and	  worsening	  prognosis	  [42,	  43].	  	  	  Transforming	  Growth	  Factor	  (TGF)	  	  The	  transforming	  growth	  factor	  family	  is	  made	  of	  several	  proteins,	  which	  share	  the	   same	   morphology.	   They	   are	   all	   homodimeric	   polypeptides	   affecting	   cell	  growth,	   embryogenesis,	   cell	   differentiation,	   cell	   migration	   and	   adhesion,	  morphogenesis,	  immune	  cell	  activation,	  wound	  healing	  and	  cell	  survival.	  There	  are	   three	   isoforms	   of	   TGF-­‐β	   that	   are	   expressed	   in	   gliomas	   [44].	   TGF-­‐β	  modulates	  bFGF,	  EGF	  and	  PDGF.	  Those	  together	  have	  a	  synergistic	  effect	  on	  cell	  proliferation,	  cell	  migration	  and	  invasion	  [45].	  Glioma	  patients	  with	  high	  TGF-­‐β	  have	  been	  shown	  to	  have	  poor	  prognosis	  [46].	  	  Fibroblast	  Growth	  Factor	  (FGF)	  	  This	  growth	  factor	  family	  has	  several	  members	  many	  of	  which	  have	  been	  found	  in	  the	  brain.	  Some	  of	  them	  induce	  angiogenesis	  and	  others	  are	  modulating	  their	  effects	   via	   the	   tyrosine	   kinase	   activity.	   bFGF	   has	   been	   found	   to	   be	   a	   key	  molecule	   in	   promoting	   astrocytic	   tumours	   and	   is	   present	   in	   virtually	   all	   CNS	  tumours	   including	   meningiomas,	   nerve	   sheath	   tumours,	   gliomas,	   and	  ependymomas	  [47].	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Intermediate	  signalling	  pathways	  	  These	   pathways	   relay	   information	   from	   cell	   surface	   receptors	   to	   the	   nucleus.	  They	   all	   have	   effects	   at	   transcriptional	   level.	   These	   are	   three	   main	   types:	  tyrosine	   kinases,	   G-­‐proteins	   and	   IP3/DAG.	   The	   ras	   and	   the	   src	   oncogenes	   are	  also	  signalling	  molecules	  associated	  with	  development	  of	  brain	  tumours.	  	  Ras	  is	  part	  of	  the	  protein	  family	  of	  small	  GTPases.	  Small	  GTPases	  are	  a	  family	  of	  hydrolase	  enzymes	  that	  can	  bind	  and	  hydrolyze	  guanosine	  triphosphate	  (GTP).	  When	  activated,	  it	  switches	  on	  other	  proteins,	  which	  turn	  on	  genes	  that	  regulate	  cell	   growth,	   differentiation	   and	   survival.	   Overactive	   ras	   signalling	   is	   an	  important	  mechanism	   in	   cancer	   development.	   Ras	   is	   a	  monomeric	   G	   protein,	  which	   gets	   activated	   by	   binding	   to	   GTP	   –the	   “on”	   status-­‐	   and	   inactivated	   by	  binding	   to	   GDP	   –	   the	   “off	   “	   status.	   A	   mutated	   ras	   with	   a	   change	   in	   3D	  conformation	  has	  reduced	  GDPase	  activity	  that	  renders	  ras	  constitutively	  active,	  sending	  continuously	  signals	  to	  the	  nucleus.	  It	  is	  involved	  in	  many	  overlapping	  signalling	  pathways	  having	  several	  effects.	  Mutations	  in	  ras	  have	  been	  found	  in	  several	  tumours	  including	  gliomas	  [48].	  	  The	  protein	  src	  is	  a	  tyrosine	  kinase,	  which	  is	  located	  at	  the	  inner	  surface	  of	  the	  cellular	  membrane.	  When	  activated	  by	  a	  receptor,	  it	  initiates	  the	  tyrosine	  kinase	  cascade	  that	  has	  effects	  on	  cell	  growth,	  adhesion	  and	  cell	  motility.	  When	  it	  is	  not	  coupled	   it	   promotes	   tumour	   growth	   and	   cell	   invasion.	   The	   src	   oncogene	   has	  been	  found	  both	  in	  gliomas	  and	  in	  medulloblastomas	  [49].	  	  
Transcription	  factors	  in	  gliomas	  	  Fos	   and	   c-­‐myc	   are	   the	   two	   better-­‐known	   transcription	   factors	   that	   promote	  tumour	  formation.	  They	  interact	  directly	  with	  the	  DNA	  altering	  the	  expression	  of	  several	  genes.	  Steroids	  and	  other	  signalling	  mediators	  activate	  these	  factors.	  They	  may	   form	   homodimers	   or	   heterodimers	   that	   bind	   to	   DNA	   and	   promote	  transcription.	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  Myc	   has	   been	   found	   to	   activate	   several	   factors	   that	   promote	   abnormal	   cell	  growth,	  proliferation,	  differentiation	  as	  well	  as	  metabolism	  [50].	  Fujimoto	  and	  coworkers	  have	  reported	  that	  the	  level	  of	  myc	  expression	  positively	  correlates	  with	  the	  aggressiveness	  of	  gliomas	  and	  medulloblastomas	  [51].	  	  	  Fos	   after	   forming	   a	   heterodimers	   with	   Jun	   regulates	   cell	   growth	   and	  proliferation.	   The	   Fos-­‐Jun	   heterodimers	   binds	   to	   other	   factors	   to	   form	  complexes	   that	   promote	   transcription	   of	   genes	   for	   cell	   proliferation,	  differentiation,	  transformation	  and	  death	  [52].	  80%	  of	  malignant	  gliomas	  have	  been	  found	  to	  express	  Fos	  [53].	  	  	  
Modifiers	  of	  apoptotic	  pathways	  in	  gliomas	  	  These	   are	   protein	   transcription	   factors	   that	   modify	   the	   cell’s	   probability	   of	  entering	   the	  apoptotic	  pathway.	  Bax	   is	  a	   tumour	  suppressor	  gene	  and	  as	  such	  when	  lost	  the	  cell	  escapes	  from	  apoptosis.	  Bcl-­‐2	  when	  over	  expressed	  acts	  as	  an	  oncogene,	   leading	   to	   prevention	   of	   cell	   apoptosis.	   Both	   these	  molecules	   affect	  apoptosis	  at	  a	  transcriptional	  level	  [54].	  
1.5 The	  Cell	  Cycle	  	  There	  are	  two	  periods	  to	  the	  cell	  cycle:	  the	  first	  is	  called	  the	  interphase	  during	  which	  the	  cell	  grows,	  accumulates	  nutrients	  needed	  for	  mitosis	  and	  duplicates	  its	   DNA	   before	   proceeding	   into	   the	   second	   period	   consisting	   of	   the	   mitosis	  during	  which	   the	   cell	   splits	   itself	   into	   two	   “daughter	   cells”.	   The	   interphase	   is	  divided	  into	  three	  phases	  G1,	  S,	  G2	  followed	  by	  M.	  	  	  The	   G1	   phase,	   also	   called	   the	   growth	   phase,	   follows	   the	   mitosis.	   The	   cell	  produces	  several	  enzymes	  and	  prepares	  itself	  for	  the	  DNA	  synthesis	  needed	  in	  the	   next	   phase.	   The	   S	   phase	   is	   the	   time	   of	   DNA	   replication.	   G2	   follows	   the	   S	  phase,	  and	  the	  cell	  can	  stay	  in	  that	  phase	  till	  it	  enters	  mitosis.	  The	  main	  products	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of	   synthesis	   during	   this	   phase	   are	   the	   microtubules,	   which	   are	   vital	   for	   the	  completion	  of	  the	  mitosis.	  	  The	  following	  phase	  is	  the	  Mitosis	  when	  the	  cell,	  which	  has	  double	  the	  amount	  of	   DNA,	   divides	   its	   nucleus	   into	   two	   identical	   nuclei.	   This	   is	   followed	   by	   the	  division	  of	  the	  cytoplasm,	  the	  organelles	  and	  the	  cell	  membrane	  resulting	  in	  the	  formation	  of	  two	  daughter	  cells	  that	  are	  identical	  between	  them	  and	  to	  the	  cell	  of	  origin.	  	  	  The	  cell	   then	  will	  enter	  either	   into	  the	  G1	  phase	  to	  synthesize	  all	   the	  enzymes	  needed	   for	   DNA	   replication	   but	   if	   there	   are	   no	   signals	   to	   commit	   the	   cell	   to	  divide,	   it	   will	   exit	   temporarily	   the	   G1	   phase	   and	   will	   enter	   the	   G0	   phase	  becoming	  quiescent.	  	  	  Progression	  from	  one	  phase	  to	  another	  is	  very	  tightly	  regulated.	  This	  is	  crucial	  for	   cell	   survival,	   detection	   of	   genetic	   damage	   as	   well	   as	   prevention	   of	  uncontrolled	  division.	  The	  phases	  of	  the	  cycle	  are	  sequential,	  meaning	  that	  each	  phase	  has	  to	  be	  completed	  before	  progression	  to	  the	  following	  one	  and	  that	  the	  cycle	  is	  not	  reversible.	  	  There	   are	   two	   groups	   of	   molecules	   that	   regulate	   the	   cell	   cycle,	   the	   cyclin	  dependent	  kinases	  (CDKs)	  and	  the	  cyclins.	  These	  form	  heterodimers	  that	  when	  bound	   together	   are	   active.	   Each	   of	   the	   two	   subunits	   of	   the	   heterodimers	   is	  inactive	   in	   the	   unbound	   state.	   When	   the	   complex	   forms,	   the	   CDK	  phosphorylates	   its	   target	   proteins	   a	   process,	   which	   will	   modify	   their	   activity	  status	  and	  will	  signal	  the	  progression	  to	  the	  next	  phase.	  Cyclins	  are	  synthesised	  and	   degraded	   in	   each	   cycle	   regulating	   the	   formation	   of	   the	   Cyclin/CDK	  complexes.	  	  	  The	  first	  cyclin	  to	  be	  formed	  during	  the	  cell	  cycle	  is	  cyclin	  D.	  This	  binds	  to	  the	  CDK4,	  forming	  the	  active	  complex,	  which	  phosphorylates	  the	  pRb	  susceptibility	  protein.	   CDK4,	   when	   dissociated	   from	   the	   E2F/DP1/Rb	   complex	   renders	   the	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E2F	   genes	   active.	   This	   promotes	   the	   transcription	   of	   several	   genes	   and	   the	  formation	  of	  proteins	  such	  as	  cyclin	  E,	  cyclin	  A,	  and	  DNA	  polymerase	  etc.	  	  	  The	  cyclin	  E	  produced	  during	  this	  phase	  binds	  to	  the	  CDK2,	  forming	  the	  active	  complex	  which	  signals	  the	  progression	  of	  the	  cell	  cycle	  to	  the	  S	  phase.	  Another	  cyclin,	  cyclin	  b,	  when	  bound	  to	  the	  CDK1,	  initiates	  the	  transition	  of	  the	  cell	  cycle	  from	   G2	   to	  M	   phase.	  When	   this	   complex	   is	   deactivated,	   the	   cell	   exits	  mitosis	  [55].	  The	  cip/kip	  gene	  family,	  which	  includes	  p21,	  p27	  and	  p57	  genes,	  and	  the	  INK4a/ARF	   gene	   family	   that	   includes	   p16INK4a,	   are	   part	   of	   the	   tumour	  suppressor	  genes	  that	  are	  vital	  for	  the	  prevention	  of	  the	  progression	  of	  the	  cell	  cycle.	  	  	  The	  cip/kip	  family	  binds	  and	  inactivates	  the	  cyclin/CDK	  complex	  arresting	  the	  cell	   cycle	   in	   G1	   phase.	   Different	   molecules	   activate	   the	   various	   genes:	   p21	   is	  activated	  by	  TP53,	  which	  is	  activated	  by	  DNA	  damage.	  P27	  is	  activated	  by	  TGFb,	  which	  inhibits	  growth.	  	  	  The	   INK4a/ARF	   family	   binds	   to	   CDK4	   and	   also	   arrest	   the	   cell	   cycle	   into	   G1	  phase.	   There	   are	   several	   checkpoints	   during	   the	   cell	   cycle	   during	   which	  damaged	  DNA	  is	  repaired	  and	  all	  necessary	  processes	  of	   the	  specific	  cell	  cycle	  have	  been	   completed	  prior	   to	   progression	   to	   the	  next	   phase	   of	   the	   cycle.	   The	  two	   main	   checkpoints	   are	   the	   G1/S	   checkpoint	   also	   known	   as	   restriction	  checkpoint	   and	   the	   G2/M	   checkpoint.	   The	   gene,	   which	   plays	   a	   major	   role	   in	  activating	   both	   the	   checkpoint	  mechanisms,	   is	   TP53	   (Figure	   1-­‐1)	   and	   (Figure	  1-­‐2).	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Figure	  1-­‐1	  Apoptosis	  signal	  transducing	  pathways.	  Adapted	  from	  [56]	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Figure	  1-­‐2	  Regulation	  of	  the	  cell	  cycle.	  Adapted	  from	  [57]	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1.6 Glioma	  Diagnosis	  	  Early	   clinical	   diagnosis	   is	   a	   key	   prognostic	   factor	   for	   every	   cancer.	   Early	  diagnosis	   is	   most	   likely	   to	   be	   made	   on	   a	   patient	   who	   will	   have	   a	   better	  performance	  status,	   than	  someone	  diagnosed	   later	  during	  the	  disease	  process.	  The	   performance	   status	   of	   the	   patient,	   which	   is	   classified	   according	   to	   the	  Karnofsky	  score,	  is	  a	  major	  predictor	  of	  suitability	  for	  treatment	  appropriate	  for	  each	  patient.	   It	   is	   intuitive	  that	  a	  patient	  with	  a	  better	  Karnofsky	  score	  will	  be	  able	   to	   tolerate	   more	   aggressive	   multimodality	   treatment	   than	   one	   who	   is	  diagnosed	  later	  in	  the	  disease	  with	  a	  worse	  performance	  status.	  This	  is	  a	  major	  challenge	   for	   gliomas.	   The	   diagnosis	   is	   based	   on	   a	   careful	   history	   and	  examination	   of	   a	   patient	   who	   usually	   presents	   with	   slowly	   progressive	  symptoms	  with	  the	  exception	  of	  epilepsy	  and	  haemorrhagic	  tumours.	  The	  most	  common	  symptoms	  of	  a	  patient	  with	  a	  glioma	  are	  headache,	  symptoms	  of	  raised	  intracranial	   pressure	   such	   as	   nausea	   and	   vomiting,	   symptoms	   caused	   by	   the	  location	  of	  the	  tumour	  such	  as	  memory	  decline,	  sensory	  and	  or	  motor	  deficits,	  visual/auditory	   changes,	   and	   non	   specific	   symptoms	   such	   as	   depression	   and	  loss	  of	  appetite.	  New	  onset	  of	  seizures	  or	  a	   focal	  deficit	   is	  highly	  suggestive	  of	  the	  presence	  of	  an	  underlying	  lesion.	  	  	  The	   next	   step	   in	   the	   diagnosis	   of	   patient	   with	   glioma	   is	   a	   careful	   physical	  examination	  of	  the	  patient.	  This	  will	  aid	  in	  trying	  to	  locate	  the	  lesion,	  as	  well	  as	  determining	  the	  performance	  status	  of	  the	  patient.	  	  	  Imaging	  of	  the	  neuroaxis	  follows	  in	  the	  diagnosis.	  The	  initial	  screening	  is	  made	  with	   a	   computerised	   tomography	   (CT)	   scan,	   which	   is	   a	   rapid	   and	   relatively	  inexpensive	   imaging	   method.	   The	   CT	   highlights	   the	   presence	   of	   calcification,	  mass	  effect,	  oedema,	  haemorrhage	  and	  hydrocephalus.	  Although	  CT	  is	  very	  good	  in	  visualising	  supratentorial	  tumours,	  it	  is	  limited	  in	  the	  ability	  to	  highlight	  the	  presence	  of	  tumours	  in	  the	  cerebellum	  and	  brainstem.	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Magnetic	  Resonance	  (MR)	   imaging	   is	  superior	  to	  CT	  in	  detecting,	   locating,	  and	  assessing	  tumour	  extent.	  It	  is	  though	  limited	  in	  its	  capacity	  in	  assessing	  tumour	  invasion	   to	   adjacent	   normal	   brain	   [58,	   59].	   Both	   imaging	   techniques	   can	   be	  combined	  with	  administration	  of	  contrast,	  which	  enhances	  the	  tumour	  mass	  as	  it	  “leaks”	  out	  of	  the	  disrupted	  blood-­‐brain	  barrier.	  	  More	   advanced	   MR	   techniques	   that	   combine	   anatomical	   information	   with	  cellular	  metabolism,	   such	   as	  MR	   spectroscopy	   (MRS),	   diffusion	   and	   perfusion	  MR,	   functional	   MR	   (fMRI),	   diffusion	   tensor	   imaging	   (DTI),	   are	   able	   to	  demonstrate	  the	  extent	  and	  the	  nature	  of	  gliomas	  as	  well	  as	  the	  relation	  of	  the	  lesion	  with	  eloquent	  areas	  of	   the	  brain.	  MRS	  detects	   freely	  mobile	  metabolites	  such	   as	   lactate,	   glutamine,	   creatinine,	   choline,	   lipid,	   and	   generats	   metabolic	  spectra.	  It	  is	  not	  widely	  used	  in	  clinical	  practice	  but	  it	  is	  helpful	  in	  detecting	  the	  most	  malignant	  part	  of	  the	  tumour	  that	  could	  aid	  surgical	  planning	  and	  to	  grade	  the	   glioma	   [60].	   MR	   perfusion	   and	   MR	   diffusion	   acquire	   physiological	   data,	  while	  water	  suppressed	  proton	  spectroscopy	  MR	  acquires	  metabolic	  data,	  both	  providing	   measurements	   of	   biological	   properties	   of	   the	   tumour	   as	   well	   as	  changes	  in	  tumour	  vascularity,	  cellularity,	  proliferation	  and	  also	  progression	  to	  a	  higher	  grade	  [61].	  	  Another	   imaging	   technique,	   which	   has	   proven	   useful	   in	   detecting	   tumour	  residue	  post	   treatment,	   is	  Positron	  Emission	  Tomography	  (PET).	  This	   imaging	  technique	   used	   18-­‐fluorodeoxyglucose	   to	   “light	   up”	   metabolically	   active	   cells	  [62].	  PET	   is	  also	  very	  helpful	   in	  differentiating	  between	  recurrent	   tumour	  and	  radiation	  necrosis,	  which	  is	  vital	  for	  determining	  the	  correct	  management	  plan	  for	  the	  patient	  [63].	  	  	  Dynamic	   susceptibility-­‐weighted	   contrast-­‐enhanced	   perfusion	   MR	   (DSC	   MRI)	  provides	   information	   about	   blood	   volume	   and	   blood	   flow	   of	   the	   tumour	   and	  complements	   conventional	   MR	   in	   evaluating	   angiogenesis	   and	  microvasculature.	  Dynamic	  contrast	  enhanced	  MR,	  detects	  the	  status	  of	  vascular	  and	   endothelial	   permeability.	   It	   has	   been	   reported	   that	   quantitative	  measurement	   of	  microvascular	   permeability	   correlates	  with	   the	   glioma	   grade	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[64,	   65].	   Although	  not	   currently	   used	  widely	   in	   clinical	   practice,	   it	   potentially	  can	  help	   the	   surgeon	   to	  biopsy	   the	  most	  malignant	  part	   of	   the	   tumour;	   it	   can	  monitor	   the	   efficacy	   of	   chemotherapy	   especially	  when	   using	   antiangiogenesis	  drugs	  and	  also	  differentiate	  between	  radiation	  necrosis	  and	   recurrent	   tumour	  [59].	  	  	  	  
1.7 Prognosis	  of	  gliomas	  	  Prognosis	   varies	   according	   to	   the	   glioma	   grade.	   Pilocytic	   astrocytomas	   (WHO	  grade	  I)	  have	  the	  potential	  for	  cure	  following	  total	  surgical	  resection.	  	  	  Age,	  preoperative	  functional	  status	  and	  extent	  of	  surgical	  resection	  are	  the	  most	  important	   prognostic	   factors	   for	   Grade	   II	   astrocytomas.	   Survival	   rates	   are	  improved	   in	   patients	   with	   lesions	   that	   can	   be	   totally	   resected.	   Philippon	   and	  coworkers	   have	   reported	   that	   the	   5-­‐year	   survival	   rate	   decreases	   dramatically	  from	  80%	   for	  patients	  who	  underwent	   gross	   total	   resection	   to	  50%	   for	   those	  who	  had	  partial	  resection	  and	  to	  45%	  for	  those	  biopsied	  only	  [66].	  	  Prognosis	   for	  malignant	   gliomas	   (anaplastic	   astrocytomas	  WHO	   grade	   III	   and	  glioblastoma	   multiforme	   WHO	   grade	   IV)	   remains	   dismal,	   despite	  pharmacological	   advances	   in	   chemotherapeutic	   agents	   and	   technical	  improvements	   in	  both	  neurosurgery	  and	  radiation	  delivery.	   In	  fact,	   the	  goal	  of	  treatment	   is	   to	   improve	  quality	  of	   life	  rather	  than	  cure.	  Again,	   in	  this	  group	  of	  gliomas,	  age,	  preoperative	  functional	  status	  and	  histological	  grade	  are	  the	  main	  prognostic	  factors.	  The	  gold	  standard	  of	  therapy	  for	  the	  anaplastic	  astrocytomas	  is	   macroscopic	   total	   resection,	   followed	   by	   radiation	   therapy.	   Chemotherapy	  treatment	   remains	   controversial	   [67,	   68].	   Median	   survival	   is	   2-­‐3	   years,	   with	  18%	  5-­‐year	  survival	  [69].	  	  Glioblastoma	   multiforme	   has	   an	   average	   survival	   of	   less	   than	   a	   year	   even	  following	  optimal	  aggressive	  multimodality	  therapy.	  5-­‐year	  survival	  is	  less	  than	  5%.	   The	   gold	   standard	   of	   treatment	   for	   glioblastoma	   multiforme	   is	   radical	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resection,	  followed	  by	  radiotherapy	  and	  chemotherapy.	  The	  younger	  the	  patient	  and	   the	  better	   the	  performance	  status,	   the	   longer	   the	   time	  to	  progression	  and	  the	  longer	  the	  overall	  survival	  [70-­‐72].	  	  	  
1.8 Treatment	  of	  gliomas	  	  The	  treatment	  of	  gliomas	  is	  multimodal	  and	  includes	  surgery,	  radiotherapy	  and	  chemotherapy.	   The	   extent	   of	   surgery,	   mode	   of	   radiotherapy	   and	   type	   of	  chemotherapy	  is	  dependent	  on	  the	  histological	  diagnosis	  of	  the	  glioma,	  as	  well	  as	   the	   clinical	   condition	   of	   the	   patient.	   Currently	   a	   combination	   of	   all	   these	  modalities	   is	   given	   to	   suitable	   patients.	   Unfortunately	   these	   tumours	   are	  incurable	  and	  the	  aim	  of	  therapy	  is	  to	  prolong	  high	  quality	  survival.	  	  
1.8.1 Surgery	  	  Surgical	  options	  are	  biopsy,	  subtotal	  or	  gross	  total	  resection.	  The	  purpose	  of	  the	  surgical	   intervention	   is	   to	   provide	   tissue	   for	   definitive	   diagnosis,	   alleviate	  symptoms	  of	  raised	  intracranial	  pressure	  and	  provide	  maximal	  cytoreduction	  of	  malignant	   cells.	   The	   type	   of	   surgical	   intervention	  will	   depend	   on	   the	   location	  and	   size	   of	   the	   tumour,	   presence	   of	   mass	   effect	   or	   increased	   intracranial	  pressure,	  the	  patient’s	  condition	  and	  the	  risk	  of	  surgery.	  Complete	  resection	  of	  the	  tumour	  is	  impossible	  due	  to	  its	  infiltrative	  nature.	  Studies	  have	  shown	  that	  the	  survival	   increases	  with	  the	  increase	  of	  the	  extent	  of	  surgical	  resection	  [73,	  74].	  All	  surgical	  modalities	  provide	  diagnostic	  clarification	  of	  the	  tumour	  in	  98%	  of	  patients.	  Gross	  total	  resection	  may	  also	  provide	  relief	  of	  symptoms	  and	  signs	  of	  increased	  intracranial	  pressure	  as	  well	  as	  improve	  neurology	  and	  functional	  status	   of	   the	   patient.	   It	   may	   also	   improve	   tolerability	   during	   radiotherapy	  treatment	  due	  to	  reduced	  steroid	  requirements.	  	  	  Surgical	  planning	  is	  one	  of	  the	  most	  important	  steps	  of	  the	  surgical	  treatment.	  It	  should	  be	  tailored	  to	  individual	  patient	  need,	  maximising	  the	  extent	  of	  resection	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whilst	   minimising	   the	   morbidity	   of	   the	   procedure.	   Although	   there	   has	   been	  development	   in	   the	   surgical	   techniques,	   which	   have	   helped	   in	   achieving	  minimal	  risks	  during	  surgery,	  the	  survival	  of	  patients	  has	  not	  improved	  [75].	  	  	  For	   non-­‐eloquent	   areas	   of	   the	   brain	   affected	   by	   a	   glioma,	   the	   traditional	  craniotomy	  under	  general	  anaesthesia	   is	  widely	  used.	  This	  has	  been	  enhanced	  with	  the	  use	  of	  image	  guidance.	  However,	  for	  patients	  whose	  eloquent	  areas	  of	  the	   brain	   are	   affected	   by	   gliomas,	   pre	   operative	   functional	   MR,	   fusion	   of	  functional	   and	   anatomical	   imaging	   and	   neuronavigation,	   are	   vital	   adjuncts	   to	  the	   surgeon	   to	   prevent	   new	   neurological	   deficits	   [76].	   Furthermore,	   the	  development	   of	   better	   anaesthetic	   drugs	   as	   well	   as	   techniques	   and	  intraoperative	   functional	   monitoring	   has	   enabled	   the	   safe	   performance	   of	  awake	  craniotomies	  with	  even	  better	  results	  in	  terms	  of	  extent	  of	  excision	  with	  minimal	  neurological	  deficits	  [77].	  One	  adjunct,	  which	  allows	  maximal	  resection	  of	   tumour	   around	   the	   motor	   cortex	   is	   monitoring	   of	   the	   corticospinal	   motor	  evoked	  potential	  (D-­‐wave).	  When	  the	  amplitude	  of	  the	  D-­‐wave	  decreases	  by	  less	  than	   30%,	   this	   is	   suggestive	   of	   postoperative	   preservation	   of	   motor	   function	  [78].	   Use	   of	   intra-­‐operative	   MR	   has	   been	   demonstrated	   to	   maximise	   tumour	  resection	  [79].	  Also	  the	  possibility	  to	  fuse	  functional	  MRI	  with	  neuronavigation	  helps	   prevent	   development	   of	   new	   motor	   deficit	   after	   surgery.	   It	   has	   been	  reported	   that	   a	   safe	   lesion–to-­‐activation	   distance	   is	   10mm	   for	   complete	  resection	  [80].	  	  	  
1.8.2 Radiotherapy	  	  Radiotherapy	   is	   the	   primary	   adjuvant	   treatment	   after	   surgical	   resection	   of	  gliomas.	  It	  uses	  x-­‐rays/	  γ-­‐rays	  to	  damage	  the	  DNA	  of	  dividing	  cells	  and	  cause	  cell	  apoptosis.	  Standard	  treatment	  dose	  for	  glioma	  is	  whole	  brain	  radiation	  with	  60	  Gy	   using	   conventional	   external	   beam	   radiation,	   in	   fractionated	   doses.	   This	  treatment	  usually	  starts	  a	  couple	  of	  weeks	  after	  surgery,	  allowing	  the	  wound	  to	  heal.	  Although	  this	  treatment	  has	  been	  reported	  to	  increase	  survival	  of	  patients	  with	   grade	   III	   and	   grade	   IV	   gliomas	   regardless	   of	   the	   extent	   of	   surgical	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resection,	   the	   mean	   survival	   time	   is	   still	   disappointing,	   ranging	   from	   16-­‐70	  weeks	  [81,	  82].	  	  Radiation	   treatment	   for	   low-­‐grade	   gliomas,	   on	   the	   contrary,	   is	   controversial	  mainly	   because	   of	   the	   long-­‐term	   side	   effects	   of	   radiation	   to	   the	   normal	   brain	  and	  the	  young	  age	  of	  patients	  [83,	  84].	  	  	  To	  maximise	  the	  effects	  of	  radiation	  therapy	  to	  the	  malignant	  tissue,	  minimising	  its	  effects	  to	  surrounding	  normal	  brain,	  which	  has	  minimal	  tolerability	  to	  x-­‐rays,	  Woo	   and	   coworkers,	   have	   reported	   on	   novel	   ways	   of	   delivering	   radiation	  therapy	   to	   the	   tumour	   bed,	   sensitizing	   the	   tumour	   cells	   to	   the	   effects	   of	  radiation	  either	  chemically	  or	  thermally,	  or	  using	  alternative	  radiating	  particles	  such	  as	  neutrons	  or	  heavy	  ions	  [85].	  	  	  The	   use	   of	   stereotaxy	   has	   revolutionised	   delivery	   of	   radiation	   therapy.	  Stereotactic	  radiotherapy	  is	  delivered	  by	  external	  beam.	  External	  beam	  can	  be	  fractionated	  and	  deliver	  an	  even	  dose	  of	   radiation	   to	  a	  specific	  area	  or	  can	  be	  delivered	   as	   one-­‐session	   using	   intensity	   modulated	   radiation	   therapy	   which	  shapes	   the	   beam	   to	   approximate	   the	   tumour	   as	   closely	   as	   possible,	   avoiding	  damage	  to	  adjacent	  structures.	  This	  modality	  of	  radiotherapy	   is	  widely	  known	  with	   the	   various	   brand	   names	   as	   Gamma	   Knife,	   Novalis	   Tx,	   CyberKnife	  radiosurgery	  [86].	  	  Brachytherapy	   involves	   the	   placement	   of	   radioactive	   implants	   to	   the	   tumour	  that	  emit	  radiation	  for	  a	  prolonged	  period	  of	  time.	  This	  type	  of	  radiotherapy	  is	  called	   interstitial	   brachytherapy	  when	   the	   implants	   are	   placed	   in	   the	   tumour	  bed,	  or	  intracavitary	  brachytherapy,	  when	  the	  tumour	  is	  cystic	  or	  the	  implants	  are	   placed	   to	   existing	   anatomical	   cavities.	   Using	   permanent,	   low-­‐activity	  implants	  has	  been	  reported	  to	  improve	  outcome,	  without	  the	  risk	  of	  side	  effects	  and	  that	  of	  radiation	  necrosis	  [87].	  	  An	   emerging	   novel	   technique	   of	   delivering	   radiotherapy	   is	   Radio-­‐immunotherapy.	   This	   technique	   uses	   monoclonal	   antibodies	   labelled	   with	  radioactive	  ions,	  to	  selectively	  irradiate	  tumour	  rather	  than	  normal	  cells	  [88].	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  The	   side	   effects	   of	   radiotherapy	   treatment	   can	   be	   grouped	   as	   acute,	   early-­‐delayed	   and	   late-­‐delayed	   side	   effects.	   The	   early	   side	   effects	   occur	   during	  treatment	   and	   are	   readily	   responsive	   to	   steroids.	   These	   include	   reversible	  neurological	   deficits	   due	   to	   tissue	   damage.	   Early-­‐delayed	   side	   effects	   include	  nausea,	   vomiting,	   dysphagia,	   cerebral	   and	   cerebellar	   dysfunction,	   which	   are	  presumably	  due	  to	  transient	  demyelination.	  These	  occur	  weeks	  to	  months	  after	  treatment.	   The	   late-­‐delayed	   side	   effects	   are	   non-­‐reversible	   cerebral	   or	  cerebellar	  dysfunction	  and	  are	  the	  result	  of	  radiation	  necrosis.	  These	  occur	  six	  months	  to	  years	  after	  the	  end	  of	  treatment	  [89].	  	  	  
1.8.3 Chemotherapy	  	  Chemotherapy	  uses	  cytotoxic	  drugs	  to	  kill	  or	  render	  tumour	  cells	  radiosensitive.	  These	   are	   delivered	   either	   systemically	   using	   the	   oral,	   intravenous	   and	  intraarterial	  route,	  or	  locally	  using	  an	  intrathecal	  or	  intracavitary	  delivery.	  The	  blood-­‐brain	   barrier	   (BBB)	   protects	   the	   brain	   from	   most	   chemotherapeutic	  regimens,	  limiting	  the	  drug	  choice	  and	  method	  of	  delivery	  of	  those	  drugs	  for	  the	  treatment	  of	  gliomas.	  	  	  The	  use	  of	  post-­‐operative	  chemotherapy	  has	  been	  correlated	  with	  an	  increase	  in	  the	  survival	  of	  patients	  with	  malignant	  gliomas	  [90].	  The	  drugs	  are	  classified	  as	  cell	  cycle	  specific	  and	  non	  cell	  cycle	  specific.	  	  	  Cell	   cycle	   specific	   drugs	   include	   microtubule	   modulators,	   which	   derive	   from	  plant	   alkaloids.	   Microtubules	   are	   dynamic	   complexes	   made	   from	   the	   protein	  tubulin.	  These	  complexes	  promptly	  polymerize	  and	  depolymerize	  in	  cells	  while	  undergoing	  two	  dynamic	  processes	  called	  dynamic	  instability	  and	  treadmilling.	  Microtubules	   are	   crucial	   during	   the	  mitosis	   of	   the	   cell	   cycle	   as	   they	   attach	   to	  each	  chromosome	  and	  guide	  it	  towards	  the	  new	  forming	  daughter	  cell,	  making	  sure	  that	  the	  correct	  numbers	  of	  chromosomes	  end	  up	  in	  the	  correct	  cell.	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The	  main	  microtubule	  modulator	  drugs	  are	  vinca	  alkaloids	  and	  taxane	  alkaloids.	  Vincristine,	  vinblastine	  and	  vinorelbine	  are	  examples	  of	  vinka	  alkaloids.	  Those	  inhibit	   the	   polymerization	   of	   the	   microtubules	   that	   impedes	   mitosis.	  Vinorelbine	   is	   a	   second-­‐generation	   semi	   synthetic	   vinka	   alkaloid,	   which	   has	  different	   binding	   site	   from	   that	   of	   the	   natural	   products	   Vincristine	   and	  Vinblastine	   and	   shows	   increased	   antitumour	   activity	   with	   reduced	  neurotoxicity	  and	  reduced	  affinity	  for	  p–glycoprotein	  [91].	  	  The	   group	   of	   taxane	   alkaloids	   such	   as	   paclitaxel	   and	   docetaxel	   stimulate	   the	  polymerization	   of	   the	   microtubules	   stabilizing	   them,	   hence	   prohibiting	   the	  crucial	   dynamic	   instability	   of	   the	  microtubules	   during	   the	   process	   of	  mitosis.	  Both	  groups	  lead	  to	  cell	  death	  via	  apoptosis	  [92].	  	  	  Paclitaxel	   has	   been	   very	   effective	   in	   treating	   various	   cancers	   and	   is	   used	  currently	   in	   breast,	   lung	   and	   ovarian	   carcinomas.	   It	   is	   a	   highly	   hydrophobic	  compound,	  which	  binds	  to	  the	  b-­‐tubulin	  subunit	  of	  microtubules	  at	  the	  M-­‐loop	  stabilising	   lateral	   contact	   between	   protofilaments.	   As	   it	   is	   hydrophobic,	   it	  requires	   solubilisation	   in	  an	  alcohol-­‐based	  molecule.	  This	   is	   thought	   to	  be	   the	  base	  of	  the	  adverse	  reaction	  that	  it	  causes	  to	  patients.	  It	  is	  unfortunately	  also	  a	  good	   substrate	   for	   the	   p-­‐glycoprotein.	   P-­‐	   glycoprotein	   is	   a	   plasma	  membrane	  protein,	  which	  acts	  a	  drug	  efflux	  pump.	  Paclitaxel	   is	  bound	  and	  pumped	  out	  of	  the	   cell,	   abolishing	   its	   effects.	   There	   have	   been	   reports	   of	   p53	   transcription	  inactivity	   increases	   sensitivity	   to	   microtubule	   modulating	   drugs.	   This	   is	  mediated	  by	  the	  regulation	  of	  microtubule-­‐associated	  protein	  4	  (MAP4),	  which	  when	  abundant	  increases	  microtubule	  polymerization	  and	  binding	  to	  paclitaxel.	  Expression	  of	  MAP4	  is	  down	  regulated	  by	  p53	  transcription	  [93].	  	  Non-­‐cycle	   specific	   drugs	   include	   Topoisomerase	   inhibitors	   and	   alkylating	  agents.	  Topoisomerase	   inhibitors	   include	  etoposide,	   tenisopide,	   irinotecan	  and	  topotecan.	  Etoposide	  causes	  single	  and	  double	  strand	  DNA	  breaks	  that	  are	  dose	  dependent,	   at	   concentrations	   used	   in	   vivo	   [94].	   Topoisomerase	   II	   and	   I	   are	  enzymes	  expressed	  only	  in	  dividing	  cells	  during	  specific	  mitotic	  phases.	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Alkylating	  agents	  are	  the	  second	  group	  of	  non-­‐cycle	  specific	  chemotherapeutic	  agents	   used	   for	   the	   treatment	   of	   malignant	   gliomas.	   These	   agents	   act	   by	  attaching	   an	   alkyl	   group	   (CnH2n+1)	   to	   DNA.	   This	   causes	   crosslinking	   of	   the	  guanine	   nucleobases	   in	   the	   double-­‐helix	   strands	   of	   the	   DNA,	   making	   them	  unable	  to	  uncoil,	  a	  process,	  which	  is	  necessary	  for	  replication.	  The	  end	  result	  is	  the	  death	  of	  the	  cell.	  	  There	   are	   three	   groups	   of	   alkylating	   agents:	   the	   nitrogen	   mustards;	   the	  nitrosoureas	  and	  the	  alkyl	  sulfonates.	  The	  nitrogen	  mustards	  include	  agents	  like	  cyclophosphamide,	   chlorambucil	   and	   melphalan.	   These	   agents	   were	   the	   first	  alkylating	   agents	   to	   be	   used	   in	  medicine.	   Prior	   to	   their	   use	   in	   chemotherapy,	  they	  were	  used	  as	  chemical	  weapons	  in	  World	  War	  I.	  	  Nitrosoureas	   are	   commonly	   used	   for	   the	   treatment	   of	   malignant	   gliomas.	  Carmustine	  (BCNU)	  and	  Lomustine	  (CCNU)	  are	  examples	  of	  these	  agents.	  These	  are	  dialkylating	  agents	  as	   they	  act	   in	   two	  different	  3-­‐7-­‐N	  Guanine	  nucleobases	  causing	   crosslinking	   of	   the	   DNA	   strand,	   if	   the	   residues	   are	   located	   in	   two	  different	  strands	  of	  DNA.	  If	  the	  residues	  are	  on	  the	  same	  strand,	  the	  effect	  of	  the	  drug	   is	   called	   limpet	   attachment.	   This	   does	   not	   prevent	   the	   separation	   of	   the	  DNA	   helix,	   but	   renders	   the	   DNA	   inaccessible	   to	   the	   enzymes	   required	   for	  replication.	  As	  a	  result,	  the	  cell	  enters	  apoptosis	  and	  dies.	  	  Temozolomide	   is	   another	   alkylating	   agent,	   which	   has	   revolutionised	   the	  treatment	   of	  malignant	   gliomas	   over	   the	   last	   ten	   years	   as	   it	   increased	   overall	  survival	   by	   2-­‐3	  months.	   It	   is	   an	   imidazotetrazine	   derivative,	  which	   attaches	   a	  methyl	  group	  to	  the	  guanine	  nucleobase	  of	  DNA,	  preventing	  its	  replication	  and	  causing	   cell	   death	   [95].	   It	   mediates	   its	   action	   by	   it	   active	   metabolite,	   which	  forms	  spontaneously	  after	  administration.	  It	   is	  a	  well-­‐tolerated	  agent,	  which	  is	  administered	  via	   the	  oral	   route.	  Using	  adjuvant	  Temozolomide	   for	   six	  months	  after	   radiotherapy	   in	   the	   treatment	   of	   glioblastomas,	   known	   as	   the	   Stupp	  protocol,	  has	  shown	  an	  increase	  in	  survival	  over	  radiotherapy	  alone	  [96].	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The	   DNA	   mismatch	   repair	   enzyme	   O6-­‐methylguanine-­‐methyl-­‐transferase	  (MGMT),	   removes	   alkyl	   adducts	   from	   the	   O6	   position	   of	   guanine	   and	   the	   O4	  position	  of	  thymine,	  repairing	  the	  lesions	  caused	  by	  Temozolomide	  [97].	  It	  has	  been	   reported	   that	   methylation	   of	   the	   MGMT	   gene	   promoter	   region	   leads	   to	  inactive	   enzyme	   production	  which	   increases	   survival	   of	   patients	   treated	  with	  Temozolomide	   after	   radiotherapy	   versus	   patients	   treated	   with	   radiotherapy	  alone	  [98,	  99].	  	  Platinum	   based	   chemotherapeutic	   agents	   are	   described	   as	   “alkylating-­‐like”	  agents	  as	  act	   in	  a	  similar	  manner.	  They	  from	  adducts	   in	  the	  N7	  position	  of	  the	  adenine	   and	   guanine	   nucleobases.	   This	   causes	   permanent	   DNA	   damage,	  blocking	   the	   action	   of	   the	   DNA	   polymerase,	   preventing	   cell	   replication	   and,	  leading	   to	   cell	   death.	   Another	   mode	   of	   action	   of	   cisplatin	   in	   human	   glial	   cell	  lines,	   which	   leads	   to	   apoptosis,	   is	   mediated	   by	   the	   activation	   of	   the	   ERK	  signalling	   pathway,	   which	   activates	   numerous	   upstream	   pathways	   and	   the	  caspase-­‐3	  pathway	  [100].	  	  
1.9 Alternative	  Therapeutic	  Modalities	  	  As	   survival	   has	   not	   improved	   significantly	   with	   improvement	   in	  chemotherapeutic	   agents	   and	   radiation	   therapy,	   there	  has	   been	   an	   interest	   in	  developing	   other	   therapeutic	   modalities.	   These	   modalities	   include	   biological	  response	   modifiers,	   gene	   therapy,	   Oncolytic	   viruses,	   immunotherapy	   and	  inhibitors	   of	   angiogenesis.	   These	   therapies	   exploit	   the	   molecular	   differences	  between	  normal	  glial	  cells	  and	  glioma	  cells,	  but	  have	  yet	  to	  be	  proven	  effective.	  	  
1.9.1 Biological	  response	  modifiers	  	  These	   agents	   can	   modify	   the	   phenotype	   of	   tumour	   cells.	   The	   most	   widely	  studied	  are	  the	  interferons	  (IFN),	  interleukins	  (IL)	  and	  tumour	  necrosis	  factor-­‐α	  (TNF-­‐α).	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Interferons	   are	   cytokines	   that	   modulate	   immune	   response	   and	   tumour	  cytotoxicity.	   There	   have	   been	   reports	   of	   IFN-­‐α	   and	   IFN-­‐β	   inhibiting	   tumour	  growth	  in	  rodent	  glioma	  models.	  Yung	  and	  coworkers	  have	  reported	  that	  IFN-­‐β	  is	  more	  active	  than	  IFN-­‐α	  [101].	  	  Interleukins	   are	   molecules	   that	   activate	   lymphocytes	   and	   leukocytes.	  Benveniste	  and	  coworkers	  have	  reported	  the	  anti-­‐glioma	  in	  vitro	  activity	  of	  IL-­‐2	  [102].	  	  
1.9.2 Gene	  Therapy	  	  The	   lack	  of	   systemic	   toxicity	   and	   the	  ease	  of	   application	  during	   surgery	  make	  gene	  therapy	  an	  attractive	  treatment	  modality	  for	  brain	  tumours.	  Genes	  can	  be	  introduced	  to	  the	  DNA	  of	  the	  target	  cell	  either	  directly	  or	  indirectly	  (Figure	  1-­‐3).	  A	  direct	   introduction	  of	  genetic	  material	  without	  any	  vector	   (cellular	  or	  viral)	  can	   be	   achieved	   via	   systemic	   delivery,	   aerosol	   or	   microcellular	   injection.	  Indirect	   gene	   delivery	   can	   be	   performed	   via	   transplantation	   of	   genetically	  engineered	   cells,	   or	   via	   inoculation	   of	   recombinant	   defective	   virus	   into	   the	  target	  DNA	  [103].	  	  There	   have	   been	   studies	   where	   an	   adenovirus	   is	   used	   to	   deliver	   the	   herpes	  simplex	  virus	  thymidine	  kinase	  (HSV-­‐tk)	  gene	  to	  the	  dividing	  glioma	  cells.	  The	  kinase	   that	   is	   produced	   in	   the	   infected	   cells	   blocks	   DNA	   replication	   by	  phosphorylating	  nucleoside	  analogs	  to	  form	  nucleotide-­‐like	  precursors	  [103].	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Figure	  1-­‐3	  Mechanism	  of	  gene	  therapy.	  Adapted	  from	  [103]	  	  	  
1.9.3 Oncolytic	  viruses	  	  Oncolytic	  viruses	  replicate	  selectively	  in	  neoplastic	  tissues.	  This	  has	  a	  result	  the	  lysis	  of	  the	  neoplastic	  cell	  (Figure	  1-­‐4).	  There	  have	  been	  both	  in	  vitro	  and	  in	  vivo	  studies	   that	   have	   demonstrated	   that	   certain	   strains	   of	   reovirus	   can	   take	  advantage	   of	   the	   Ras-­‐signaling	   pathway	   of	   human	   gliomas	   to	   replicate	   [104].	  Ikeda	  and	  coworkers	  have	  demonstrated	  that	  human	  immune	  response	  impairs	  viral	   activity	   [105].	   It	   remains	   to	   be	   seen	   if	   the	   oncolytic	   viral	   therapy	   will	  translate	  into	  an	  alternative	  therapeutic	  modality	  for	  malignant	  gliomas.	  	  
	   33	  
	  
Figure	  1-­‐4	  Mechanism	  of	  action	  of	  oncolytic	  virus.	  Adapted	  from	  [106]	  	  	  
1.9.4 Immunotherapy	  	  Immunotherapy	   is	   an	  exciting	   therapeutic	  modality	   for	   the	   treatment	  of	  brain	  tumours.	  Its	  specificity	  and	  the	  memory	  of	  the	  immune	  system	  could	  potentially	  eliminate	   infiltrating	   tumour	   selectively	   without	   damaging	   the	   surrounding	  normal	  brain.	  	  	  Passive,	  active	  and	  adoptive	   immunotherapy	  are	  currently	  under	   investigation	  as	  a	  means	  of	  therapy	  [107].	  	  Passive	   immunotherapy	  employs	  the	  use	  of	  monoclonal	  antibodies	   in	  order	   to	  induce	  tumour	  cell	  death	  either	  directly	  or	  by	  delivering	  radiotherapy	  or	  toxins	  [108].	  Active	   immunotherapy	   utilises	   vaccination	   with	   reproductive	   incompetent	  autologous	   or	   even	   allogeneic	   tumour	   cells	   in	   order	   to	   induce	   a	   specific	   anti-­‐tumour	  response	  [109].	  Adoptive	  immunotherapy	  induces	  response	  either	  by	  ex	  vivo	  stimulation	  of	  the	  patient’s	   own	   immune	   effector	   lymphocytes	   or	   by	   injection	   of	   activated	   LAK+	  IL-­‐2	  directly	  into	  the	  tumour	  via	  an	  Ommaya	  reservoir	  [110,	  111].	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1.9.5 Inhibitors	  of	  Angiogenesis	  	  Neoangiogenesis	   is	   a	   cardinal	   feature	   for	   tumour	   survival	   and	   is	   required	   in	  order	  for	  the	  tumour	  to	  increase	  in	  size	  by	  more	  than	  1-­‐2	  mm	  in	  diameter.	  This	  is	  possible	  through	  a	  continuous	  process	  of	  balancing	  regulators	  of	  angiogenesis	  towards	  promotion	  and	  absorption	  of	  new	  blood	  vessels.	  	  	  	  The	  extracellular	  matrix	  over	  expresses	  and	  mobilises	  angiogenetic	  proteins	  as	  well	   as	   cells	   such	   as	   macrophages	   which	   themselves	   produce	   angiogenetic	  proteins.	   Vascular	   endothelial	   growth	   factor	   (VEGF),	   basic	   fibroblastic	   growth	  factor	   (bFGF)	   and	   platelet-­‐derived	   growth	   factor	   (PDGF)	   are	   the	   cardinal	  angiogenic	  proteins.	  Angiostatin,	  endostatin	  and	  thrombostatin	  are	  endogenous	  inhibitors	  of	  angiogenesis.	  	  	  	  During	  angiogenesis,	  a	  series	  of	  events	  occurs	  such	  as	  activation	  of	  endothelial	  cells,	   proteolytic	   degradation	   of	   the	   extracellular	   matrix	   and	   the	   basement	  membrane,	   proliferation	   and	   migration	   of	   endothelial	   cells,	   endothelial	   tube	  formation,	   fusion	   and	   reassembly	   of	   the	   extracellular	  matrix.	   These	  processes	  involve	   many	   enzymes,	   including	   the	   matrix	   metalloproteinases,	   the	   serine	  proteases	  and	  the	  cathepsins,	  which	  promote	  release	  of	  stored	  growth	  factors,	  which	  in	  turn	  promote	  more	  angiogenesis.	  	  	  	  The	  more	  studied	  enzymes	  in	  the	  antiangiogenesis	  treatment	  of	  brain	  tumours	  are	  the	  matrix	  metalloproteinase	  inhibitors	  (MMPIs).	  The	  MMP	  family	  is	  a	  group	  of	   twelve	   secreted	   as	   well	   as	   membrane-­‐bound	   zinc	   endopeptidases.	   Other	  proteolytic	  enzymes	  activate	  them	  in	  order	  to	  digest	  the	  extracellular	  matrix.	  	  	  	  MMPs	   are	   upregulated	   in	   both	   primary	   and	   secondary	   brain	   tumours	   and	  correlate	  with	  malignant	   progression	   as	   shown	   by	   Van	  Meter	   and	   coworkers	  [112].	   However	   clinical	   trials	   have	   failed	   to	   demonstrate	   good	   therapeutic	  efficacy.	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1.9.6 Biomarkers	  	  There	   has	   been	   growing	   interest	   in	   identifying	   biomarkers	   for	   malignant	  gliomas.	  A	  biomarker	   is	  a	  measurable	  substance,	  which	  can	  used	   to	   indicate	  a	  biological	  state.	  Such	  state	  may	  be	  a	  normal	  biological	  process,	  a	  disease	  or	  even	  a	   pharmacological	   response	   to	   treatment.	   Examples	   of	   commonly	   used	  biomarkers	   include	  Hb1Ac	   for	  diabetes	  mellitus,	   blood	  pressure	  monitoring	   in	  hypertension,	  and	  chromosomal	  abnormalities	  in	  genetic	  syndromes.	  	  	  Molecular	   biomarkers	   are	   widely	   used	   for	   disease	   monitoring	   in	   several	  common	   cancers,	   such	   as	   prostate	   cancer,	   ovarian	   cancer	   and	   hepatocellular	  cancer.	   In	   recent	   years,	   several	   studies	   have	   identified	   potential	   candidate	  molecules	  as	  brain	  tumour	  biomarkers	  but	  so	  far	  very	  few	  of	  them	  are	  used	  in	  clinical	  practice	  [113].	  Amongst	  the	  most	  promising	  ones	  for	  clinical	  use	  are	  the	  Cytokines	   and	  Angiogenesis	   factors	   [114]	   (see	   introductions	  of	  Chapter	  4	   and	  5).	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1.10 Aims	  of	  the	  following	  study	  	  The	  aims	  of	  the	  present	  study	  are	  two	  fold.	  Firstly	  it	  seeks	  to	  evaluate	  the	  use	  of	  
in	  vitro	  chemosensitivity	  assays	  in	  primary	  glioma	  cell	  cultures.	  Secondly	  it	  aims	  to	   identify	   novel	   brain	   tumour	   biomarkers	   from	   serum	   samples	   of	   patients	  affected	  by	  malignant	  brain	  tumours.	  
In	   vitro	   chemosensitivity	   testing	   is	   a	   well-­‐established	   idea.	   However,	   it	   has	  failed	  to	  make	  an	  impact	  in	  routine	  clinical	  practice.	  This	  study	  aims	  to	  correlate	  the	   results	   of	   chemosensitivity	   testing	   with	   clinical	   data	   of	   treatment	   and	  survival	  in	  an	  attempt	  to	  “validate”	  the	  in	  vitro	  findings	  and	  assess	  the	  potential	  use	  of	  this	  in	  clinical	  practice.	  Although	   several	   molecules	   have	   been	   proposed	   as	   potential	   brain	   tumour	  biomarkers,	   none	   so	   far	   has	   been	   found	   to	   be	   useful	   in	   clinical	   practice.	   This	  study	  investigates	  the	  feasibility	  of	  collecting	  blood	  samples	  from	  patients	  and	  controls	   in	   a	   clinical	   setting.	   It	   also	   tries	   to	   identify	   possible	   molecules	   that	  could	  serve	  as	  malignant	  brain	   tumour	  biomarkers.	   It	  acts	  as	  a	  pilot	   study	   for	  further	  projects	  in	  this	  field	  in	  our	  institution.	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2 CHEMOSENSITIVITY	   TESTING	   IN	   PRIMARY	   GLIOMA	  
CULTURES	  	  
2.1 Introduction	  	  Chemosensitivity	  is	  defined	  as	  the	  susceptibility	  of	  a	  microbial	  pathogen	  to	  the	  action	  of	  a	  chemical	  agent.	  Medical	  oncology	  has	  adopted	  this	  concept	  in	  order	  to	   investigate	   the	   responsiveness	   of	   cancer	   cells	   to	   various	   chemotherapeutic	  agents	   [115].	   Successful	   implementation	   of	   this	   notion	   could	   then	   lead	   to	  personalised	  chemotherapy	  treatment	  where	  tailored	  drug-­‐dose	  combination	  is	  administered	   soon	   after	   the	   chemosensitivity	   testing.	   This	   could	   potentially	  maximise	  the	  chances	  of	  survival	  for	  the	  cancer	  patients.	  	  	  Chemosensitivity	   studies	   are	  mainly	   performed	  on	   cell	   cultures.	   These	   can	  be	  either	  primary	  cell	  cultures	  or	  cell	   lines	  (aka	   immortalized	  cell	   lines).	  Primary	  cell	  cultures	  derive	  directly	  from	  the	  parent	  tissue	  and	  have	  the	  same	  karyotype	  and	  chromosome	  number	  as	  the	  cells	  of	  the	  tissue	  of	  origin.	  Most	  primary	  cell	  cultures	  have	  a	   limited	  lifespan,	  which	  is	  approximately	  less	  than	  19	  passages.	  On	  the	  other	  hand,	  cell	  lines	  have	  been	  derived	  from	  primary	  cell	  cultures	  that	  can	   proliferate	   indefinitely	   given	   appropriate	   fresh	   medium	   and	   space.	   The	  genetic	  make	  up	  of	  the	  cell	  lines	  differs	  from	  that	  of	  the	  primary	  cell	  cultures	  as	  well	  as	  their	  tissue	  of	  origin.	  The	   first	   successfully	   cultured	   human	  malignant	   tumour	   cells	   were	   the	   HeLa	  cells,	  which	  were	  produced	  by	  a	  patient	  with	  cervical	  cancer	  [116].	  There	  is	  an	  ongoing	  scientific	  debate	  with	  regards	  to	  how	  representative	  these	  cell	  lines	  are	  of	  the	  original	  tumour.	  It	  is	  inevitable	  that	  with	  every	  cell	  passage	  there	  is	  clonal	  selection	   of	   rapidly	   dividing	   cells.	   Therefore,	   subsequent	   cell	   populations	  will	  carry	  only	  a	  fraction	  of	  the	  genetic	  heterogeneity	  that	  was	  originally	  present	  in	  the	  primary	  cell	  culture.	  These	  genetic	  differences	  in	  cell	  lines	  present	  a	  limit	  as	  to	  how	  useful	  these	  cultures	  are	  in	  research	  and	  consequently	  in	  clinical	  studies.	  In	  the	  case	  of	  human	  gliomas,	  there	  are	  currently	  more	  than	  30	  known	  cell	  lines.	  	  
	   38	  
	  Given	   the	   above	   limitations	   of	   the	   cell	   lines	   there	   is	   a	   growing	   trend	   towards	  using	   primary	   glioma	   cell	   cultures.	   In	   addition,	   primary	   glioma	   cultures	   are	  more	   representative	   of	   the	   considerable	   genetic	   heterogeneity	   of	   tumours	  between	   patients	   and	   therefore	   more	   suitable	   for	   chemosensitivity	   studies.	  Currently	   primary	   glioma	   cultures	   are	   routinely	   produced	   in	   the	   laboratory	  albeit	  with	  varying	  degrees	  of	  success	  [117].	  	  Primary	   culture	   is	   an	   established	   and	   successful	   method	   of	   drug	   testing	   in	  several	   disciplines;	   however,	   there	   are	   a	   few	   limitations	   when	   used	   to	   test	  chemosensitivity	   in	   glial	   tumours.	   This	   is	   mainly	   due	   to	   the	   fact	   that	   the	  laboratory	   conditions	  do	  not	   resemble	   the	   in	   vivo	   environment	   of	   the	   tumour	  bed	  [118,	  119].	  For	  example,	  tumour	  cells	  in	  flasks	  grow	  as	  a	  monolayer,	  which	  represents	  partly	  the	  natural	  form	  of	  cell	  growth.	  In	  addition,	  this	  monolayer	  of	  cells	  lacks	  the	  supportive	  network	  of	  other	  cells	  such	  as	  microglia	  and	  neurons.	  Furthermore,	  primary	  cultures	  growing	  in	  flasks	  are	  feeding	  on	  growth	  medium	  rather	  than	  on	  nutrients	  from	  the	  blood	  supply.	  	  An	   important	   consideration	   when	   using	   primary	   cultures	   is	   the	   fact	   that	   the	  brain	  is	  an	  immunologically	  privileged	  organ.	  The	  cells,	  which	  provide	  this	  role,	  are	  not	  present	   in	   this	   type	  of	   in	   vitro	   environment.	  As	   such	  primary	   cultures	  are	  deprived	  from	  any	  immunological	  interaction.	  	  	  Another	   limitation	   is	   the	   type	   of	   drugs	   that	   can	   be	   used	   for	   chemosensitivity	  testing.	   These	   drugs	   need	   to	   act	   directly	   on	   the	   primary	   tumour	   cells	   (i.e.	  cytostatic	  or	  cytotoxic).	  Drugs	  that	  act	  on	  a	  different	  target,	  such	  as	  on	  the	  blood	  supply	  and	  vasculature,	  would	  not	  be	  effective	  when	  tested	   in	  vitro.	  The	  same	  applies	  for	  drugs	  that	  require	  activation	  in	  a	  remote	  site	  such	  as	  the	  kidney	  or	  liver	  [120].	  	  As	  mentioned	  previously,	   the	   cells	   in	   the	   culture	  have	   to	   be	   representative	   of	  the	   original	   tumour.	   However,	   as	   the	   most	   proliferative	   tumour	   cells	   will	   be	  forming	  the	  confluent	  monolayer,	  malignant	  quiescent	  cells	  will	  not	  be	  included	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in	  the	  chemosensitivity	  testing.	  Performing	  the	  chemosensitivity	  testing	  directly	  onto	   the	   fresh	   tissue	   specimen	   could	   potentially	   alleviate	   such	  misrepresentation	  [121].	  However,	  the	  specimen	  that	  arrives	  in	  the	  laboratory	  also	   contains	   other	   cells	   types	   as	   well	   as	   debris.	   These	   include	   cells	   such	   as	  erythrocytes,	   leucocytes,	   epithelial,	   endothelial	   and	   normal	   neuronal	   cells,	   as	  well	  as	  other	   tissue	  and	  bone	  dust	   from	  the	  craniotomy.	  Given	  this	  mixture	  of	  cells	   and	   material,	   it	   would	   be	   very	   hard	   to	   correlate	   the	   results	   of	   the	  chemosensitivity	  assay	  with	  the	  cell	  type	  responding	  to	  the	  drug	  tested.	  	  As	   mentioned	   above,	   chemosensitivity	   testing	   could	   be	   a	   useful	   method	   in	  predicting	  in	  vivo	  response	  to	  cancer	  treatment.	  For	  example,	  ovarian,	  colon	  and	  breast	   cancer	   patients	   treated	  with	   drugs	   that	   have	   shown	   in	   vitro	   effectivity	  showed	  an	  improved	  overall	  survival	  [122].	  	  Conversely,	  when	  leukaemia,	  colon	  and	  gastric	  cancer	  patients	  were	  treated	  with	  drugs	  that	  were	  resistant	  in	  vitro,	  their	  overall	  survival	  was	  poorer	  [123].	  Moreover,	  Pieters	  and	  coworkers	  have	  shown	  that	   in	  vitro	   chemosensitivity	   testing	   is	  more	   important	   than	  any	  other	  laboratory	  or	  clinical	  variable	  in	  predicting	  what	  form	  of	  chemotherapy	  is	  to	  be	  used	  [124].	  	  Kronblith	   and	   Szypko	   (1978)	   were	   amongst	   the	   first	   to	   perform	  chemosensitivity	   testing	   in	   malignant	   gliomas.	   More	   specifically,	   using	   the	   in	  
vitro	  Giemsa	  staining,	  they	  tested	  24	  malignant	  glioma	  cultures	  with	  Carmustine	  (BCNU)	  and	  found	  that	  18	  out	  of	  24	  cultures	  were	  sensitive	  at	  33µg/ml	  [125].	  Other	  studies	  went	  one	  step	  further	  and	  correlated	  the	  in	  vitro	  chemosensitivity	  results	  of	  glioma	  cultures	  with	  the	  survival	  benefits	  of	  their	  donor	  patients.	  For	  example,	   Bogdahn	   treated	   17	   cultures	   with	   Carmustine	   using	   the	   14C	   leucine	  and	   3H	   uridine	   uptake	   method	   [126].	   He	   reported	   that	   7	   out	   of	   17	   sensitive	  patients	  had	  a	  recurrence	  free	  survival	  (RFS)	  of	  15	  months.	  On	  the	  other	  hand,	  the	   remaining	   10	   patients	   who	   were	   resistant	   to	   Carmustine	   had	   a	   RFS	   of	   6	  months	  [126].	  In	  another	  study,	  Rosenblum	  treated	  10	  malignant	  gliomas	  with	  BCNU.	   Using	   the	   colony-­‐forming	   assay	   he	   reported	   that	   4	   out	   of	   10	   primary	  cultures	   were	   sensitive	   in	   vitro.	   Of	   those	   four	   patients,	   3	   patients	   responded	  with	  a	  prolonged	  RFS	  [127].	  A	  few	  years	  later,	  Darling	  and	  coworkers	  tested	  99	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glioma	  cultures	  with	  Procarbazine,	  Lomustine	  (CCNU)	  and	  Vincristine	  using	  an	  amino	   acid	   precursors	   uptake	   assay	   [128].	   Only	   thirty-­‐three	   out	   of	   those	   99	  tumour	  patients	  had	  clinical	  data	  available.	  They	  reported	   that	  when	  patients,	  whose	  tumours	  were	  sensitive	  in-­‐vitro	  to	  CCNU,	  were	  treated	  with	  the	  drug	  had	  a	   longer	   overall	   survival.	   Furthermore,	   no	   correlation	  was	   observed	   between	  survival	  time	  and	  the	  other	  two	  drugs	  used.	  	  	  As	   seen	   above,	   a	   number	   of	   different	   assays	   have	   been	   used	   to	   measure	  chemosensitivity.	   A	   brief	   overview	   of	   the	   most	   commonly	   used	   assays	   is	  provided	  in	  the	  section	  below.	  	  
2.1.1 Micro	  Cytotoxicity	  Assay	  	  	  This	   assay	   was	   one	   of	   the	   earliest	   to	   be	   used	   in	   chemosensitivity	   testing	   in	  malignant	   gliomas.	   It	   measures	   the	   ability	   of	   the	   malignant	   cells	   to	   remain	  attached	   to	   the	  culture	  petri	  dish	  after	   they	  have	  been	  exposed	   to	   the	  various	  drug	   concentrations	   tested.	   Briefly,	   the	   malignant	   cells	   are	   plated	   in	   a	   micro	  titre	  plate	  and	  are	  exposed	  to	  the	  various	  drug	  concentrations	  for	  a	  fixed	  period	  of	  time.	  Following	  this,	  the	  drug	  is	  washed	  out	  and	  incubation	  for	  a	  further	  fixed	  period	  of	   time	  with	  a	  drug	   free	  medium	  takes	  place.	  The	  plate	   is	   then	  stained	  with	   4%	   Giemsa	   stain	   and	   the	   number	   of	   the	   attached	   cells	   to	   each	   well	   is	  counted.	   This	  measurement	   is	   used	   to	   generate	   a	   drug	   response	   curve	   [129].	  The	  major	  drawback	  of	   this	  assay	   is	   that	   it	  does	  not	  distinguish	  between	  alive	  and	  dead	  cells	  and	  as	  such	  more	  often	   than	  not,	   sensitivity	   is	  underestimated.	  Furthermore,	   a	   wide	   variation	   between	   wells	   treated	   with	   the	   same	   drug	  concentration	   is	  observed	  as	  only	  a	  small	  number	  of	  cells	  are	  plated	   into	  each	  well.	  	  
2.1.2 Colony	  Forming	  Assay	  	  Salmon	  and	  Hamburger	   first	  used	   this	   assay	  when	  attempting	   to	  measure	   the	  growth	  of	  a	  stem	  cell	  population	  [130].	  A	  single	  cell	  suspension	  of	   the	  tumour	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tissue	   sample	  was	   plated	   on	   a	   soft	   agar	   or	   as	   a	  monolayer	   on	   a	   culture	   flask.	  This	  was	   left	   to	   incubate	   for	  2-­‐4	  weeks.	  During	   that	   period,	   some	   cells	  would	  have	  formed	  a	  colony	  of	  minimum	  50	  cells,	  having	  gone	  through	  at	   least	  6	  cell	  cycles.	  This	  would	   imply	  a	  substantial	  proliferative	  activity.	  The	  colonies	  were	  treated	   with	   the	   test	   drug	   concentrations	   and	   the	   number	   and	   size	   of	   the	  treated	  colonies	  was	  compared	  with	  the	  untreated	  ones.	  An	  arbitrary	  figure	  of	  70%	  inhibition	  of	  colony	  formation	  was	  taken	  as	  the	  cut-­‐off	  to	  mark	  sensitivity.	  The	   drawbacks	   of	   this	   assay	   are	   as	   follows:	   Firstly	   the	   technical	   difficulty	   in	  obtaining	  the	  single	  cell	  suspension	  [131].	  Secondly,	  the	  possibility	  that	  some	  of	  the	   colonies	   are	  derived	   from	  pre-­‐existing	   groups	  of	   cells.	   And	   thirdly,	   it	  may	  not	  measure	  quiescent	  cells,	  which	  may	  later	  enter	  the	  cell	  cycle.	  On	  the	  other	  hand,	   this	   is	  one	  of	   the	   few	  assays	  available	  able	   to	  measure	   in	  vitro	   radiation	  sensitivity.	  	  	  
2.1.3 Radiolabelled	  Assays	  	  	  These	   assays	   measure	   the	   inhibition	   of	   incorporation	   of	   radiolabelled	  precursors	  during	  the	  synthesis	  of	  DNA,	  RNA	  and	  proteins.	  Such	  precursors	  can	  be	   thymidine,	   uridine	   and	   amino	   acids.	   The	   measurement	   of	   the	   amount	   of	  radioactivity	   incorporated	   into	   a	   substrate	   as	   a	   function	   of	   time	   and	   enzyme	  concentration	  allows	  enzyme	  activity	  to	  be	  quantified	  [132].	  	  During	   these	   assays,	   cells	   are	   exposed	   to	   various	   drug	   concentrations	   and	  allowed	   to	   recover	   for	   a	   fixed	   period	   of	   time.	   They	   are	   then	   exposed	   to	   the	  radioactive	  precursor	  and	  the	  resulting	  uptake	  of	  radioactivity	  is	  measured.	  	  	  Overall,	  these	  assays	  are	  inexpensive,	  sensitive,	  accurate,	  relatively	  easy	  to	  use	  and	   provide	   results	   within	   a	   short	   timeframe.	   However,	   there	   are	   a	   few	  drawbacks,	  which	   can	  potentially	  provide	   inaccurate	   chemosensitivity	   results.	  Firstly,	   inhibition	   of	   synthesis	   or	   replication	   can	   be	   a	   temporary	   effect	   [133].	  Secondly,	   cells	   that	   receive	   a	   potential	   lethal	   drug	   concentration	   can	   still	  undergo	  several	  cell	  cycles	  prior	  to	  their	  death.	  And	  thirdly,	  these	  assays	  do	  not	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account	  for	  quiescent	  cells	  as	  they	  only	  measure	  cells	  in	  the	  S	  or	  G1	  phase	  of	  the	  cell	  cycle.	  	  	  
2.1.4 Multicellular	  Tumour	  Spheroid	  Assays	  	  	  These	  assays	  use	  tumour	  spheroids	  grown	  in	  soft	  agar	  or	  serum	  free	  media.	  The	  spheroids	   can	   be	   picked	   up	   individually	   and	   analysed	   histologically	   after	  fixation	  and	  staining.	  These	  assays	  are	  useful	  as	  tumour	  models	  in	  studying	  cell-­‐to-­‐cell	  interactions	  and	  drug	  penetration	  [134].	  	  
2.1.5 Colorimetric	  assays	  	  This	   group	   of	   assays	   have	   been	   widely	   used	   for	   chemosensitivity	   testing	   in	  malignant	  gliomas	   [135].	  Amongst	   them,	   the	  most	  popular	  one	   is	   the	  MTT	  (3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐2,	   5-­‐diphenyl-­‐2H-­‐tetrazolium	   bromide)	   assay	   [117,	  136].	   In	   this	   assay,	   the	   MTT	   is	   converted	   by	   mitochondrial	   enzymes	   to	   a	  coloured	  insoluble	  formazan	  product.	  This	  product	  is	  then	  solubilised	  in	  alcohol	  or	   a	   detergent	   and	   the	   absorption	   is	  measured.	   Recently	   this	   assay	   has	   been	  simplified	  by	  avoiding	  the	  second	  step	  of	  solubilisation	  when	  a	  one	  step	  reagent	  is	   used	   [137].	  The	  main	  drawback	  of	   this	   assay	   is	   that	   the	  number	  of	   tumour	  cells	  limits	  its	  sensitivity.	  	  	  
2.1.6 Luminescent	  assays	  	  Bioluminescence-­‐based	  assays	  are	  widely	  used	  in	  several	  biological	  and	  medical	  disciplines	   and	   are	   based	   on	   the	   measurement	   of	   ATP	   in	   living	   cells.	  Bioluminescence	  is	  detected	  by	  the	  interaction	  of	  a	  substrate	  luciferin	  and	  ATP	  together	   with	   an	   enzyme	   called	   luciferase,	   which	   produces	   light.	   More	  specifically,	   luciferase	   catalyses	   the	   mono-­‐oxygenation	   of	   the	   compound	  luciferin	   to	   oxyluciferin	   in	   an	   ATP	   dependent	   fashion.	   The	   oxyluciferin	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produced,	   is	   in	   an	   excited	   state	   that	   decays	   emitting	   a	   photon	   to	   reach	   its	  ground	  state.	  	  	  The	   assay	  measures	   the	   emitted	   photon	   quantitatively	   in	   a	   luminometer.	   The	  measured	   luminescence	   is	  directly	  proportional	   to	   the	  quantity	  of	  ATP	  and	  as	  such	   to	   the	   number	   of	   cells.	   ATP	   concentration	   relates	   to	   cell	   number	   and	   it	  degrades	   rapidly	   after	   cell	   death.	  Measuring	   ATP	  would	   therefore	   provide	   an	  estimate	  of	  the	  biomass	  [138].	  	  	  Chemosensitivity	  assays	  that	  are	  using	  bioluminescence	  have	  been	  reported	  as	  being	  more	  sensitive	  than	  other	  methods.	  In	  addition,	  they	  correlate	  better	  with	  patient	  response	  to	  treatment	  in	  breast	  and	  ovarian	  cancers	  when	  compared	  to	  other	   assays	   [139-­‐141].	   Petty	   and	   coworkers	   have	   demonstrated	   that	   the	  bioluminescence-­‐based	  ATP	  assay	  is	  able	  to	  down	  to	  1500	  cells	  per	  well	  where	  the	  MTT	  assay	   could	  not	   detect	   fewer	   than	  25.000	   cells	   per	  well	   [142].	  Work	  performed	   previously	   in	   our	   laboratory	   has	   demonstrated	   that	   this	   assay	   can	  reliably	   assess	   chemosensitivity	   in	   gliomas	   even	   with	   fewer	   than	   2000	   cells	  available	  per	  well	  [143].	  	  	  There	   are	   several	   points	   that	   have	   to	   be	   considered	   when	   interpreting	   the	  results	  of	  an	  ATP	  assay,	  as	  several	  factors	  are	  known	  to	  affect	  ATP	  levels	  in	  cells.	  These	   include	   cellular	   factors	   such	   as	   age,	   density	   and	   growth	   of	   the	   cell	  population	  as	  well	  as	   the	  stage	  of	   cell	  division	  and	  any	  changes	   to	   the	  growth	  rate.	  Moreover,	  environmental	  factors	  such	  as	  nutrient	  availability,	  any	  changes	  in	  oxygen	  tension,	  temperature	  and	  pressure,	  the	  presence	  of	  heavy	  metals	  and	  radiation,	   as	   well	   as	   mutagens	   could	   also	   affect	   the	   results	   of	   the	   ATP	   assay	  [142,	  143].	  	  	  Finally,	  laboratory	  equipment	  used	  for	  the	  assay	  could	  also	  influence	  the	  results.	  For	  instance,	  the	  type	  of	  microtiter	  plate	  must	  be	  carefully	  considered	  as	  cross-­‐talk	   (spill-­‐over	   of	   light)	   between	   neighbouring	   wells	   has	   to	   be	   kept	   to	   the	  minimum.	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2.2 Aims	  	  This	  study	  uses	  the	  ATP	  luminescence-­‐based	  assay	  to	  measure	  chemosensitivity	  of	  primary	  glioma	  cultures.	  	  	  tumours	  were	   used.	   These	  were	   Temozolomide	   (Temozolomide),	   Carmustine	  (BCNU)	  and	  Cisplatin	  (Cis).	  	  The	  aim	  of	  this	  study	  was	  to	   investigate	  whether	  these	  drugs	  had	  a	  significant	  effect	  on	  primary	  glioma	  cultures.	  Furthermore,	   in	  addition	   to	   the	   therapeutic	  dose	   of	   each	  drug,	   a	   ten-­‐fold	   increase	   and	  decrease	   of	   this	   concentration	  was	  tested	   for	   kill	   efficacy.	   The	   obtained	   results	  were	   then	   analysed	   for	   statistical	  difference	  and	  also	  used	  for	  the	  calculation	  of	  the	  lethal	  dose	  50	  (LD50)	  of	  each	  drug.	  An	  additional	  aim	  of	  this	  work	  was	  to	  determine	  whether	  age	  or	  gender	  play	  a	  significant	  role	  in	  chemosensitivity	  testing.	  	  Finally,	  chemosensitivity	  testing	  was	  evaluated	  as	  a	  potential	  tool,	  which	  could	  be	   used	   in	   clinical	   practice.	   This	   was	   done	   by	   comparing	   the	   obtained	  chemosensitivity	   results	  with	   the	   available	   survival	   data	   from	  donor	   patients.	  This	  way,	  comparisons	  could	  be	  made	  between	  in	  vitro	  and	  in	  vivo	  data	  allowing	  evaluation	  of	  its	  potential	  contribution	  to	  clinical	  practice.	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2.3 Materials	  and	  methods	  	  	  
2.3.1 Ethical	  approval	  	  A	   protocol	   for	   obtaining	   tumour	   tissue	   from	   patients,	   along	  with	   background	  information	  for	  the	  project	  to	  be	  undertaken	  and	  consent	  forms	  for	  patients	  and	  next	  of	  kin	  (appendix	  1)	  were	  drawn	  up	  and	  ethical	  approval	  was	  received	  from	  the	   Cambridgeshire	   3	   Research	   Ethics	   Committee	   at	   the	   National	   Research	  Ethics	  Service.	  Consent	  was	  obtained	  on	  most	  occasions	  by	  the	  lead	  researcher	  (E	   Lekka),	   but	   also	   by	   other	   trained	   Neurosurgeons	   and	   clinical	   nurse	  practitioners.	  The	  patients	  were	  informed	  about	  using	  tumour	  tissue	  surplus	  to	  diagnostic	   means	   for	   purposes	   of	   laboratory	   culture	   and	   drug	   testing.	   If	   the	  patient	  was	  unable	  to	  consent,	  a	  separate	  form	  was	  used	  to	  obtain	  assent	  from	  the	  next	  of	  kin.	  If	  there	  was	  no	  surplus	  tumour	  tissue,	  then	  the	  biopsied	  tissue	  was	   used	   solely	   for	   diagnostic	   purposes.	   It	   was	   stipulated	   that	   no	   additional	  surgical	  procedure	  would	  be	  performed	  solely	  for	  purposes	  of	  obtaining	  tissue	  for	   research.	   The	   decision	   about	   how	   much	   surplus	   tissue	   was	   present	   was	  made	   by	   a	   consultant	   Neuropathologist,	   who	   also	   performed	   the	   tumour	  diagnosis.	   The	   patients	   /	   relatives	   were	   also	   given	   an	   information	   leaflet	  explaining	  details	   of	   the	   research	  and	   its	  non-­‐interventional	  nature	   (appendix	  1).	  As	  all	   the	  primary	  culture	  work	  was	  done	   in	  a	  hospital	   setting,	  disposal	  of	  waste	  material	  /	  tissue	  was	  done	  in	  a	  standard	  fashion	  as	  clinical	  waste	  and	  was	  incinerated.	  Ethical	  permission	  was	  also	  obtained	  form	  the	  ethics	  committee	  of	  the	   University	   of	   Central	   Lancashire	   to	   perform	   sensitivity	   studies	   on	   the	  cultured	  primary	  cells	  and	  their	  subsequent	  disposal.	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2.3.2 Chemosensitivity	  	  Primary	  tissue	  cultures	  were	  successfully	  grown	  from	  12	  patients.	  These	  were	  treated	   with	   Temozolomide,	   Carmustine	   and	   Cisplatin	   at	   three	   different	  concentrations	   (therapeutic	   concentration,	   10-­‐fold	   higher	   and	   10-­‐fold	   lower).	  The	  therapeutic	  concentrations	  used	  have	  been	  reported	  in	  the	  literature	  [144,	  145].	  Detergent	   is	  highly	  cytotoxic.	  As	  a	  result	  minimal	   levels	  of	   luminescence	  are	   detected.	   Cells	   treated	   with	   detergent	   were	   used	   as	   positive	   controls.	  Negative	   controls	   were	   cells	   left	   untreated.	   Controls	   were	   used	   in	   order	   to	  establish	   the	   baseline	   and	   maximum	   values	   for	   the	   experiments.	   The	  measurements	   were	   obtained	   using	   the	   CellTiter-­‐GloTM	   Luminescent	   Cell	  Viability	   Assay	   made	   by	   Promega	   according	   to	   manufacturer’s	  recommendations.	   The	   amount	   of	   luminescence	   generated	   is	   directly	  proportional	  to	  the	  ATP	  content,	  which	  reveals	  metabolically	  active	  cells.	  	  	  
2.3.3 Primary	  glial	  culture	  	  	  Fresh	   tumour	   tissue	  was	   obtained	   in	   the	   operating	   theatre	   from	  52	   patients.	  The	  tissue	  was	  collected	  either	  by	  image-­‐guided	  biopsy	  or	  by	  debulking	  surgery.	  Once	  collected,	  the	  tissue	  was	  immediately	  put	  into	  “Collection	  medium”	  (10	  ml	  Penicillin	   and	   Streptomycin	   solution,	   5	   ml	   Amphotericin	   B	   solution	   added	   to	  500	   ml	   of	   DMEM)	   and	   was	   brought	   to	   the	   laboratory	   where	   it	   was	   handled	  under	   a	   class	   III	   ventilation	   hood.	   Forty-­‐nine	   specimens	   were	   processed	  immediately,	   while	   the	   remaining	   three	   were	   stored	   at	   4°C	   for	   less	   than	   24	  hours.	  A	  consultant	  Neuropathologist	  handled	  the	  specimen	  with	  flamed	  forceps	  and	   sterile	   scalpel.	   After	   transferring	   the	   tissue	   to	   a	   petri	   dish,	   some	   fresh	  collection	  medium	  was	  added	  and	  obvious	  non-­‐tumorous	  or	  necrotic	  material	  was	   removed.	   Initially	   sufficient	   tumour	   tissue	   was	   removed	   for	   diagnostic	  purposes.	  All	  specimens	  had	  tissue	  confirmation	  of	  malignant	  glioma	  by	  smear	  preparation	   prior	   to	   entering	   our	   study.	   The	   tumour	   fragments	   were	   then	  transferred	   to	   a	   fresh	   petri	   dish	  with	   fresh	   Collection	  Medium	   and	   diced	   into	  small	  pieces	  using	  sterile	  crossed	  scalpels.	  These	  were	  then	  transferred	  to	  a	  15	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ml	  sterile	  centrifuge	  tube	  containing	  10-­‐15	  ml	  Collection	  Medium.	  Larger	  pieces	  were	   allowed	   to	   settle	   and	   the	   supernatant	   was	   discarded.	   This	   process	   was	  repeated	  twice	  in	  order	  to	  remove	  necrotic,	  non-­‐viable	  material.	  	  The	   tumour	   fragments	   were	   then	   resuspended	   in	   10	   ml	   Complete	   Growth	  Medium	  in	  25	  cm3	  cell	  culture	  flask	  and	  1	  ml	  of	  collagenase	  solution	  was	  added.	  The	   flask	   was	   placed	   in	   the	   incubator	   for	   4	   hours	   at	   37oC.	   The	   flask	   was	  mechanically	   agitated	   every	   15	  minutes	   until	   the	   tissue	  was	   reduced	   to	   small	  cell	   aggregates.	   The	  monitoring	   of	   the	   disaggregation	  was	   done	  with	   periodic	  inspection	  under	  an	  inverted	  microscope.	  	  The	   preparation	   was	   then	   pipetted	   several	   times	   to	   promote	   further	  disaggregation,	   then	   centrifuged	   at	   1000	   rpm	   (250g)	   for	   5	   minutes	   and	   the	  enzyme	  solution	  was	  discarded.	  The	   cells	   were	   finally	   washed	   in	   10	   ml	   Complete	   Growth	   Medium,	   then	  centrifuged	  again	  at	  1000	  rpm	  (250g)	  for	  5	  minutes,	  discarding	  the	  supernatant.	  The	   cells	   were	   then	   resuspended	   in	   10	   ml	   of	   Complete	   Growth	   Medium	   and	  finally	  transferred	  to	  a	  25cm3	  cell	  culture	  flask	  leaving	  them	  to	  incubate	  at	  37oC.	  After	   72	   hours	   of	   incubation,	   the	   medium	   and	   non-­‐adherent	   material	   was	  discarded.	   The	   culture	   was	   refed	   with	   fresh	   Complete	   Growth	   Medium	   and	  returned	  to	  the	  incubator.	  The	   culture	   was	   examined	   twice	   a	   week	   under	   the	   inverted	   microscope	   and	  refed	   as	   required.	   Once	   confluence	  was	   achieved,	   the	   culture	  was	   trypsinised	  and	   used	   for	   Chemosensitivity	   testing	   or	   divided	   into	   two	   flasks	   to	   promote	  further	  growth.	  The	  Growth	  medium	  used	  was	  Ham’s	  F10	  nutrient	  mixture	  (Sigma	  Aldrich,	  cat.	  no.	   N2147,	   LOT	   no:	   018K2343,	   RNBB0737	   and	   RNBB3121)	   and	   DMEM	  (Dulbecco’s	  Modified	  Eagle’s	  Medium)	  in	  a	  1:1	  ratio,	  with	  10%	  foetal	  calf	  serum,	  and	  0.5%	  penicillin	  /	  streptomycin	  and	  1%	  L-­‐glutamine	  (when	  not	  premixed	  in	  the	  medium),	   sterile	   filtered.	  The	   full	   composition	  of	  Ham’s	  F10	  and	  DMEM	   is	  given	  in	  appendix	  2.	  The	  growing	  cultures	  were	  regularly	  inspected,	  and	  media	  changed	   when	   the	   colour	   became	   orange	   to	   yellow,	   and	   trypsinised	   when	  confluence	   was	   achieved.	   Up	   to	   half	   the	   medium	   from	   culture	   flasks	   from	  cultures	   that	   grew	   well	   was	   filtered	   (0.2	   μm)	   and	   stored	   as	   conditioned	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medium.	   This	   conditioned	   medium	   was	   used	   to	   augment	   growth	   of	   slower	  growing	  cultures.	  	  
2.3.4 Passaging	  cell	  cultures	  	  Spent	  medium	  was	  removed	  from	  the	  culture	   flask	  by	  aspiration	  and	  the	   flask	  was	  then	  washed	  twice	  with	  10ml	  of	  Hank’s	  balanced	  salt	  solution	  (HBSS).	  One	  ml	  of	  0.25%	  Trypsin/EDTA	  solution	  (stored	  as	  5	  ml	  aliquots	  at	  -­‐20°C)	  was	  then	  pipetted	  into	  the	  flask.	  The	  flask	  was	  left	  to	  incubate	  for	  2-­‐10	  minutes	  until	  the	  cells	   began	   to	   detach.	   This	   process	   was	   confirmed	   by	   observing	   at	   intervals	  under	  an	  inverted	  microscope.	  Two	  milliliters	  of	  Complete	  Growth	  Medium	  was	  then	  added	  to	  the	  flask	  to	  inactivate	  the	  trypsin	  and	  the	  cells	  were	  pipetted	  to	  resuspend	   and	   to	   break	   down	   any	   large	   cell	   aggregates.	   The	   trypsinised	   cells	  were	   counted	   in	   a	   cell	   coulter	   counter,	   and	   further	   dilutions	   performed	   if	  necessary.	  Depending	  on	  the	  cell	  density,	  the	  total	  volume	  of	  the	  medium	  in	  the	  flask	  was	  then	  split	  into	  two	  or	  three	  new	  flasks	  adding	  fresh	  growth	  medium.	  These	  were	  then	  placed	  in	  a	  CO2	  incubator	  at	  37°C	  to	  continue	  cell	  growth.	  The	  volume	  of	  medium	  required	  to	  be	  added	  was	  calculated	  based	  on	  the	  number	  of	  tests	  to	  be	  performed,	  and	  the	  number	  of	  cells	  per	  ml	  of	  fluid	  required.	  For	  the	  ATP	  assay,	  96-­‐well	  white	  microtiter	  plates	  with	  micro	  clear	  bottoms	  (Nunc	  or	  Grenier)	  were	  used.	  	  
2.3.5 Cell	  counting	  method	  using	  the	  coulter	  counter	  	  After	   switching	   on	   the	   Coulter	   Particle	   Counter	   (Beckman	   Coulter	   Z1),	   the	  aperture	  tube	  was	  flushed	  using	  10	  ml	  of	  ISOTON	  II	  diluent.	  The	  parameters	  on	  the	  SETUP	  screen	  were	  set	  as:	  100µm	  C,	  Kd=	  58	  and	  Select	  units	  <µm>	  Set	  lower	  size:	  10	  µm.	  On	  the	  OUTPUT	  screen	  the	  result	  type	  was	  set	  as	  <concentration>	  and	   the	   dilution	   factor	   as	   1E+02.	   The	   first	   count	   was	   used	   to	   calculate	   the	  background	   particle	   count.	   The	   fluid	   used	   was	   ISOTON	   II	   diluent	   only.	   The	  result	   displayed	   was	   the	   number	   of	   particles	   above	   10	   µm	   in	   size	   per	   ml	   of	  diluent.	   A	   hundred	   microliters	   of	   cell	   suspension	   was	   then	   pipetted	   into	   an	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Accuvette	   II	   vial	   and	   10	  ml	   of	   ISOTON	   II	   diluent	   was	   added.	   Each	   count	  was	  repeated	   three	   times	  and	   the	  average	  was	   calculated.	  After	   completing	  all	   cell	  counts	  the	  diluent	  solutions	  were	  replaced	  with	  distilled	  water	  and	  the	  coulter	  counter	  switched	  off.	  
2.3.6 Making	  up	  media	  	  All	  media,	  antibiotic	  solutions	  and	  cell	  culture	  supplements	  were	  commercially	  obtained	  from	  Sigma-­‐Aldrich.	  	  
Biopsy	  Collection	  Medium	  	  Ten	  milliliters	  of	  Penicillin	  or	  Streptomycin	  solution	  and	  5	  ml	  of	  Amphotericin	  B	  solution	  were	  added	  to	  500	  ml	  of	  a	  1:1	  mixture	  of	  DMEM	  and	  Ham’s	  F-­‐12.	  This	  was	  aliquoted	  in	  to	  15	  ml	  in	  30	  ml	  Universal	  containers	  (sterile	  CSF	  bottles)	  and	  stored	  at	  4°C.	  	  
Complete	  Growth	  Medium	  	  Twelve	   and	   a	   half	   milliliters	   of	   L-­‐Glutamine	   solution,	   5	   ml	   Penicillin	   or	  Streptomycin	  solution	  and	  55	  ml	  Fetal	  Calf	  Serum	  were	  added	  to	  1000	  ml	  of	  a	  1:1	  mixture	  of	  DMEM	  and	  Ham’s	  F-­‐12.	  Growth	  media	  for	  every	  primary	  culture	  was	  kept	  separate	  in	  labeled	  bottles	  and	  stored	  at	  4°C.	  	  
Collagenase	  Solution	  	  Five	  hundred	  milligrams	  of	  Collagenase	  Type	  1A	  was	  dissolved	   in	  31.25	  ml	  of	  balanced	  salt	  solution	  and	  aliquoted	  into	  1	  ml	  lots.	  These	  were	  stored	  at	  –20°C.	  The	  concentration	  of	  collagenase	  achieved	  was	  2000	  digestion	  units	  per	  ml.	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2.3.7 Defining	  passages	  	  A	   passage	   was	   defined	   as	   every	   trypsinisation	   performed	   in	   order	   to	   detach	  adherent	  cells.	  The	  first	  trypsinisation	  was	  performed	  after	  confluence	  has	  been	  achieved;	   subsequent	   to	   disaggregation	   and	   plating	   of	   the	   tumour	   tissue	  was	  defined	   as	   passage	   0.	   This	   was	   always	   performed	   at	   confluence.	   Every	  subsequent	   trypsinisation	   was	   given	   an	   increasing	   number	   (i.e.	   passage	   1,	  passage	   2,	   passage	   3).	   Occasionally	   in	   order	   to	   increase	   cell	   density,	  trypsinisation	   was	   performed	   at	   sub	   confluence,	   by	   putting	   cells	   in	   smaller	  flasks,	   or	   concentrating	   cells	   from	   three	   flasks	   into	   one.	   The	   proliferative	  capacity	  of	  the	  cells	  was	  not	  reflected	  into	  the	  time	  to	  passage	  in	  these	  cases.	  	  	  
2.3.8 Preparation	  of	  chemotherapeutic	  drugs	  	  
Temozolomide	  	  Temozolomide	   (100	   mg)	   was	   dissolved	   in	   200ml	   growth	   medium,	   aliquoted	  into	  200	  aliquots	  of	  1ml	  and	  stored	  at	  –20°C.	  To	  make	  Stock	  1	  solution	  900μl	  of	  growth	  medium	  was	  added	  to	  100μl	  storage	  solution	  (dilution	  500μg	   in	  10ml,	  or	  50μg	  in	  1ml).	  To	  make	  Stock	  2	  solution	  900μl	  of	  growth	  medium	  was	  added	  to	  100μl	  of	  Stock	  1	  solution	  (Dilution	  50μg	  in	  10ml,	  or	  5μg	  in	  1ml).	  The	  volumes	  and	   final	   concentrations	   in	   a	   96	  well	   plate	  were	   as	   in	   the	   table	   below	   (Table	  2-­‐1):	  	  
Table	  2-­‐1	  Temozolomide	  final	  dilutions	  and	  volumes	  required	  for	  carrying	  out	  the	  ATP	  assay.	  	   Stock	  2	   Stock	  1	   Storage	  sol	  Final	  Dilutions	  (µg	  /	  ml)	   2	   20	   200	  Vol	  of	  Cell	  Suspension	  (µl)	   200	   200	   200	  Vol	  of	  Growth	  Medium	  (µl)	   120	   120	   120	  Vol	  of	  stock	  solution	  (µl)	   80	   80	   80	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BCNU	  (Carmustine)	  	  Carmustine	  (100	  mg)	  was	  dissolved	  in	  40	  ml	  of	  growth	  medium	  and	  aliquoted	  into	  200	  aliquots	  of	  1	  ml.	  The	  aliquots	  of	  200μl	  with	  dilution	  of	  2500μg	  in	  1ml	  were	  stored	  at	  –20°C.	  To	  make	  Stock	  1	  solution	  1800μl	  of	  growth	  medium	  was	  added	  to	  the	  one	  aliquot	  of	  the	  above	  storage	  solution	  (dilution	  250μg	  in	  1ml).	  To	  make	  Stock	  2	  solution	  900μl	  of	  growth	  medium	  was	  added	  to	  100μl	  of	  Stock	  1	   solution	   (dilution	   25μg	   in	   1ml).	   To	  make	   Stock	   solution	   3,	   900µl	   of	   growth	  medium	  was	  added	  to	  100µl	  of	  Stock	  solution	  2	  (dilution	  2.5µg	  in	  1ml).	  The	   volumes	   and	   final	   concentrations	   in	   a	   96	  well	   plate	  were	   as	   in	   the	   table	  below	  (Table	  2-­‐2):	  	  
Table	  2-­‐2	  Carmustine	  final	  dilutions	  and	  volumes	  required	  for	  carrying	  out	  the	  ATP	  assay.	  	   Stock	  3	   Stock	  2	   Stock	  1	  Final	  Dilutions	  (µg	  /	  ml)	   1	   10	   100	  Vol	  of	  Cell	  Suspension	  (µl)	   200	   200	   200	  Vol	  of	  Growth	  Medium	  (µl)	   120	   120	   120	  Vol	  of	  stock	  solution	  (µl)	   80	   80	   80	  	  
Cisplatin	  	  Cisplatin	   (25	  mg)	  was	   dissolved	   in	   25ml	   growth	  medium,	   aliquoted	   into	   125	  aliquots	  of	  200μl	  and	  stored	  at	  –20°C	  (dilution	  1000μg	  in	  1ml).	  To	  make	  Stock	  1	  solution	   1800μl	   of	   growth	   medium	   was	   added	   to	   one	   aliquot	   of	   the	   above	  storage	   solution	   (dilution	   100μg	   in	   1ml).	   To	   make	   Stock	   2	   solution	   900μl	   of	  growth	  medium	  was	  added	  to	  100μl	  of	  Stock	  1	  solution	  (dilution	  10μg	  in	  1ml).	  To	  make	  Stock	  solution	  3,	  900µl	  of	  growth	  medium	  was	  added	  to	  100µl	  of	  Stock	  solution	  2	   (dilution	  1µg	   in	  1ml).The	   volumes	   and	   final	   concentrations	   in	   a	   96	  well	  plate	  were	  as	  in	  the	  Table	  2-­‐3:	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Table	  2-­‐3	  Cisplatin	  final	  dilutions	  and	  volumes	  required	  for	  carrying	  out	  the	  ATP	  assay.	  	   Stock	  3	   Stock	  2	   Stock	  1	  Final	  Dilutions	  (µg	  /	  ml)	   0.4	   4	   40	  Vol	  of	  Cell	  Suspension	  (µl)	   200	   200	   200	  Vol	  of	  Growth	  Medium	  (µl)	   120	   120	   120	  Vol	  of	  stock	  solution	  (µl)	   80	   80	   80	  	  	  
Detergent	  	  	  Fifty	   microliters	   of	   detergent	   (Igepal	   CA-­‐30	   from	   Sigma,	   product	   number	   I-­‐3021)	   were	   diluted	   with	   1550µl	   of	   complete	   growth	   medium.	   Two	   hundred	  microliters	  were	  used	  for	  each	  well.	  	  
2.3.9 	  Cell-­‐Titer-­‐Glo	  Luminescent	  Cell	  Viability	  Assay	  
	  The	  CellTiter-­‐Glo®	  Luminescent	  Cell	  Viability	  Assay	   is	  a	  homogeneous	  method	  of	  determining	  the	  number	  of	  viable	  cells	  in	  culture	  based	  on	  quantisation	  of	  the	  ATP	   present,	   which	   signals	   the	   presence	   of	   metabolically	   active	   cells.	   The	  CellTiter-­‐Glo®	  Assay	  is	  designed	  for	  use	  with	  multiwell-­‐plate	  formats,	  making	  it	  ideal	   for	   automated	   high-­‐throughput	   screening	   (HTS),	   cell	   proliferation	   and	  cytotoxicity	   assays.	   The	   homogeneous	   assay	   procedure	   involves	   addition	   of	   a	  single	   reagent	   (CellTiter-­‐Glo®	   Reagent)	   directly	   to	   cells	   cultured	   in	   serum-­‐supplemented	   medium.	   Cell	   washing,	   removal	   of	   medium	   (except	   when	   a	  cytotoxic	   agent	   interferes	   with	   the	   fluorescent	   signal)	   or	   multiple	   pipetting	  steps	   are	   not	   required.	   Addition	   of	   CellTiter-­‐Glo®	   reagent	   followed	   by	  mixing	  results	   in	   cell	   lysis	  and	  generation	  of	   a	   luminescent	   signal	  proportional	   to	   the	  amount	   of	   ATP	   present.	   The	   amount	   of	   ATP	   is	   directly	   proportional	   to	   the	  number	   of	   cells	   present	   in	   culture	   in	   agreement	  with	   previous	   reports	   [146].	  The	  CellTiter-­‐Glo®	  Assay	  relies	  on	  the	  properties	  of	  a	  proprietary	  thermostable	  luciferase	   (Ultra-­‐Glo.	   Recombinant	   Luciferase),	   which	   in	   the	   presence	   of	   ATP	  and	  molecular	   oxygen	   catalyses	   the	  mono-­‐oxygenation	   of	   luciferin	   generating	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luminescence.	   The	   half-­‐life	   of	   the	   produced	   luminescence	   is	   greater	   than	   five	  hours	   (depending	   on	   the	   cell	   type	   and	   culture	   medium	   used)	   allowing	  processing	   of	   multiple	   plates.	   The	   lyophilized	   CellTiter-­‐Glo®	   Substrate	   and	  CellTiter-­‐Glo®	  Buffer	  should	  be	  stored	  at	  -­‐20°C.	  For	  frequent	  use,	  the	  CellTiter-­‐Glo®	  Buffer	  can	  be	  stored	  at	  4°C	  or	  at	  room	  temperature	  for	  48	  hours	  without	  loss	  of	  activity.	  Reconstituted	  CellTiter-­‐Glo®	  Reagent	  (Buffer	  plus	  Substrate)	  can	  be	  stored	  at	  4°C	  for	  48	  hours	  with	  ~5%	  loss	  of	  activity	  or	  at	  4°C	  for	  4	  days	  with	  ~20%	  loss	  of	  activity.	  	  The	   unique	   homogeneous	   format	   reduces	   pipetting	   errors	   that	   may	   be	  introduced	   during	   the	   multiple	   steps	   required	   by	   other	   ATP-­‐measurement	  methods.	   The	   amount	   of	   ATP	   in	   cells	   correlates	   with	   cell	   viability.	   Within	  minutes	  after	  loss	  of	  membrane	  integrity,	  cells	  lose	  the	  ability	  to	  synthesize	  ATP	  and	   endogenous	   ATPases	   destroy	   any	   remaining	   ATP.	   The	   CellTiter-­‐Glo®	  Reagent	   does	   three	   things	   upon	   addition	   to	   cells.	   It	   lyses	   cell	   membranes	   to	  release	   ATP;	   it	   inhibits	   endogenous	   ATPases,	   and	   it	   provides	   luciferin	   and	  luciferase	  necessary	  to	  measure	  ATP	  using	  a	  bioluminescent	  reaction.	  The	  glow	  type	  luminescence	  in	  this	  assay	  is	  obtained	  by	  slow	  inhibition	  of	  the	  luciferase	  reaction,	   while	   at	   the	   same	   time	   stabilizing	   the	   ATP	   giving	   a	   constant	   light	  output,	  which	  lasts	  for	  3	  –	  5	  hours	  (personal	  communication	  from	  Promega).	  	  	  
Assay	  methodology	  	  Each	   individual	   tumour	   was	   cultured	   according	   to	   the	   culture	   protocol	  described	   previously.	   Confluence	   was	   assessed	   daily	   under	   the	   inverted	  microscope	  and	  when	  near	  confluence	  was	  achieved	  the	  cells	  were	  trypsinised	  (as	   described	   in	   section	   2.3.4).	   One	   milliliter	   of	   trypsin	   was	   used	   in	   25	   cm3	  flasks,	  and	  3	  ml	  of	   trypsin	  was	  used	   in	  75	  cm3	   flasks.	  The	  cells	  were	  detached	  from	  the	  flask	  and	  the	  trypsin	  was	  neutralized	  with	  double	  its	  volume	  of	  growth	  medium.	  The	  cells	  were	  thoroughly	  mixed	  by	  pipetting	  and	  counted	  in	  a	  coulter	  counter.	  The	  required	  volume	  of	  cell	  suspension	  medium	  was	  calculated,	  after	  taking	  into	  account	  the	  number	  of	  drugs	  and	  dilutions	  to	  be	  used	  for	  the	  assay.	  To	  the	  remaining	  cell	  suspension	  further	  growth	  medium	  was	  then	  added	  and	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the	  flask	  was	  placed	  in	  the	  incubator.	  An	  estimate	  of	  the	  number	  of	  cells	  (initial)	  per	  well	  was	  calculated.	  Two	  hundred	  microliters	  of	  cell	  suspension	  was	  added	  to	  each	  well	  of	  a	  96-­‐well	  plate	  and	  left	  for	  72	  hours	  in	  the	  incubator	  in	  order	  to	  allow	   the	   cells	   to	   attach	   and	   grow.	  White	   plates	  with	   clear	   bottoms	   (Nunc	   or	  Grenier)	  were	  used	  for	  the	  assay.	  After	  72	  hours,	  the	  media	  was	  aspirated	  from	  each	  well	   and	   replaced	   immediately	  with	   120	   µl	   of	   complete	   growth	  medium	  and	  80	  µl	  of	  appropriate	  drug	  solutions.	  Two	  hundred	  microliters	  of	  detergent	  solution	  was	   added	   to	  wells	   labelled	   “detergent”.	   Two	   hundred	  microliters	   of	  complete	  growth	  medium	  was	  added	  to	  wells	   labelled	  “media	  only”.	  The	  plate	  was	  returned	  to	  the	  incubator	  and	  left	  for	  48	  hours.	  	  The	  96-­‐well	  plate	  layout	  was	  as	  shown	  in	  the	  table	  below	  (Table	  2-­‐4):	  	  
Table	  2-­‐4	  Layout	  of	  the	  96-­‐well	  plate	  showing	  the	  wells	  used	  by	  each	  of	  the	  solutions.	  Cis:	  Cisplatin,	  
TMZ:	  Temozolomide,	  BCNU	  Carmustine.	  	  
	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   11	   12	  
A	   	   	   	   	   	   	   	   	   	   	   	   ATP	  
B	   	   Cis	   Cis	   Cis	   BCNU	   BCNU	   BCNU	   TMZ	   TMZ	   TMZ	   	   0.25μg/ml	  
C	   	   0.4	  
µg/ml	   4	  µg/ml	  	   40	  µg/ml	   1	  µg/ml	   10	  µg/ml	   100	  µg/ml	   2	  µg/ml	   20	  µg/ml	   200	  µg/ml	   	   ATP	  
D	   	   	   	   	   	   	   	   	   	   	   	   0.5μg/ml	  
E	   	   	   	   	   	   	   	   	   	   	   	   ATP	  
F	   	   Media	   	   	   	   	   Detergent	   	   	   	   	   1μg/ml	  
G	   	   	   	   	   	   	   	   	   	   	   	   ATP	  
H	   	   	   	   	   	   	   	   	   	   	   	   2μg/ml	  	  
Reagent	  Preparation	  	  After	  thawing	  the	  CellTiter-­‐Glo®	  Buffer	  the	  buffer	  and	  the	  lyophilized	  CellTiter-­‐Glo®	  Substrate	  were	  allowed	  to	  equilibrate	  to	  room	  temperature	  prior	  to	  use.	  The	   CellTiter-­‐Glo®	   Buffer	   volume	   (10	   mls)	   was	   added	   to	   the	   CellTiter-­‐Glo®	  Substrate	   to	   reconstitute	   the	   enzyme-­‐substrate	   mixture	   which	   formed	   the	  CellTiter-­‐Glo®	   Reagent.	   The	   CellTiter-­‐Glo®	   Reagent	  was	   then	  mixed	   by	   gently	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vortexing,	   swirling	  or	   by	   inverting	   the	   contents	  until	   a	   homogeneous	   solution	  was	  obtained.	  	  	  
Protocol	  for	  carrying	  out	  the	  assay	  	  The	  multiwell	  plate	  and	  its	  contents	  were	  equilibrated	  to	  room	  temperature	  for	  approximately	   30	   minutes.	   That	   was	   an	   important	   step	   as	   temperature	   can	  affect	  the	  rate	  of	  reaction	  of	  luciferase	  and	  therefore	  the	  intensity	  of	  the	  signal.	  Insufficient	  equilibration	  could	  result	  in	  a	  temperature	  gradient	  effect	  between	  the	  wells	  in	  the	  centre	  and	  on	  the	  edge	  of	  the	  plates.	  	  	  Whilst	  the	  plate	  was	  equilibrating,	  the	  20	  µg/ml	  stock	  ATP	  was	  serially	  diluted	  to	  make	  the	  four	  required	  ATP	  concentrations.	  Then,	  900	  µl	  of	  PBS	  were	  added	  to	  100	  µl	  of	  20	  µg/ml	  of	  ATP	  to	  make	  1	  ml	  of	  Stock	  1	  solution	  of	  ATP	  (dilution	  of	  2µg/ml).	  To	  make	  Stock	  2	  solution,	  500	  µl	  of	  PBS	  were	  added	  to	  500	  µl	  of	  Stock	  1	  (dilution	  of	  1µg/ml).	  To	  make	  Stock	  3	  solution,	  500	  µl	  of	  PBS	  were	  added	  to	  500	  µl	  of	  Stock	  2	  (dilution	  of	  0.5µg/ml).	  To	  make	  Stock	  4	  solution,	  500	  µl	  of	  PBS	  were	  added	  to	  500	  µl	  of	  Stock	  3	  (dilution	  of	  0.25µg/ml).The	  volumes	  and	  final	  concentrations	  of	  ATP	  are	  shown	  in	  the	  table	  below	  (Table	  2-­‐5):	  	  
Table	  2-­‐5	  ATP	  final	  dilutions	  and	  volumes	  required	  for	  carrying	  out	  the	  ATP	  assay.	  Final	  Conc	  of	  ATP	   Vol	  of	  ATP	  	   Vol	  PBS	  2	  µg/ml	  Stock	  1	   100	  µl	  of	  20	  µg/ml	   900	  µl	  1	  µg/ml	  Stock	  2	   500	  µl	  of	  2	  µg/ml	   500	  µl	  0.5	  µg/ml	  Stock	  3	   500	  µl	  of	  1	  µg/ml	   500	  µl	  0.25	  µg/ml	  Stock	  4	   500	  µl	  of	  0.5	  µg/ml	   500	  µl	  	  The	  medium	  from	  each	  well	  of	  the	  multiwell	  plate	  was	  removed	  and	  each	  well	  was	  washed	  with	  100	  µl	  of	  PBS.	  Then,	  100	  µl	  of	  PBS	  were	  added	   to	  each	  well	  and	  two	  replicates	  of	  each	  of	  the	  ATP	  standards	  were	  added	  to	  the	  final	  column	  (Table	  2-­‐4	  column	  12).	  An	  equal	  volume	  (100	  µl)	  of	  CellTiter-­‐Glo®	  Reagent	  was	  added	   to	  each	  well	   to	  ensure	   the	  correct	  1x	   concentration	  of	   the	   reagent.	  The	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contents	  were	  mixed	  for	  2	  minutes	  on	  an	  orbital	  shaker	  to	  induce	  cell	  lysis.	  The	  plate	  was	  then	  incubated	  at	  25°C	  for	  10	  minutes	  to	  stabilize.	  Luminescence	  was	  measured	  in	  a	  plate	  reader	  (Tecan	  GENios	  Pro®)	  (Figure	  2-­‐1).	  	  	  
	  
Figure	  2-­‐1	  ATP	  Luminescent	  Assay	  Protocol.	  	  
2.3.10 Lethal	  Dose	  50	  (LD50)	  	  The	  lethal	  dose	  (LD)	  indicates	  lethality	  of	  a	  substance	  and	  is	  a	  commonly	  used	  concept	   in	   chemosensitivity	   studies.	   The	   number	   that	   follows	   the	   lethal	   dose	  indicates	   the	   percentage	   of	   the	   kill	   produced	   by	   the	   substance.	   For	   example,	  LD50	   is	   the	  drug	  dose	   that	  kills	  50%	  of	   the	   treated	  population.	  Following	   this	  convention,	   a	   cell	   line	   or	   primary	   culture	   is	   defined	   arbitrarily	   as	   being	  chemosensitive	  after	  exposure	  to	  a	  drug	  concentration,	  when	  the	  cells	  surviving	  are	  50%	  of	  the	  untreated	  cells.	  For	  the	  ATP	  assay	  used	  in	  this	  study,	  the	  LD50	  is	  the	  dose	  of	  the	  drug	  at	  which	  the	  luminescence	  measured	  was	  half	  of	  the	  one	  of	  the	  untreated	  cells.	  The	  values	  obtained	  were	   in	   four	  repeats	  and	  the	  mean	  of	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each	   drug	   concentration	  was	   plotted	   on	   a	   graph.	   A	   linear	   trendline	  was	   then	  fitted	  on	  each	  plot	  and	  used	  to	  calculate	  the	  LD50.	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2.4 Results:	  	  
2.4.1 Establishing	  primary	  glioma	  cultures	  	  Fifty-­‐two	  brain	  tumour	  specimens	  were	  received	  during	  the	  period	  of	  May	  2009	  to	  November	  2010.	  Of	  those,	  forty-­‐five	  were	  successfully	  cultured	  whereas	  the	  remaining	   seven	   did	   not	   grow.	   Thirty-­‐three	   out	   of	   the	   forty-­‐five	   successful	  cultures	   got	   contaminated	   prior	   to	   testing	   and	   therefore	   discarded.	  Contamination	   is	   a	   well-­‐known	   problem	   in	   primary	   tissue	   culture.	   The	  contamination	  observed	  in	  this	  study	  is	  in	  line	  with	  the	  contamination	  levels	  of	  reported	   studies	   as	  well	   as	   previous	   studies	   in	   our	   institution.	   The	   remaining	  twelve	  cultures	  were	  taken	  forward	  to	  chemosensitivity	  testing	  (Table	  2-­‐6).	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Table	  2-­‐6	  Summary	  of	  attempted	  primary	  glioma	  cultures.	  BTNW	  NO.	   PROGRESS	   DRUG	  TESTING	   BTNW	  NO.	   PROGRESS	   DRUG	  TESTING	  338	   Tested	   BCNU,	  TMZ,	  Cis	   453	   No	  growth	   	  	  352	   Contaminated	   	  	   458	   Contaminated	   	  	  365	   Tested	   BCNU,	  TMZ,	  Cis	   460	   Contaminated	   	  	  370	   Tested	   BCNU,	  TMZ,	  Cis	   462	   Contaminated	   	  	  374	   Tested	   BCNU,	  TMZ,	  Cis	   470	   Contaminated	   	  	  377	   Tested	   	  BCNU,	  TMZ,	  Cis	   482	   Contaminated	   	  	  382	   Tested	   BCNU,	  TMZ,	  Cis	   484	   Contaminated	   	  	  390	   Contaminated	   	  	   500	   Tested	   BCNU,	  TMZ,	  Cis	  396A	   Contaminated	   	  	   502	   Contaminated	   	  	  396B	   Contaminated	   	  	   512	   No	  growth	   	  	  404	   Contaminated	   	  	   515	   No	  growth	   	  	  410	   Contaminated	   	  	   522	   Contaminated	   	  	  411	   Contaminated	   	  	   533	   Tested	   BCNU,	  TMZ,	  Cis	  412A	   Contaminated	   	  	   535	   Contaminated	   	  412B	   Contaminated	   	  	   538	   Tested	   BCNU,	  TMZ,	  Cis	  416	   Contaminated	   	  	   544	   Contaminated	   	  	  418	   Contaminated	   	  	   545	   No	  growth	   	  	  421	   Contaminated	   	  	   546	   Tested	   BCNU,	  TMZ,	  Cis	  428	   No	  growth	   	  	   590	   Tested	   BCNU,	  TMZ,	  Cis	  435	   Contaminated	   	  	   597	   Tested	   BCNU,	  TMZ,	  Cis	  	  436	   Contaminated	   	  	   626	   Contaminated	   	  	  439	   Contaminated	   	  	   632	   No	  growth	   	  	  442	   Contaminated	   	  	   640	   No	  growth	   	  	  445A	   Contaminated	   	  	   651	   Contaminated	   	  	  445B	   Contaminated	   	  	   676	   Contaminated	   	  	  452	   Contaminated	   	  	   693	   Contaminated	   	  	  
Summary	   of	   attempted	   primary	   glioma	   cultures.	   Out	   of	   fifty-­‐two,	   seven	   did	   not	  
grow,	   thirty-­‐three	   got	   contaminated	   and	   twelve	   were	   successfully	   tested.	   BCNU	  
Carmustine,	  TMZ	  Temozolomide,	  Cis	  Cisplatin.	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2.4.2 Chemo-­‐sensitivity	  Analysis	  	  To	   compare	   the	   effect	   of	   the	   drug	   dosage	   on	   the	   kill	   efficiency	   of	   the	   drugs	  tested,	   the	   nonparametric	   Kolmogorov-­‐Smirnov	   statistical	   test	   (KS	   test)	   was	  used	  [147].	  The	  Kolmogorov–Smirnov	  statistic	  quantifies	  the	  distance	  between	  the	  empirical	  distribution	  functions	  of	  two	  samples.	  In	  this	  case,	  the	  cumulative	  distribution	   of	   the	   cells	   from	   each	   concentration	   of	   each	   drug	   was	   pair-­‐wise	  compared	   against	   the	   cumulative	   distribution	   of	   each	   of	   the	   two	   control	   cell	  cultures	   (those	   containing	   only	   the	   growth	   medium	   and	   those	   with	   the	  detergent).	  For	  a	  drug	  to	  be	  effective	  at	  a	  given	  concentration	  it	  needs	  to	  exhibit	  kill	   efficiency	   greater	   than	   the	   one	   observed	   when	   only	   the	   control	   growth	  medium	  is	  used.	  Moreover,	  the	  higher	  the	  kill	  efficiency	  of	  the	  drug,	  the	  closer	  to	  the	  kill	  efficiency	  observed	  by	  the	  detergent	  it	  would	  be.	  The	  null	  hypothesis	  in	  this	  case	  suggests	  that	  the	  drugs	  tested	  are	  not	  significantly	  different	  from	  each	  of	   the	   two	   controls.	   In	   terms	   of	   evaluating	   statistical	   significance	   given	   a	  calculated	  p-­‐value,	  both	  significance	   levels	  α=0.001	   (conservative)	  and	  α=0.05	  (widely	   used)	  were	   considered.	   If	   a	   test	   of	   significance	   gives	   a	   p-­‐value	   lower	  than	  the	  significance	  level	  α,	  the	  null	  hypothesis	  is	  rejected	  and	  the	  sample	  can	  be	  considered	  as	  being	  statistically	  significantly	  different	  from	  the	  control	  it	  was	  compared	  against.	  	  
2.4.2.1 Statistical	  package	  	  The	   statistical	   analysis	   was	   performed	   using	   the	   R	   software	   environment	   for	  statistical	   computing	   and	   graphics	   (version	   2.15.1)	   running	   under	   Windows	  Vista	  OS	  with	  2GB	  RAM	  [148].	  All	  the	  statistical	  tests	  used	  here	  were	  included	  in	  the	  R	  Stats	  package.	  	  
Comparison	  of	  drug	  concentrations	  against	  the	  two	  controls	  	  	  In	   this	   section,	   three	   concentrations	   (100x,	   10x,	   and	   1x	  where	   10x	   being	   the	  therapeutic	   dose)	   from	   each	   tested	   drug	   (Cisplatin,	   Carmustine	   and	  Temozolomide)	  were	   compared	   against	   the	   kill	   efficiency	   of	   both	   the	   growth	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medium	  and	  the	  detergent.	  The	  results	  of	   the	  comparison	  are	  shown	  on	  Table	  2-­‐7	  and	  Figure	  2-­‐2.	  	  
Table	  2-­‐7	  Comparison	  of	  the	  kill	  efficiency	  of	  each	  of	  the	  three	  drugs	  to	  the	  growth	  medium	  and	  the	  
detergent.	  
Drugs	  tested	  	  (All	   Ages	   and	  Genders)	   Medium	   Detergent	  
	  
Proximity	   to	  
Medium	  
(KS	  
Distance)	   p-­‐value	  
Proximity	   to	  
Detergent	  
(KS	  
Distance)	   p-­‐value	  
Cis100	   0.521	   <0.001	   0.917	   <0.001	  
Cis10	   0.271	   0.059	   0.917	   <0.001	  
Cis1	   0.167	   0.522	   0.938	   <0.001	  
Carmu100	   0.188	   0.368	   0.917	   <0.001	  
Carmu10	   0.188	   0.368	   0.938	   <0.001	  
Carmu1	   0.167	   0.522	   0.938	   <0.001	  
TMZ100	   0.313	   <0.001	   0.958	   <0.001	  
TMZ10	   0.229	   0.161	   0.979	   <0.001	  
TMZ1	   0.167	   0.522E	   0.958	   <0.001	  
Comparison	   of	   the	   kill	   efficiency	   of	   three	   concentrations	   of	   Cisplatin	   (Cis100,	  
Cis10,	   Cis1),	   Carmustine	   (Carmu100,	   Carmu10,	   Carmu1)	   and	   Temozolomide	  
(TMZ100,	  TMZ10,	  TMZ1)	  against	   that	  of	   the	  growth	  medium	  and	   the	  detergent.	  
Significant	  values	  are	  shown	  in	  bold.	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Figure	  2-­‐2	  Boxplot	  summarizing	  the	  Relative	  Light	  Units	  (RLU)	  measured	  in	  cultures	  of	  all	  patients	  
tested	   with	   Cisplatin	   (Cis),	   Carmustine	   (Carmu),	   Temozolomide	   (TMZ)	   in	   three	   concentrations	  
(x100,	  x10,	  and	  x1).	  RLU	  of	  the	  untreated	  cultures	  (Medium)	  and	  those	  treated	  with	  Detergent	  are	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Drug	  kill	  efficiency	  across	  different	  age	  groups	  	  In	  order	  to	  determine	  whether	  age	  plays	  a	  role	  on	  the	  kill	  efficiency	  of	  the	  drug	  the	  results	  were	  reanalysed	  after	  grouping	  them	  into	  two	  age	  groups	  (over	  65	  and	  under	  65	  years	  of	  age).	  The	  results	  of	  this	  analysis	  are	  shown	  in	  Table	  2-­‐8	  and	  Table	  2-­‐9	  and	  Figure	  2-­‐3	  and	  Figure	  2-­‐4.	  	  
Table	  2-­‐8	  Comparison	  of	  the	  kill	  efficiency	  of	  each	  drug	  to	  the	  growth	  medium	  in	  the	  over	  65	  years	  
age	  group.	  
Drugs	  used	  
(Age	  >65,	  All	  Genders)	  
Proximity	  to	  Medium	  
(KS	  Distance)	   p-­‐value	  
Cis100	   0.464 <0.05 
Cis10	   0.321 0.111 
Cis1	   0.179 0.773 
Carmu100	   0.179 0.763 
Carmu10	   0.179 0.773 
Carmu1	   0.214 0.549 
TMZ100	   0.429 <0.05 
TMZ10	   0.321 0.111 
TMZ1	   0.179 0.773 
Comparison	   of	   the	   kill	   efficiency	   of	   three	   concentrations	   of	   Cisplatin	   (Cis100,	  
Cis10,	   Cis1),	   Carmustine	   (Carmu100,	   Carmu10,	   Carmu1)	   and	   Temozolomide	  
(TMZ100,	  TMZ10,	  TMZ1)	  against	  that	  of	  the	  growth	  medium	  in	  both	  genders	  for	  
the	  over	  65	  years	  age	  group.	  Significant	  values	  are	  shown	  in	  bold.	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Figure	  2-­‐3	  Boxplot	  summarizing	  the	  Relative	  Light	  Units	  (RLU)	  measured	  in	  cultures	  of	  all	  patients	  
over	  65	  years	  of	  age	  tested	  with	  Cisplatin	  (Cis),	  Carmustine	  (Carmu),	  Temozolomide	  (TMZ)	  in	  three	  
concentrations	  (x100,	  x10,	  and	  x1)	  and	  the	  untreated.	  Asterisk	  (*)	  indicates	  statistical	  significance	  
between	  datasets	  with	  P<0.05.	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Table	  2-­‐9	  Comparison	  of	  the	  kill	  efficiency	  of	  each	  of	  the	  three	  drugs	  to	  the	  growth	  medium	  in	  the	  
under	  65	  years	  age	  group	  
Drugs	  used	  
(Age	  <65,	  All	  Genders)	  
Proximity	  to	  Medium	  
(KS	  Distance)	   p-­‐value	  
Cis100	   0.800 <0.001 
Cis10	   0.350 0.173 
Cis1	   0.400 0.081 
Carmu100	   0.400 0.081 
Carmu10	   0.400 0.081 
Carmu1	   0.400 0.081 
TMZ100	   0.250 0.571 
TMZ10	   0.400 0.081 
TMZ1	   0.400 0.081 
Comparison	   of	   the	   kill	   efficiency	   of	   three	   concentrations	   of	   Cisplatin	   (Cis100,	  
Cis10,	   Cis1),	   Carmustine	   (Carmu100,	   Carmu10,	   Carmu1)	   and	   Temozolomide	  
(TMZ100,	  TMZ10,	  TMZ1)	  against	  that	  of	  the	  growth	  medium	  in	  both	  genders	  for	  
the	  under	  65	  years	  age	  group.	  Significant	  values	  are	  shown	  in	  bold.	  	  
	  
Figure	  2-­‐4	  Boxplot	  summarizing	  the	  Relative	  Light	  Units	  (RLU)	  measured	  in	  cultures	  of	  all	  patients	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three	   concentrations	   (x100,	   x10,	   and	   x1)	   and	   the	   untreated.	   Asterisk	   (*)	   indicates	   statistical	  
significance	  between	  datasets	  with	  P<0.001.	  	  In	  the	  under	  65	  years	  age	  group,	  only	  Cisplatin	  100x	  showed	  a	  significant	  effect	  when	   compared	   to	   the	   Control	   (growth	  medium)	   but	   this	   time	  with	   a	   higher	  confidence	   score	   (α=0.001).	   None	   of	   the	   remaining	   drugs	   and	   concentrations	  had	  shown	  any	  significant	  kill	  effect	  (α=0.05).	  	  Comparing	  Table	  2-­‐8	  and	  Table	  2-­‐9,	  the	  age	  group	  of	  under	  65	  years	  exhibits	  a	  better	  response	  to	  the	  drugs	  as	  their	  KS	  Distance	  values	  were	  consistently	  equal	  or	  greater	  than	  those	  of	  the	  over	  65	  years	  age	  group.	  In	  addition,	  the	  p-­‐values	  of	  the	   under	   65	   years	   age	   group	  where	   overall	   lower	   than	   those	   of	   the	   over	   65	  years	  age	  group	  and	  in	  some	  cases	  not	  too	  distant	  from	  the	  significance	  cut-­‐off	  value	  of	  0.05	  (0.08106).	  This	  suggests	  that	  the	  under	  65	  years	  age	  group	  might	  respond	   better	   to	   chemotherapy	   treatment	   with	   the	   aforementioned	   drugs	  although	  this	  is	  just	  a	  comparison	  of	  the	  significance	  of	  the	  observed	  results	  and	  should	  be	  treated	  with	  caution.	  	  
Drug	  kill	  efficiency	  in	  relation	  to	  gender	  	  In	  order	  to	  determine	  whether	  gender	  plays	  a	  role	  on	  the	  kill	  efficiency	  of	   the	  drug,	   the	   datasets	   were	   reanalysed	   after	   being	   divided	   into	   male	   and	   female	  groups.	  The	  results	  of	  this	  analysis	  are	  shown	  in	  Table	  2-­‐10	  and	  Table	  2-­‐11	  and	  Figure	  2-­‐5	  and	  Figure	  2-­‐6.	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Table	  2-­‐10	  Comparison	  of	  the	  kill	  efficiency	  of	  each	  drug	  for	  female	  patients	  from	  both	  age	  groups	  
Drug	  tested	  
(Female,	  All	  Ages	  )	  
Proximity	  to	  Medium	  
(KS	  Distance)	   p-­‐value	  
Cis100	   0.714 <0.0001 
Cis10	   0.429 <0.05 
Cis1	   0.286 0.205 
Carmu100	   0.321 0.111 
Carmu10	   0.286 0.205 
Carmu1	   0.286 0.205 
TMZ100	   0.393 <0.05 
TMZ10	   0.286 0.205 
TMZ1	   0.286 0.205 
Comparison	   of	   the	   kill	   efficiency	   of	   three	   concentrations	   of	   Cisplatin	   (Cis100,	  
Cis10,	   Cis1),	   Carmustine	   (Carmu100,	   Carmu10,	   Carmu1)	   and	   Temozolomide	  
(TMZ100,	  TMZ10,	  TMZ1)	  against	  that	  of	  the	  growth	  medium	  for	  female	  patients	  in	  
both	  age	  groups.	  Significant	  values	  are	  shown	  in	  bold.	  	  	  
	  	  
Figure	   2-­‐5	   Boxplot	   summarizing	   the	   Relative	   Light	   Units	   (RLU)	   measured	   in	   cultures	   of	   female	  

















Quartile	  3	  min	  median	  max	  Quartile	  1	  
	  	  	  	  	  	  	  *	   	  	  **	   	  	  *	  	  **	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  **	  
	   68	  
concentrations	  (x100,	  x10,	  and	  x1)	  and	  the	  untreated.	  Asterisks	  (*)	  indicates	  statistical	  significance	  
between	  datasets	  with	  *	  P<0.001	  and	  **	  P<0.05.	  	  Based	   on	   these	   results,	   Cisplatin	   100x	   exhibited	   a	   significantly	   different	   kill	  efficiency	  to	  the	  one	  observed	  by	  the	  growth	  medium	  (α=0.001).	  Cisplatin	  10x	  and	   Temozolomide	   100x	   were	   also	   had	   a	   significant	   effect	   at	   the	   less	  conservative	   cut	   off	   value	   of	   α=0.05.	   None	   of	   the	   remaining	   tested	   drugs	   and	  concentrations	  had	  shown	  any	  significant	  kill	  effect.	  	  	  
Table	  2-­‐11	  Comparison	  of	  the	  kill	  efficiency	  of	  each	  drug	  for	  male	  patients	  from	  both	  age	  groups.	  
Drug	  tested	  
(Male,	  All	  Ages	  )	  	  
Proximity	  to	  Medium	  
(KS	  Distance)	   p-­‐value	  
Cis100	   0.600 <0.001 
Cis10	   0.200 0.819 
Cis1	   0.250 0.571 
Carmu100	   0.200 0.832 
Carmu10	   0.200 0.832 
Carmu1	   0.300 0.336 
TMZ100	   0.250 0.571 
TMZ10	   0.250 0.571 
TMZ1	   0.250 0.571 
Comparison	   of	   the	   kill	   efficiency	   of	   three	   concentrations	   of	   Cisplatin	   (Cis100,	  
Cis10,	   Cis1),	   Carmustine	   (Carmu100,	   Carmu10,	   Carmu1)	   and	   Temozolomide	  
(TMZ100,	  TMZ10,	  TMZ1)	  against	  that	  of	  the	  growth	  medium	  for	  male	  patients	  in	  
both	  age	  groups.	  Significant	  values	  are	  shown	  in	  bold.	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Figure	   2-­‐6	   Boxplot	   summarizing	   the	   Relative	   Light	   Units	   (RLU)	   measured	   in	   cultures	   of	   male	  
patients	   tested	   with	   Cisplatin	   (Cis),	   Carmustine	   (Carmu),	   Temozolomide	   (TMZ)	   in	   three	  
concentrations	  (x100,	  x10,	  and	  x1)	  and	  the	  untreated.	  Asterisk	  (*)	  indicates	  statistical	  significance	  





















Quartile	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2.4.3 Clinical	  profile	  and	  chemosensitivity	  results	  of	  each	  individual	  patient	  	  
BTNW	  338	  	  
Clinical	  History:	  This	  71-­‐year-­‐old	  male	  presented	  with	  self-­‐limiting	  episodes	  of	  generalised	   tonic-­‐clonic	   seizures.	  On	  examination	  he	  had	  a	  GCS	  of	  14/15	  with	  receptive	  and	  expressive	  dysphasia	  and	  right	  upper	  limb	  power	  of	  4+/5.	  He	  did	  not	  receive	  any	  adjuvant	  treatment	  and	  died	  after	  5	  weeks.	  	  
Radiology:	  CT	  scan	  revealed	  a	  left	  temporal	  lesion.	  	  
Surgery:	  Craniotomy	  and	  debulking	  performed	  on	  the	  1st	  of	  May	  2009.	  	  
Histology:	  Histopathology	  revealed	  a	  Glioblastoma	  multiforme	  WHO	  grade	  IV.	  	  
Primary	  culture:	  Culture	  became	  confluent	  after	  24	  days.	  	  
Chemosensitivity	   results:	   ATP	   luminescent	   assay	   revealed	   resistance	   to	   all	  drugs	   used	   (Table	   2-­‐12	   and	   Figure	   2-­‐7).	   Given	   the	   observed	   dose	   response	  trends	  Cisplatin	  was	  expected	  to	  reach	  LD50	  at	  55.67	  μg/ml.	  
	  
Table	  2-­‐12	  Chemosensitivity	  results	  for	  the	  tested	  drug.	  Drug	   ATP	  assay	  LD50	  (μg/ml)	  Cisplatin	   Resistant	  (55.67)	  Carmustine	   Resistant	  	  Temozolomide	   Resistant	  	  
Resistance	  indicates	  that	  the	  calculated	  LD50	  does	  not	  fall	  within	  the	  range	  of	  the	  
tested	  drug	  concentrations.	  Calculated	  LD50	  is	  shown	  in	  parenthesis.	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Figure	  2-­‐7	  Dose	  response	  curves	  for	  BTNW	  338	  using	  the	  ATP	  assay.	  The	  data	  points	  are	  means	  of	  4	  
repeats.	  The	  error	  bars	  represent	  standard	  deviations.	  Linear	  trend	  line	  was	  fitted	  on	  the	  data	  points	  
to	  assist	  the	  calculation	  of	  LD50.	  
	  
y	  =	  4.3476x	  +	  91748	  























Linear(Temozolomide)	  Linear(Carmustine)	  Linear(Cisplatin)	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BTNW	  365	  	  
Clinical	   History:	   This	   42-­‐year-­‐old	   female	   presented	   with	   one	   episode	   of	  generalised	   tonic-­‐clonic	   seizures,	   sleeplessness	   and	   increased	   anxiety	   for	   two	  days.	   On	   examination	   she	   had	   a	   GCS	   of	   15/15	   with	   no	   focal	   neurological	  findings.	  She	  received	  adjuvant	  Radiotherapy.	  She	  died	  after	  163	  weeks.	  	  
Radiology:	  CT	  scan	  revealed	  a	  right	  fronto-­‐parietal	  lesion.	  	  	  
Surgery:	  Craniotomy	  and	  debulking	  performed	  on	  the	  30th	  of	  June	  2009.	  	  
Histology:	  Histopathology	  revealed	  a	  WHO	  grade	  II	  Fibrillary	  Astrocytoma	  with	  atypical	   features.	   It	   was	   felt	   that	   overall	   “sampling”	   was	   under-­‐grading	   this	  tumour.	  	  
Primary	  culture:	  Culture	  became	  confluent	  after	  20	  days.	  	  
Chemosensitivity	   results:	   ATP	   luminescent	   assay	   revealed	   resistance	   to	  Carmustine	   and	  Temozolomide.	   Cisplatin	   reached	   a	   50%	   cell	   kill.	   (Table	   2-­‐13	  and	  Figure	  2-­‐8).	  Given	   the	  observed	  dose	  response	   trends	  Temozolomide	  was	  expected	  to	  reach	  LD50	  at	  228.04	  μg/ml.	  	  
	  
Table	  2-­‐13	  Chemosensitivity	  results	  for	  the	  tested	  drugs	  Drug	   ATP	  assay	  LD50	  (μg/ml)	  Cisplatin	   Sensitive	  (32.57)	  Carmustine	   Resistant	  Temozolomide	   Resistant	  (228.04)	  
Resistance	  indicates	  that	  the	  calculated	  LD50	  does	  not	  fall	  within	  the	  range	  of	  the	  
tested	  drug	  concentrations.	  Calculated	  LD50	  is	  shown	  in	  parenthesis.	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Figure	  2-­‐8	  Dose	  response	  curves	  for	  BTNW	  365	  using	  the	  ATP	  assay.	  The	  data	  points	  are	  means	  of	  4	  
repeats.	   The	   error	   bars	   represent	   standard	   deviations.	   Linear	   trend	   line	   was	   fitted	   on	   the	   data	  
points	  to	  assist	  the	  calculation	  of	  LD50.	  	  
y	  =	  -­‐3476.2x	  +	  1E+06	  
y	  =	  -­‐23367x	  +	  968397	  


















Log	  Drug	  Concentration	  (μg/ml)	  
BTNW	  365	  	  
Temozolomide	  Cisplatin	  Carmustine	  Linear(Temozolomide)	  Linear(Cisplatin)	  Linear(Carmustine)	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BTNW	  374	  	  
Clinical	  History:	  This	  34-­‐year-­‐old	  female	  presented	  with	  a	  four-­‐week	  history	  of	  malaise,	   nausea	   and	   vertigo.	   On	   examination	   she	   had	   a	   GCS	   of	   15/15	   with	  cerebellar	   signs	   (nystagmus	   and	   past-­‐pointing)	   as	   well	   as	   visual	   disturbance.	  She	  received	  adjuvant	  Radiotherapy	  (54	  Gys)	  with	  concomitant	  Temozolomide	  chemotherapy.	  She	  died	  after	  30	  weeks.	  	  
Radiology:	   CT	   scan	  was	   initially	   thought	   to	   be	   normal,	   but	  when	   an	  MR	  was	  performed,	  it	  revealed	  a	  posterior	  fossa	  lesion.	  	  
Surgery:	   Posterior	   fossa	   craniotomy	   and	   debulking	   performed	   on	   the	   17th	   of	  July	  2009.	  	  
Histology:	  Histopathology	  revealed	  a	  Glioblastoma	  multiforme	  WHO	  grade	  IV.	  	  
Primary	  culture:	  Culture	  became	  confluent	  after	  5	  days.	  	  
Chemosensitivity	   results:	   ATP	   luminescent	   assay	   revealed	   resistance	   to	  Carmustine	   and	  Temozolomide.	   Cisplatin	   reached	   a	   50%	   cell	   kill.	   (Table	   2-­‐14	  and	  Figure	  2-­‐9).	  Given	   the	  observed	  dose	  response	   trends	  Temozolomide	  was	  expected	  to	  reach	  LD50	  at	  209.33	  μg/ml.	  
	  
Table	  2-­‐14	  Chemosensitivity	  results	  for	  the	  tested	  drugs	  Drug	   ATP	  assay	  LD50	  (μg/ml)	  Cisplatin	   Sensitive	  (33.50)	  Carmustine	   Resistant	  Temozolomide	   Resistant	  (209.33)	  
Resistance	  indicates	  that	  the	  calculated	  LD50	  does	  not	  fall	  within	  the	  range	  of	  the	  
tested	  drug	  concentrations.	  Calculated	  LD50	  is	  shown	  in	  parenthesis.	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Figure	  2-­‐9	  Dose	  response	  curves	  for	  BTNW	  374	  using	  the	  ATP	  assay.	  The	  data	  points	  are	  means	  of	  4	  
repeats.	   The	   error	   bars	   represent	   standard	   deviations.	   Linear	   trend	   line	   was	   fitted	   on	   the	   data	  
points	  to	  assist	  the	  calculation	  of	  LD50.	  	  	  
y	  =	  -­‐22844x	  +	  998504	  
y	  =	  2900.2x	  +	  884800	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BTNW	  544	  	  
Clinical	  History:	  This	  68-­‐year-­‐old	  male	  presented	  with	  aphasia,	  which	  resolved	  on	  steroids.	  On	  examination	  he	  had	  a	  GCS	  of	  15/15	  and	  normal	  limb	  power.	  He	  received	   adjuvant	   Radiotherapy	   (54	   Gys)	   with	   concomitant	   Temozolomide	  chemotherapy.	  He	  died	  after	  89	  weeks.	  	  
Radiology:	  CT	  scan	  revealed	  a	  left	  fronto-­‐parietal	  lesion.	  	  
Surgery:	  Craniotomy	  and	  debulking	  performed	  on	  the	  25th	  of	  November	  2009.	  	  
Histology:	  Histopathology	  revealed	  a	  Glioblastoma	  multiforme	  WHO	  grade	  IV.	  	  
Primary	  culture:	  Culture	  became	  confluent	  after	  56	  days.	  	  
Chemosensitivity	   results:	   ATP	   luminescent	   assay	   revealed	   resistance	   to	  Carmustine	   and	  Temozolomide.	   Cisplatin	   reached	   a	   50%	   cell	   kill.	   (Table	   2-­‐15	  and	  Figure	  2-­‐10).	  	  
	  
Table	  2-­‐15	  Chemosensitivity	  results	  for	  the	  tested	  drugs	  Drug	   ATP	  assay	  LD50	  (μg/ml)	  Cisplatin	   Sensitive	  (37.54)	  Carmustine	   Resistant	  	  Temozolomide	   Resistant	  	  
Resistance	  indicates	  that	  the	  calculated	  LD50	  does	  not	  fall	  within	  the	  range	  of	  the	  
tested	  drug	  concentrations.	  Calculated	  LD50	  is	  shown	  in	  parenthesis.	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Figure	  2-­‐10	  Dose	  response	  curves	  for	  BTNW	  544	  using	  the	  ATP	  assay.	  The	  data	  points	  are	  means	  of	  
4	  repeats.	  The	  error	  bars	  represent	  standard	  deviations.	  Linear	   trend	   line	  was	   fitted	  on	   the	  data	  
points	  to	  assist	  the	  calculation	  of	  LD50.	  	  	  	  	  	  	  
y	  =	  -­‐37.092x	  +	  155518	  
y	  =	  -­‐2760.4x	  +	  129545	  
























Linear(Temozolomide)	  Linear(Cisplatin)	  Linear(Carmustine)	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BTNW	  370	  	  
Clinical	  History:	  This	  66-­‐year-­‐old	  female	  presented	  with	  a	  three-­‐week	  history	  of	   headaches,	   poor	   concentration,	   feeling	   unwell,	   confusion	   and	  memory	   loss.	  On	   examination	   she	   had	   a	   GCS	   of	   14/15	  with	   confusion	   and	   dysphasia.	   Limb	  power	  was	   globally	   reduced	   to	   4/5.	   She	   received	   palliative	   radiotherapy	   and	  died	  after	  6	  weeks.	  	  
Radiology:	  CT	  scan	  revealed	  a	  left	  frontal	  lesion	  crossing	  the	  midline	  along	  the	  corpus	  callosum.	  	  
Surgery:	  Craniotomy	  and	  debulking	  performed	  on	  the	  13th	  of	  July	  2009.	  	  
Histology:	  Histopathology	   revealed	   a	  Glioblastoma	  multiforme	  WHO	  grade	   IV	  with	  gliosarcomatous	  features.	  	  
Primary	  culture:	  Culture	  became	  confluent	  after	  21	  days.	  	  
Chemosensitivity	   results:	   ATP	   luminescent	   assay	   revealed	   resistance	   to	  Carmustine	   and	  Temozolomide.	   Cisplatin	   reached	   a	   50%	   cell	   kill.	   (Table	   2-­‐16	  and	  Figure	  2-­‐11).	  	  
	  
Table	  2-­‐16	  Chemosensitivity	  results	  for	  the	  tested	  drugs	  Drug	   ATP	  assay	  LD50	  (μg/ml)	  Cisplatin	   Sensitive	  (25.96)	  Carmustine	   Resistant	  	  Temozolomide	   Resistant	  
Resistance	  indicates	  that	  the	  calculated	  LD50	  does	  not	  fall	  within	  the	  range	  of	  the	  
tested	  drug	  concentrations.	  Calculated	  LD50	  is	  shown	  in	  parenthesis.	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Figure	  2-­‐11	  Dose	  response	  curves	  for	  BTNW	  370	  using	  the	  ATP	  assay.	  The	  data	  points	  are	  means	  of	  
4	  repeats.	  The	  error	  bars	  represent	  standard	  deviations.	  Linear	   trend	   line	  was	   fitted	  on	   the	  data	  
points	  to	  assist	  the	  calculation	  of	  LD50.	  	  
y	  =	  -­‐2402.4x	  +	  140889	  
y	  =	  83.372x	  +	  130366	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BTNW	  382	  	  
Clinical	  History:	  This	  75-­‐year-­‐old	  female	  presented	  with	  a	  six	  week	  history	  of	  dysphasia	  and	  right	  sided	  hemiparesis.	  On	  examination	  she	  had	  a	  GCS	  of	  14/15	  with	   receptive	   and	   expressive	   dysphasia	   and	   right	   hemiparesis	   of	   4/5.	   She	  received	  any	  adjuvant	   radiotherapy	  but	  no	   chemotherapy	   treatment.	   She	  died	  after	  109	  weeks.	  	  
Radiology:	  CT	  scan	  revealed	  a	  left	  frontal	  lesion.	  	  
	  
Surgery:	  Craniotomy	  and	  debulking	  performed	  on	  the	  04th	  of	  August	  2009.	  	  	  
Histology:	  Histopathology	  revealed	  a	  Glioblastoma	  multiforme	  WHO	  grade	  IV.	  	  	  
Primary	  culture:	  Culture	  became	  confluent	  after	  56	  days.	  	  
Chemosensitivity	   results:	   ATP	   luminescent	   assay	   revealed	   sensitivity	   to	   all	  three	  drugs	  tested.	  (Table	  2-­‐17	  and	  Figure	  2-­‐12).	  	  
	  
Table	  2-­‐17	  Chemosensitivity	  results	  for	  the	  tested	  drugs.	  Drug	   ATP	  assay	  LD50	  (μg/ml)	  Cisplatin	   Sensitive	  (<0.4)	  	  Carmustine	   Sensitive	  (<	  1)	  Temozolomide	   Sensitive	  (64.3)	  
Resistance	  indicates	  that	  the	  calculated	  LD50	  does	  not	  fall	  within	  the	  range	  of	  the	  
tested	  drug	  concentrations.	  Calculated	  LD50	  is	  shown	  in	  parenthesis.	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Figure	  2-­‐12	  Dose	  response	  curves	  for	  BTNW	  382	  using	  the	  ATP	  assay.	  The	  data	  points	  are	  means	  of	  
4	  repeats.	  The	  error	  bars	  represent	  standard	  deviations.	  Linear	   trend	   line	  was	   fitted	  on	   the	  data	  
points	  to	  assist	  the	  calculation	  of	  LD50.	  	  
y	  =	  -­‐34.809x	  +	  26050	  
y	  =	  -­‐176.31x	  +	  6710.1	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BTNW	  377	  	  
Clinical	  History:	  This	  45-­‐year-­‐old	  female	  presented	  with	  a	  four-­‐month	  history	  of	   headaches,	   confusion	   and	   memory	   loss.	   On	   examination	   he	   had	   a	   GCS	   of	  15/15	  and	  no	  focal	  neurological	  findings.	  She	  underwent	  adjuvant	  radiotherapy	  treatment	   with	   concomitant	   Temozolomide	   chemotherapy.	   She	   died	   after	   53	  weeks.	  	  
Radiology:	  CT	  scan	  revealed	  a	  left	  temporal	  lesion.	  	  
Surgery:	  Craniotomy	  and	  debulking	  with	  Gliadel	  wafers	  performed	  on	  the	  22nd	  of	  July	  2009.	  	  	  
Histology:	  Histopathology	  revealed	  a	  Glioblastoma	  multiforme	  WHO	  grade	  IV.	  	  
Primary	  culture:	  Culture	  became	  confluent	  after	  25	  days.	  	  
Chemosensitivity	   results:	   ATP	   luminescent	   assay	   revealed	   resistance	   to	  Carmustine	   and	  Temozolomide.	   Cisplatin	   reached	   a	   50%	   cell	   kill.	   (Table	   2-­‐18	  and	  Figure	  2-­‐13).	  	  
	  
	  
Table	  2-­‐18	  Chemosensitivity	  results	  for	  the	  tested	  drugs.	  Drug	   ATP	  assay	  LD50	  (μg/ml)	  Cisplatin	   Sensitive	  (32.30)	  Carmustine	   Resistant	  Temozolomide	   Resistant	  
Resistance	  indicates	  that	  the	  calculated	  LD50	  does	  not	  fall	  within	  the	  range	  of	  the	  
tested	  drug	  concentrations.	  Calculated	  LD50	  is	  shown	  in	  parenthesis.	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Figure	  2-­‐13	  Dose	  response	  curves	  for	  BTNW	  377	  using	  the	  ATP	  assay.	  The	  data	  points	  are	  means	  of	  
4	  repeats.	  The	  error	  bars	  represent	  standard	  deviations.	  Linear	   trend	   line	  was	   fitted	  on	   the	  data	  
points	  to	  assist	  the	  calculation	  of	  LD50.	  	  
y	  =	  44.962x	  +	  51115	  
y	  =	  -­‐517.93x	  +	  47319	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BTNW	  500	  	  
Clinical	  History:	   This	   72-­‐year-­‐old	   female	  presented	  with	  headaches,	  memory	  loss	  and	  personality	  changes.	  On	  examination	  she	  had	  a	  GCS	  of	  15/15	  with	  no	  focal	  neurological	   findings.	  She	  received	  palliative	  radiotherapy	  and	  died	  after	  17	  weeks.	  	  
Radiology:	  CT	  scan	  revealed	  a	  right	  frontal	  lesion.	  	  
Surgery:	  Craniotomy	  and	  debulking	  performed	  on	  the	  23rd	  of	  March	  2010.	  	  
Histology:	  Histopathology	  revealed	  a	  Glioblastoma	  multiforme	  WHO	  grade	  IV.	  	  
Primary	  culture:	  Culture	  became	  confluent	  after	  73	  days.	  	  
Chemosensitivity	   results:	   ATP	   luminescent	   assay	   revealed	   resistance	   to	  Cisplatin	   and	   Carmustine.	   Temozolomide	   reached	   a	   50%	   cell	   kill.	   (Table	   2-­‐19	  and	   Figure	   2-­‐14).	   Given	   the	   observed	   dose	   response	   trends	   Cisplatin	   was	  expected	  to	  reach	  LD50	  at	  45.28	  μg/ml.	  
	  
	  
Table	  2-­‐19	  Chemosensitivity	  results	  for	  the	  tested	  drugs.	  Drug	   ATP	  assay	  LD50	  (μg/ml)	  Cisplatin	   Resistant	  (45.28)	  Carmustine	   Resistant	  Temozolomide	   Sensitive	  (102.7)	  
Resistance	  indicates	  that	  the	  calculated	  LD50	  does	  not	  fall	  within	  the	  range	  of	  the	  
tested	  drug	  concentrations.	  Calculated	  LD50	  is	  shown	  in	  parenthesis.	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Figure	  2-­‐14	  Dose	  response	  curves	  for	  BTNW	  500	  using	  the	  ATP	  assay.	  The	  data	  points	  are	  means	  of	  
4	  repeats.	  The	  error	  bars	  represent	  standard	  deviations.	  Linear	   trend	   line	  was	   fitted	  on	   the	  data	  
points	  to	  assist	  the	  calculation	  of	  LD50.	  	  	  
y	  =	  -­‐628.11x	  +	  163457	  
















Log	  Drug	  Concentration	  (μg/ml)	  





	   86	  
BTNW	  533	  	  
Clinical	   History:	   This	   67-­‐year-­‐old	   male	   presented	   with	   sudden	   onset	   of	  expressive	  dysphasia.	  On	  examination	  he	  had	  a	  GCS	  of	  14/15	  with	  receptive	  and	  expressive	   dysphasia	   and	   no	   focal	   neurological	   deficit.	   He	   received	   adjuvant	  radiotherapy	   (54	   Gys)	   with	   concomitant	   Temozolomide	   treatment	   and	   died	  after	  21	  weeks.	  	  
Radiology:	  CT	  scan	  revealed	  a	  left	  temporal	  lesion.	  	  
Surgery:	  Craniotomy	  and	  debulking	  performed	  on	  the	  11th	  of	  May	  2010.	  	  
Histology:	  Histopathology	  revealed	  a	  Glioblastoma	  multiforme	  WHO	  grade	  IV.	  	  
Primary	  culture:	  Culture	  became	  confluent	  after	  24	  days.	  	  
Chemosensitivity	   results:	   ATP	   luminescent	   assay	   revealed	   resistance	   to	  Cisplatin	   and	   Carmustine.	   Temozolomide	   reached	   a	   50%	   cell	   kill.	   (Table	   2-­‐20	  and	   Figure	   2-­‐15).	   Given	   the	   observed	   dose	   response	   trends	   Cisplatin	   was	  expected	  to	  reach	  LD50	  at	  82.86	  μg/ml.	  
	  
	  
Table	  2-­‐20	  Chemosensitivity	  results	  for	  the	  tested	  drugs.	  Drug	   ATP	  assay	  LD50	  (μg/ml)	  Cisplatin	   Resistant	  (82.86)	  Carmustine	   Resistant	  	  Temozolomide	   Sensitive	  (2)	  
Resistance	  indicates	  that	  the	  calculated	  LD50	  does	  not	  fall	  within	  the	  range	  of	  the	  
tested	  drug	  concentrations.	  Calculated	  LD50	  is	  shown	  in	  parenthesis.	  	  
	   87	  
	  
Figure	  2-­‐15	  Dose	  response	  curves	  for	  BTNW	  533	  using	  the	  ATP	  assay.	  The	  data	  points	  are	  means	  of	  
4	  repeats.	  The	  error	  bars	  represent	  standard	  deviations.	  Linear	   trend	   line	  was	   fitted	  on	   the	  data	  
points	  to	  assist	  the	  calculation	  of	  LD50.	  	  	  
y	  =	  -­‐916.61x	  +	  219907	  
y	  =	  -­‐166.04x	  +	  111012	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BTNW	  546	  	  
	  
Clinical	   History:	   This	   50-­‐year-­‐old	   female	   presented	   with	   headache.	   On	  examination	   she	  had	  a	  GCS	  of	  14/15	  with	   receptive	  and	  expressive	  dysphasia	  and	  left	  sided	  hemiparesis.	  She	  did	  not	  receive	  any	  adjuvant	  treatment	  because	  of	  her	  poor	  Karnofsky	  score	  (60).	  She	  died	  after	  3	  weeks.	  	  
Radiology:	  CT	  revealed	  a	  right	  frontal	  intrinsic	  lesion.	  	  	  
Surgery:	  Craniotomy	  and	  debulking	  performed	  on	  the	  25th	  of	  May	  2010.	  	  
Histology:	  Histopathology	  revealed	  a	  Glioblastoma	  multiforme	  WHO	  grade	  IV.	  	  
Primary	  culture:	  Culture	  became	  confluent	  after	  44	  days.	  	  
Chemosensitivity	   results:	   ATP	   luminescent	   assay	   revealed	   resistance	   to	  Temozolomide.	   Cisplatin	   and	   Carmustine	   reached	   a	   50%	   cell	   kill.	   (Table	   2-­‐21	  and	  Figure	  2-­‐16).	  	  
	  
	  
Table	  2-­‐21	  Chemosensitivity	  results	  for	  the	  tested	  drugs.	  Drug	   ATP	  assay	  LD50	  (μg/ml)	  Cisplatin	   Sensitive	  (19.29)	  Carmustine	   Sensitive	  (7.7)	  Temozolomide	   Resistant	  
Resistance	  indicates	  that	  the	  calculated	  LD50	  does	  not	  fall	  within	  the	  range	  of	  the	  
tested	  drug	  concentrations.	  Calculated	  LD50	  is	  shown	  in	  parenthesis.	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Figure	  2-­‐16	  Dose	  response	  curves	  for	  BTNW	  546	  using	  the	  ATP	  assay.	  The	  data	  points	  are	  means	  of	  
4	  repeats.	  The	  error	  bars	  represent	  standard	  deviations.	  Linear	   trend	   line	  was	   fitted	  on	   the	  data	  
points	  to	  assist	  the	  calculation	  of	  LD50.	  	  	  	  	  
y	  =	  -­‐88.831x	  +	  136699	  
y	  =	  -­‐1711.3x	  +	  113433	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BTNW	  590	  
	  
Clinical	  History:	  This	  52-­‐year-­‐old	  male	  presented	  with	  headaches,	  expressive	  dysphasia	  and	  right	  upper	  limb	  weakness	  4/5.	  On	  examination	  he	  had	  a	  GCS	  of	  15/15	  with	  expressive	  dysphasia.	  He	  received	  adjuvant	  radiotherapy	  (54	  Gys)	  with	   concomitant	   Temozolomide	   followed	   by	   adjuvant	   Temozolomide	  chemotherapy	  treatment.	  He	  died	  after	  80	  weeks.	  	  
Radiology:	  CT	  revealed	  a	  left	  frontal	  intrinsic	  lesion.	  	  
Surgery:	  Craniotomy	  and	  debulking	  performed	  on	  the	  15th	  of	  July	  2010.	  	  	  
Histology:	  Histopathology	  revealed	  a	  Glioblastoma	  multiforme	  WHO	  grade	  IV.	  	  
Primary	  culture:	  Culture	  became	  confluent	  after	  203	  days.	  	  
Chemosensitivity	   results:	   ATP	   luminescent	   assay	   revealed	   resistance	   to	  Carmustine	   and	  Temozolomide.	   Cisplatin	   reached	   a	   50%	   cell	   kill.	   (Table	   2-­‐22	  and	  Figure	  2-­‐17).	  Given	  the	  observed	  dose	  response	  trends	  Temozolomide	  was	  expected	  to	  reach	  LD50	  at	  483.12	  μg/ml.	  
	  
	  
Table	  2-­‐22	  Chemosensitivity	  results	  for	  the	  tested	  drugs.	  Drug	   ATP	  assay	  LD50	  (μg/ml)	  Cisplatin	   Sensitive	  (25.92)	  Carmustine	   Resistant	  Temozolomide	   Resistant	  (483.12)	  
Resistance	  indicates	  that	  the	  calculated	  LD50	  does	  not	  fall	  within	  the	  range	  of	  the	  
tested	  drug	  concentrations.	  Calculated	  LD50	  is	  shown	  in	  parenthesis.	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Figure	  2-­‐17	  Dose	  response	  curves	  for	  BTNW	  590	  using	  the	  ATP	  assay.	  The	  data	  points	  are	  means	  of	  
4	  repeats.	  The	  error	  bars	  represent	  standard	  deviations.	  Linear	   trend	   line	  was	   fitted	  on	   the	  data	  
points	  to	  assist	  the	  calculation	  of	  LD50.	  	  	  	  
y	  =	  -­‐133.87x	  +	  123565	  
y	  =	  -­‐2149x	  +	  114612	  
y	  =	  -­‐127.02x	  +	  128114	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BTNW	  597	  	  
Clinical	   History:	   This	   73-­‐year-­‐old	   male	   presented	   with	   mild	   headache	   and	  unsteadiness.	   On	   examination	   he	   had	   a	   GCS	   of	   15/15	   with	   no	   neurological	  deficits.	   He	   received	   adjuvant	   radiotherapy	   (54	   Gys)	   with	   concomitant	  Temozolomide	   followed	   by	   adjuvant	   Temozolomide	   chemotherapy	   treatment.	  He	  died	  after	  108	  weeks.	  	  
Radiology:	  CT	  revealed	  a	  right	  frontal	  intrinsic	  lesion.	  	  
Surgery:	  Craniotomy	  and	  debulking	  performed	  on	  the	  21st	  of	  July	  2010.	  	  
Histology:	  Histopathology	  revealed	  a	  Glioblastoma	  multiforme	  WHO	  grade	  IV.	  	  
Primary	  culture:	  Culture	  became	  confluent	  after	  51	  days.	  	  
Chemosensitivity	   results:	   ATP	   luminescent	   assay	   revealed	   resistance	   to	  Carmustine	   and	  Temozolomide.	   Cisplatin	   reached	   a	   50%	   cell	   kill.	   (Table	   2-­‐23	  and	   Figure	   2-­‐18).	   Given	   the	   observed	   dose	   response	   trends	   Both	   Carmustine	  and	   Temozolomide	   were	   expected	   to	   reach	   LD50	   at	   167	   μg/ml	   and	   628.82	  μg/ml	  respectively.	  	  	  
Table	  2-­‐23	  Chemosensitivity	  results	  for	  the	  tested	  drugs.	  Drug	   ATP	  assay	  LD50	  (μg/ml)	  Cisplatin	   Sensitive	  (18.16)	  Carmustine	   Resistant	  (167)	  Temozolomide	   Resistant	  (628.82)	  
Resistance	  indicates	  that	  the	  calculated	  LD50	  does	  not	  fall	  within	  the	  range	  of	  the	  
tested	  drug	  concentrations.	  Calculated	  LD50	  is	  shown	  in	  parenthesis.	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Figure	  2-­‐18	  Dose	  response	  curves	  for	  BTNW	  597	  using	  the	  ATP	  assay.	  The	  data	  points	  are	  means	  of	  
4	  repeats.	  The	  error	  bars	  represent	  standard	  deviations.	  Linear	   trend	   line	  was	   fitted	  on	   the	  data	  
points	  to	  assist	  the	  calculation	  of	  LD50.	  	  	  	  
y	  =	  -­‐56.953x	  +	  70886	  
y	  =	  -­‐953.58x	  +	  52393	  


















Log	  Drug	  Concentration	  (μg/ml)	  
BTNW	  597	  	  
Temozolomide	  Cisplatin	  Carmustine	  Linear(Temozolomide)	  Linear(Cisplatin)	  Linear(Carmustine)	  
	   94	  
	  
2.4.4 Summary	  of	  LD50	  concentrations	  	  
	  
Figure	   2-­‐19	   LD50	   values	   for	   all	   patients.	   Values	   below	   the	  maximum	   drug	   concentration	   tested	  
represent	  LD50s.	  Maximum	  tested	  drug	  concentrations	  were:	  Cisplatin	  40	  μg/ml,	  Carmustine	  100	  













	  	  	  
LD50	  values	  	  
Cisplatin	  Carmustine	  Temozolomide	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It	  is	  apparent	  from	  Figure	  2-­‐19	  that	  almost	  all	  primary	  cultures	  but	  three	  were	  resistant	  to	  Temozolomide	  (BTNW	  500,	  BTNW	  382	  and	  BTNW	  533).	  Only	  one	  (BTNW	   382)	   out	   of	   the	   three	   cultures	   sensitive	   to	   Temozolomide	   was	   also	  sensitive	  to	  Cisplatin	  and	  Carmustine,	  making	  this	  culture	  sensitive	  to	  all	  three	  drugs	   tested.	  The	  other	   two	  Temozolomide	  sensitive	  cultures	  (BTNW	  500	  and	  BTNW	  533)	  were	  not	  sensitive	  to	  any	  other	  drug	  used.	  	  Carmustine	  was	  the	  drug	  with	  least	  kill	  effect.	  In	  fact	  only	  BTNW	  546	  and	  BTNW	  382	   demonstrated	   sensitivity	   to	   it.	   Both	   these	   cultures	   responded	   also	   to	  Cisplatin.	  	  	  Cisplatin	  was	   the	  drug	  with	  most	  kill	   effect	   as	  nine	  out	  of	   the	   twelve	   cultures	  were	  sensitive	  to	  it	  (BTNW	  370,	  BTNW	  597,	  BTNW	  590,	  BTNW	  544,	  BTNW	  546,	  BTNW	  377,	  BTNW	  365,	  BTNW	  374,	  BTNW	  382).	  Only	  two	  of	  these	  nine	  cultures	  (BTNW	  546	  and	  BTNW	  382)	  responded	  to	  other	  drugs	  in	  addition	  to	  Cisplatin.	  The	   remaining	   three	   cultures	   (BTNW	   338,	   BTNW	   500,	   BTNW	   533)	   were	  resistant	  to	  Cisplatin.	  Of	  these	  three	  BTNW	  500	  and	  BTNW	  533	  were	  sensitive	  to	   Temozolomide	   whereas	   BTNW	   338	   was	   the	   only	   culture	   resistant	   to	   all	  drugs.	  	  BTNW	  382	  was	  the	  most	  sensitive	  culture,	  responding	  to	  all	  drugs	  tested.	   It	   is	  important	  to	  emphasize	  that	  the	  concentrations	  required	  to	  produce	  kill	  effect	  to	   this	   culture	  were	   very	   small	   for	   all	   three	   drugs	   used	   (Cisplatin<0.4	   μg/ml,	  Carmustine	  <1	  μg/ml,	  Temozolomide	  64	  μg/ml).	  	  BTNW	  546	  was	  the	  second	  most	  sensitive	  culture	  responding	  to	  both	  Cisplatin	  and	   Carmustine,	   again	   at	   very	   low	   concentrations	   (Cisplatin	   19.29	   μg/ml	   and	  Carmustine	  7.7	  μg/ml).	  	  Based	  on	  these	  results,	   the	  average	  LD50	  for	  Temozolomide	  was	  14.08	  μg/ml,	  Carmustine	  0.73	  μg/ml,	  Cisplatin	  18.80	  μg/ml.	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2.4.5 Comparison	  of	  in	  vitro	  and	  in	  vivo	  data	  
	  In	   order	   to	   determine	   whether	   the	   results	   of	   the	   chemosensitivity	   studies	  exhibit	   any	   similarities	   with	   the	   clinical	   outcome,	   the	   in	   vitro	   results	   were	  compared	  to	  the	  clinical	  data	  for	  each	  patient.	  	  	  
BTNW	  338	  suffered	  from	  a	  Glioblastoma.	  In	  view	  of	  his	  age	  (71	  years)	  and	  his	  poor	   Karnofsky	   score	   (<70),	   he	   did	   not	   receive	   any	   adjuvant	   treatment.	   The	  overall	  survival	  (OS)	  of	  this	  patient	  was	  five	  weeks.	  The	  primary	  culture	  grown	  from	   this	   patient	   was	   resistant	   to	   all	   the	   drugs	   used.	   This	   finding	   suggests	  agreement	   between	   the	   clinical	   course	   of	   this	   patient	   and	   the	   in	   vitro	   results	  obtained.	  	  	  
BTNW	  370	  suffered	  from	  a	  butterfly	  Glioblastoma.	  In	  view	  of	  the	  extent	  of	  the	  tumour	  she	  received	  palliative	  radiotherapy.	  Her	  overall	  survival	  was	  six	  weeks.	  The	  in	  vitro	  results	  of	  the	  primary	  culture	  of	  this	  patient	  revealed	  resistance	  to	  all	   drugs	   except	   from	   Cisplatin.	   The	   LD50	   for	   Cisplatin	  was	   25.49	   μg/ml,	   five	  times	   the	   therapeutic	   dose	   of	   this	   drug.	   This	   finding	   suggests	   a	   possible	  agreement	   between	   the	   clinical	   course	   of	   this	   patient	   and	   the	   in	   vitro	   results	  obtained.	  	  	  
BTNW	  597	  suffered	  from	  a	  Glioblastoma.	  Despite	  his	  age	  (73	  years),	  as	  he	  had	  a	  good	   Karnofsky	   score	   he	   received	   radiotherapy	   with	   concomitant	  Temozolomide,	  followed	  by	  adjuvant	  Temozolomide	  chemotherapy.	  His	  overall	  survival	  was	   108	  weeks.	   The	   in	   vitro	   chemosensitivity	   results	   for	   this	   patient	  revealed	   resistance	   to	   Temozolomide	   and	   Carmustine	   and	   sensitivity	   to	  Cisplatin.	   The	   LD50	   for	   Temozolomide	   was	   expected	   to	   reach	   significance	   at	  628.82	  μg/ml.	  His	  OS	  survival	  outperformed	  the	  expected	  survival	   for	  his	  age,	  even	  with	  the	  Stupp	  chemotherapy	  regime.	  This	  observation	  suggests	  a	  possible	  agreement	  between	  the	  in	  vitro	  results	  obtained	  for	  this	  patient	  and	  his	  clinical	  course.	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BTNW	   590	   suffered	   from	   a	   Glioblastoma.	   Despite	   his	   poor	   Karnofsky	   score	  (70),	  he	  received	   the	  Stupp	  chemotherapy	  regime.	  His	  overall	   survival	  was	  80	  weeks,	   outperforming	   the	   expected	   survival	   reported	   in	   the	   literature.	   The	   in	  
vitro	   chemosensitivity	   results	   for	   this	   patient	   revealed	   sensitivity	   to	   Cisplatin	  and	  resistance	  to	  Carmustine	  and	  Temozolomide.	  However,	  Temozolomide	  was	  expected	   to	   reach	   significance	   at	   LD50	   483,12	   μg/ml.	   This	   observation	   could	  suggest	  a	  possible	  agreement	  between	  the	  clinical	  outcome	  for	  this	  patient	  with	  the	  in	  vitro	  results	  of	  his	  primary	  culture.	  	  
BTNW	  500	  suffered	  from	  a	  Glioblastoma.	  In	  view	  of	  her	  age	  (72	  years)	  and	  poor	  Karnofsky	  score	  (<70),	  she	  received	  palliative	  radiotherapy.	  Her	  overall	  survival	  was	   17	  weeks.	   The	   in	   vitro	   chemosensitivity	   to	   Temozolomide	   obtained	   from	  the	   primary	   culture	   for	   this	   patient	   was	   102.70	   μg/ml.	   There	   was	   no	   other	  sensitivity	   to	   the	   remaining	   drugs	   used.	   Keeping	   in	   mind	   that	   she	   received	  palliative	   radiotherapy,	   the	   slightly	   longer	   OS	   without	   receiving	   any	  chemotherapy	   treatment,	  would	   indicate	   a	   possible	   predictive	   value	   of	   the	   in	  
vitro	  results	  of	  this	  patient.	  	  
BTNW	  544	  suffered	  from	  a	  Glioblastoma.	  In	  view	  of	  his	  age	  (68	  years)	  and	  good	  Karnofsky	   score	   (>	   70),	   he	   received	   radiotherapy	   with	   concomitant	  Temozolomide,	  followed	  by	  adjuvant	  Temozolomide	  chemotherapy.	  OS	  for	  this	  patient	   was	   89	   weeks.	   The	   primary	   culture	   of	   this	   patient	   was	   sensitive	   to	  Cisplatin	   at	   37.54	  μg/ml.	   This	   value	   is	   nine	   times	  higher	   than	   the	   therapeutic	  concentration	  of	   this	  drug.	  His	  overall	  survival	  exceeds	   the	  one	  expected	   from	  the	   reported	   literature	   even	   for	   patients	   receiving	   the	   Stupp	   regime	   of	  chemoradiotherapy.	   His	   in	   vitro	   findings	   of	   chemosensitivity	   do	   not	   seem	   to	  agree	  with	  his	  clinical	  course.	  	  	  
BTNW	   546	   suffered	   from	   a	   Glioblastoma.	   As	   her	   Karnofsky	   score	   was	   60,	  despite	   her	   age	   (50	   years)	   she	   did	   not	   receive	   any	   adjuvant	   treatment.	   Her	  overall	  survival	  was	  only	  3	  weeks.	  The	  in	  vitro	  sensitivity	  results	  for	  this	  patient	  revealed	  sensitivity	  to	  both	  Cisplatin	  and	  Carmustine	  but	  not	  to	  Temozolomide.	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As	  this	  patient	  did	  not	  receive	  any	  adjuvant	  treatment,	  it	  is	  difficult	  to	  draw	  any	  conclusions	  between	  in	  vitro	  and	  the	  clinical	  data	  available.	  
	  
BTNW	   377	   suffered	   from	   a	   Glioblastoma.	   She	   was	   45	   years	   old	   at	   diagnosis	  with	   a	   good	   Karnofsky	   score	   (100).	   Intraoperatively	   she	   received	   six	   Gliadel	  wafers.	   This	   was	   then	   followed	   by	   adjuvant	   radiotherapy	   with	   concomitant	  Temozolomide	  and	  adjuvant	  Temozolomide	  chemotherapy.	  Her	  overall	  survival	  was	   53	   weeks.	   The	   primary	   culture	   obtained	   from	   this	   patient	   was	   only	  sensitive	  to	  Cisplatin	  (LD50	  32.30	  μg/ml).	  This	  concentration	  is	  eight	  times	  the	  therapeutic	   concentration	   of	   Cisplatin.	   The	   patient	   was	   treated	   with	   a	  combination	   of	   Carmustine	   wafers,	   radiotherapy	   and	   Temozolomide	  chemotherapy.	   Her	   OS	   was	   less	   than	   the	   expected	   OS	   of	   patients	   receiving	  similar	  treatment,	  giving	  the	  in	  vitro	  results	  a	  possible	  predictive	  value.	  	  
BTNW	   365	   suffered	   from	   a	   Grade	   II	   Fibrillary	   Astrocytoma	   with	   atypical	  features.	   She	  was	   42	   years	   old	   at	   diagnosis.	   Her	  Karnofsky	   score	  was	   >70.	   In	  view	   of	   the	   radiological	   appearances,	   this	   patient	   was	   treated	   as	   a	   grade	   III	  astrocytoma	   and	   received	   postoperative	   radiotherapy.	   She	   died	   after	   163	  weeks.	   The	   primary	   culture	   obtained	   from	   this	   patient	   showed	   sensitivity	   to	  Cisplatin	  (LD50	  32.57	  μg/ml)	  but	  not	  to	  the	  other	  drugs	  used.	  As	  this	  patient	  did	  not	   have	   chemotherapy	   treatment,	   it	   is	   difficult	   to	   draw	   any	   conclusions	  between	  the	  in	  vitro	  and	  the	  clinical	  data	  available.	  	  
BTNW	  374	  suffered	  from	  a	  Glioblastoma.	  In	  view	  of	  her	  young	  age	  (34	  years)	  and	   good	  Karnofsky	   score	   (>70),	   she	   received	   radiotherapy	  with	   concomitant	  Temozolomide,	   followed	   by	   adjuvant	   Temozolomide	   chemotherapy.	   Overall	  survival	  	  for	  this	  patient	  was	  30	  weeks.	  The	  primary	  culture	  obtained	  from	  this	  patient	   was	   sensitive	   to	   Cisplatin	   with	   LD50	   (33.50	   μg/ml)	   eight	   times	   the	  therapeutic	   concentration	   for	   this	  drug.	  She	   received	   the	  Stupp	  chemotherapy	  regime.	   Her	   overall	   survival	   was	   worse	   than	   the	   one	   expected	   from	   the	  published	  literature.	  The	  in	  vitro	  results	  for	  this	  patient	  would	  concord	  with	  the	  observed	  clinical	  course.	  	  
	   99	  
BTNW	  533	  suffered	  from	  a	  Glioblastoma.	  In	  view	  of	  his	  age	  (76	  years)	  and	  good	  Karnofsky	   score	   (>70),	   he	   received	   radiotherapy	   with	   concomitant	  Temozolomide,	   followed	  by	  adjuvant	  Temozolomide	  chemotherapy	  His	  overall	  survival	   was	   21	   weeks.	   The	   primary	   culture	   obtained	   form	   this	   patient	   was	  sensitive	  to	  Temozolomide	  (LD50	  2	  μg/ml).	  He	  received	  radiotherapy	  with	  the	  Stupp	  chemotherapy	  regime	  and	  unlike	  his	  in	  vitro	  response	  his	  OS	  was	  only	  21	  weeks.	  	  	  
BTNW	  382	  suffered	  from	  a	  Glioblastoma.	  In	  view	  of	  her	  age	  (75	  years)	  and	  poor	  Karnofsky	   score	   (<70),	   she	   only	   received	   adjuvant	   radiotherapy.	   Her	   overall	  survival	  was	   109	  weeks.	   The	   primary	   culture	   obtained	   from	   this	   patient	  was	  sensitive	  to	  all	  drugs	  tested.	  The	  LD50	  for	  the	  drugs	  used	  was	  low	  (Cisplatin<0.4	  μg/ml,	  Carmustine	  <1	  μg/ml,	  Temozolomide	  64	  μg/ml)	  potentially	  making	  her	  a	  suitable	   candidate	   for	   chemotherapy.	   Her	   clinical	   course	   would	   confirm	   the	  good	  predictive	  value	  of	  the	  results	  obtained	  from	  the	  in	  vitro	  chemosensitivity	  testing	  for	  her.	  	  Overall	   the	   in-­‐vitro	   results	   of	   this	   study	   are	   in	   agreement	   with	   the	   clinical	  outcome.	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2.5 Discussion	  	  Fifty-­‐two	  tumour	  specimens	  were	  used	  in	  the	  present	  study	  in	  order	  to	  produce	  primary	   cell	   cultures.	   Twelve	   of	   those	   gave	   rise	   to	   cell	   cultures,	   which	   were	  tested	  with	   three	   chemotherapeutic	   agents.	   These	  drugs	  were	  Temozolomide,	  Carmustine	   and	   Cisplatin	   in	   three	   different	   concentrations	   (therapeutic	  concentration,	  10-­‐fold	  higher	  and	  10-­‐fold	   lower).	  The	  results	  have	  shown	  that	  Cisplatin	  and	  Temozolomide	  were	  effective	  at	  the	  highest	  concentration	  tested.	  Younger	   age	   was	   more	   responsive	   to	   these	   drugs.	   In	   addition,	   females	   were	  significantly	   more	   receptive	   to	   chemotherapy	   treatment.	   The	   LD50	  concentration	  was	  calculated	  for	  each	  culture	  and	  the	  results	  were	  compared	  to	  the	  clinical	  data	  available	  for	  the	  donor	  patient.	  	  	  A	  culture	  is	  defined	  arbitrarily	  as	  chemosensitive	  to	  a	  particular	  drug,	  when	  the	  concentration	  of	  the	  drug	  provokes	  at	   least	  50%	  cell	  death	  when	  compared	  to	  the	   untreated	  population.	  However,	   the	   value	   that	   defines	   chemosensitivity	   is	  culture	  specific	  and	  therefore	  potentially	  highly	  variable	  between	  cultures.	  	  	  The	   drugs	   tested	   in	   the	   present	   study	   are	   commonly	   administered	   as	  chemotherapeutic	   agents	   to	   patients	   treated	   in	   our	   Institution.	   Of	   these	   three	  drugs,	   the	   doses	   of	   Cisplatin	   and	   Carmustine	   were	   comparable	   to	   their	   peak	  plasma	  concentration,	  whilst	  the	  dose	  used	  for	  Temozolomide	  was	  equivalent	  to	  its	   Cerebrospinal	   Fluid	   (CSF)	   levels.	   The	   peak	   plasma	   concentration	   of	   each	  drug	  was	  defined	  as	   its	   therapeutic	  dose.	   In	  order	   to	  observe	  a	  dose	  response	  effect	   for	   each	   of	   these	   drugs,	   two	   additional	   concentrations,	   ten	   times	   lower	  and	  ten	  times	  higher,	  were	  included	  in	  this	  project.	  	  	  The	  central	  nervous	  system	  (CNS)	   is	  a	  pharmacological	   sanctuary	  and	  as	  such	  peak	  plasma	   concentrations	  of	   drugs	   are	  not	   reflected	   in	   their	  CSF	   levels.	   For	  the	   purpose	   of	   this	   study,	   it	   was	   assumed	   that	   the	   levels	   of	   each	   drug	   in	   the	  Cerebrospinal	  Fluid	  (CSF)	  were	  similar	  to	  their	  peak	  plasma	  concentrations.	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As	   there	  were	  no	  previously	   reported	  cisplatin	  peak	  plasma	  concentrations	   in	  patients	   with	   malignant	   gliomas	   it	   is	   difficult	   to	   draw	   any	   comparative	  conclusions.	   The	   closest	   study	   that	   could	   be	   found	   was	   by	   Himmelstein	   and	  coworkers	   who	   studied	   Cisplatin	   therapeutic	   concentrations	   in	   patients	   with	  head	   and	   neck	   cancers.	   They	   found	   that	   for	   these	   patients	   the	   therapeutic	  concentrations	   of	   Cisplatin	   was	   6	   µg/ml	   [149].	   Another	   relevant	   study	  performed	   by	   Belliveau	   and	   coworkers	   reported	   cisplatin	   peak	   plasma	  concentrations	   of	   4	   µg/ml	   in	   five	   patients	   [150].	   Unlike	   Cisplatin,	   the	   peak	  plasma	  concentrations	  of	  Temozolomide	  and	  Carmustine	  have	  been	  previously	  determined	   in	   patients	   with	   malignant	   gliomas.	   The	   reported	   concentrations	  were	  4	  µg/ml	  for	  Temozolomide	  and	  0.1	  µg/ml	  for	  Carmustine	  [144].	  	  	  In	  the	  case	  of	  malignant	  gliomas,	  there	  could	  be	  several	  factors	  responsible	  for	  poor	   chemosensitivity.	   For	   instance,	   one	   of	   them	   could	   be	   the	   poor	   drug	  delivery	   to	   the	   tumour	  site.	  This	  could	  be	  due	  to	  poor	  penetration	  of	   the	  drug	  through	  the	  BBB,	  altered	  blood	  tumour	  supply	  or	  even	  impeded	  drug	  diffusion	  within	   the	   tumour	   mass.	   Another	   possible	   factor	   for	   poor	   response	   to	  chemotherapy	   could	   be	   a	   suboptimal	   intracellular	   drug	   concentration.	   For	  example,	   the	   tumour	   cells	   might	   not	   be	   able	   to	   take	   up	   the	   drug	   or	   have	  increased	  efflux	  mechanisms	  [151,	  152].	  Furthermore,	  cancer	  cells	  could	  suffer	  physiological	   alterations,	   which	   could	   affect	   processes	   such	   as	   apoptosis	   and	  drug	   metabolism	   (pro-­‐drug	   activation	   or	   drug	   break	   down).	   Lastly,	   as	  chemotherapeutic	  agents	  are	  known	  to	  cause	  DNA	  damage,	  cancer	  cells	  that	  are	  able	   to	   rapidly	   repair	   their	   DNA	   could	   manifest	   chemoresistance.	   Poor	  chemosensitivity	   could	   be	   also	   a	   result	   of	   the	   failure	   of	   mechanisms	   that	  promote	  and	  execute	  apoptosis.	  For	  example,	  the	  tumour	  suppressor	  gene	  p53	  senses	   DNA	   damage	   by	   detecting	   DNA	   strand	   breaks	   caused	   by	   the	   drugs.	  Tumours	  with	   functioning	  p53,	  will	  promote	  cell	  death,	  whereas	  p53	  defective	  tumours	  could	  be	  more	  resistant	  to	  DNA	  damage	  [22].	  	  As	  it	  is	  impossible	  to	  perform	  chemosensitivity	  testing	  in	  patients	  directly,	  this	  study	  uses	  primary	  glioma	  cultures	  that	  derived	  from	  tissue	  donated	  from	  those	  patients.	   The	   results	   indicate	   that	   Cisplatin	   40	   µg/ml	   together	   with	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Temozolomide	  200	  µg/ml	  were	  found	  to	  be	  effective.	  This	  finding	  that	  Cisplatin	  is	   the	   drug	  with	   good	   kill	   effect	   is	   well	   documented	   in	   the	   literature	   both	   in	  malignant	  glioma	  primary	  cultures	  and	  cell	   lines	   [153-­‐157].	  Temozolomide	  on	  the	   other	   hand	   has	   been	   described	   as	   having	   variable	   effect.	   In	   those	   cases	  where	  Temozolomide	  was	  effective,	  the	  cell	  kill	  produced	  was	  found	  to	  be	  dose	  dependent	   [158,	   159].	   Both	   drugs	   demonstrated	   kill	   effect	   when	   used	   at	   the	  highest	   concentrations,	   which	   is	   in	   accordance	   with	   the	   reported	   literature	  [159].	  Lower	  drug	  concentrations	  used	  were	  not	  found	  to	  be	  effective	  possibly	  due	   to	   the	   fact	   that	  not	  enough	  active	  compound	  was	   taken	  up	  by	   the	   tumour	  cells.	  	  	  Temozolomide	   is	   now	   the	   standard	   of	   care	   for	   the	   treatment	   of	   malignant	  gliomas	  [160].	  Standard	  of	  care	   is	  defined	  as	   the	   therapy	  that	  experts	  agree	   is	  appropriate,	  accepted	  and	  widely	  used.	  As	  such,	  Temozolomide	  has	  replaced	  the	  previous	  PCV	  (Procarbazine/CCNU	  a.k.a.	  Lomustine/Vincristine)	  chemotherapy	  regime	   for	   malignant	   gliomas.	   The	   dose	   as	   well	   as	   the	   frequency	   of	  administering	   Temozolomide	   chemotherapy	   is	   widely	   investigated	   and	   new	  methods	  have	  been	  proposed	  [161,	  162].	  PCV	  is	  currently	  used	  as	  a	  second	  line	  treatment	  after	  recurrence	  when	  previously	  treated	  with	  Temozolomide.	  	  	  	  Cisplatin	   can	   also	   be	   used	   as	   second	   line	   treatment	   after	   recurrence.	   Despite	  this,	   it	   is	  mainly	  used	   in	  patients	  who	  develop	   further	  recurrence	  as	   third	   line	  treatment,	   when	   both	   Temozolomide	   and	   PCV	   have	   been	   used,	   and	   even	  repeated.	  The	  use	  of	  Cisplatin	  is	   limited	  by	  the	  considerable	  side	  effects	  that	  it	  produces,	   such	   as	   nephrotoxicity,	   ototoxicity,	   nausea,	   vomiting,	   electrolyte	  disturbance	   in	   the	   form	   of	   hypomagnesaemia,	   hypocalcaemia	   and	  hypokalaemia,	  haemolytic	  anaemia	  and	  myelotoxicity	  [163].	  	  	  There	   is	   a	   clear	   need	   for	   predicting	   which	   is	   the	   most	   suitable	   drug	   dose	  combination	   for	   the	   individual	   patient	   affected	   by	   malignant	   glioma.	   For	  example,	   it	   is	   known	   that	   the	   response	   to	   Temozolomide	   depends	   on	   the	  methylation	   status	   of	   the	   MGMT	   (O6-­‐methylguanine	   methyltransferase)	  promoter	   [98].	   Although	   MGMT	   testing	   is	   available,	   it	   is	   not	   widely	   used	   in	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clinical	  practice.	  Temozolomide	  is	  used	  for	  treatment	  in	  all	  patients	  affected	  by	  malignant	  gliomas	  regardless	  of	  their	  MGMT	  methylation	  status.	  	  	  This	   study,	   although	   small	   (12	   patients),	   demonstrates	   a	   good	   agreement	  between	   chemosensitivity	   testing	   and	   clinical	   outcome.	   Further	   studies	   are	  required	   in	   order	   to	   validate	   its	   predictive	   value	   in	   clinical	   practice.	   In	   vitro	  chemosensitivity	   studies,	   if	   successful,	   could	   provide	   an	   additional	   line	   of	  evidence	   in	   supporting	   the	   choice	   of	   chemotherapy	   drug	   and	   concentration	  tailored	  to	  each	  patient.	  	  	  The	  mode	   of	   action	   of	   all	   three	   drugs	   tested	   is	   by	   causing	   DNA	   damage	   (see	  Chapter	   1).	   Facilitating	   the	   access	   to	   these	   drugs	   to	   the	   DNA,	   could	   improve	  their	  efficacy.	  Ways	  to	  achieve	  this	  would	  be	  by	  enhancing	  the	  drug	  formulation,	  improving	  drug	  delivery	  and	  rendering	  the	  target	  cells	  more	  susceptible	  to	  the	  drug.	   Slow	   release	   formulations	   and	   longer	   half-­‐life	   could	   lead	   to	   improved	  stability	  of	  the	  drug’s	  active	  component.	  Similarly,	  disruption	  of	  the	  intercellular	  tumour	   matrix	   and	   facilitating	   both	   transmembrane	   and	   intracellular	   drug	  transport	   would	   improve	   the	   drug’s	   access	   to	   its	   substrate.	   Furthermore,	  inhibition	   of	   the	   metabolic	   pathways	   that	   cause	   drug	   deactivation	   and	  suppression	  of	  DNA	  repair	  mechanisms	  would	  render	  cells	  more	  vulnerable	  to	  the	   drug’s	   activity.	   There	   are	   several	   studies	   already	   focusing	   on	   the	  enhancement	  of	  the	  overall	  effect	  of	  chemotherapy	  drugs	  [158,	  164-­‐167].	  	  	  As	   expected,	   this	   study	   has	   found	   considerable	   variability	   in	   the	   response	   of	  individual	   patients	   to	   the	   tested	   drugs	   and	   concentrations.	   For	   example,	  Cisplatin	  was	   effective	   in	   nine	   patients,	   but	   three	   others	  were	   resistant.	   Even	  between	   the	   nine	   sensitive	   patients,	   there	   was	   great	   variation	   of	   their	   LD50	  concentration.	   The	   variability	   observed	   could	   be	   a	   result	   of	   the	   extensive	  genetic	  heterogeneity	  of	  the	  malignant	  glial	  cells.	  For	  instance,	  malignant	  glioma	  cells	   were	   found	   to	   have	   several	   genetic	   alterations	   including	   1p/19q	   loss	   of	  heterozygosity,	   EGFR	   amplification	   and	   isocitrate	   dehydrogenase	   1	   (IDH1)	  mutations	  [168].	  	  
	   104	  
Another	   possible	   cause	   for	   the	   variability	   observed	   could	   be	   related	   to	   the	  tissue	  specimen	  cultures.	  For	  example,	  the	  specimen	  arriving	  in	  the	  laboratory	  could	   be	   part	   of	   the	   necrotic	   rather	   than	   the	   actively	   dividing	   area	   of	   the	  tumour,	  and	  as	  such	  would	  not	  give	  rise	  to	  a	  culture	  that	  is	  representative	  of	  the	  tumour.	   Furthermore,	   as	   there	   are	   quiescent	   cells	   in	   the	   culture,	   the	  chemosensitivity	  measurements	  might	  not	  be	  entirely	  accurate.	  Quiescent	  cells	  will	   not	   be	   killed	   by	   the	   drug,	   but	   still	   be	   accounted	   for	   by	   the	   ATP	   assay	  measurement.	  	  	  Assay	   methodology	   could	   also	   be	   accounted	   for	   the	   variability	   observed.	  Parameters	   like	   drug	   exposure	   time,	   dosing	   frequency,	   initial	   number	   of	   cells	  and	   number	   of	   replicates	   could	   potentially	   affect	   the	   observed	   variability.	  Standard	  laboratory	  procedures	  such	  as	  tissue	  culturing,	  sterile	  handling	  as	  well	  as	  good	  laboratory	  practices	  would	  reduce	  the	  likelihood	  of	  variability	  between	  samples.	  	  In	  the	  present	  study,	  chemosensitivity	  to	  the	  drugs	  tested	  was	  evaluated	  using	  the	   LD50	   concentration.	   The	   average	   LD50	   for	   Temozolomide	   was	   164.08	  μg/ml	   (±	  68.49),	   Carmustine	  84.06	  μg/ml	   (±37.26)	   and	  Cisplatin	  28.80	  μg/ml	  (±11.79).	  Studies	  on	  mice	  and	  rats	  have	  reported	  LD50	  of	  1937	  mg/m2	  after	  oral	  administration	  of	  Temozolomide.	  When	  Temozolomide	  was	  administered	  via	  an	  intraperitoneal	   injection,	  the	  LD50	  was	  1414	  mg/m2	  [169].	  A	  study	  performed	  in	   our	   Institution	   using	   short-­‐term	   primary	   cultures	   of	   malignant	   gliomas,	  reported	  LD50	  concentrations	  for	  Cisplatin	  and	  Carmustine	  as	  being	  1-­‐37	  μg/ml	  and	   10-­‐90 μg/ml	   respectively	   [168].	   Given	   the	   great	   variability	   found	   in	   the	  present	  study	  of	  the	  LD50	  between	  patients,	  a	  mean	  LD50	  value	  would	  not	  be	  very	  informative.	  On	  the	  contrary,	  the	  LD50	  value	  for	  each	  individual	  would	  be	  more	   appropriate	   and	   relevant	   to	   the	   patient’s	   chemosensitivity	   profile.	  Nevertheless,	   calculating	   the	   LD50	   for	   each	   drug	   was	   not	   always	  straightforward.	   A	   larger	   number	   of	   tested	   concentrations	   as	   well	   as	   more	  replicates	   would	   facilitate	   a	   more	   precise	   calculation	   of	   the	   LD50.	   The	   only	  constraint	  to	  this	  approach	  would	  be	  the	  limited	  number	  of	  available	  cells	  from	  the	  primary	  culture.	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  The	  novelty	  of	  this	  study	  lies	  in	  the	  use	  of	  primary	  glioma	  cultures	  at	  passage	  0	  as	   opposed	   to	   short-­‐term	   glioma	   cultures	   or	   glioma	   cell	   lines.	   This	   type	   of	  culture	  is	  more	  suitable	  for	  chemosensitivity	  studies	  as	  it	  is	  more	  representative	  of	   the	   considerable	   genetic	   heterogeneity	   of	   malignant	   gliomas	   between	  patients.	   On	   the	   contrary,	   glioma	   cell	   lines	   carry	   a	  more	   homogenous	   genetic	  load,	   as	   with	   every	   passage	   there	   is	   clonal	   selection	   of	   rapidly	   dividing	   cells.	  Such	  genetic	  misrepresentation	  in	  cell	  lines	  poses	  a	  limit	  as	  to	  their	  usefulness	  in	  research	  and	  clinical	  studies.	  	  Age	  was	  another	  factor	  that	  influenced	  chemosensitivity	  in	  the	  present	  study.	  	  Overall	   the	   under	   65	   years	   age	   group	   responded	   better	   to	   chemotherapy	  treatment	  with	   the	   aforementioned	   drugs	   although	   it	  was	   hard	   to	   draw	   solid	  conclusions	   based	   on	   these	   findings.	   These	   results	   concord	  with	   the	   reported	  literature	  where	  there	  is	  no	  consensus	  on	  the	  role	  of	  age	  in	  relation	  to	   in	  vitro	  chemosensitivity	  [126,	  170,	  171].	  On	  the	  other	  hand,	  age	  is	  a	  known	  prognostic	  factor	   in	   gliomas	   in	   clinical	   practice.	   Several	   studies	   have	   identified	   that	  amongst	  others,	   age	   is	  an	   important	   factor	   that	   influences	   survival	   in	  patients	  with	   high-­‐grade	   glioma	   [172-­‐174].	   This	   could	   be	   due	   to	   the	   accumulation	   of	  more	  genetic	  defects	  over	  a	  period	  of	  time	  or	  because	  of	  the	  reduced	  capacity	  of	  aged	  cells	  to	  repair	  DNA	  damage.	  	  	  The	  results	  of	   this	  study	  have	  also	  shown	  that	   females	  were	  more	  sensitive	  to	  the	   tested	   drugs	   at	   the	   different	   doses	   than	   the	   males.	   Similar	   findings	   have	  been	  reported	  in	  the	  literature,	  but	  the	  cause	  of	  this	  observation	  is	  still	  unclear	  [175].	  	  Another	   advantage	   of	   the	   present	  work	   is	   the	   availability	   of	   clinical	   data	   that	  enabled	   a	   retrospective	   evaluation	   of	   the	   chemosensitivity	   results.	   There	  was	  good	  agreement	  between	   in	  vivo	  and	   in	  vitro	  results	   for	  nine	  out	  of	  the	  twelve	  patients	  tested.	  For	  example,	  BTNW	  377	  received	  Temozolomide	  chemotherapy	  but	   survived	   only	   53	  weeks,	   despite	   her	   young	   age.	   In	   vitro	   chemosensitivity	  testing	   for	   the	   same	  patient	   revealed	   that	   she	  was	   resistant	   to	  Temozolomide	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but	   sensitive	   to	   Cisplatin	   (LD50	   32.30	   μg/ml).	   The	   results	   of	   the	  chemosensitivity	   testing	   for	   this	   patient	   were	   predictive	   of	   her	   bad	   clinical	  outcome	  when	  she	  was	  treated	  with	  what	  is	  currently	  best	  practice.	  One	  could	  speculate	   that	   her	   outcome	   might	   have	   been	   different	   if	   she	   was	   offered	  Cisplatin	  chemotherapy	  instead.	  	  An	   important	   factor	   that	   guides	   chemotherapy	   treatment	   is	   the	   side	  effects	  of	  drugs	  used.	  Patients	  are	  closely	  monitored	  during	  the	  course	  of	  their	  treatment	  in	   an	   attempt	   to	   predict	   the	   onset	   of	   side	   effects	   not	   clinically	   apparent.	  Chemosensitivity	   testing	   would	   avoid	   the	   use	   of	   drugs,	   which	   would	   not	   be	  beneficial	   to	   the	   patient	   as	   well	   as	   their	   side	   effects.	   In	   order	   for	   in	   vitro	  chemosensitivity	   results	   to	   translate	   into	   clinical	   practice,	   the	   concentrations	  tested	  in	  the	  present	  study	  were	  within	  the	  range	  of	  those	  used	  clinically.	  Such	  methodology	  makes	   this	   study	   relevant	   to	   clinical	   practice.	   Another	   potential	  benefit	  of	  in	  vitro	  chemosensitivity	  testing	  is	  its	  predictive	  value	  when	  it	  comes	  to	  the	  choice	  of	  chemotherapy	  treatment.	  For	  example,	  chemosensitivity	  testing	  has	  shown	  that	  BTNW	  382	  was	  very	  sensitive	  to	  all	  three	  drugs.	  However,	  she	  did	  not	  receive	  any	  chemotherapy	  treatment	  because	  of	  her	  age	  (75	  years)	  and	  Karnofsky	   score	   (60).	   Should	   the	   chemosensitivity	   testing	   results	   have	   been	  taken	  into	  account,	  this	  patient	  might	  have	  had	  a	  better	  clinical	  course.	  	  	  Growing	  primary	  glioma	  cultures	  and	  subsequent	  chemosensitivity	  testing	  is	  a	  challenging	   technique	   and	   requires	   specialised	   skills.	   Such	   expertise	   would	  establish	  standard	  operating	  procedures	  as	  well	  as	  tackle	  issues	  such	  as	  tissue	  availability,	   stagnant	   or	   slow	   growth	   and	   contamination	   control	   more	  effectively.	   For	   that	  matter,	   brain	   tumour	   banks	   are	   invaluable	   assets	   as	   they	  provide	  access	  to	  the	  much-­‐needed	  tissue.	  	  	  Overall	  this	  study	  suggests	  that	  chemosensitivity	  testing	  can	  be	  a	  valuable	  tool	  to	   complement	   clinical	   practice.	   However,	   more	   studies	   are	   required	   to	  strengthen	   the	   findings	   of	   the	   present	   work,	   so	   that	   chemosensitivity	   testing	  becomes	  routinely	  used	  in	  chemotherapy	  treatment.	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3 TEMOZOLOMIDE	  EVALUATION	  IN	  GLIOMA	  CELL	  LINES	  	  
3.1 Introduction	  Glioblastoma	  is	  the	  most	  malignant	  tumor	  of	  central	  nervous	  system	  neoplasms	  with	  poor	  overall	  survival.	  Treatment	  of	  glioblastomas	   is	  challenging	  and	  very	  little	   progress	   was	   made	   until	   the	   last	   decade.	   A	   phase	   III	   randomised	   trial	  conducted	  by	  the	  European	  Organisation	  for	  Research	  and	  Treatment	  of	  Cancer	  (EORTC)	  and	  the	  National	  Cancer	  Institute	  of	  Canada	  Clinical	  Trials	  Unit	  (NCIC),	  revolutionised	   chemotherapy	   treatment	  of	  newly	  diagnosed	  glioblastoma.	  The	  results	   of	   this	   trial,	   published	   in	   2005,	   showed	   a	   significant	   benefit	   of	   both	  median	   and	   two-­‐year	   survival	   of	   patients	   treated	   by	   radiotherapy	   with	  concomitant	   chemotherapy	   with	   Temozolomide	   (TMZ),	   followed	   by	   adjuvant	  Temozolomide	  chemotherapy	  [96].	  The	  survival	  benefit	  continued	  through	  to	  5	  years	  of	   follow-­‐up,	  with	  a	  few	  patients	  surviving	  longer	  than	  5	  years	  [99].	  The	  “Stupp	   regime”,	   named	   after	   Roger	   Stupp	   who	   conducted	   the	   trial,	   includes	  concomitant	   daily	   Temozolomide	   during	   initial	   radiotherapy	   treatment,	  followed	  by	  six	  cycles	  of	  adjuvant	  Temozolomide	  (for	  five	  days	  during	  a	  28-­‐day	  cycle).	   In	  another	  study,	  Temozolomide	  was	  also	   found	   to	   improve	  survival	   in	  patients	  with	  recurrent	  glioblastoma	  [176].	  	  	  Temozolomide	   is	   an	   Imidazotetrazinone	   methylating	   agent,	   which	   is	   100%	  bioavailable	  after	  oral	  administration	  and	  is	  excreted	  by	  the	  kidney.	  It	  has	  very	  few	  side	  effects	  making	  it	  well	  tolerated	  by	  patients.	  	  Temozolomide	  hydrolyses	  spontaneously	   to	   its	   active	   metabolite	   5-­‐(3-­‐methyl	   triazen-­‐1-­‐yl)	   imidazole-­‐4-­‐carboxamide	  (MTIC)	  at	  physiological	  pH.	  MTIC	  is	  degraded	  within	  seconds	  into	  methyldiazonium	   and	   into	   an	   inactive	   metabolite	   5-­‐aminoimidazole-­‐4-­‐carboxamide	  (AIC).	  	  
 MTIC	  acts	  by	  methylating	  O6	  and	  alkylating	  N7	  position	  of	  guanine.	  When	  DNA	  mismatch	   repair	   enzymes	   attempt	   to	   excise	   O6-­‐methyl-­‐N7-­‐alkylguanine,	   they	  generate	   single-­‐	   and	   double-­‐strand	   DNA	   breaks.	   These	   lead	   to	   activation	   of	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apoptotic	   pathways,	   which	   cause	   cell	   death.	   Agarwala	   and	   coworkers	   have	  reported	   that	   the	   double	   strand	   DNA	   breaks	   are	   formed	   in	   a	   cell	   when	  Temozolomide	  is	  present	  for	  at	  least	  two	  cell	  cycles	  [177].	  	  Prior	  to	  Temozolomide	  there	  had	  been	  no	  significant	   improvement	  of	  survival	  of	   glioma	   sufferers	   for	   almost	   twenty	   years.	   Temozolomide	   has	   been	   a	  major	  breakthrough	   for	   treating	   glioma	   patients,	   offering	   a	   survival	   benefit	   without	  the	  unwanted	  side	  effects	  of	  previous	  chemotherapeutic	  agents	  used.	  	  Despite	  its	  efficacy	  in	  clinical	  practice,	  Temozolomide	  does	  not	  appear	  to	  be	  as	  effective	  in	  in	  vitro	  chemosensitivity	  studies.	  This	  observation	  together	  with	  the	  anecdotal	  reports	  of	  the	  poor	  in	  vitro	  effect	  of	  Temozolomide,	  initiated	  a	  series	  of	  experiments	  that	  investigated	  the	  reason	  behind	  this	  observation.	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3.2 Hypothesis	  There	  were	  two	  hypothesis	  formed	  that	  could	  explain	  the	  poor	  in	  vitro	  effect	  of	  Temozolomide.	  The	  first	  one	  proposed	  that	  as	  Temozolomide	  is	  inactivated	  too	  rapidly	   it	   does	   not	   have	   enough	   time	   to	   produce	   an	   effect	   on	   the	   cells.	   The	  second	   hypothesis	   proposed	   that	   the	   cells	   require	   a	   longer	   exposure	   to	  Temozolomide	  in	  order	  to	  have	  an	  observable	  kill	  effect.	  	  	  
3.3 Aims	  of	  the	  following	  study	  This	  chapter	   investigates	   the	  poor	   in	  vitro	   effect	  of	  Temozolomide	  on	  primary	  cell	   cultures,	   which	   was	   observed	   in	   the	   previous	   chapter	   (Chapter	   2	  Chemosensitivity	  Testing	  in	  Primary	  Glioma	  Cultures).	  	  Based	  on	  the	  fact	  that	  Temozolomide	  has	  a	  short	  half-­‐life,	  this	  study	  investigates	  as	   to	  whether	  daily	  application	  of	  Temozolomide,	  as	  opposed	  to	  a	  single	  dose,	  would	  improve	  its	  kill	  efficiency.	  	  In	   addition,	   given	   that	   Temozolomide	   causes	   DNA	   damage,	   this	   chapter	   also	  examines	  the	  possibility	  of	  improving	  its	  efficacy	  in	  in	  vitro	  studies	  by	  cell	  cycle	  synchronisation	  prior	  to	  Temozolomide	  application.	  	  Furthermore,	  it	  aims	  to	  optimise	  Temozolomide’s	  in	  vitro	  use.	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3.4 Materials	  and	  methods	  	  	  Six	   established	   glioma	   cell	   lines	   were	   used	   to	   determine	   the	   effect	   of	  Temozolomide	  in	  vitro.	  These	  were	  the	  U373,	  U257,	  IN1265,	  IN859,	  IN077,	  and	  1321N1.	  The	  cell	  lines	  were	  synchronised	  into	  the	  “S”	  phase	  of	  their	  cell	  cycle	  by	  repeated	  rounds	  of	  feeding	  and	  starvation.	  The	  synchronisation	  of	  the	  cell	  lines	  was	  confirmed	  by	  DNA	  analysis	  using	  a	  Flow	  Cytometer	  (Becton	  Dickinson	  (BD)	  FACSAria)	   (Figure	   3-­‐1).	   Once	   the	   cell	   lines	   were	   synchronised,	   they	   were	  treated	  with	  either	  a	  single	  or	  a	  daily	  dose	  of	  Temozolomide.	  Daily	  cell	  counts	  were	   performed	   for	   five	   days	   and	   compared	   to	   those	   of	   the	   untreated	  population.	  Cisplatin	  was	  used	  as	  a	  positive	  control	  and	  Carmustine	  (BCNU)	  was	  used	  as	  a	  negative	  control.	  	  
	  
Figure	  3-­‐1	  BD	  FACSAria	  III	  Adapted	  by	  [178].	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3.4.1 Preparation	   of	   cells	   from	   flow	   cytometry	   to	   demonstrate	   cell	   cycle	  
synchronization	  	  Cells	   from	   each	   cell	   line	   were	   counted	   to	   500.000	   cells	   per	   flask	   and	   the	  appropriate	  volume	  was	  then	  placed	  in	  three	  25	  cm3	  flasks.	  All	  three	  flasks	  were	  returned	  to	  the	  incubator	  and	  the	  cells	  were	  allowed	  to	  attach	  and	  grow	  for	  48	  hours.	   Flask	   No	   1	   was	   trypsinised	   as	   per	   protocol	   and	   the	   sample	   was	   then	  taken	   for	   Propidium	   Iodide	   staining.	   The	   complete	   growth	   medium	   was	  aspirated	  from	  flasks	  No	  2	  and	  No	  3	  and	  replaced	  with	  equal	  volume	  of	  serum-­‐free	  media.	  Both	  flasks	  were	  then	  returned	  to	  the	  incubator	  for	  24	  hours.	  After	  24	  hours	   flask	  No	  2	  was	   trypsinised	   and	   taken	   for	  Propidium	   Iodide	   staining.	  The	   serum	   free	  medium	  was	  aspirated	   from	   flask	  No	  3	  and	   replaced	  with	   the	  same	  volume	  of	   complete	   growth	  medium.	  Flask	  No	  3	  was	   then	  placed	   in	   the	  incubator	   for	   another	   24	   hours.	   Following	   the	   24	   hours,	   flask	   No	   3	   was	  trypsinised	  and	  stained	  with	  Propidium	  Iodide	  as	  per	  protocol.	  	  
3.4.2 Preparation	   of	   cultures	   to	   test	   delayed	   response	   of	   cell	   lines	   to	  
Temozolomide	  	  Twelve	  35mm	  Petri	  dishes	  were	  labelled	  as	  C1,	  1,	  1S,	  C2,	  2,	  2S,	  C3,	  3,	  3S,	  C4,	  4,	  4S	   and	   two	   as	   medium.	   A	   cell	   suspension	   of	   each	   cell	   line	   was	   prepared	  containing	   2000	   cells/ml	   and	   1ml	   of	   the	   cell	   solution	   and	   1ml	   of	   complete	  growth	  medium	  were	  added	  to	  each	  petri	  dish.	  All	  petri	  dishes	  were	  returned	  to	  the	  incubator	  for	  24	  hours	  to	  allow	  cells	  to	  attach.	  After	  24	  hours,	  the	  complete	  growth	   medium	   was	   aspirated	   from	   all	   the	   dishes.	   Two	   millilitres	   of	   new	  complete	   growth	  medium	  were	   added	   to	   dishes	   C1,	   1,	   C2,	   2,	   C3,	   3,	   C4,	   4	   and	  medium.	  Two	  millilitres	  of	  serum-­‐free	  medium	  were	  added	  to	  dishes	  1S,	  2S,	  3S	  and	  4S.	  All	   dishes	  were	   returned	   to	   the	   incubator	   for	   a	   further	  24	  hours.	  The	  media	   from	   all	   of	   the	   dishes	   was	   then	   aspirated	   and	   replaced	   with	   2ml	   of	  complete	  growth	  media.	  All	  dishes	  were	  returned	  to	  the	  incubator	  for	  24	  hours.	  The	   complete	   growth	  media	   from	  all	   of	   the	  dishes	  was	   aspirated	   except	   from	  ‘Media’	  and	  replaced	  with	  1.2ml	  (1200μl)	  of	  new	  media.	  Then	  0.8	  ml	  (800	  μl)	  of	  10	  μg/ml	  Carmustine	  solution	  was	  added	  to	  dishes	  C1,	  C2,	  C3	  &	  C4	  and	  0.8	  ml	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(800	  μl)	  of	  20	  μg/ml	  Temozolomide	  solution	  were	  added	  to	  all	  other	  dishes.	  The	  culture	   dishes	   were	   returned	   to	   the	   incubator	   for	   24	   hours.	   After	   24	   hours,	  dishes	  C1,	  1	  and	  1S	  were	  washed	  with	  Hanks	  to	  remove	  dead	  cells.	  They	  were	  subsequently	   trypsinised	   together	  with	  one	  of	   the	   ‘Media’	  dishes	  and	   the	  cells	  were	   counted	   in	   the	   coulter	   counter	   as	   per	   protocol.	   This	   step	  was	   repeated	  every	  24	  hours	  with	  the	  next	  number	  of	  dishes.	  Finally,	   the	   last	   ‘Medium’	  dish	  was	  trypsinised	  at	  the	  same	  time	  as	  C4,	  4	  and	  4S	  and	  the	  cells	  were	  counted.	  	  	  
3.4.3 Propidium	  Iodide	  nucleic	  acid	  stain	  	  
Phosphate	  Buffered	  Saline	  (0.01M),	  pH	  7.2	  	  This	   solution	   contained	   0.74	   g	   di-­‐Sodium	   Phosphate	   anhydrous,	   0.22	   g	  Potassium	   di-­‐Hydrogen	   Orthophosphate,	   3.6	   g	   Sodium	   Chloride	   and	   500	   ml	  Distilled	  Water.	  	  
Propidium	  Iodide	  Staining	  Solution	  	  This	  solution	  contained	  350	  µl	  PBS,	  50	  µl	  of	  500	  µg/ml	  Propidium	  Iodide	  and	  5	  µl	  of	  10	  mg/ml	  RNase.	  (Ribonuclease	  A	   from	  bovine	  pancreas,	  Cat	  No	  R6513	  10	  
mg.	  This	  was	  dissolved	  in	  sterile	  water	  to	  make	  up	  10	  mg/ml	  concentration.)	  	  	  
Method	  	  The	  cells	  were	  trypsinised	  for	  5	  minutes,	  and	  then	  two	  volumes	  of	  the	  complete	  growth	   medium	   were	   added	   to	   inactivate	   the	   trypsine.	   Then	   the	   trypsinised	  culture	  was	  centrifuged	  for	  5	  minutes	  at	  250g,	  the	  supernatant	  was	  pipetted	  off	  and	   the	   cells	   were	   resuspended	   in	   1ml	   PBS.	   The	   cells	   were	   then	   centrifuged	  again,	  the	  PBS	  was	  pipetted	  off	  and	  replaced	  with	  1	  ml	  of	  ice-­‐cold	  70%	  ethanol	  drop	  wise	  whilst	  vortexing	  to	  prevent	  clumping.	  This	  cell	  suspension	  could	  be	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safely	   stored	   at	   –20oC	   until	   staining	   and	   analysis.	   If	   proceeding	   with	   the	  staining,	  the	  cells	  were	  centrifuged	  for	  5	  minutes	  at	  1000	  RPM,	  the	  70%	  ethanol	  was	  pipetted	  off	  and	  the	  cells	  were	  resuspended	  in	  1	  ml	  ice-­‐cold	  PBS.	  The	  cells	  were	  centrifuged	  again,	  the	  PBS	  was	  pipetted	  off	  and	  replaced	  with	  Propidium	  Iodide	   (PI)	   staining	   solution	   (final	   volume	   500	   µl	   /	   500,000	   cells).	   The	   cells	  were	   then	   incubated	   at	   37oC	   for	  30	  minutes	   and	   then	  kept	   at	   4oC	   in	   the	  dark	  until	  Flow	  Cytometry	  analysis,	  preferably	  on	  the	  same	  day.	  The	  Flow	  Cytometer	  used	  was	  an	  A	  Becton	  Dickinson	  (BD)	  FACSAria	  with	  a	  488nm	  blue	  laser	  fitted	  with	   a	   doublet	   discrimination	   module.	   The	   emitted	   PI	   fluorescence	   was	  detected	  using	  the	  PE	  detector	  in	  conjunction	  with	  the	  575/26	  band	  pass	  filter.	  This	   detector	   collects	   a	   fluorescence	   wavelength	   of	   575	   with	   a	   26nm	   range	  (from	  562-­‐588	  nm).	  Ten	  thousand	  single	  cells	  were	  acquired	  per	  sample	  at	  the	  lowest	  flow	  rate	  possible.	  A	  Forward	  Scatter	  (FCS)	  and	  a	  Side	  Scatter	  (SSC)	  plot	  was	  used	  to	  measure	  relative	  size	  and	  internal	  complexity	  of	  the	  cells	  examined.	  Internal	  complexity	  is	  the	  presence	  of	  granules	  or	  lobed	  nuclei	  within	  the	  cells.	  Cells	  with	  high	  internal	  complexity,	  have	  a	  higher	  side	  scatter.	  This	  FCS/SSC	  plot	  was	   used	   to	   ensure	   the	   whole	   cell	   population	   was	   included	   in	   the	   analysis,	  excluding	  large	  clumps	  or	  debris.	  This	  was	  achieved	  by	  placing	  a	  region	  around	  the	  cell	  population	  to	  be	  analysed.	  A	  doublet	  discrimination	  plot	  (PE-­‐W/PE-­‐A)	  was	   also	   used,	   in	   order	   to	   ensure	   the	   analysis	   of	   single	   cells	   rather	   than	   cell	  aggregates.	   A	   DNA	   content	   histogram	   was	   obtained	   from	   the	   area	   marked.	  Boxes	   around	   the	   peaks	   of	   the	   histogram	   were	   inserted	   manually	   in	   the	  appropriate	  place.	  This	  way	  the	  percentage	  of	  cells	  in	  each	  stage	  of	  the	  cell	  cycle	  (G0G1,	  S	  and	  G2M)	  was	  estimated.	  More	  accurate	  calculation	  of	  each	  stage	  of	  the	  cell	  cycle	  could	  have	  been	  made	  with	  the	  use	  of	  the	  Modfit	  software.	  At	  the	  time	  of	  these	  experiments	  this	  was	  not	  available	  in	  our	  laboratory.	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3.5 Results	  	  
3.5.1 Flow	  cytometric	  analysis	  of	  cell	  cycle	  distribution	  	  Flow	  cytometry	  was	  used	  to	  monitor	  the	  cell	  synchronisation	  process.	  Samples	  were	  exposed	  to	  a	  round	  of	  feeding,	  starvation	  followed	  by	  further	  feeding	  prior	  to	  their	  analysis	  on	  the	  flow	  Cytometer.	  The	  cell	  line	  U373	  is	  used	  as	  an	  example	  to	  illustrate	  the	  three	  different	  stages	  of	  the	  synchronisation	  process	  as	  shown	  in	  the	  figure	  below.	  	  	  	  
	   	   	  	  
	  
Figure	  3.1	  Flow	  cytometric	  analysis	  of	   the	  cell-­‐cycle	  distribution	  of	  U373.	  Top	  row	   illustrates	   the	  
doublet	  discrimination	  plot	  associated	  with	  the	  Cellquest	  software	  used	  to	   identify	   the	  single	  cell	  
population	  denoted	  by	  region	  P1	  (red	  area	  inside	  polygon).	  Cells	  examined	  were	  part	  of	  a	  culture	  
after	   feeding	   (left	   panel),	   starvation	   (middle	   panel)	   and	   refeeding	   (right	   panel).	   Bottom	   row	  
illustrates	   the	   DNA	   histogram	   obtained	   from	   region	   P1	   analysed	   to	   calculate	   the	   relative	  
percentage	  of	  the	  population	  in	  G0G1,	  S	  and	  G2M.	  Regions	  P2,	  P3	  and	  P4	  correspond	  to	  G0G1,	  S	  and	  
G2M	  respectively.	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Table	  3-­‐1	  Percentage	  of	  cells	  in	  the	  different	  cell	  cycle	  phases	  during	  a	  round	  of	  feeding,	  starvation	  
and	  refeeding	  for	  cell	  line	  U373.	  Population	  (cell	  cycle	  phase)	   Feeding	  (%)	   Starvation	  (%)	   Refeeding	  (%)	  P1	  (all)	   83.5	   77.3	   56.4	  P2	  (G0G1)	   69.6	   69.2	   45.6	  P3	  (S)	   8.8	   14.2	   26.0	  P4	  (G2M)	   21.4	   16.0	   27.4	  	  	  As	   seen	   form	   the	   Table	   3-­‐1	   above,	   after	   a	   round	   of	   feeding,	   starvation	   and	  refeeding,	  the	  number	  of	  cells	  in	  the	  S	  phase	  has	  increased	  from	  8.8%	  to	  26%.	  This	  is	  important	  as	  these	  cells	  are	  targeted	  during	  Temozolomide	  treatment.	  In	  addition,	  quiescent	  cells	   that	  were	  resting	   into	  G0G1	  phase	  have	  dropped	   from	  69.6%	   to	   45.6%	   indicating	   that	   they	   are	   re-­‐entering	   the	   cell	   cycle	   and	   thus	  becoming	  vulnerable	  to	  Temozolomide.	  	  	  
3.5.2 Temozolomide	  analysis	  	  Temozolomide	   is	   used	   as	   first	   line	   chemotherapy	   treatment	   for	   patients	  with	  glioblastoma.	  However,	   in	   in	  vitro	   chemosensitivity	  studies	  on	  primary	  human	  glioblastoma	   cultures	   it	   does	   not	   have	   the	   same	   effectiveness.	   Six	   established	  cell	   lines	  were	  used	  to	  determine	  the	  effect	  of	  Temozolomide	   in	  vitro.	  The	  cell	  lines	  were	  treated	  either	  with	  repeated	  daily	  doses	  of	  Temozolomide	  or	  with	  a	  single	  treatment	  at	  the	  onset	  of	  the	  experiment.	  In	  addition,	  as	  Temozolomide	  is	  known	  to	  cause	  DNA	  breaks	  its	  efficacy	  was	  tested	  during	  the	  DNA	  replication	  phase	  (S-­‐phase)	  where	  it	  was	  expected	  to	  be	  most	  effective.	  Like	  above,	  the	  drug	  was	  delivered	  to	  the	  synchronized	  cells	  repeatedly	  on	  a	  daily	  basis	  (T“s”	  daily),	  or	  only	  once	  at	  the	  onset	  of	  the	  experiment	  (T“s”	  once).	  As	  negative	  control	  each	  line	   was	   treated	   with	   BCNU	   (Carmustine).	   Cisplatin	   was	   also	   included	   in	   the	  experiment	  as	  positive	  control.	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To	   compare	   the	   effect	   of	   the	   single	   treatment	   versus	   the	   “Daily”	   one,	   the	  Kolmogorov–Smirnov	   statistical	   test	   (KS	   test)	   was	   used.	   The	   Kolmogorov–Smirnov	   statistic	   quantifies	   the	   distance	   between	   the	   empirical	   distribution	  functions	   of	   two	   samples.	   In	   this	   case,	   the	  KS	   test	  was	   used	   for	   the	   pair-­‐wise	  comparison	   of	   the	   cumulative	   distributions	   of:	   a)	   Temozolomide	   “once”	   vs.	  Temozolomide	   “daily”,	   b)	   Temozolomide	   synchronised	   “daily”	   vs.	  Temozolomide	  “daily”,	  c)	  Temozolomide	  synchronised	  “once”	  vs.	  Temozolomide	  “once”	   and	   d)	   Temozolomide	   synchronised	   “once”	   vs.	   Temozolomide	  synchronised	  “daily”.	  	  In	   terms	   of	   evaluating	   statistical	   significance	   given	   a	   calculated	   p-­‐value,	   both	  significance	   levels	   α=0.001	   (conservative)	   and	   α=0.05	   (widely	   used)	   were	  considered.	   The	   null	   hypothesis	   is	   that	   the	   two	   samples	   have	   a	   similar	  cumulative	  distribution.	   If	  a	   test	  of	   significance	  gives	  a	  p-­‐value	   lower	   than	   the	  significance	  level	  α,	  the	  null	  hypothesis	  is	  rejected	  and	  the	  two	  samples	  can	  be	  considered	  as	  being	  statistically	  significantly	  different.	  	  
Statistical	  package	  	  The	   statistical	   analysis	   was	   performed	   using	   the	   R	   software	   environment	   for	  statistical	   computing	   and	   graphics	   (version	   2.15.1)	   running	   under	   Windows	  Vista	  OS	  with	  2GB	  RAM	  [148].	  All	  the	  statistical	  tests	  used	  here	  were	  included	  in	  the	  R	  Stats	  package.	  	  
3.5.3 Comparison	  of	  single	  vs.	  daily	  treatment	  	  To	  compare	  the	  effect	  of	  the	  single	  treatment	  versus	  the	  “Daily”	  one,	  the	  KS	  test	  was	  used	   to	  analyse	   the	  data.	  The	   results	  of	   the	   comparison	  between	   the	   two	  dosing	  methods	  in	  the	  kill	  efficiency	  for	  each	  drug	  after	  4	  days	  of	  incubation	  is	  shown	  in	  Table	  3-­‐2	  and	  Figure	  3-­‐2	  and	  Figure	  3-­‐3.	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Table	  3-­‐2	  Comparison	  of	  once	  versus	  daily	  dosing	  methods	  in	  the	  kill	  efficiency	  of	  Temozolomide.	  	  	   ks	  distance	   p-­‐value	  Comparing	  Plate	  T	  	  (Once	  vs.	  daily)	   0.352 <0.05 Comparing	  Plate	  T"s"	  (Once	  vs.	  daily)	   0.222 0.139 
Temozolomide	  on	  non-­‐synchronised	  cells	  (T)	  and	  Temozolomide	  on	  synchronised	  
cells	   (T”s”)	   after	   four	   days	   of	   incubation.	   p-­‐values	   as	   determined	  by	   the	  KS	   test.	  
Significant	  results	  are	  shown	  in	  bold.	  
	  	  	  
	  
Figure	  3-­‐2	  Comparison	  of	  single	  vs.	  daily	  dose	  of	  Temozolomide	  on	  non-­‐synchronised	  cells	  after	  four	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Figure	  3-­‐3	  Comparison	  of	  single	  vs.	  daily	  dose	  of	  Temozolomide	  on	  synchronised	  cells	  after	  four	  days	  
of	  incubation.	  Temo	  “s”	  once:	  single	  dose	  of	  Temozolomide	  on	  synchronised	  cells;	  Temo	  “s”	  daily:	  daily	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3.5.4 Effect	  of	  cell	  culture	  synchronization	  on	  Temozolomide’s	  kill	  efficacy	  during	  
single	  application.	  	  	  To	   determine	   the	   effect	   of	   the	   cell	   synchronisation	   on	   the	   kill	   efficiency	   of	   a	  single	  dose	  of	  Temozolomide,	  we	  compared	  the	  two	  datasets	  using	  the	  KS	  test.	  The	  results	  from	  this	  comparison	  are	  summarised	  on	  Table	  3-­‐3	  and	  Figure	  3-­‐4.	  	  	  
Table	  3-­‐3	  Comparison	  of	  synchronisation	  and	  single	  dosing	  in	  the	  kill	  efficiency	  of	  Temozolomide.	  	  Comparing	  Plate	  T	  once	  vs.	  T	  "s"	  once	   ks	  distance	   p-­‐value	  Day	  1	   0.185 0.313 Day	  2	   0.148 0.594 Day	  3	   0.167 0.441 
Day	  4	   0.241 0.088 
Comparison	   of	   Temozolomide	   single	   dose	   on	   synchronised	   versus	   non-­‐
synchronised	   culture	   cells	   from	   day	   1	   to	   day	   4	   of	   incubation	   (p-­‐value	   as	  
determined	   by	   the	   KS	   test).
	  
Figure	   3-­‐4	  Comparison	   of	   single	   dose	   of	   Temozolomide	   on	   synchronised	   vs.	   non-­‐synchronised	   cells	  
after	  four	  days	  of	  incubation.	  Temo	  “s”	  once:	  single	  dose	  of	  Temozolomide	  on	  synchronised	  cells;	  Temo	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Based	   on	   these	   results,	   there	   was	   no	   significant	   difference	   between	   the	  synchronous	   and	   asynchronous	   cell	   cultures	   when	   they	   were	   treated	   with	   a	  single	  dose	  of	  Temozolomide.	   Still,	   from	  day	  2	  of	   the	   incubation	  onwards,	   the	  ks-­‐distance	   was	   gradually	   increasing	   and	   on	   day	   4	   the	   p-­‐value	   was	   dropped	  close	   to	   the	   cut	   off	   value	   of	   α=0.05	   (0.088).	   One	   could	   speculate	   that	   further	  incubation	  might	  have	  led	  to	  further	  reduction	  of	  the	  p-­‐value	  but	  this	  remains	  to	  be	  tested	  in	  the	  lab.	  	  	  	  
3.5.5 Effect	  of	  cell	  culture	  synchronization	  on	  Temozolomide’s	  kill	  efficacy	  during	  
daily	  application.	  	  	  Similarly	   to	   the	   single	   dose,	   the	   effect	   of	   the	   cell	   synchronisation	   when	  Temozolomide	   was	   applied	   on	   a	   daily	   basis	   on	   both	   synchronous	   and	  asynchronous	  cell	  cultures	  was	  tested.	  The	  two	  datasets	  were	  compared	  using	  the	  KS	  test	  and	  the	  results	  are	  summarised	  on	  Table	  3-­‐4	  and	  Figure	  3-­‐5.	  	  	  	  
Table	  3-­‐4	  Comparison	  of	  synchronisation	  and	  daily	  dosing	  in	  the	  kill	  efficiency	  of	  Temozolomide.	  Comparing	  Plate	  T	  daily	  vs.	  T	  "s"	  daily	   ks	  distance	   p-­‐value	  Day	  1	   0.222 0.139 Day	  2	   0.130 0.755 Day	  3	   0.204 0.213 
Day	  4	   0.111 0.893 
Comparison	   of	   daily	   dosing	   of	   Temozolomide	   on	   synchronous	   and	   non-­‐
synchronised	   culture	   cells	   from	   day	   1	   to	   day	   4	   of	   incubation	   (p-­‐value	   as	  
determined	  by	  the	  KS	  test).	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Figure	  3-­‐5	  Comparison	  of	  daily	  dosing	  of	  Temozolomide	  on	  synchronised	  vs.	  non	  synchronised	  cells	  
after	  four	  days	  of	  incubation.	  Temo	  daily:	  daily	  dose	  of	  Temozolomide	  on	  non-­‐synchronised	  cells;	  
Temo”s”	  daily:	  daily	  dose	  of	  Temozolomide	  on	  synchronised	  cells.	  	  From	  these	  results	  we	  can	  conclude	  that	  the	  kill	  effect	  of	  the	  daily	  dosing	  of	  the	  drug	  didn’t	  seem	  to	  be	  affected	  by	  the	  cell	  culture	  synchronisation	  (α=0.05).	  	  	  The	   last	   two	   experiments	   suggest	   that	   given	   the	   experimental	   setup	   the	   cell	  culture	   synchronization	   does	   not	   have	   a	   significant	   impact	   on	   the	  Temozolomide’s	   kill	   efficiency	   for	   the	   given	   concentration,	   frequency	   of	  application,	  and	  duration	  of	  the	  experiment	  as	  determined	  by	  the	  KS	  statistical	  test.	  	  	  
3.5.6 Comparison	  of	  cell	  culture	  synchronization	  and	  frequency	  of	  application	  on	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stronger	   role	   than	   the	   other,	   the	   kill	   efficiency	   of	   Temozolomide	   between	   the	  two	   cell	   populations	   would	   be	   significantly	   different.	   The	   two	   datasets	   were	  compared	  using	   the	  KS	   test	   and	   the	   results	  are	   summarised	  on	  Table	  3-­‐5	  and	  Figure	  3-­‐6.	  	  	  
Table	  3-­‐5	  Comparison	  of	  synchronisation	  and	  dosing	  in	  the	  kill	  efficiency	  of	  Temozolomide.	  	  Comparing	  Plate	  T	  "s"	  once	  vs.	  T	  daily.	  	   ks	  distance	   p-­‐value	  Day	  1	   0.222 0.139 Day	  2	   0.222 0.139 Day	  3	   0.259 0.053 
Day	  4	   0.185 0.313 
Comparison	   of	  Temozolomide	   single	   dose	   on	   synchronised	   versus	  Temozolomide	  
daily	  dose	  on	  non-­‐synchronised	  culture	  cells	  from	  day	  1	  to	  day	  4	  of	  incubation	  (p-­‐
value	  as	  determined	  by	  the	  KS	  test).	  	  
	  
Figure	   3-­‐6	   Comparison	   of	   Temozolomide	   single	   dose	   on	   synchronised	   versus	   Temozolomide	   daily	  
dose	   on	   non	   synchronised	   culture	   cells	   after	   four	   days	   of	   incubation.	   Temo	   daily:	   daily	   dose	   of	  
Temozolomide	   on	   non-­‐synchronised	   cells;	   Temo	   ”s”	   once:	   single	   dose	   of	   Temozolomide	   on	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Based	   on	   these	   results	   there	  was	   no	   significant	   difference	   between	   the	   effect	  caused	   by	   cell	   synchronisation	   and	   frequency	   of	   drug	   application	   to	  Temozolomide’s	   kill	   efficacy	   when	   comparing	   single	   application	   on	  synchronised	  cells	  to	  daily	  application	  on	  non-­‐synchronised	  cells.	  Still,	  on	  day	  3	  of	   the	   incubation,	   the	   p-­‐value	   dropped	   close	   to	   the	   cut	   off	   value	   of	   α=0.05	  (0.053)	  before	  it	  increased	  again	  on	  day	  4.	  	  	  
	   124	  
3.5.7 Comparison	  of	  cell	  culture	  synchronization	  and	  frequency	  of	  application	  on	  
Temozolomide’s	  kill	  efficacy	  (T	  once	  vs.	  T	  “s”	  daily).	  	  	  In	  order	  to	  confirm	  that	  synchronisation	  and	  daily	  application	  had	  an	  additive	  effect,	  the	  kill	  efficiency	  of	  a	  single	  dose	  of	  Temozolomide	  on	  non-­‐synchronised	  culture	   cells	   was	   compared	   to	   that	   of	   a	   daily	   dose	   of	   Temozolomide	   on	   a	  synchronised	   cell	   population.	   If	   synchronisation	   and	   frequency	   of	   application	  had	   no	   effect,	   the	   kill	   efficiency	   of	   Temozolomide	   between	   the	   two	   cell	  populations	  would	  be	  similar.	  	  If	  either	  the	  synchronisation	  or	  the	  frequency	  of	  application	  had	  a	  stronger	  role	  than	   the	   other,	   the	   kill	   efficiency	   of	   Temozolomide	   between	   the	   two	   cell	  populations	  would	  be	  significantly	  different.	  The	   two	  datasets	  were	  compared	  using	  the	  KS	  test	  and	  the	  results	  are	  summarised	  in	  Table	  3-­‐6	  and	  Figure	  3-­‐7.	  	  	  
Table	  3-­‐6	  Comparison	  of	  synchronisation	  and	  dosing	  in	  the	  kill	  efficiency	  of	  Temozolomide.	  	  Comparing	  Plate	  T	  once	  vs.	  T	  “s”	  daily.	  	   ks	  distance	   p-­‐value	  Day	  1	   0.241 0.087 Day	  2	   0.296 <0.05 Day	  3	   0.352 <0.05 
Day	  4	   0.352 <0.05 
Comparison	   of	   Temozolomide	   single	   dose	   on	   non-­‐synchronised	   versus	  
Temozolomide	   daily	   dose	   on	   synchronised	   culture	   cells	   from	   day	   1	   to	   day	   4	   of	  
incubation	  (p-­‐value	  as	  determined	  by	  the	  KS	  test).	  	  	  
	   125	  
	  
Figure	  3-­‐7	  Comparison	  of	  Temozolomide	   single	  dose	  on	  non-­‐synchronised	  versus	  Temozolomide	  
daily	  dose	  on	   synchronised	   culture	   cells	   after	   four	  days	  of	   incubation.	  Temo	  once:	   single	  dose	  of	  
Temozolomide	   on	   non-­‐synchronised	   cells;	   Temo	   “s”	   daily:	   daily	   dose	   of	   Temozolomide	   on	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Table	  3-­‐7	  Summary	  of	  p	  values	  between	  the	  different	  datasets.	  	  	   T	  once	   T	  “s”	  once	   T	  daily	   T	  “s”	  daily	   Cis	  once	   Car	  once	  T	  “s”	  once	   0.088      T	  daily	   <0.001 0.139     T	  “s”	  daily	   <0.05 0.313 0.893    Cis	  once	   <0.001 <0.001 0.001 <0.001   Car	  once	   <0.05 <0.05 <0.001 0.001 <0.001  Medium	   <0.05 <0.001 <0.001 <0.001 <0.001 0.088 
T	  once:	  single	  dose	  of	  Temozolomide	  on	  non-­‐synchronised	  cells;	  T	  ”s”	  once:	  single	  
dose	  of	  Temozolomide	  on	  synchronised	  cells.	  T	  daily:	  daily	  dose	  of	  Temozolomide	  
on	  non-­‐synchronised	  cells;	  T	  ”s”	  daily:	  daily	  dose	  of	  Temozolomide	  on	  synchronised	  
cells;	  Cis	  once:	  single	  dose	  of	  Cisplatin	  on	  synchronised	  cells;	  Car	  once:	  single	  dose	  
of	  Carmustine	  on	  synchronised	  cells.	  Bold	  values	  indicate	  p	  value	  below	  0.05.	  Red	  
values	  in	  italics	  indicate	  p	  value	  equal	  or	  below	  0.001.	  	  
	  The	   table	   above	   (Table	   3-­‐7)	   summarises	   the	   effect	   of	   the	   different	   drugs	   and	  their	   frequency	   of	   application	   to	   the	   synchronised	   and	   non-­‐synchronised	   cell	  lines.	  Briefly:	  	  	  
• Daily	  application	  of	  Temozolomide	  on	  non-­‐synchronised	  cells	  was	  better	  than	  a	  single	  dose.	  	  
• Daily	  application	  of	  Temozolomide	  to	  non-­‐synchronised	  cells	  had	  similar	  effect	  to	  daily	  application	  of	  Temozolomide	  on	  synchronised	  cells.	  
• Single	  dose	  of	  Temozolomide	  to	  non-­‐synchronised	  cells	  had	  similar	  effect	  to	  a	  single	  dose	  of	  Temozolomide	  on	  synchronised	  cells.	  
• Daily	  application	  of	  Temozolomide	  to	  non-­‐synchronised	  cells	  had	  similar	  effect	  to	  a	  single	  dose	  of	  Temozolomide	  on	  synchronised	  cells.	  	  
• Daily	  application	  of	  Temozolomide	  on	  synchronised	  cells	  was	  better	  than	  single	  dose	  of	  Temozolomide	  on	  non-­‐synchronised	  cells.	  
• Frequency	  of	   application	  of	  Temozolomide	  did	  not	   change	   the	   effect	   of	  Temozolomide	  on	  synchronised	  cells.	  
• Single	   application	   of	   Cisplatin	   exhibited	   a	   better	   kill	   effect	   than	  Temozolomide	   regardless	   of	   Temozolomide’s	   frequency	   of	   application	  and	  cell	  synchronisation.	  
	   127	  
• Cisplatin	   and	   Temozolomide	   exhibited	   a	   better	   kill	   effect	   than	   a	   single	  dose	  of	  Carmustine.	  
• Carmustine	  did	  not	  produce	  a	  significant	  kill	  effect,	  as	  it	  was	  no	  different	  to	  the	  medium.	  	  
• Temozolomide	  and	  Cisplatin	  had	  a	  significantly	  better	  kill	  effect	  than	  the	  medium.	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3.6 Discussion	  	  This	   study	   investigates	   the	   reasons	   that	   lead	   to	   Temozolomide’s	   reduced	  efficiency	  when	  used	   in	   chemosensitivity	   studies.	   Temozolomide’s	   suboptimal	  performance	   in	   vitro	   was	   also	   compared	   to	   that	   of	   other	   drugs	   used	   in	   the	  treatment	   of	   malignant	   gliomas,	   nominally	   Carmustine	   and	   Cisplatin.	   The	  results	   from	   this	   work	   showed	   that	   the	   frequency	   of	   application	   on	   the	   non-­‐synchronised	  cell	   lines	  was	  a	  contributing	  factor	  to	  Temozolomide’s	  efficiency.	  The	   daily	   application	   of	   Temozolomide	   gave	   a	   significantly	   better	   cell	   kill	  compared	   to	   a	   single	   dose	   at	   the	   onset	   of	   the	   experiment.	   This	   finding	   is	   in	  accordance	  with	  previously	  published	  studies	  [179],	  [180].	  	  It	   is	   likely	   that	   the	   observed	   improvement	   of	   Temozolomide’s	   performance	  when	  it	  was	  administered	  daily	  was	  due	  to	  the	  four-­‐fold	  increase	  of	  the	  amount	  of	  drug	  used	  compared	  to	  the	  single	  dose	  (80	  µg	  vs.	  20	  µg).	  A	  fair	  comparison	  would	   have	   been	   the	   administration	   of	   the	   same	   total	   amount	   to	   both	  populations	   but	   at	   different	   frequencies	   (daily	   versus	   once).	   Another	   possible	  explanation	  for	  the	  frequency	  of	  application	  effect	  observed	  is	  Temozolomide’s	  short	  half-­‐life.	  It	  is	  well	  known	  from	  Temozolomide’s	  pharmacokinetics	  that	  its	  active	  component	   is	  very	  rapidly	  degraded	  to	   the	   inactive	  metabolite	  before	   it	  gets	  removed	  from	  the	  blood	  circulation.	  The	  whole	  process	  takes	  up	  to	  a	   few	  seconds	   to	   complete.	   It	   is	   reasonable	   to	   assume	   that	   a	   similar	   fate	   for	  Temozolomide	  is	  also	  taking	  place	  during	  its	  use	  in	  in	  vitro	  experiments.	  Single	  application	  of	  Temozolomide	  in	  cell	  cultures	  might	  have	  been	  rapidly	  degraded	  before	  it	  could	  have	  a	  measurable	  effect	  to	  the	  cell	  population.	  	  	  As	  Temozolomide	  causes	  methylation	  and	  alkylation	  of	  DNA,	  it	  is	  predominantly	  effective	  during	  the	  DNA	  replication	  phase	  of	  the	  cell	  cycle	  also	  known	  as	  the	  “S”	  phase.	  Based	  on	  that,	  it	  is	  likely	  that	  only	  the	  cells	  that	  are	  in	  “S”	  phase	  when	  the	  active	  Temozolomide	  is	  present	  would	  be	  susceptible	  to	  it.	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Therefore,	   one	  way	   to	   improve	   the	   kill	   effect	   of	   the	  drug	  would	  have	  been	   to	  influence	  the	  “vulnerability”	  of	  the	  cell	  populations	  prior	  to	  their	  treatment	  with	  Temozolomide.	   In	   other	   words,	   synchronisation	   of	   the	   cell	   population	   and	  subsequent	   treatment	  with	   Temozolomide	  while	   the	  majority	   of	   them	   are	   on	  the	   “S”	   phase	   of	   the	   cell	   cycle	   should	   in	   theory	   have	   made	   them	   more	  susceptible	  to	  the	  drug.	  Adema	  and	  coworkers	  have	  confirmed	  this	  hypothesis	  by	  combining	  Temozolomide	  with	  drugs	  that	  cause	  cell	  cycle	  arrest	  in	  “S”	  phase.	  Using	   this	   method,	   they	   have	   observed	   a	   significant	   enhancement	   of	   the	  cytotoxic	  effect	  in	  the	  treated	  lung	  cancer	  cell	  lines	  [181].	  	  	  Interestingly,	   not	   all	   findings	   of	   this	   present	   study	   concord	   with	   the	   above	  hypothesis	   and	   the	   previously	   published	   reports.	   More	   specifically,	  synchronisation	   of	   cell	   populations	   did	   not	   increase	   the	   kill	   effect	   of	  Temozolomide	  when	  compared	  to	  the	  non-­‐synchronised	  population.	  A	  possible	  explanation	   for	   this	   observation	   is	   that,	   the	   effect	   of	   the	   cell	   synchronisation	  was	   masked	   by	   the	   stronger	   impact	   of	   Temozolomide’s	   daily	   application.	   A	  longer	   exposure	   to	   daily	   application	   of	   Temozolomide	   on	   synchronised	   cells	  might	   have	   revealed	   a	   significant	   difference	   when	   compared	   to	   the	   non-­‐synchronised	   ones	   as	   the	   four-­‐day	   period	   might	   not	   have	   been	   enough.	  Similarly,	   synchronisation	   did	   not	   produce	   a	   significant	   difference	   when	  Temozolomide	   was	   applied	   as	   a	   single	   dose.	   As	   there	   was	   no	  masking	   effect	  caused	   by	   the	   frequency	   of	   application,	   there	   should	   have	   been	   a	   significant	  improvement	   to	   the	   kill	   effect	   of	   the	   synchronised	   compared	   to	   the	   non-­‐synchronised	  population.	  Given	  the	  fact	  that	  there	  was	  a	  trend	  of	  a	  decreasing	  p	  value	  over	  the	  four-­‐day	  period,	  one	  could	  speculate	  that	  a	  longer	  exposure	  could	  have	   produced	   the	   expected	   effect.	   Future	   experiments	   could	   clarify	   this	  hypothesis	  by	  allowing	  longer	  incubation	  periods.	  	  	  Further	  support	  the	  above	  hypothesis	  that	  synchronisation	  is	  equally	  important	  to	   the	   frequency	   of	   application,	   is	   provided	   by	   the	   fact	   that	   when	   compared	  there	  was	  no	  significant	  difference	  between	  them.	  This	  suggests	  that	  both	  have	  an	   equally	   prominent	   effect.	   In	   addition,	   even	   from	   day	   2	   the	   daily	  Temozolomide	   dose	   on	   synchronised	   cells	   exhibited	   a	   strikingly	   better	   effect	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when	  compared	  to	  the	  single	  dose	  of	  Temozolomide	  on	  non-­‐synchronised	  ones.	  This	   demonstrates	   the	   beneficial	   impact	   of	   both	   cell	   synchronisation	   and	  frequency	  of	  dosing	  on	  the	  Temozolomide’s	  kill	  efficiency.	  	  Of	   the	   other	   two	   drugs	   tested,	   Cisplatin	   displayed	   a	  much	   stronger	   kill	   effect	  than	  any	  of	  the	  other	  drug	  used.	  Carmustine	  on	  the	  other	  hand,	  was	  not	  found	  to	  exhibit	   any	   significant	   kill	   effect.	   In	   fact	   its	   efficacy	   was	   comparable	   to	   the	  medium.	   Both	   observations	   did	   not	   come	   as	   a	   surprise	   and	   are	   in	   agreement	  with	   the	   reported	   literature.	  More	   specifically,	   Cisplatin	   has	   been	   reported	   to	  have	  a	  good	  kill	  effect	  both	  in	  malignant	  glioma	  primary	  cultures	  and	  cell	  lines	  [156,	  157].	  Carmustine	  on	  the	  other	  hand,	  has	  been	  reported	  as	  having	  variable	  effect	  with	  few	  cultures	  showing	  in	  vitro	  sensitivity	  [126,	  127].	  	  	  It	   is	   apparent	   from	   this	   study	   that	   both	   frequency	   of	   application	   and	   cell	  synchronisation	   could	   enhance	   the	   sensitivity	   of	   in	   vitro	   testing	   of	  chemotherapeutic	   agents.	   Such	   enhancements	   increase	   handling	   time	   and	  require	   specialised	   equipment.	   Given	   the	   added	   value	   that	   they	   provide	   to	  chemosensitivity	  testing	  they	  should	  be	  worth	  the	  investment.	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4 BIOMARKERS	  IN	  GLIOMAS:	  CYTOKINES	  	  
4.1 Introduction	  	  There	   has	   been	   growing	   interest	   in	   discovering	   biomarkers	   for	   malignant	  gliomas.	  A	  biomarker	   is	  a	  measurable	  substance,	  which	  can	  used	   to	   indicate	  a	  biological	  state.	  Such	  state	  can	  be	  a	  normal	  biological	  process,	  a	  disease	  or	  even	  a	   pharmacological	   response	   to	   treatment.	   Examples	   of	   commonly	   used	  biomarkers	   include	  Hb1Ac	   for	  diabetes	  mellitus,	   blood	  pressure	  monitoring	   in	  hypertension,	  and	  chromosomal	  abnormalities	  in	  genetic	  syndromes.	  	  	  Biomarkers	   are	   also	   widely	   used	   as	   part	   of	   disease	   monitoring	   in	   several	  common	  cancers,	  such	  as	  prostate	  cancer,	  ovarian	  cancer,	  hepatocellular	  cancer,	  to	   name	   a	   few.	   In	   recent	   years,	   several	   studies	   have	   identified	   potential	  candidate	  molecules	   as	   brain	   tumour	  biomarkers	   but	   so	   far	   very	   few	  of	   them	  have	  been	  used	  in	  clinical	  practice	  [113].	  Amongst	  the	  most	  promising	  ones	  for	  clinical	  use	  are	  the	  Cytokines	  and	  Angiogenesis	  factors	  [114].	  Cytokines	  are	  the	  main	   focus	   of	   this	   chapter	  whereas	   the	   Angiogenesis	   factors	   are	   expanded	   in	  Chapter	  5.	  	  Cytokines	   are	   small	   protein	   molecules	   that	   are	   secreted	   by	   cells	   of	   diverse	  embryological	   origin	   during	   both	   physiological	   and	   pathological	   metabolic	  pathways.	   They	   are	   signalling	   molecules	   that	   are	   used	   in	   intercellular	  communication,	   triggering	   inflammation	   or	   in	   response	   to	   infection.	   They	   can	  be	   classified	   as	   proteins,	   peptides	   or	   glycoproteins	   and	   include	   interleukins,	  lymphokines	  and	  cell	  signal	  molecules,	  such	  as	  tumour	  necrosis	  factor	  and	  the	  interferons.	  These	  molecules	  have	  been	  investigated	  as	  potential	  biomarkers	  for	  brain	  tumours	  as	  well	  as	  molecules	  for	  targeted	  therapy	  [182];	  [183].	  	  Virtually	  all	  nucleated	  cells,	  but	  especially	  endothelial	  cells,	  epithelial	  cells	  and	  macrophages	  are	   the	  main	  producers	  of	   cytokines	  and	  mainly	   interleukins.	  As	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these	  cells	  are	  found	  everywhere	  in	  the	  body,	  interleukins	  have	  systemic	  rather	  than	   local	   effects.	   The	   ubiquitous	   production	   of	   the	   interleukins	   is	   one	   of	   the	  features	  that	  differentiate	  them	  from	  the	  hormones.	  Interleukins	  are	  produced	  in	  response	  to	  physiological	  processes	  of	  intercellular	  communication	  as	  well	  as	  in	   response	   to	   trauma	   or	   inflammation.	   As	   such	   they	   can	   be	  measured	   in	   the	  blood	  of	  healthy	  individuals.	  	  	  There	   have	   been	   several	   studies	   investigating	   the	   “normal”	   range	   of	  inflammatory	   cytokines	   in	   healthy	   individuals.	   In	   the	   plasma	   of	   healthy	  volunteers,	   IL-­‐6	   concentration	   was	   found	   to	   be	   between	   0.01	   to	   11.5	   pg/mL	  with	   a	  median	   concentration	   of	   1.46	   pg/mL	   [183].	   Similarly,	   in	   the	   serum	   of	  healthy	  individuals,	  IL-­‐6	  was	  also	  found	  to	  be	  in	  the	  1	  pg/mL	  range	  [184]	  [185]	  with	  slight	  increase	  during	  the	  menstrual	  cycle	  [186],	  and	  larger	  increase	  after	  surgery	  (30-­‐430	  pg/mL)[187].	  	  	  Ferrucci	  and	  coworkers	  [188]	  have	  demonstrated	  that	  the	  concentrations	  of	  the	  interleukins	   increase	   with	   age	   in	   healthy	   individuals.	   They	   claimed	   that	   the	  older	  population	  has	  a	  constitutional	  “pro-­‐inflammatory	  state”	  as	  well	  as	  a	  more	  profound	   cytokine	   response	   after	   a	   noxious	   stimulus.	  There	   are	   some	   studies	  that	   also	   report	   an	   age	   difference	   in	   the	   circulating	   levels	   of	   IL-­‐6,	   C-­‐reactive	  protein	  (CRP)	  and	  other	  inflammatory	  biomarkers	  both	  in	  serum	  and	  in	  plasma	  [189].	  Ershler	  and	  coworkers	  reported	  that	  serum	  IL-­‐6	  levels	  are	  normally	  non	  detectable,	   but	   become	   so	  with	   increasing	   age.	   This	   observation	   supports	   the	  previous	   hypothesis	   of	   the	   age	   related	   abnormal	   regulation	   of	   IL-­‐6	   gene	  expression.	   They	   also	   speculated	   that	   IL-­‐6	   contributes	   to	   the	   pathogenesis	   of	  several	   age-­‐associated	   diseases	   such	   as	   lymphoma,	   Alzheimer’s	   disease,	   and	  osteoporosis [190, 191].	   Other	   studies	   involving	   healthy	   individuals	   have	   also	  demonstrated	  that	  age	  is	  associated	  with	  higher	  baseline	  levels	  of	  inflammatory	  cytokines.	   Environmental	   factors	   (i.e.	   smoking,	   infections,	   obesity,	   genetic	  factors	   and	   declining	   function	   of	   sex	   hormones)	   as	   well	   as	   age-­‐associated	  diseases	  were	  found	  to	  be	  contributing	  causes	  to	  this	  observation.	  However,	  the	  definition	  of	  “healthy	  status”	  in	  those	  studies	  is	  debatable	  [192,	  193].	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Krabbe	   and	   coworkers	   have	   extensively	   investigated	   the	   cause	   of	   the	   “pro-­‐inflammatory	   state”	   of	   the	   older	  healthy	   individuals.	   They	  have	  measured	   the	  baseline	   levels	   of	   several	   cytokines	   between	   two	   age	   groups	   of	   healthy	  volunteers.	  The	  younger	  group	  had	  a	  mean	  age	  of	  24	  years	  whereas	   the	  older	  group	  had	  a	  mean	  age	  of	  66	  years.	  All	  volunteers	  were	  screened	  for	  disease	  and	  had	  negative	  past	  medical	  history	  and	  physical	  examination.	  In	  addition,	  none	  of	  the	  volunteers	  used	  any	  medication,	  nor	  did	  they	  have	  any	  febrile	  illness	  in	  the	  fortnight	  preceding	  the	  study.	  Blood	  screening	  showed	  normal	  white	  blood	  cell	  (WBC)	  count,	  WBC	  differential	  count,	  CRP,	  blood	  glucose	  levels,	  kidney	  function,	  liver	   function,	   and	   coagulation	   screen.	   All	   individuals	   had	   a	   normal	  electrocardiogram	   (ECG).	   Furthermore,	   all	   older	   volunteers	   underwent	   an	  exercise	   ECG	   that	   was	   found	   to	   be	   normal.	   The	   study	   concluded	   that	   the	  baseline	  cytokine	  load	  did	  not	  differ	  between	  the	  two	  age	  groups.	  However,	  the	  older	   age	   group	   produced	   a	   more	   rapid	   and	   longer	   lasting	   acute	   phase	  inflammatory	   response	   when	   compared	   to	   the	   younger	   age	   group.	   This	  observation	  could	  be	  caused	  by	  a	  primary	  impairment	  of	  the	  mechanisms	  that	  turn	  off	  the	  inflammatory	  response.	  Another	  possible	  explanation	  could	  be	  the	  accumulation	   of	   cardiovascular	   risk	   factors	   and	   diseases	   with	   aging.	   The	  baseline	  plasma	  levels	  reported	  in	  the	  Krabbe	  study	  as	  normal	  for	  Il-­‐6,	  IL-­‐8	  and	  IL-­‐10	  were	  0.156	  pg/ml,	  31.2	  pg/ml,	  and	  0.781	  pg/ml	  respectively	  [194].	  	  	  Other	  studies,	  which	  applied	  strict	  criteria	   for	  good	  health,	  adequate	  nutrition	  and	  absence	  of	  diseases	  have	  also	   failed	   to	  detect	  any	  significant	  difference	   in	  the	   production	   of	   IL-­‐1	   and	   IL-­‐6	   between	   young,	   middle-­‐aged,	   and	   older	  participants	   [195].	   Kim	   and	   coworkers	   have	   profiled	   a	   large	   number	   of	  cytokines	   in	   serum	   of	   young	   (below	   45	   years)	   and	   elderly	   (over	   65	   years)	  healthy	   individuals	   using	   a	  multiplexed	   bead-­‐based	   immunoassay.	   The	   serum	  levels	  of	  EGF,	  FGF-­‐2,	  Flt-­‐3L,	  INF-­‐	  a2,	  INF-­‐g,	  IL-­‐10,	  IL-­‐15,	  IL-­‐17,	  IL-­‐1b,	  IL-­‐2,	  IL-­‐6,	  IL-­‐8,	  IP-­‐10,	  MIP-­‐1b,	  PDGF-­‐AA,	  TNF-­‐a,	  and	  VEGF	  that	  they	  reported	  did	  not	  show	  any	  significant	  difference	  between	  the	  two	  age	  groups.	  Participants	  of	  the	  older	  group	  had	   significantly	  higher	   systolic	  blood	  pressure	   (SBP),	   total	   cholesterol,	  triglyceride	  (TG),	  serum	  albumin,	  serum	  blood	  urea	  nitrogen	  (BUN),	  and	  serum	  creatinine	   levels.	  The	  serum	  circulating	   levels	   (pg/ml)	  which	   they	  reported	  as	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normal	  for	  IL-­‐6,	  IL-­‐8	  and	  IL-­‐10	  were:	  2.91	  (±	  6.45),	  23.99	  (±	  29.7)	  and	  1.32	  (±	  3.06)	  respectively	  for	  the	  under	  45,	  and	  2.57	  (±	  5.22),	  27.6	  (±43.9)	  and	  1.58	  (±	  6.17)	  for	  the	  over	  65	  [196].	  	  	  Togo	   and	   coworkers	   tried	   to	   understand	   if	   there	   is	   a	   circadian	   rhythm	   to	   the	  secretion	  of	  these	  molecules.	  They	  demonstrated	  that	  the	  concentrations	  of	  the	  inflammatory	   cytokines	   varied	   during	   the	   sleep-­‐awake	   cycle.	   Although	   their	  concentrations	   were	   uniformly	   low,	   there	   were	   bursts	   of	   secretion,	   which	  occurred	  during	  nighttime.	  The	  circulating	  plasma	  concentrations	  (pg/ml)	  that	  they	  reported	  as	  normal	   for	  healthy	   individuals	  were:	  16.8	  (±15.3)	  awake	  and	  12.2	  (±11.5)	  asleep	  for	  IL-­‐6;	  11.8	  (±5.4)	  awake	  and	  12.5	  (±6.4)	  asleep	  for	  IL-­‐8;	  and	  0.95	  (±0.38)	  awake	  and	  0.84	  (±0.38)	  asleep	  for	  IL-­‐10	  [197].	  	  In	   addition	   to	   the	   cytokine	   producing	   cells	   mentioned	   above,	   there	   is	  accumulating	   evidence	   that	   certain	   cells	   of	   the	  Central	  Nervous	   System	   (CNS)	  also	   secrete	   several	   cytokines.	   These	   cell	   types	   include	   choroid	   plexus,	  ependymal	   cells,	   endothelial	   cells	   of	   the	  Blood	  Brain	  Barrier	   (BBB),	  microglia,	  neurons	   and	   astrocytes	   [198-­‐200].	   Follow	   up	   studies	   will	   shed	   light	   to	   the	  extent	   of	   the	   contribution	   of	   these	   cell	   types	   to	   the	   total	   concentration	   of	  circulating	  cytokines.	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4.2 Aims	  	  This	  study	  explores	  the	  feasibility	  of	  collecting	  serum	  and	  plasma	  samples	  from	  patients	  and	  healthy	  volunteers	  (controls)	  pre-­‐	  and	  post-­‐operatively.	  In	  addition	  it	  investigates	  the	  use	  of	  cytokines	  IL-­‐6,	  IL-­‐8	  and	  IL-­‐10	  as	  potential	  biomarkers	  for	   malignant	   brain	   tumours.	   Furthermore,	   it	   scrutinises	   the	   effect	   of	  parameters	  such	  as	   the	  presence	  of	  brain	  tumour,	   the	  operative	  stage,	   the	  age	  and	  the	  gender	  to	  the	  serum	  levels	  of	  these	  cytokines.	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4.3 Materials	  and	  methods	  	  	  Serum	   samples	  were	   collected	   from	   36	   patients	   and	   36	   controls	   immediately	  pre-­‐operatively	  and	  within	  24	  hours	  after	  the	  operation.	  Control	  patients	  were	  defined	  as	  patients	   treated	   surgically	  under	  a	  general	   anaesthetic	   in	  Preston’s	  Neurosurgical	  Unit	  for	  benign	  disease	  (degenerative	  spinal	  disease	  such	  as	  disc	  protrusion	  or	   ligamentous	   thickening),	  with	  no	  past	  medical	  history	   including	  no	  known	  malignancy.	  None	  of	  the	  controls	  were	  on	  regular	  medications	  and	  in	  particular	   steroids	   of	   any	   form.	   The	   concentrations	   of	   8	   cytokines	   were	  measured	   using	   the	   Bio-­‐Plex	   Pro	   Cytokines	   Assay	   (Bio-­‐Rad)	   according	   to	  manufacturer’s	  instructions	  [201].	  The	  protocol	  is	  briefly	  outlined	  below.	  	  	  
4.3.1 Multiplex	  bead-­‐based	  immunoassay	  
	  Simultaneous	  measurement	  of	   serum	  concentrations	  of	   granulocyte-­‐monocyte	  colony-­‐stimulating	  factor	  (GM-­‐CSF),	  interferon	  γ	  (INF-­‐γ),	  IL-­‐10,	  IL-­‐8,	  IL-­‐6,	  IL-­‐	  4,	  IL-­‐2,	   and	   Tumour	   necrosis	   factor-­‐	   α	   (TNF-­‐α),	   was	   performed	   using	  commercially	   available	   multiplex	   bead-­‐based	   sandwich	   immunoassay	   kit	  (Bioplex)	  as	  per	  the	  manufacturer’s	  instructions.	  Briefly,	  serum	  samples	  (50	  μl	  per	  well)	   or	   standards	   (50	  μl	  per	  well)	  were	   incubated	  with	  50	  μl	   of	   the	  pre-­‐mixed	  bead	  sets	  in	  pre-­‐wetted	  96-­‐	  well	  micro	  titer	  plates	  at	  room	  temperature	  for	   30	   minutes.	   After	   washing,	   25	   μl	   of	   the	   fluorescent	   detection	   antibody	  mixture	   was	   added	   for	   30	   min.	   After	   washing	   further	   50	   μl	   of	   streptavidin-­‐phycoerythrin	   was	   added	   to	   each	   well	   for	   an	   additional	   10	   min	   at	   room	  temperature.	  After	  washing	  125	  microliters	  of	  assay	  buffer	  was	  added	  to	  each	  well.	  The	  plate	  was	  shaken	  at	  1100rpm	  for	  30	  sec	  at	  room	  temperature	  prior	  to	  placing	  it	  into	  the	  reader.	  A	  range	  of	  3.2-­‐10,000	  pg/mL	  recombinant	  full-­‐length	  cytokine	   proteins	  was	   used	   to	   establish	   standard	   curves	   and	   to	  maximize	   the	  sensitivity	   and	   dynamic	   range	   of	   the	   assay.	   Cytokine	   levels	   were	   determined	  using	   a	   Bio-­‐Plex	   200	   System	   (Bio-­‐Rad	   Laboratories	   INC),	   and	   the	   Bio-­‐Plex	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Manager	   software	   was	   used	   for	   data	   acquisition	   and	   analysis.	   The	   data	   are	  reported	  as	  relative	  median	  fluorescent	  intensities	  [196].	  	  
4.4 Results	  	  
4.4.1 Biomarker	  analysis	  	  Eight	  biomarkers	  were	  measured	  using	  the	  Bio-­‐Plex	  Pro	  Cytokines	  Assay	  (Bio-­‐Rad	   Laboratories	   Inc.).	   Of	   these,	   3	   cytokines	   (IL-­‐6,	   IL-­‐8	   and	   IL-­‐10)	   were	   the	  most	  significant	  ones.	  The	  raw	  measurements	  from	  these	  three	  biomarkers	  are	  summarized	  in	  the	  Appendix	  4.	  	  
	  
Outlier	  removal	  	  Some	   of	   the	   measured	   concentrations	   were	   significantly	   outside	   of	   the	  physiological	   range	   and	   therefore	   the	   datasets	   were	   examined	   for	   potential	  outliers.	  Outlier	  removal	  was	  done	  using	  the	  method	  commonly	  referred	  to	  as	  the	   Quartile	   or	   Fourth-­‐Spread	   method	   [202].	   Essentially,	   it	   involves	   the	  identification	   of	   the	   boundaries	   of	   each	   of	   the	   quartiles	   in	   the	   data	   set.	   The	  difference	  between	  the	  75th	  and	  25th	  percentiles	  is	  the	  fourth	  spread	  (fs).	  The	  Upper	  and	  Lower	  Outlier	  Boundaries	  are	  equal	   to	  1.5	   times	   the	   fourth	  spread	  above	  and	  below	  the	  median.	  Using	  the	  Fourth-­‐Spread	  method	  the	  outliers	  were	  removed	   from	   the	   datasets	   prior	   to	   continuing	   with	   the	   analysis.	   Once	   the	  outliers	  were	  removed,	  the	  remaining	  data	  presented	  a	  more	  uniform	  spread	  as	  shown	  in	  the	  boxplot	  below	  (Figure	  4-­‐1).	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Figure	   4-­‐1:	   Boxplot	   summarizing	   the	   pre-­‐	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   the	  
three	  cytokines	  measured	  in	  the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only).	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Table	  4-­‐1The	  Shapiro-­‐Wilk	  scores	  and	  p-­‐values	  as	  determined	  for	  the	  various	  datasets.	  
Shapiro-­‐Wilk	  Normality	  Test	   	  
Cytokines	  data	   	  IL6-­‐Pre	   W	  =	  1.98E-­‐01,	  p-­‐value	  =	  <0.05	  IL6-­‐Post	   W	  =	  9.02E-­‐01,	  p-­‐value	  =	  <0.05	  IL8-­‐Pre	   W	  =	  9.30E-­‐01,	  p-­‐value	  =	  <0.05	  IL8-­‐Post	   W	  =	  9.36E-­‐01,	  p-­‐value	  =	  0.065	  IL10-­‐Pre	   W	  =	  7.24E-­‐01,	  p-­‐value	  =	  <0.001	  IL10-­‐Post	   W	  =	  9.41E-­‐01,	  p-­‐value	  =	  0.115	  Control-­‐IL-­‐6-­‐Pre	   W	  =	  8.67E-­‐01,	  p-­‐value	  =	  <0.05	  Control-­‐IL-­‐8-­‐Pre	   W	  =	  8.10E-­‐01	  p-­‐value	  =	  0.001	  Control-­‐IL-­‐10-­‐Pre	   W	  =	  8.49E-­‐01,	  p-­‐value	  =	  <0.001	  
Values	  above	   the	  0.05	  cut	  off	   score	  suggest	  normal	  distribution	  of	   the	  respective	  
datasets.	   Generally	   the	   Cytokine	   datasets	   do	   not	   appear	   to	   be	   distributed	  
normally.	  Significant	  values	  are	  shown	  in	  bold.	  	  	  In	   terms	   of	   evaluating	   statistical	   significance	   given	   a	   calculated	   p-­‐value,	   both	  significance	   levels	   α=0.001	   (conservative)	   and	   α=0.05	   (widely	   used)	   were	  considered.	   If	   a	   test	  of	   significance	  gives	  a	  p-­‐value	   lower	   than	   the	  significance	  level	   α,	   the	   null	   hypothesis	   is	   rejected	   and	   the	   results	   are	   considered	   as	  'statistically	  significant'.	  	  
Statistical	  package	  	  The	   statistical	   analysis	   was	   performed	   using	   the	   R	   software	   environment	   for	  statistical	   computing	   and	   graphics	   (version	   2.15.1)	   running	   under	   Windows	  Vista	  OS	  with	  2GB	  RAM	  [148].	  All	  the	  statistical	  tests	  used	  here	  were	  included	  in	  the	  R	  Stats	  package.	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4.4.2 Cytokines	  analysis	  	  The	  results	  of	  the	  analysis	  of	  the	  cytokine	  IL-­‐6,	  IL-­‐8	  and	  IL-­‐10	  are	  summarised	  in	   the	   table	   below	   (Table	   4-­‐2).	   A	   more	   detailed	   description	   of	   the	   results	   is	  provided	  in	  the	  sections	  below.	  	  
Table	  4-­‐2	  Summary	  of	  the	  p-­‐values	  as	  resulted	  from	  the	  analysis	  of	  the	  cytokine	  levels	  (IL-­‐6,	  IL-­‐8,	  IL-­‐
10)	  across	  the	  different	  datasets.	  Significant	  values	  are	  shown	  in	  bold.	  	   Age	  group	   Cytokines	  	   	   IL-­‐6	   IL-­‐8	   IL-­‐10	  Controls	  vs.	  Pre-­‐op	  Patients	   0-­‐100	  	   <0.001	   <0.05	   <0.001	  Controls	  vs.	  Pre-­‐op	  Patients	   0-­‐39	   0.128	   1.000	   0.128	  Controls	  vs.	  Pre-­‐op	  Patients	   40-­‐69	   <0.001	   <0.05	   <0.001	  Controls	  vs.	  Pre-­‐op	  Patients	   70-­‐100	   <0.05	   0.431	   <0.05	  Pre-­‐op	  vs.	  Post-­‐op	  Patients	   0-­‐100	   <0.001	   <0.001	   <0.001	  Pre-­‐op	  vs.	  Post-­‐op	  Patients	   0-­‐39	   0.100	   0.629	   0.100	  Pre-­‐op	  vs.	  Post-­‐op	  Patients	   40-­‐69	   <0.001	   <0.001	   <0.001	  Pre-­‐op	  vs.	  Post-­‐op	  Patients	   70-­‐100	   <0.001	   <0.001	   <0.001	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  Pre-­‐operative	  cytokine	  level	  comparison	  between	  Controls	  and	  Patients	  (all	  
age	  groups)	  	  To	   determine	   whether	   the	   cytokine	   levels	   of	   patients	   with	   malignant	   glioma	  were	   different	   from	   the	   levels	   in	   patients	   with	   benign	   disease	   and	   no	  malignancy,	   the	   measurements	   were	   compared	   using	   the	   Wilcoxon	   test.	   The	  results	  of	  the	  test	  are	  shown	  on	  the	  first	  row	  of	  Table	  4-­‐2	  and	  Figure	  4-­‐2,	  Figure	  4-­‐3	  and	  Figure	  4-­‐4.	  	  The	  levels	  of	  all	  three	  Cytokines	  were	  significantly	  different	  (IL-­‐6,	  P<0.001;	  IL-­‐8	  and	  IL-­‐10,	  P<0.05)	  between	  patients	  with	  malignant	  tumour	  and	  patients	  with	  benign	  disease	  prior	  to	  the	  operation.	  	  	  As	   there	  was	   indeed	   a	   strong	   difference	   on	   the	   cytokine	   pre-­‐operative	   levels	  between	   the	   Controls	   and	   the	   tumour	   patients,	   a	   closer	   investigation	   was	  undertaken	   into	  whether	   this	   trend	  was	  equally	   common	  across	  our	  arbitrary	  assigned	  age	  groups:	  0-­‐39,	  40-­‐69,	  70-­‐100	  years.	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Figure	  4-­‐2	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐6	  measured	  in	  
the	   malignant	   patients	   and	   the	   controls	   (pre-­‐	   only)	   across	   all	   age	   groups.	   Asterisk	   (*)	   indicates	  
statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	  4-­‐3	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐8	  measured	  in	  
the	   malignant	   patients	   and	   the	   controls	   (pre-­‐	   only)	   across	   all	   age	   groups.	   Asterisk	   (*)	   indicates	  
statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	  4-­‐4	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐10	  measured	  in	  
the	   malignant	   patients	   and	   the	   controls	   (pre-­‐	   only)	   across	   all	   age	   groups.	   Asterisk	   (*)	   indicates	  
statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Pre-­‐operative	   cytokine	   level	   comparison	   between	   Controls	   and	   Patients	   (age	  
group	  0-­‐39	  years)	  	  The	  pre-­‐operative	  cytokine	   levels	  assayed	  were	  tested	  in	  order	  to	   identify	  any	  statistical	  difference	  between	  the	  Controls	  and	  the	  tumour	  patients	  for	  the	  age	  group	   0-­‐39	   years.	   The	   results	   from	   this	   comparison	   using	   Wilcoxon	   test	   are	  shown	  on	  the	  second	  row	  of	  Table	  4-­‐2	  and	  Figure	  4-­‐5,	  Figure	  4-­‐6	  and	  Figure	  4-­‐7.	  Based	   on	   them,	   none	   of	   three	   pre-­‐operative	   Cytokine	   levels	   was	   significantly	  different	   (α=0.05)	  between	   the	  Controls	   and	   the	   tumour	  patients	   for	   the	  0-­‐39	  years	  age	  group.	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Figure	  4-­‐5	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐6	  measured	  in	  
the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only)	  in	  the	  0-­‐39	  age	  group.	  
	  
Figure	  4-­‐6	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐8	  measured	  in	  
the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only)	  in	  the	  0-­‐39	  age	  group.	  
	  
Figure	  4-­‐7	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐10	  measured	  in	  
the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only)	  in	  the	  0-­‐39	  age	  group.	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Pre-­‐operative	   cytokine	   level	   comparison	   between	   Controls	   and	   Patients	   (age	  
group	  40-­‐69	  years)	  	  Similarly,	   the	   pre-­‐operative	   cytokine	   levels	   between	   the	   Controls	   and	   the	  tumour	  patients	  for	  the	  age	  group	  40-­‐69	  years	  were	  compared.	  The	  results	  from	  the	  Wilcoxon	  test	  for	  this	  age	  group	  are	  shown	  on	  the	  third	  row	  of	  Table	  4-­‐2	  and	  Figure	  4-­‐8,	  Figure	  4-­‐9	  and	  Figure	  4-­‐10.	  	  Based	   on	   these	   results,	   the	   levels	   of	   all	   three	   pre-­‐operative	   Cytokines	   were	  significantly	  different	  between	  the	  Controls	  and	  the	  tumour	  patients	  for	  this	  age	  group	  (IL-­‐6	  P<0.001;	  IL-­‐8P<0.05;	  IL-­‐10	  P<0.05).	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Figure	  4-­‐8	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐6	  measured	  in	  
the	  malignant	   patients	   and	   the	   controls	   (pre-­‐	   only)	   in	   the	   40-­‐69	   age	   group.	   Asterisk	   (*)	   indicates	  
statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	  4-­‐9	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐8	  measured	  in	  
the	  malignant	   patients	   and	   the	   controls	   (pre-­‐	   only)	   in	   the	   40-­‐69	   age	   group.	   Asterisk	   (*)	   indicates	  
statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	  4-­‐10	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐10	  measured	  
in	  the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only)	   in	  the	  40-­‐69	  age	  group.	  Asterisk	  (*)	   indicates	  
statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Pre-­‐operative	   cytokine	   level	   comparison	   between	   Controls	   and	   Patients	   (age	  
group	  70-­‐100	  years)	  	  The	  last	  age	  group	  to	  be	  tested	  for	  any	  difference	  in	  the	  pre-­‐operative	  cytokine	  levels	  between	  the	  Controls	  and	  the	  tumour	  patients	  was	  the	  70-­‐100	  years.	  The	  results	  from	  the	  Wilcoxon	  test	  for	  this	  age	  group	  are	  shown	  on	  the	  fourth	  row	  of	  Table	  4-­‐2	  and	  Figure	  4-­‐11,	  Figure	  4-­‐12	  and	  Figure	  4-­‐13.	  	  The	   analysis	   has	   shown	   that	   only	   the	   pre-­‐operative	   levels	   of	   IL-­‐6	   were	  significantly	  different	  between	  the	  Controls	  and	  the	  tumour	  patients	  for	  this	  age	  group	  (P<0.001).	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Figure	  4-­‐11	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐6	  measured	  in	  
the	  malignant	   patients	   and	   the	   controls	   (pre-­‐	   only)	   in	   the	   70-­‐100	  age	  group.	   Asterisk	   (*)	   indicates	  
statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  	  
	  
Figure	  4-­‐12	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐8	  measured	  in	  
the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only)	  in	  the	  70-­‐100	  age	  group.	  
	  
Figure	  4-­‐13	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐10	  measured	  
in	  the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only)	  in	  the	  70-­‐100	  age	  group.	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Pre-­‐	  vs.	  post-­‐	  operative	  Cytokine	  level	  comparison	  (all	  age	  groups)	  	  One	   of	   the	  main	   questions	   of	   this	   study	  was	  whether	   there	  was	   a	   significant	  difference	   in	   the	   levels	   of	   patient’s	   pre-­‐	   and	   post-­‐operative	   cytokines.	   To	  address	  this	  question,	  the	  Wilcoxon	  test	  was	  applied	  on	  the	  measured	  cytokine	  concentrations	   and	   the	   results	   of	   the	   analysis	   are	   shown	   on	   the	   fifth	   row	   of	  Table	  4-­‐2	  and	  Figure	  4-­‐14,	  Figure	  4-­‐15	  and	  Figure	  4-­‐16.	  	  The	   levels	   of	   all	   three	   Cytokines	   were	   significantly	   different	   (P<0.001)	   on	  patients	  prior	   to	  and	  after	   their	  operation.	  Based	  on	   these	   findings,	   that	   there	  was	  indeed	  a	  strong	  difference	  on	  the	  cytokine	  levels	  pre-­‐	  and	  post-­‐operatively,	  the	  data	  were	  further	  analysed	  in	  order	  to	  check	  whether	  this	  trend	  was	  equally	  common	  across	  our	  arbitrary	  assigned	  age	  groups:	  0-­‐39,	  40-­‐69,	  70-­‐100	  years.	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Figure	   4-­‐14	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   IL-­‐6	  
measured	   in	   the	   malignant	   patients	   in	   all	   age	   groups.	   Asterisk	   (*)	   indicates	   statistical	   difference	  
between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	   4-­‐15	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   IL-­‐8	  
measured	  in	  the	  malignant	  patients	  in	  all	  age	  groups.	  
	  
Figure	  4-­‐16	  Boxplot	   summarizing	   the	  pre	  and	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	   IL-­‐10	  
measured	   in	   the	   malignant	   patients	   in	   all	   age	   groups.	   Asterisk	   (*)	   indicates	   statistical	   difference	  
between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Pre-­‐	  vs.	  post-­‐	  operative	  Cytokine	  level	  comparison	  (age	  group	  0-­‐39	  years)	  	  The	  pre-­‐	  and	  post-­‐operative	  cytokine	   levels	  were	  analysed	   further	   in	  order	   to	  identify	   a	   statistical	   difference	   between	   the	   samples	   for	   the	   age	   group	   0-­‐39	  years.	  The	  results	   from	  this	  comparison	  using	  Wilcoxon	  test	  are	  shown	  on	  the	  sixth	  row	  of	  Table	  4-­‐2	  and	  Figure	  4-­‐17,	  Figure	  4-­‐18	  and	  Figure	  4-­‐19.	  	  There	   was	   no	   significant	   difference	   (α=0.05)	   between	   the	   three	   Cytokine	  assayed	   on	   patients	   prior	   to	   and	   after	   the	   operation	   for	   the	   0-­‐39	   years	   age	  group.	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Figure	   4-­‐17	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   IL-­‐6	  
measured	  in	  the	  malignant	  patients	  in	  the	  0-­‐39	  age	  group.	  
	  
Figure	   4-­‐18	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   IL-­‐8	  
measured	  in	  the	  malignant	  patients	  in	  the	  0-­‐39	  age	  group.	  
	  
Figure	  4-­‐19	  Boxplot	   summarizing	   the	  pre	  and	  post-­‐operative	  serum	  concentration	   (pg/ml)	  of	   IL-­‐10	  
measured	  in	  the	  malignant	  patients	  in	  the	  0-­‐39	  age	  group.	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Pre-­‐	  vs.	  post-­‐operative	  Cytokine	  level	  comparison	  (age	  group	  40-­‐69	  years)	  	  Similarly,	   the	   levels	   of	   the	   cytokines	   between	   the	   pre-­‐	   and	   post-­‐operative	  samples	   for	   the	   age	   group	   40-­‐69	   years	   were	   analysed	   to	   look	   for	   statistical	  difference.	  The	  results	  from	  the	  Wilcoxon	  test	  for	  this	  age	  group	  are	  shown	  on	  the	  seventh	  row	  of	  Table	  4-­‐2	  and	  Figure	  4-­‐20,	  Figure	  4-­‐21	  and	  Figure	  4-­‐22.	  	  There	   was	   a	   significant	   difference	   in	   the	   levels	   of	   three	   Cytokines	   assayed	  (P<0.001)	  on	  patients	  prior	  to	  and	  after	  the	  operation	  for	  this	  age	  group.	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Figure	   4-­‐20	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   IL-­‐6	  
measured	   in	   the	   malignant	   patients	   in	   the	   40-­‐69	   age	   group.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	   4-­‐21	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   IL-­‐8	  
measured	   in	   the	   malignant	   patients	   in	   the	   40-­‐69	   age	   group.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	   4-­‐22Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   IL-­‐10	  
measured	   in	   the	   malignant	   patients	   in	   the	   40-­‐69	   age	   group.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Pre-­‐	  vs.	  post-­‐	  operative	  Cytokine	  level	  comparison	  (age	  group	  70-­‐100	  years)	  	  The	  last	  age	  group	  to	  be	  tested	  for	  any	  difference	  in	  the	  cytokine	  levels	  pre-­‐	  and	  post	  operatively	  was	   the	  70-­‐100	  years.	  The	  results	   from	  the	  Wilcoxon	   test	   for	  this	  age	  group	  are	  shown	  on	  the	  eighth	  row	  of	  Table	  4-­‐2	  and	  Figure	  4-­‐23,	  Figure	  4-­‐24	  and	  Figure	  4-­‐25.	  	  The	  analysis	  has	  shown	  that	  the	  levels	  of	  all	  three	  cytokines	  were	  significantly	  different	   (P<0.001)	   on	   patients	   prior	   to	   and	   after	   the	   operation	   for	   this	   age	  group.	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Figure	   4-­‐23	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   IL-­‐6	  
measured	   in	   the	   malignant	   patients	   in	   the	   70-­‐100	   age	   group.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	   4-­‐24	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   IL-­‐8	  
measured	   in	   the	   malignant	   patients	   in	   the	   70-­‐100	   age	   group.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	  4-­‐25	  Boxplot	   summarizing	   the	  pre	  and	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	   IL-­‐10	  
measured	   in	   the	   malignant	   patients	   in	   the	   70-­‐100	   age	   group.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Age	  group	  comparison	  within	  the	  pre-­‐	  and	  the	  post-­‐operation	  datasets	  	  	  In	  the	  above	  analysis	  it	  has	  been	  established	  whether	  there	  is	  any	  difference	  in	  the	   cytokine	   levels	   for	   the	   different	   age	   groups	   between	   the	   pre-­‐	   and	   post-­‐operative	   samples	   and	   between	   the	   Controls	   and	   the	   pre-­‐operative	   patient	  samples.	  	  	  The	  next	  thing	  to	  look	  into	  is	  whether	  age	  plays	  a	  role	  on	  the	  levels	  of	  pre-­‐	  and	  post-­‐operative	  cytokines	  as	  well	  as	  on	  the	  Controls.	  Using	  the	  Wilcoxon	  test	  the	  levels	  of	  cytokines	  were	  compared	  between	  the	  three	  age	  groups	  in	  the	  pre-­‐	  or	  post-­‐operative	  datasets.	  The	  results	  are	  shown	  in	  Table	  4-­‐3,	  Table	  4-­‐4,	  Table	  4-­‐5	  and	  Table	  4-­‐6	  respectively.	  	  
	  
Table	   4-­‐3	   Comparison	   of	   the	   cytokine	   levels	   between	   the	   different	   age	   groups	   in	   the	   Control	   pre-­‐
operation	   datasets	   (p-­‐values	   as	   determined	   by	   the	  Wilcoxon	   test).	   Significant	   values	   are	   shown	   in	  
bold.	   	   0-­‐39	  vs.	  40-­‐69	   0-­‐39	  vs.	  70-­‐100	   40-­‐69	  vs.	  70-­‐100	  Control	  IL-­‐6	  (Pre-­‐op)	   0.350 <0.05 0.078 Control	  IL-­‐8	  (Pre-­‐op)	   0.078 0.176 0.335 	  Control	  IL-­‐10	  (Pre-­‐op)	   0.128 <0.05 0.221 
	  
	  
Table	  4-­‐4	   Comparison	  of	   the	   IL-­‐6	   levels	   between	   the	  different	  age	  groups	   in	   the	  pre-­‐	   and	   the	  post-­‐
operation	  datasets	  IL-­‐6	  (Pre)	   0-­‐39	   40-­‐69	   70-­‐100	   IL-­‐6	  (Post)	  0-­‐39	   	   0.6608	   0.8784	   0-­‐39	  40-­‐69	   N/A	   	   0.6475	   40-­‐69	  70-­‐100	   0.8312	   0.3156	   	   70-­‐100	  
p-­‐values	  as	  determined	  by	  the	  Wilcoxon	  test.	  Significant	  values	  are	  shown	  in	  bold.	  
White	   cells	   represent	   preoperative	   p	   values;	   light	   grey	   cells	   represent	  
postoperative	   values.	   N/A	   means	   not	   enough	   data	   were	   available	   to	   allow	   the	  
comparison.	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Table	  4-­‐5	   Comparison	  of	   the	   IL-­‐8	   levels	   between	   the	  different	  age	  groups	   in	   the	  pre-­‐	   and	   the	  post-­‐
operation	  datasets.	  IL-­‐8	  (Pre)	   0-­‐39	   40-­‐69	   70-­‐100	   IL-­‐8	  (Post)	  0-­‐39	   	   0.4975	   0.6107	   0-­‐39	  40-­‐69	   0.7497	   	   0.3162	   40-­‐69	  70-­‐100	   1	   0.3118	   	   70-­‐100	  
p-­‐values	  as	  determined	  by	  the	  Wilcoxon	  test.	  Significant	  values	  are	  shown	  in	  bold.	  
White	   cells	   represent	   preoperative	   p	   values;	   light	   grey	   cells	   represent	  
postoperative	  values.	  
	  
Table	  4-­‐6	  Comparison	  of	   the	  IL-­‐10	   levels	  between	  the	  different	  age	  groups	   in	  the	  pre-­‐	  and	  the	  post-­‐
operation	  datasets.	  IL-­‐10	  (Pre)	   0-­‐39	   40-­‐69	   70-­‐100	   IL-­‐10	  (Post)	  0-­‐39	   	   0.6107	   0.8851	   0-­‐39	  40-­‐69	   0.793	   	   0.6114	   40-­‐69	  70-­‐100	   0.9191	   0.4334	   	   70-­‐100	  
p-­‐values	  as	  determined	  by	  the	  Wilcoxon	  test.	  Significant	  values	  are	  shown	  in	  bold.	  
White	   cells	   represent	   preoperative	   p	   values;	   light	   grey	   cells	   represent	  
postoperative	  values.	  	  	  Significant	   difference	  was	   observed	   only	   between	   the	   0-­‐39	   years	   and	   70-­‐100	  years	  age	  groups	  for	  the	  IL-­‐6	  and	  IL-­‐10	  on	  the	  Control	  samples	  (P<0.05).	  	  No	   significant	   difference	   on	   the	   levels	   of	   the	   tested	   cytokines	   was	   observed	  between	   the	  different	  age	  groups	  either	  prior	   to	  or	  after	   the	  operation	  on	   the	  samples	  from	  Patients	  with	  glioblastoma	  (α=0.05).	  	  
Effect	  of	  gender	  on	  pre-­‐	  and	  post-­‐operative	  cytokine	  levels	  	  	  Finally,	   it	  was	  investigated	  whether	  gender	  had	  an	  effect	  on	  the	  pre-­‐	  and	  post-­‐operative	   cytokine	   levels	   as	   well	   as	   between	   the	   tumour	   Patients	   and	   the	  Controls.	  This	  was	  achieved	  by	  grouping	  the	  patients	  based	  on	  their	  gender.	  The	  cytokine	   levels	   of	   the	   different	   gender	   groups	   were	   compared	   using	   the	  Wilcoxon	   test.	   The	   results	   of	   the	   analysis	   are	   shown	   in	   Table	   4-­‐7	   and	   Figure	  4-­‐26,	  Figure	  4-­‐27,	  Figure	  4-­‐28,	  Figure	  4-­‐29,	  Figure	  4-­‐30	  and	  Figure	  4-­‐31.	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Table	  4-­‐7	  Comparison	  of	  pre-­‐	  and	  post-­‐operative	  levels	  of	  cytokines	  IL-­‐6,	  IL-­‐8	  and	  IL-­‐10	  and	  gender	  (P	  
values	  as	  determined	  by	  the	  Wilcoxon	  test).	  Significant	  values	  are	  shown	  in	  bold.	  	   Cytokine	  	   	   IL-­‐6	   IL-­‐8	   IL-­‐10	  All	  data	  vs.	  Male	   Pre-­‐op	   0.752	   0.501	   0.758	  	   Post-­‐op	   0.533	   0.818	   0.722	  All	  data	  vs.	  Female	   Pre-­‐op	   0.577	   0.387	   0.629	  	   Post-­‐op	   0.388	   0.755	   0.517	  Female	  vs.	  Male	   Pre-­‐op	   0.477	   0.185	   0.495	  	   Post-­‐op	   0.204	   0.646	   0.387	  Pre-­‐op	  vs.	  Post-­‐op	   All	  Male	   <0.001	   <0.001	   <0.001	  Pre-­‐op	  vs.	  Post-­‐op	   All	  Female	   <0.001	   <0.001	   0.001	  Male	  Control	  vs.	  Male	  Patient	   Pre-­‐op	   <0.001	   <0.05	   <0.05	  Female	  Control	  vs.	  Female	  Patient	   Pre-­‐op	   <0.001	   <0.05	   0.413	  Male	  Control	  vs.	  Female	  Control	   Pre-­‐op	   0.334	   0.552	   0.354	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Figure	   4-­‐26	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   IL-­‐6	  
measured	   in	   the	   male	   malignant	   patients	   across	   all	   age	   groups.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	   4-­‐27	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   IL-­‐8	  
measured	   in	   the	   male	   malignant	   patients	   across	   all	   age	   groups.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Figure	  4-­‐28	  Boxplot	   summarizing	   the	  pre	  and	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	   IL-­‐10	  
measured	   in	   the	   male	   malignant	   patients	   across	   all	   age	   groups.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	   4-­‐29	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   IL-­‐6	  
measured	   in	   the	   female	  malignant	   patients	   across	   all	   age	   groups.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	   4-­‐30	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   IL-­‐8	  
measured	   in	   the	   female	  malignant	   patients	   across	   all	   age	   groups.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Figure	  4-­‐31	  Boxplot	   summarizing	   the	  pre	  and	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	   IL-­‐10	  
measured	   in	   the	   female	  malignant	   patients	   across	   all	   age	   groups.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	  4-­‐32	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐6	  measured	  in	  
the	  malignant	  patients	  of	  each	  gender	  in	  all	  age	  groups.	  
	  
Figure	  4-­‐33	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐8	  measured	  in	  
the	  malignant	  patients	  of	  each	  gender	  in	  all	  age	  groups.	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Figure	  4-­‐34	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐10	  measured	  
in	  the	  malignant	  patients	  of	  each	  gender	  in	  all	  age	  groups.	  
	  
Figure	  4-­‐35	  Boxplot	  summarizing	  the	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐6	  measured	  
in	  the	  malignant	  patients	  of	  each	  gender	  in	  all	  age	  groups.	  
	  
Figure	  4-­‐36	  Boxplot	  summarizing	  the	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐8	  measured	  
in	  the	  malignant	  patients	  of	  each	  gender	  in	  the	  all	  age	  groups.	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Figure	  4-­‐37	  Boxplot	  summarizing	  the	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	  IL-­‐10	  measured	  
in	  the	  malignant	  patients	  of	  each	  gender	  in	  all	  age	  groups.	  
	  
Figure	  4-­‐38	  Boxplot	  summarizing	  the	  serum	  concentration	  (pg/ml)	  of	  IL-­‐6	  measured	  in	  the	  controls	  
(pre-­‐	  only)	  of	  both	  genders	  in	  all	  age	  groups.	  
	  
Figure	  4-­‐39	  Boxplot	  summarizing	  the	  serum	  concentration	  (pg/ml)	  of	  IL-­‐8	  measured	  in	  the	  controls	  
(pre-­‐	  only)	  of	  both	  genders	  in	  all	  age	  groups.	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Figure	  4-­‐40	  Boxplot	  summarizing	  the	  serum	  concentration	  (pg/ml)	  of	  IL-­‐10	  measured	  in	  the	  controls	  
(pre-­‐	  only)	  of	  both	  genders	  in	  all	  age	  groups.	  	  According	  to	  these	  results,	  neither	  the	  male	  nor	  the	  female	  group	  had	  displayed	  any	  significant	  difference	  against	  the	  combined	  dataset	  (males	  and	  females)	  as	  well	  as	  against	  the	  opposite	  gender	  (α=0.05).	  This	  suggests	  that	  gender	  does	  not	  seem	  to	  play	  a	  significant	  role	  for	  patients	  with	  glioblastoma	  multiforme.	  These	  observations	   held	   true	   for	   both	   gender	   groups	   regardless	   of	   their	   operative	  stage	  (pre-­‐	  vs.	  post-­‐)	  (Figure	  4-­‐32,	  Figure	  4-­‐33,	  Figure	  4-­‐34,	  Figure	  4-­‐35,	  Figure	  4-­‐36	  and	  Figure	  4-­‐37).	  On	  the	  contrary,	  when	  the	  operative	  stage	  was	  compared	  against	   each	   other	   for	   each	   gender	   group,	   both	   male	   and	   female	   groups	   had	  shown	  significant	  difference	   for	  all	   three	  cytokines	  (P<0.001;	  All	  Female	   IL-­‐10	  <0.05).	  	  	  Similarly	   to	   the	   results	   above,	   gender	   did	   not	   seem	   to	   have	   an	   effect	   in	   the	  preoperative	  Controls	   (α=0.05)	  either	   (see	  Male	  Control	  vs.	  Female	  Control	   in	  Table	  4-­‐7	  as	  well	  as	  Figure	  4-­‐38,	  Figure	  4-­‐39	  and	  Figure	  4-­‐40).	  However,	  with	  the	   only	   exception	   of	   IL-­‐10	   in	   females,	   both	   male	   and	   female	   Controls	   had	  significantly	  different	  cytokine	  levels	  from	  their	  equivalent	  patient	  samples	  (IL-­‐6	   P<0.001;	   IL-­‐8	   P<0.05).	   This	   observation	   confirms	   the	   significant	   difference	  observed	  previously	  between	  the	  Controls	  and	  the	  Patients	  when	  the	  male	  and	  female	  data	  were	  combined	  (Table	  4-­‐2).	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4.5 Discussion	  	  The	  serum	  concentrations	  of	  three	  cytokines	  were	  measured	  from	  patients	  with	  malignant	   gliomas	   as	   well	   as	   from	   controls	   affected	   by	   degenerative	   spinal	  disease.	  All	  three	  cytokines	  were	  found	  to	  be	  higher	  in	  the	  controls	  compared	  to	  the	   preop	   patients.	   In	   addition,	   the	   preoperative	   levels	   of	   all	   three	   cytokines	  were	  lower	  than	  those	  observed	  postoperatively.	  Age	  and	  gender	  did	  not	  play	  a	  role	  on	  the	  angiogenesis	  factor	  concentrations.	  	  	  In	   this	   study,	   the	   concentrations	  observed	   in	   the	   serum	  of	   control	   individuals	  preoperatively	  were	  1-­‐2	  pg/ml	  for	  IL-­‐6,	  4	  pg/ml	  for	  IL-­‐8	  and	  1	  pg/ml	  for	  IL-­‐10.	  These	  concentrations	  are	  slightly	  higher	  when	  compared	  to	  the	  values	  reported	  in	   the	   literature.	   This	   finding	   is	   not	   surprising	   as	   all	   healthy	   controls	   were	  affected	   by	   degenerative	   spinal	   disease.	   It	   is	   well	   known	   that	   degenerative	  spinal	   disease	   both	   in	   the	   form	   of	   disc	   protrusion	   as	   well	   as	   ligamentous	  thickening	   fuels	  an	   inflammatory	  response.	  Healthy	  controls	  were	  recruited	   in	  this	  study	  just	  before	  they	  underwent	  laminectomy	  or	  microdiscectomy	  under	  a	  general	   anaesthetic.	   They	   had	   a	   negative	   history	   of	  malignancy,	   inflammatory	  disease,	   autoimmune	   disease,	   asthma,	   epilepsy	   and	   recent	   illness	   (within	   a	  fortnight).	   All	   individuals	   underwent	   routine	   blood	   tests	   including	   full	   blood	  count	  (FBC),	  urea	  and	  electrolytes	  (U&E),	  liver	  function	  tests	  (LFT),	  coagulation	  screen	  as	  well	  as	  electrocardiogram	  (ECG),	  which	  were	  normal.	  	  	  The	  preoperative	  concentrations	  of	   the	  same	  cytokines	  of	  patients	  affected	  by	  brain	  tumours	  were	  found	  to	  be	  significantly	   lower	  than	  the	  concentrations	  of	  the	  controls	   (IL-­‐6	  range	  between	  1	  pg/ml,	   IL-­‐8	  2.5	  pg/ml	  and	   IL-­‐10	  0	  pg/ml).	  This	  difference	  in	  the	  preoperative	  levels	  could	  be	  explained	  by	  the	  fact	  that	  all	  patients	   were	   on	   high	   dose	   of	   Dexamethasone.	   As	   this	   drug	   has	   anti-­‐inflammatory	  effects,	   it	   is	   logical	   to	   think	  that	   it	  antagonises	   the	   inflammatory	  response	  of	  the	  patient	  to	  the	  tumour.	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Controls	  on	  the	  other	  hand,	  were	  not	  administered	  Dexamethasone	  or	  any	  other	  steroidal	  drug	  for	  that	  matter,	  but	  most	  of	  them	  were	  taking	  regular	  analgesics	  in	  the	  form	  of	  paracetamol,	  non-­‐steroidals	  and/or	  opioids	  which	  do	  not	  exhibit	  anti-­‐inflammatory	  effects.	  	  The	  difference	  in	  the	  preoperative	  concentrations	  of	  cytokines	  between	  controls	  and	  patients	  could	  also	  be	  explained	  by	  the	  drugs	  received	  by	  patients	  but	  not	  controls.	  For	  example,	  antiepileptic	  drugs	  (AED)	  such	  as	  Sodium	  Valproate	  were	  found	   to	   inhibit	   production	   of	   IL-­‐6	   [205].	   These	   AEDs	  were	   received	   only	   by	  patients	  but	  not	   controls.	   Some	  of	  our	  patients	  were	   taking	  Sodium	  Valproate	  regularly,	  which	  could	  have	  influenced	  the	  concentration	  of	  the	  circulating	  IL-­‐6.	  	  In	  accordance	  with	  the	  previously	  reported	  literature,	   in	  this	  study	  gender	  did	  not	  have	  an	  effect	  on	  the	  preoperative	  cytokine	   levels	  of	  controls	  and	  patients	  alike	  [206].	  Similarly,	  age	  did	  not	   influence	  the	  preoperative	  cytokine	   levels	  of	  the	  control	  and	  patient	  datasets.	  However,	  there	  is	  discrepancy	  in	  the	  literature	  as	  to	  whether	  age	  contributes	  to	  a	  change	  in	  the	  circulating	  baseline	  levels	  of	  the	  inflammatory	  cytokines	  [188,	  194].	  A	  possible	  explanation	  for	  the	  inconsistency	  in	  the	  various	  studies	  might	  be	  that	  the	  elderly	  participants	  were	  not	  screened	  for	   associated	   diseases,	   such	   as	   hypertension,	   cardiovascular	   disease,	  cerebrovascular	   disease,	   diabetes	   mellitus,	   cancer,	   or	   chronic	   renal	   disease,	  which	  could	  increase	  inflammation	  and	  hence	  influence	  the	  cytokine	  levels.	  	  When	  comparing	  the	  preoperative	  with	  the	  postoperative	  concentrations	  of	  the	  patients	  all	   three	  cytokines	  had	  a	  significant	   increase.	  This	  observation	  can	  be	  due	  to	  the	   inflammatory	  response	  of	   the	  tumour	  as	  well	  as	   that	  of	   the	  healthy	  tissue	  undergoing	  the	  trauma	  of	  the	  operation.	  In	  addition,	  it	  is	  possible	  that	  the	  disruption	  of	  the	  blood	  brain	  barrier	  (BBB)	  during	  the	  operation	  might	  facilitate	  the	  easier	  entry	  of	  the	  cytokines	  in	  the	  circulating	  blood.	  	  	  When	   the	   group	   of	   patients	   was	   subdivided	   into	   three	   different	   age	   groups,	  there	  was	   no	   significant	   difference	   of	   the	   pre-­‐	   versus	   post-­‐operative	   cytokine	  concentrations	  seen	  in	  the	  young	  age	  group	  (0-­‐39	  yrs).	  This	  was	  not	  the	  case	  for	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the	   other	   two	   age	   groups	   (40-­‐69	   and	   70-­‐100	   yrs).	   One	   hypothesis	   is	   that	   the	  response	   of	   the	   younger	   group	   to	   the	   tumour	   or	   the	   operation	   is	   less	   intense	  than	   that	  observed	   in	   the	  older	   age	  groups.	  As	  previously	   reported,	   age	  has	   a	  role	   to	   play	   in	   the	   increasing	   levels	   of	   the	   inflammatory	   cytokines	   in	   patients	  [188].	   This	   effect	   was	   found	   to	   be	   exacerbated	   by	   cardiovascular	   or	  cerebrovascular	   disease,	   diabetes,	   genetic	   factors	   as	   well	   as	   environmental	  factors	   like	  smoking	  and	  obesity.	  The	  cytokine	  concentrations	  observed	   in	  our	  study	   might	   have	   been	   affected	   by	   the	   fact	   that	   some	   of	   our	   patients	   were	  suffering	  by	  one	  or	  more	  of	  the	  aforementioned	  factors.	  Another	  possibility	  for	  the	  lack	  of	  difference	  between	  the	  pre-­‐	  and	  postoperative	  cytokine	  levels	  in	  the	  young	  age	  group	  might	  be	   its	  small	  sample	  size	  comprising	  only	   four	  patients.	  As	   such,	   the	   sample	   is	   potentially	   too	   small	   to	   give	   statistically	   conclusive	  results.	  On	  the	  other	  hand,	  the	  other	  two	  age	  groups	  were	  populated	  by	  a	  good	  number	  of	  individuals	  (16	  for	  the	  40-­‐69	  and	  15	  for	  the	  70-­‐100	  years	  age	  group)	  making	  the	  statistical	  analysis	  more	  robust.	  	  	  It	  is	  clear	  from	  the	  observed	  results	  that	  the	  operation	  itself	  plays	  a	  major	  role	  in	   the	   difference	   seen	   between	   the	   pre-­‐	   and	   postoperative	   cytokine	  concentrations.	  The	  production	  and	  release	  of	  the	  inflammatory	  cytokines	  into	  the	  blood	  of	  the	  patients	  might	  be	  affected	  by	  factors	  like	  the	  breakdown	  of	  the	  BBB,	  the	  tumour	  neovasculature	  and	  the	  inflammatory	  response	  of	  the	  tumour	  and	  the	  healthy	  tissues	  to	  the	  operation.	  	  It	   has	   been	  well	   established	   that	   inflammation	   plays	   an	   important	   role	   in	   the	  aetiopathogenesis	   and	  manifestation	  of	  pathological	  brain	   changes	   [207,	  208].	  During	  inflammation,	  activated	  glial	  cells,	  neurons	  and	  immune	  cells	  that	  invade	  brain	   tissue,	   produce	   pro-­‐inflammatory	   cytokines.	   Within	   the	   CNS,	   cytokines	  stimulate	   inflammatory	   processes	   that	   may	   impair	   blood-­‐brain	   barrier	  permeability,	   promote	   apoptosis	   of	   neurons	   and	   oligodendrocytes	   as	   well	   as	  induce	  myelin	  damage.	  	  There	   is	   accumulating	   evidence	   suggesting	   that	   inflammatory	   cytokine	   levels	  are	   different	   between	   men	   and	   women	   [207].	   This	   could	   be	   a	   result	   of	   the	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hormone	  oestrogen	   and	   its	   anti-­‐inflammatory	   effect	  within	   the	  CNS	  providing	  neuroprotection	   [209].	   The	   fact	   that	   oestrogen	   may	   modulate	   cytokine	  expression,	  and	  that	  gender	  differences	  of	  cytokine	  production	  are	  apparent	  in	  animal	  models	  of	  Parkinson’s	  disease	  (PD)	  and	  Multiple	  Sclerosis	  (MS),	  suggests	  an	   important	   connection	   between	   oestrogen	   and	   cytokines	   in	  neurodegeneration	   [207,	   210].	  The	  neuroprotective	   effects	   of	   oestrogens	  vary	  with	   reproductive	   age	   in	   females.	   Johnson	   and	   coworkers	   have	   shown	   that	  oestrogens	   attenuate	   the	   production	   of	   inflammatory	   cytokines	   in	   females.	  Following	   inflammatory	   stimuli,	   females	   of	   reproductive	   age	   generate	   fewer	  inflammatory	  cytokines	  [209].	  	  	  Despite	   this	   literature	   evidence	   of	   a	   gender	   effect	   on	   the	   cytokine	   levels,	   the	  present	   study	   did	   not	   identify	   a	   significant	   difference.	   A	   possible	   explanation	  might	  be	  that	  the	  female	  sample	  size	  comprised	  mostly	  postmenopausal	  women	  and	   as	   such	   oestrogen	   did	   not	   affect	   the	   production	   of	   cytokines.	   Further	  recruitment	   of	   younger	   female	   patients	  would	   shed	  more	   light	   as	   to	  whether	  there	  is	  gender	  effect	  on	  the	  cytokines.	  	  	  This	  work	  suggests	  that	  all	  three	  tested	  cytokines	  are	  suitable	  candidates	  to	  be	  used	  as	  biomarkers	  for	  malignant	  gliomas.	   	  Provided	  that	  the	  results	  observed	  are	   not	   influenced	   by	   drugs	   administered	   to	   the	   patients,	   these	   biomarkers	  would	  allow	  clinicians	  to	  follow	  up	  patients	  during	  the	  course	  of	  their	  disease	  in	  terms	  of	  monitoring	  response	  to	  treatment	  as	  well	  as	  early	  detection	  of	  disease	  recurrence.	   Further	   studies	   involving	   patients	   affected	   by	   malignant	   brain	  tumours	   who	   are	   not	   yet	   on	   Dexamethasone	   or	   AEDs	   would	   elucidate	   if	   the	  differences	  observed	  were	  due	  to	  the	  tumour	  or	  the	  drugs.	  All	   three	  cytokines	  are	  novel	  biomarkers	  for	  this	  disease	  as	  there	  are	  no	  previous	  reports	  on	  their	  involvement	  in	  malignant	  gliomas.	  Another	  novelty	  of	  this	  work	  is	  that	  there	  are	  no	  previous	  studies	  investigating	  the	  pre	  vs.	  postoperative	  levels	  of	  cytokines	  in	  patients	   with	   malignant	   gliomas.	   As	   such,	   this	   work	   offers	   a	   significant	  contribution	  towards	  a	  better	  understanding	  of	   these	  molecules	  and	  their	  role	  in	   this	   disease.	   Further	   studies	   with	   larger	   cohort	   of	   healthy	   controls	   and	  patients	   would	   increase	   the	   reliability	   of	   the	   use	   of	   these	   molecules	   as	  
	   170	  
biomarkers	   for	   malignant	   gliomas	   while	   it	   would	   allow	   novel	   ones	   to	   be	  discovered.	  	  	  	  
	   171	  
5 BIOMARKERS	  IN	  GLIOMAS:	  ANGIOGENESIS	  FACTORS	  	  
5.1 Introduction	  	  The	   importance	   of	   biomarker	   discovery	   for	   malignant	   gliomas	   has	   been	  mentioned	   in	   Chapter	   4	   and	   therefore	   will	   not	   be	   discussed	   again	   here.	   This	  Chapter	   focuses	   on	   the	   use	   of	   Angiogenesis	   factors	   as	   potential	   brain	   tumour	  biomarkers.	  	  Vasculogenesis	   is	   the	   de	   novo	   formation	   of	   blood	   vessels	   from	   angioblasts.	  These	   are	   cells	   that	   derive	   from	   the	   mesoderm	   and	   can	   differentiate	   into	  endothelial	   cells	   but	   have	   not	   yet	   acquired	   all	   the	   endothelial	   cell	   markers.	  Vasculogenesis	   is	   a	   complex	   process,	   involving	   interactions	   between	   the	   cells	  and	  the	  extracellular	  matrix	  both	  spatially	  and	  temporally.	  	  	  Angiogenesis	   (sprouting	  and	   intussusceptive)	   is	  defined	  as	   the	  growth	  of	  new	  blood	   vessels	   from	   existing	   vasculature.	   This	   process	   is	   largely	   restricted	   to	  embryogenesis	  and	  rarely	   in	  adults,	  mainly	  during	  physiological	  menstruation	  and	   pathological	   wound	   healing.	   The	   mechanism	   of	   new	   vessel	   formation	   is	  different	   in	   the	   two	   types	   of	   angiogenesis.	   Sprouting	   angiogenesis	   is	   the	  formation	  of	  new	  vessels	  by	  sprouts	  of	  endothelial	  cells,	  which	  grow	  towards	  an	  angiogenic	   stimulus.	   It	   involves	   several	   steps	   including	   the	   enzymatic	  degradation	  of	  the	  basement	  membrane,	  the	  proliferation	  and	  migration	  of	  the	  endothelial	  cells	  (EC)	  towards	  the	  angiogenic	  stimulus,	  the	  EC	  tubule	  formation,	  the	  vessel	  fusion	  and	  pruning	  and	  finally	  the	  pericytes	  stabilisation.	  This	  type	  of	  angiogenesis	   adds	   vessels	   in	   parts	   of	   tissue	   that	   lack	   vasculature.	  Intussusceptive	   or	   splitting	   angiogenesis	   on	   the	   other	   hand,	   produces	   new	  vessel	   formation	  by	  splitting	  an	  existing	  vessel	   into	  two.	  This	  occurs	  when	  the	  vessel	  wall,	   extends	   into	   the	   lumen	   of	   the	   vessel,	   causing	   the	   single	   vessel	   to	  split	   into	   new	   vessels.	   This	   type	   of	   angiogenesis	   requires	   reorganisation	   of	  existing	   endothelial	   cells,	   rather	   than	   proliferation	   and	   migration.	   For	   this	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reason	  it	  is	  thought	  to	  be	  faster	  and	  more	  efficient	  than	  sprouting	  angiogenesis	  (Figure	   5-­‐1)	   [211].	   Pantsulaia	   and	   coworkers	   demonstrated	   that	   genetic,	  hereditary	   and	   environmental	   factors	   shared	   by	  members	   of	   the	   same	   family	  influence	   the	   concentrations	   of	   angiogenesis	   factors	   in	   a	   healthy	   population	  [212].	  Other	  pathological	  conditions,	  which	  can	  stimulate	  angiogenesis,	  include	  atherosclerosis,	   osteomyelitis,	   diabetic	   retinopathy,	   psoriasis,	   and	   tumour	  growth	  [213].	  	  	  
	  
Figure	  5-­‐1	  Basic	  types	  of	  primary	  vascular	  growth.	  Adapted	  by	  [211]	  	  	  It	   is	  widely	   reported	   in	   the	   literature	   that	   the	   tumour	   produces	   angiogenesis	  factors	   in	   response	   to	   hypoxia,	   to	   promote	   its	   neoangiogenesis	   and	   growth	  [214-­‐219].	  	  In	   the	   case	   of	   tumour	   angiogenesis,	   the	   tumour	   cells	   produce	   angiogenesis	  factors	  that	  activate	  endothelial	  cells.	  These	  activated	  endothelial	  cells	  produce	  proteolytic	   enzymes	   that	   break	   down	   the	   basement	   membrane	   allowing	   the	  migration	  of	  the	  endothelial	  cells	  and	  the	  release	  of	  bound	  vascular	  endothelial	  growth	   factor	   (VEGF)	   into	   the	   surrounding	   tissue.	   The	   migrated	   endothelial	  cells	  start	  to	  proliferate	  forming	  tube-­‐like	  structures	  that	  finally	  mature	  in	  new	  vessel	  formation	  [220].	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In	  the	  last	   few	  years	  many	  already	  known	  growth	  factors	  have	  been	  identified	  as	   having	   angiogenic	   activity	   as	  well.	   Those	   include	   fibroblast	   growth	   factors	  (αFGF	  or	  FGF-­‐1	  and	  βFGF	  or	  FGF-­‐2),	   transforming	  growth	   factors	   (TGF-­‐α	  and	  TGF-­‐β),	  platelet-­‐derived	  growth	  factor	  (PDGF),	  hepatocyte	  growth	  factor	  (HGF),	  granulocyte	  colony-­‐stimulating	  factor	  (G-­‐CSF),	  tumour	  necrosis	  factor-­‐	  α	  (TNF-­‐	  α),	  inteleukin-­‐8	  (IL-­‐8)	  and	  prostaglandins	  (PGE1	  and	  PGE2)	  [214,	  215].	  Some	  of	  those	   factors	   are	   also	   considered	   being	   members	   of	   the	   “generic	   family”	   of	  cytokines.	  
 Tumour	  angiogenesis	  is	  a	  cardinal	  feature	  for	  tumour	  growth	  as	  well	  as	  for	  the	  development	  of	  metastatic	  disease.	  Several	  pro-­‐inflammatory	  cytokines,	  such	  as	  IL-­‐1,	  IL-­‐6,	  and	  TNF,	  stimulate	  VEGF	  gene	  expression	  in	  a	  tissue-­‐specific	  way.	  It	  is	  known	  that	  VEGF	  mRNA	  is	  produced	  in	  five	  isoforms	  by	  nonmalignant	  as	  well	  as	  malignant	   cells.	   Hypoxia,	   hypoglycemia	   and	   inflammation	   are	   the	   triggers	   for	  nonmalignant	  production	  of	  VEGF.	  	  	  There	  is	  a	  fine	  balance	  between	  activating	  and	  inhibiting	  mediators	  controlling	  angiogenesis	   in	   tumours	   [214].	  Malignant	  cells	  produce	  VEGF	  constitutively	   in	  high	   concentrations	   even	   in	   normoxic	   conditions,	   due	   to	   genetic	   alterations.	  VEGF	  is	  a	  protein	  that	  binds	  the	  basal	  membrane	  of	  the	  endothelium	  initiating	  several	  effects	  on	  the	  endothelial	  cells,	  from	  stimulation	  of	  mitosis,	  to	  inhibiting	  apoptosis	   and	   increasing	   permeability	   to	   the	   vascular	   endothelium.	   Its	   role	   is	  important	   both	   in	   physiological	   as	   well	   as	   pathophysiological	   angiogenesis	  (embryogenesis,	  physiological	  menstrual	  cycle,	  abnormal	  wound	  healing)	  [221].	  Several	   previous	   studies	   have	   investigated	   the	   site	   of	   production	   of	   VEGF.	  Several	  organs	  such	  as	  lungs,	  adrenal	  glands,	   liver,	  heart,	  stomach	  mucosa	  and	  kidneys	  have	  been	  found	  to	  produce	  this	  protein.	  It	  is	  also	  known	  that	  platelets	  and	  leukocytes	  release	  VEGF	  during	  blood	  clotting.	  Today,	  it	  is	  assumed	  that	  all	  tissues	  have	  the	  potential	  to	  produce	  this	  growth	  factor	  [222].	  	  	  Normal	   physiological	   concentrations	   of	   VEGF	   have	   been	  measured	   by	   several	  studies.	   It	   is	   clear	   when	   looking	   at	   the	   literature	   that	   the	   reported	   “normal	  ranges”	   are	   in	   many	   studies	   different	   by	   two	   to	   three	   hundred-­‐fold	   between	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studies.	  This	   is	  mainly	  due	   to	   the	   fact	   that	   the	  assays	  used	  measure	   total	   free	  circulating	   VEGF	   (competitive	   immunoassays)	   as	   others	   measure	   only	   free	  VEGF	   (immunoassays	   with	   neutralizing	   antibodies).	   If	   the	   antibodies	   of	   the	  immunoassay	  are	  specific	  to	  one	  of	  the	  several	  isoforms	  of	  VEGF,	  the	  results	  are	  different	   again.	   Studies	   using	   competitive	   ELISAs	   reported	   concentrations	   of	  total	  free	  VEGF	  between	  3-­‐25	  x109	  pg/mL,	  a	  value	  that	  drops	  to	  1	  x109	  pg/mL	  when	   Radioimmunoassays	   (RIAs)	   are	   used	   [223-­‐225].	   When	   the	   different	  isoforms	  are	  measured	  the	  concentrations	  reported	  change	  again.	  Free	  VEGF121	  has	   been	   reported	   as	   19	   pg/mL	   [226]	   whereas	   free	   VEGF165	   was	   42	   pg/mL	  [227].	   The	  most	   commonly	   used	   commercial	   ELISA	   (Quantikine)	   detects	   both	  free	   isoforms	   VEGF121	   and	   VEGF165.	   Studies	   using	   this	   assay	   report	   plasma	  values	  of 9–150	  pg/mL	  [227-­‐231].	  	  	  Jelkmann	   reports	   higher	   values	   when	   an	   in-­‐house	   assay	   with	   polyclonal	  antibodies	   to	   detect	   VEGF	   was	   used	   [232].	   Although	   these	   values	   are	  independent	   of	   gender,	   interference	   with	   molecules	   that	   bound	   VEGF	   (i.e.	  heparin,	   2-­‐macroglobulin),	   as	   well	   as	   the	   type	   of	   sample	   used	   (serum	   versus	  plasma),	  are	   factors	  that	  are	  thought	  to	  play	  a	  crucial	  role	   into	   influencing	  the	  results	  of	  the	  assay	  used.	  When	  serum	  is	  used	  as	  sample	  type	  to	  measure	  VEGF,	  the	   reference	   interval	   for	   VEGF121/165	   is	   relatively	   high,	   averaging	   10–300	  pg/mL	  [227,	  233-­‐237].	  	  This	  difference	  in	  measured	  concentrations	  between	  the	  two	  samples	  (serum	  v	  plasma)	   is	   due	   to	   the	   VEGF	   released	   from	   platelets	   and	   leukocytes	   during	  clotting.	   It	   is	   thought	   that	   in	   fact,	   serum	   VEGF	   concentrations	   reflect	   blood	  platelet	   counts	   rather	   than	   VEGF	   produced	   by	   peripheral	   tissues	   [229,	   235,	  238].	  It	  has	  been	  reported	  that	  not	  only	  clotting,	  but	  also	  its	  duration	  as	  well	  as	  temperature	   increases	   serum	  VEGF	   concentration	   [236,	   238,	   239].	  When	   free	  VEGF121/	  165	  is	  measured	  in	  blood	  cells	  and	  plasma	  the	  values	  reported	  are	  445	  pg/mL	  and	  19	  pg/mL	  respectively.	  	  	  Jelkmann	   goes	   as	   far	   as	   recommending	   that	   citrated,	   EDTA-­‐treated,	   or	  heparinized	  plasma	  processed	  in	  glass	  tubes,	  frozen	  to	  -­‐800	  within	  one	  hour	  of	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venopuncture,	  should	  be	  the	  material	  of	  choice	  for	  measurement	  of	  VEGF	  [235].	  Wynendaele	  and	  coworkers	  suggest	  that	  in	  order	  to	  stabilize	  platelets	  the	  blood	  should	   be	   collected	   in	   CTAD	   tubes,	   which	   contain	   citrate,	   theophylline,	  adenosine,	   and	   dipyridamole	   [240].	   Several	   studies	   have	   shown	   that	   the	  concentration	   of	   circulating	   free	   VEGF121/165	   is	   elevated	   in	   malignant	   disease,	  [240,	  241]	   and	   that	   it	   increases	   further	  during	   the	  development	  of	  metastasis	  (breast	  [242],	  gastrointestinal	  [243],	  colorectal	  [230],	  prostate	  cancer	  [244]	  and	  melanoma	  [231]).	  Kondo	  and	  coworkers	  were	  the	  first	   to	  recognize	  VEGF	  as	  a	  potential	  serum	  biomarker	  in	  malignant	  disease	  [245].	  Several	  cancers	  such	  as	  brain,	  lung,	  gastrointestinal,	  hepatobiliary,	  renal,	  ovarian	  and	  others,	  are	  known	  to	   have	   increased	   serum	   free	   VEGF	   levels.	   Although	   platelets	   are	   the	   main	  culprits	  for	  the	  serum	  concentrations	  of	  VEGF	  as	  previously	  mentioned,	  Lee	  and	  coworkers	   demonstrated	   that	   blood	   platelets	   in	   tumor	   patients	   contain	  more	  releasable	  VEGF	  than	  platelets	  from	  healthy	  persons	  [246].	  They	  also	  observed	  that	  tumour	  cells	  have	  been	  forming	  aggregates	  with	  platelets	  in	  metastasis.	  By	  measuring	  VEGF	  in	  both	  healthy	  and	  cancer	  patients	  in	  serum	  and	  plasma,	  they	  demonstrated	  that	  VEGF	   in	  serum	  is	  significantly	  higher	   than	  matched	  plasma	  as	  well	   as	   that	   the	  VEGF	   difference	   between	   the	   two	   sample	   types	   correlated	  with	   the	   platelet	   count	   of	   both	   healthy	   and	   cancer	   affected	   individuals.	   They	  argue	  that	  platelet-­‐derived	  VEGF	  reflects	  the	  biology	  of	  cancer	  cells,	  and	  as	  such	  serum	   is	   more	   useful	   than	   plasma	   in	   the	   diagnosis	   and	   follow-­‐up	   of	  malignancies	  [246].	  	  However,	   it	   is	   almost	   impossible	   to	   carry	   out	   interlaboratory	   comparisons	   of	  VEGF	   serum	   data,	  mainly	   because	   the	   procedures	   for	   blood	   handling	   are	   not	  standardized	   with	   respect	   to	   clotting	   material,	   duration,	   and	   temperature.	  Therefore,	  Banks	  and	  coworkers	  suggest	  that	  plasma	  should	  be	  the	  sample	  type	  of	   choice	   for	   VEGF	   measurement,	   in	   order	   to	   make	   more	   accurate	   and	   most	  importantly	  comparable	  results	  between	  studies	  [235].	  	  	  It	   is	  known	  that	  platelets	  secrete	  VEGF,	  platelet-­‐derived	  growth	  factor	  (PDGF),	  platelet	   factor	   4	   (PF4),	   thrombospondin-­‐1	   (TSP-­‐1),	   fibroblast	   growth	   factor,	  basic	   (bFGF),	   and	   endostatin.	   Peterson	   and	   coworkers	   reported	   as	   normal	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ranges	  of	  the	  above	  mentioned	  growth	  factors	   in	  platelets	  the	  following:	  VEGF	  (0.74	   ±	   0.37	   pg/106	   platelets);	   PDGF	   (23	   ±	   6	   pg/106);	   PF4	   (12	   ±	   5	   ng/106);	  TSP-­‐1	  (31	  ±	  12	  ng/106);	  bFGF	  (0.44	  ±	  0.15	  pg/106);	  and	  endostatin	  (5.6	  ±	  3.0	  pg/106).	   They	   showed	   that	   there	   was	   an	   excellent	   correlation	   between	   the	  platelet	   levels	  calculated	  with	  the	  actin	  ELISA	  and	  complete	  blood	  count.	  They	  claim	   that	   the	   measurements	   are	   accurate	   and	   reproducible	   with	   very	   little	  biovariability,	   suggesting	   that	   platelet-­‐derived	   measurements	   for	   the	  angiogenesis	  factors	  should	  be	  the	  gold	  standard	  rather	  than	  plasma	  or	  serum	  [247].	  Age	  as	  well	  as	  gender	  does	  not	  influence	  VEGF	  levels	  [248,	  249].	  	  Platelet	   derived	   growth	   factor	   (PDGF)	   is	   another	   growth	   factor	   that	   plays	   an	  important	  role	  in	  cell	  proliferation,	  migration,	  wound	  healing	  and	  angiogenesis.	  It	   stimulates	  mitosis	   as	  well	   as	  differentiation	   for	   cells	  of	  mesenchymal	  origin	  such	  as	  smooth	  muscle	  cells,	  glial	  cells	  and	  fibroblasts.	  It	  regulates	  proliferation	  both	   in	   physiological	   and	   pathological	   conditions.	   There	   are	   several	   cells	   that	  are	   found	   to	  produce	  PDGF.	  Amongst	  others,	   platelets,	   fibroblasts,	   endothelial	  cells,	  pericytes	  and	  glioma	  cells.	  	  	  In	  the	  CNS,	  PDGF	  is	  secreted	  both	  during	  embryogenesis	  as	  well	  as	  in	  the	  adult	  [250].	   It	   has	   been	   found	   in	   neurons,	   pericytes	   and	   astrocytes.	   As	   well	   as	  stimulating	   cell	   division,	   proliferation	   and	  differentiation	   of	   progenitor	   neural	  cells	   during	   embryogenesis	   [251]	   and	   in	   the	   adult	   brain	   [252]	   it	   is	   also	  neuroprotective	  during	  injury	  [253-­‐255].	  It	  is	  well	  known	  that	  amplification	  of	  PDGF	   and	   PDGFR	   genes	   is	   frequent	   in	   human	   gliomas	   of	   all	   grades	   [256].	   Its	  mode	  of	  expression	  suggests	  that	  it	  has	  an	  autocrine	  and	  paracrine	  effect	  on	  the	  tumour	  cells	  [257].	  	  There	  are	  several	  studies	  that	  report	  the	  physiological	  concentrations	  of	  PDGF.	  The	   serum	   concentration	   reported	   varies	   slightly	   between	   studies	   from	  1700pg/ml	  [258]	  to	  1985	  (±1028)	  pg/ml	  [259].	  Plasma	  levels	  of	  PDGF	  have	  also	  been	   reported	   and	   as	   for	   VEGF,	   these	   have	   also	   a	   great	   range	   of	   variability	  between	  studies.	  The	  concentrations	  were	  ranging	  from	  not	  detectable	  (below	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1.56	   fmol/100	   microliters)	   [260]	   to	   450	   (±140)	   pg/ml	   [261].	   Age	   as	   well	   as	  gender	  does	  not	  influence	  PDGF-­‐BB	  concentrations	  [262]	  	  Follistatin	   (FLT)	   is	   a	   protein	   that	   is	   expressed	   in	   nearly	   all	   tissues.	   Its	   main	  function	  is	  to	  bind	  and	  neutralise	  TGF.	  It	  has	  been	  reported	  that	  FLT	  suppresses	  invasion	  in	  several	  malignancies	  (lung,	  ovarian	  and	  endometrial	  cancer,	  as	  well	  as	  oral	  squamous	  carcinoma)[263-­‐266].	  Several	  studies	  in	  the	  literature	  report	  the	  “normal	  range”	  of	  FLT,	  but	  as	  with	  VEGF	  and	  PDGF,	  its	  concentrations	  vary	  with	   the	  different	  assays	  used	  as	  well	  as	   the	   type	  of	   sample	  used	   to	  make	   the	  measurement.	  	  	  Widera	   and	   coworkers	   reported	   that	   serum	   concentrations	   of	   FLT	   are	   higher	  than	   that	   observed	   in	   citrated	   plasma	   and	   heparin-­‐treated	   plasma	   by	  approximately	   18%.	   The	   median	   concentration	   of	   apparently	   healthy	  individuals	  in	  serum	  is	  7180	  (range	  1060-­‐18490)	  pg/mL	  [267].	  	  Wakatsuki	  and	  coworkers	  reported	  as	  normal	  human	  serum	  FLT	  levels	  13300	  (±	   4700)	   pg/mL.	   They	   observed	   that	   FLT	   is	   present	   during	   puberty	   and	   the	  concentrations	   tend	   to	   increase	   with	   age	   and	   during	   pregnancy	   [268,	   269].	  Neither	   gender,	   nor	   the	   stage	   of	   the	   menstrual	   cycle	   had	   an	   effect	   on	   the	  concentration	   of	   circulating	   FLT	   (approximately	   450	   pg/ml).	   Interestingly,	  postmenopausal	   women	   had	   higher	   FLT	   concentrations	   than	   premenopausal	  women	  (approximately	  1400	  pg/ml)	  [270].	  	  Sakamoto	   and	   coworkers	   reported	   that	   subjects	  with	   chronic	   kidney	   disease,	  chronic	   liver	   disease,	   advanced	   solid	   cancer	   as	   well	   as	   haematological	  malignancies	   have	   higher	   concentrations	   of	   FLT	   than	   apparently	   healthy	  individuals	  [271].	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5.2 Aims	  	  This	  study	  explores	  the	  feasibility	  of	  collecting	  serum	  and	  plasma	  samples	  from	  patients	  and	  healthy	  volunteers	  (controls)	  pre-­‐	  and	  post-­‐operatively.	  In	  addition	  it	  investigates	  the	  use	  of	  angiogenesis	  factors	  VEGF,	  PDGF-­‐BB	  and	  Follistatin	  as	  potential	  biomarkers	   for	  malignant	  brain	   tumours.	  Furthermore,	   it	   scrutinises	  the	   effect	   of	   parameters	   such	   as	   the	   presence	   of	   brain	   tumour,	   the	   operative	  stage,	  the	  age	  and	  the	  gender	  to	  the	  serum	  levels	  of	  these	  angiogenesis	  factors.	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5.3 Materials	  and	  methods	  	  	  Serum	   samples	  were	   collected	   from	   36	   patients	   and	   36	   controls	   immediately	  pre-­‐operatively	  and	  within	  24	  hours	  after	  the	  operation.	  Control	  patients	  were	  defined	  as	  patients	   treated	   surgically	  under	  a	  general	   anaesthetic	   in	  Preston’s	  Neurosurgical	  Unit	  for	  benign	  disease	  (degenerative	  spinal	  disease	  such	  as	  disc	  protrusion	  or	   ligamentous	   thickening),	  with	  no	  past	  medical	  history	   including	  no	  known	  malignancy.	  None	  of	  the	  controls	  were	  on	  regular	  medications	  and	  in	  particular	   steroids	   of	   any	   form.	   The	   concentrations	   of	   8	   angiogenesis	   factors	  were	  measured	  using	  the	  Bio-­‐Plex	  Pro	  Angiogenesis	  Assay	  (Bio-­‐Rad)	  according	  to	  manufacturer’s	  instructions	  [201].	  The	  protocol	  is	  briefly	  outlined	  below.	  	  	  
Multiplex	  bead-­‐based	  immunoassay	  
 Simultaneous	   measurement	   of	   serum	   concentrations	   of	   Angiopoietin,	  Follistatin,	   Granulocyte-­‐colony	   stimulating	   factor	   (G-­‐CSF),	   Hepatocyte	   growth	  factor	   (HGF),	   IL-­‐8,	   Leptin,	   Platelet-­‐derived	   growth	   factor	   (PDGF-­‐BB),	  Platelet/Endothelial	   cell	   adhesion	   molecule-­‐1	   (PECAM-­‐1)	   and	   Vascular	  endothelial	  growth	  factor	  (VEGF),	  was	  performed	  using	  commercially	  available	  multiplex	   bead-­‐based	   sandwich	   immunoassay	   kits	   (Bioplex)	   as	   per	   the	  manufacturer’s	   instructions.	   Briefly,	   serum	   samples	   (50	   μl	   per	   well)	   or	  standards	  (50	  μl	  per	  well)	  were	  incubated	  with	  50	  μl	  of	  the	  pre-­‐mixed	  bead	  sets	  in	  pre-­‐wetted	  96-­‐	  well	  micro	   titer	  plates	  at	  room	  temperature	   for	  30	  minutes.	  After	  washing,	  25	  μl	   of	   the	   fluorescent	  detection	  antibody	  mixture	  was	  added	  for	   30	   min.	   After	   washing	   further	   50	   μl	   of	   streptavidin-­‐phycoerythrin	   was	  added	  to	  each	  well	  for	  an	  additional	  10	  min	  at	  room	  temperature.	  After	  washing	  125	  microliters	  of	  assay	  buffer	  was	  added	  to	  each	  well.	  The	  plate	  was	  shaken	  at	  1100rpm	  for	  30	  sec	  at	  room	  temperature	  prior	  to	  placing	   it	   into	  the	  reader.	  A	  range	  of	  3.2-­‐10,000	  pg/mL	  recombinant	   full-­‐length	  angiogenesis	  proteins	  was	  used	  to	  establish	  standard	  curves	  and	  to	  maximize	  the	  sensitivity	  and	  dynamic	  range	  of	   the	  assay.	  Angiogenesis	   levels	  were	  determined	  using	  a	  Bio-­‐Plex	  200	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System	   (Bio-­‐Rad	   Laboratories	   INC),	   and	   the	   Bio-­‐Plex	   Manager	   software	   was	  used	  for	  data	  acquisition	  and	  analysis.	  The	  data	  are	  reported	  as	  relative	  median	  fluorescent	  intensities	  [196].	  
	   181	  
	  
5.4 Results	  	  
5.4.1 Biomarker	  analysis	  	  Eight	  biomarkers	  measured	  using	  the	  Bio-­‐Plex	  Pro	  Angiogenesis	  and	  Cytokines	  Assay	   (Bio-­‐Rad).	   Of	   these,	   three	   angiogenesis	   factors	   (VEGF,	   PDGF-­‐BB	   and	  Follistatin)	  were	  the	  most	  significant	  ones.	  The	  raw	  measurements	   from	  these	  three	  biomarkers	  are	  summarized	  in	  Appendix	  4.	  	  
Outlier	  removal	  	  Outliers	  were	  removed	  using	  the	  Fourth-­‐Spread	  method	  as	  described	  in	  Chapter	  4.	   Once	   the	   outliers	   were	   removed,	   the	   remaining	   data	   presented	   a	   more	  uniform	  spread	  as	   shown	   in	   the	   three	  boxplots	   (Figure	  5-­‐2,	   Figure	  5-­‐3	  Figure	  5-­‐4).	  	  
Checking	  datasets	  for	  normality	  using	  Shapiro-­‐Wilk	  Normality	  test	  	  Before	   deciding	  which	   statistical	  method	   to	   be	   used	   for	   the	   data	   analysis,	   the	  data	  where	   checked	  whether	   they	   fit	   a	  normal	  distribution	  using	   the	  Shapiro-­‐Wilk	  Normality	  test	  [203].	  The	  null	  hypothesis	  for	  the	  Shapiro-­‐Wilk	  test	  is	  that	  the	  data	  are	  normally	  distributed.	  If	  the	  chosen	  cut	  off	  score	  is	  0.05	  and	  the	  p-­‐value	   is	   less	   than	   0.05,	   then	   the	   null	   hypothesis	   that	   the	   data	   are	   normally	  distributed	   is	   rejected.	   If	   the	   p-­‐value	   is	   greater	   than	   0.05,	   then	   the	   null	  hypothesis	   has	   not	   been	   rejected	   and	   therefore	   the	   data	   are	   normally	  distributed.	  	  According	  to	  this	   test	  almost	  all	  measurements	  derived	  from	  the	  Angiogenesis	  factors	  did	  resemble	  a	  normal	  distribution	  and	  thus	  the	  Student’s	  paired	  t-­‐test	  was	   used	   [272].	   The	   results	   from	   the	   Shapiro-­‐Wilk	   normality	   test	   are	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summarised	  in	  Table	  5-­‐1,	  Figure	  5-­‐2	  Boxplot	  summarising	  the	  control	  (pre-­‐	  only)	  
and	  the	  pre-­‐	  and	  post-­‐operative	  concentrations	  (pg/ml)	  of	  VEGF	  measured	  in	  the	  
malignant	  patients.	  	  	  	  
Table	  5-­‐1	  The	  Shapiro-­‐Wilk	  scores	  and	  p-­‐values	  as	  determined	  for	  the	  various	  datasets.	  	  
Shapiro-­‐Wilk	  Normality	  Test	   	  
Angiogenesis	  factor	  data	   	  VEGF-­‐Pre	   W	  =	  9.66E-­‐01,	  p-­‐value	  =	  0.422	  VEGF-­‐Post	   W	  =	  9.54E-­‐01,	  p-­‐value	  =	  0.247	  PDGF-­‐BB-­‐Pre	   W	  =	  9.66E-­‐01,	  p-­‐value	  =	  0.464	  PDGF-­‐BB-­‐Post	   W	  =	  9.47E-­‐01,	  p-­‐value	  =	  0.150	  Follistatin-­‐Pre	   W	  =	  9.81E-­‐01,	  p-­‐value	  =	  0.852	  Follistatin-­‐Post	   W	  =	  9.24E-­‐01,	  p-­‐value	  =	  <0.05	  Control-­‐VEGF	   W	  =	  9.05E-­‐01,	  p-­‐value	  =	  <0.05	  Control-­‐PDGF-­‐BB	   W	  =	  9.91E-­‐01,	  p-­‐value	  =	  0.999	  Control-­‐Follistatin	   W	  =	  9.54E-­‐01,	  p-­‐value	  =	  0.359	  
Values	  above	   the	  0.05	  cut	  off	   score	  suggest	  normal	  distribution	  of	   the	  respective	  
datasets.	   Generally	   the	   Angiogenesis	   factors	   datasets	   appear	   to	   be	   distributed	  
normally.	  Significant	  values	  are	  shown	  in	  bold.	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Figure	  5-­‐2	  Boxplot	  summarising	  the	  control	  (pre-­‐	  only)	  and	  the	  pre-­‐	  and	  post-­‐operative	  
concentrations	  (pg/ml)	  of	  VEGF	  measured	  in	  the	  malignant	  patients.	  	  
	  
Figure	  5-­‐3	  Boxplot	  summarising	  the	  control	  (pre-­‐	  only)	  and	  the	  pre-­‐	  and	  post-­‐operative	  
concentrations	  (pg/ml)	  of	  PDGF-­‐BB	  measured	  in	  the	  malignant	  patients.	  	  
	  
Figure	  5-­‐4	  Boxplot	  summarising	  the	  control	  (pre-­‐	  only)	  and	  the	  pre-­‐	  and	  post-­‐operative	  
concentrations	  (pg/ml)	  of	  Follistatin	  measured	  in	  the	  malignant	  patients.	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  In	   terms	   of	   evaluating	   statistical	   significance	   given	   a	   calculated	   p-­‐value,	   both	  significance	   levels	   α=0.001	   (conservative)	   and	   α=0.05	   (widely	   used)	   were	  considered.	   If	   a	   test	  of	   significance	  gives	  a	  p-­‐value	   lower	   than	   the	  significance	  level	   α,	   the	   null	   hypothesis	   is	   rejected	   and	   the	   results	   are	   considered	   as	  'statistically	  significant'.	  	  
Statistical	  package	  	  The	   statistical	   analysis	   was	   performed	   using	   the	   R	   software	   environment	   for	  statistical	   computing	   and	   graphics	   (version	   2.15.1)	   running	   under	   Windows	  Vista	  OS	  with	  2GB	  RAM	  [148].	  All	  the	  statistical	  tests	  used	  here	  were	  included	  in	  the	  R	  Stats	  package.	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5.4.2 Angiogenesis	  Factors	  analysis	  	  The	   results	   of	   the	   analysis	   of	   the	   angiogenesis	   factors	   VEGF,	   PDGF-­‐BB	   and	  Follistatin	   are	   summarised	   in	   the	   table	   below	   (Table	   5-­‐2).	   A	   more	   detailed	  description	  of	  the	  results	  is	  provided	  in	  the	  sections	  below.	  	  
Table	   5-­‐2	   Summary	   of	   the	   p-­‐values	   as	   resulted	   from	   the	   statistical	   analysis	   of	   the	   angiogenesis	  
factors	  (VEGF,	  PDGF-­‐BB	  and	  Follistatin)	  across	  the	  different	  datasets.	  Significant	  values	  are	  shown	  in	  
bold.	  	   Age	  group	   Angiogenesis	  factors	  	   	   VEGF	   PDGF-­‐BB	   Follistatin	  Controls	  vs.	  Pre-­‐op	  Patients	   0-­‐100	   0.472	   <0.001	   <0.001	  Controls	  vs.	  Pre-­‐op	  Patients	   0-­‐39	   0.655	   0.072	   <0.001	  Controls	  vs.	  Pre-­‐op	  Patients	   40-­‐69	   0.928	   <0.001	   <0.001	  Controls	  vs.	  Pre-­‐op	  Patients	   70-­‐100	   0.130	   <0.001	   <0.001	  Pre-­‐op	  vs.	  Post-­‐op	  Patients	   0-­‐100	   <0.001	   <0.001	   <0.001	  Pre-­‐op	  vs.	  Post-­‐op	  Patients	   0-­‐39	   0.398	   0.057	   <0.001	  Pre-­‐op	  vs.	  Post-­‐op	  Patients	   40-­‐69	   <0.001	   <0.001	   <0.001	  Pre-­‐op	  vs.	  Post-­‐op	  Patients	   70-­‐100	   <0.001	   <0.001	   <0.001	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Pre-­‐operatively	   angiogenesis	   factors	   level	   comparison	   between	   Controls	  
and	  Patients	  (all	  age	  groups)	  	  To	  determine	  whether	  the	  levels	  of	  three	  angiogenesis	  factors	  (VEGF,	  PDGF-­‐BB,	  and	   Follistatin)	   on	   patients	   with	   malignant	   tumour	   were	   different	   from	   the	  levels	   in	   patients	  with	   benign	   diseases	   and	   no	  malignancy,	   the	   datasets	  were	  compared	  using	  the	  Student’s	  paired	  t-­‐test.	  The	  results	  of	  the	  test	  are	  shown	  on	  the	  first	  row	  of	  Table	  5-­‐2	  and	  Figure	  5-­‐6	  and	  Figure	  5-­‐7.	  	  The	   levels	  of	   two	  of	   the	  three	  Cytokines	  were	  significantly	  different	  (PDGF-­‐BB	  P<0.001;	   Follistatin	   P<0.001)	   between	   patients	   with	   malignant	   tumour	   and	  patients	   with	   benign	   disease	   prior	   to	   the	   operation.	   VEGF	   didn’t	   exhibit	   any	  significant	   difference	   between	   the	   controls	   and	   the	   patients	   prior	   to	   the	  operation.	  	  	  These	   results	   were	   further	   analysed	   in	   order	   to	   establish	  whether	   this	   trend	  was	  common	  across	  our	  arbitrary	  assigned	  age	  groups:	  0-­‐39,	  40-­‐69,	  70-­‐100	  of	  years	  of	  age.	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Figure	  5-­‐5	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  VEGF	  measured	  
in	   the	   malignant	   patients	   and	   the	   controls	   (pre-­‐	   only)	   across	   all	   age	   groups.
Figure	   5-­‐6	   Boxplot	   summarizing	   the	   pre-­‐operative	   serum	   concentration	   (pg/ml)	   of	   PDGF-­‐BB	  
measured	  in	  the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only)	  across	  all	  age	  groups.	  Asterisk	  (*)	  
indicates	   statistical	   difference	   between	   datasets.	   P	   value	   shown	   in	   parenthesis.
Figure	   5-­‐7	   Boxplot	   summarizing	   the	   pre-­‐operative	   serum	   concentration	   (pg/ml)	   of	   Follistatin	  
measured	   in	   the	  malignant	  patients	  and	   the	  controls	   (pre-­‐	  only)	  across	  all	  age	  groups.	  Asterisk	   (*)	  
indicates	  statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Pre-­‐operative	   angiogenesis	   factors	   level	   comparison	   between	   Controls	   and	  
Patients	  (age	  group	  0-­‐39	  years)	  	  The	   pre-­‐operative	   levels	   of	   the	   angiogenesis	   factors	   assayed	   were	   tested	   in	  order	  to	  identify	  any	  statistical	  difference	  between	  the	  Controls	  and	  the	  tumour	  patients	   pre-­‐operatively	   for	   the	   age	   group	   0-­‐39	   years.	   The	   results	   from	   the	  Student’s	   paired	   t-­‐test	   for	   the	  0-­‐39	  years	   age	   group	  are	   shown	  on	   the	   second	  row	  of	  Table	  5-­‐2	  and	  Figure	  5-­‐8,	  Figure	  5-­‐9	  and	  Figure	  5-­‐10.	  	  Amongst	   the	   three	   angiogenesis	   factors	   assayed,	   only	   Follistatin	   showed	  difference	   on	   its	   levels	   between	   the	   Controls	   and	   the	   tumour	   patients	   pre-­‐operatively	  for	  this	  age	  group	  (P<0.001).	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Figure	  5-­‐8	  Boxplot	  summarizing	  the	  pre-­‐operative	  serum	  concentration	  (pg/ml)	  of	  VEGF	  measured	  
in	  the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only)	  across	  the	  0-­‐39	  age	  group.	  
	  
Figure	   5-­‐9	   Boxplot	   summarizing	   the	   pre-­‐operative	   serum	   concentration	   (pg/ml)	   of	   PDGF-­‐BB	  
measured	  in	  the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only)	  across	  the	  0-­‐39	  age	  group.	  	  
	  
Figure	   5-­‐10	   Boxplot	   summarizing	   the	   pre-­‐operative	   serum	   concentration	   (pg/ml)	   of	   Follistatin	  
measured	  in	  the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only)	  across	  the	  0-­‐39	  age	  group.	  Asterisk	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Pre-­‐operative	   angiogenesis	   factors	   level	   comparison	   between	   Controls	   and	  
Patients	  (age	  group	  40-­‐69	  years)	  	  Similarly,	  the	  levels	  of	  pre-­‐operative	  angiogenesis	  factors	  between	  the	  Controls	  and	   the	   tumour	   patients	   for	   the	   age	   group	   40-­‐69	   years	   were	   compared.	   The	  results	  from	  the	  Student’s	  paired	  t-­‐test	  for	  this	  age	  group	  are	  shown	  on	  the	  third	  row	  of	  Table	  5-­‐2	  and	  Figure	  5-­‐11,	  Figure	  5-­‐12	  and	  Figure	  5-­‐13.	  	  Based	   on	   these	   results,	   the	   levels	   of	   both	   PDGF-­‐BB	   and	   Follistatin	   in	   this	   age	  group	  were	  significantly	  different	  between	  the	  Controls	  and	  the	  tumour	  patients	  (PDGF-­‐BB	  P<0.001;	  Follistatin	  P<0.001).	  	  	  
	   191	  
	  
Figure	   5-­‐11	   Boxplot	   summarizing	   the	   pre-­‐operative	   serum	   concentration	   (pg/ml)	   of	   VEGF	  
measured	  in	  the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only)	  across	  the	  40-­‐69	  age	  group.	  
	  
Figure	   5-­‐12	   Boxplot	   summarizing	   the	   pre-­‐operative	   serum	   concentration	   (pg/ml)	   of	   PDGF-­‐BB	  
measured	  in	  the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only)	  across	  the	  40-­‐69	  age	  group.	  Asterisk	  
(*)	  indicates	  statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	   5-­‐13	   Boxplot	   summarizing	   the	   pre-­‐operative	   serum	   concentration	   (pg/ml)	   of	   Follistatin	  
measured	  in	  the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only)	  across	  the	  40-­‐69	  age	  group.	  Asterisk	  
(*)	  indicates	  statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Pre-­‐operative	   angiogenesis	   factors	   level	   comparison	   between	   Controls	   and	  
Patients	  (age	  group	  70-­‐100	  years)	  	  The	   last	   age	   group	   to	   be	   tested	   for	   any	   difference	   in	   the	   pre-­‐operative	  angiogenesis	   factor	   levels	   between	   the	   Controls	   and	   the	   tumour	   patients	  was	  the	  70-­‐100	  years.	  The	  results	  from	  the	  Student’s	  paired	  t-­‐test	  are	  shown	  on	  the	  fourth	  row	  of	  Table	  5-­‐2	  and	  Figure	  5-­‐14,	  Figure	  5-­‐15	  and	  Figure	  5-­‐16.	  	  The	   analysis	   has	   shown	   that	   both	   PDGF-­‐BB	   and	   Follistatin	   levels	   showed	  difference	  for	  this	  age	  group	  between	  the	  Controls	  and	  the	  tumour	  patients	  pre-­‐operatively	  (P<0.001).	  	  
	   193	  
	  
Figure	   5-­‐14	   Boxplot	   summarizing	   the	   pre-­‐operative	   serum	   concentration	   (pg/ml)	   of	   VEGF	  
measured	  in	  the	  malignant	  patients	  and	  the	  controls	  (pre-­‐	  only)	  across	  the	  70-­‐100	  age	  group.	  	  
	  
Figure	   5-­‐15	   Boxplot	   summarizing	   the	   pre-­‐operative	   serum	   concentration	   (pg/ml)	   of	   PDGF-­‐BB	  
measured	   in	   the	   malignant	   patients	   and	   the	   controls	   (pre-­‐	   only)	   across	   the	   70-­‐100	   age	   group.	  
Asterisk	  (*)	  indicates	  statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	   5-­‐16	   Boxplot	   summarizing	   the	   pre-­‐operative	   serum	   concentration	   (pg/ml)	   of	   Follistatin	  
measured	   in	   the	   malignant	   patients	   and	   the	   controls	   (pre-­‐	   only)	   across	   the	   70-­‐100	   age	   group.	  
Asterisk	  (*)	  indicates	  statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Comparison	  of	  pre-­‐	  vs.	  post-­‐operation	  levels	  of	  Angiogenesis	  factors	  (all	  age	  
groups)	  	  Similar	   to	   the	   cytokines	   study,	   this	   study	   tries	   to	   answer	   whether	   there	   is	   a	  (statistically)	  significant	  difference	  in	  the	  levels	  of	  patient’s	  angiogenesis	  factors	  pre-­‐	  and	  post-­‐operatively.	  To	  address	  this	  question,	   the	  Student’s	  paired	  t-­‐test	  was	   applied	   on	   the	   measured	   angiogenesis	   factors	   concentrations	   and	   the	  results	  from	  the	  Student’s	  paired	  t-­‐test	  are	  shown	  on	  the	  fifth	  row	  of	  Table	  5-­‐2	  and	  Figure	  5-­‐17,	  Figure	  5-­‐18	  and	  Figure	  5-­‐19.	  	  The	   levels	   of	   all	   three	   angiogenesis	   factors	   were	   significantly	   different	  (P<0.001)	  on	  patients	  prior	  to	  and	  after	  the	  operation.	  	  	  Like	  with	  the	  cytokines	  study,	  since	  there	  was	  indeed	  a	  strong	  difference	  on	  the	  angiogenesis	   factors	   levels	   pre-­‐	   and	   post-­‐operatively,	   the	   data	   were	   further	  analysed	  in	  order	  to	  check	  if	  this	  trend	  was	  common	  on	  all	  three	  age	  groups:	  0-­‐39,	  40-­‐69,	  70-­‐100	  years.	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Figure	  5-­‐17	  Boxplot	   summarizing	   the	  pre	  and	  post-­‐operative	  serum	  concentration	   (pg/ml)	  of	  VEGF	  
measured	  in	  the	  malignant	  patients	  across	  all	  age	  groups.	  Asterisk	  (*)	  indicates	  statistical	  difference	  
between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	  5-­‐18	  Boxplot	  summarizing	  the	  pre	  and	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	  PDGF-­‐
BB	   measured	   in	   the	   malignant	   patients	   across	   all	   age	   groups.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	   5-­‐19	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	  
Follistatin	  measured	  in	  the	  malignant	  patients	  across	  all	  age	  groups.	  Asterisk	  (*)	  indicates	  statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Pre-­‐	  vs.	  post-­‐operative	  angiogenesis	  factors	  level	  comparison	  (age	  group	  0-­‐
39	  years)	  	  The	   levels	   of	   the	   pre	   and	   post-­‐operative	   angiogenesis	   factors	   were	   analysed	  further	  in	  order	  to	  identify	  a	  statistical	  difference	  between	  the	  samples	  for	  the	  age	  group	  0-­‐39	  years.	  The	  results	  from	  the	  Student’s	  paired	  t-­‐test	  for	  the	  0-­‐39	  years	  age	  group	  are	  shown	  on	  the	  sixth	  row	  of	  Table	  5-­‐2	  and	  Figure	  5-­‐20,	  Figure	  5-­‐21	  and	  Figure	  5-­‐22.	  	  Amongst	   the	   three	   angiogenesis	   factors	   tested,	   only	   Follistatin	   showed	  difference	  on	  its	   levels	  pre-­‐	  and	  post-­‐	  operatively	  (P<0.001)	  for	  this	  age	  group	  whereas	  PDGF-­‐BB	  was	  just	  above	  the	  5%	  cut	  off	  value	  (0.05684).	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Figure	  5-­‐20	  Boxplot	  summarizing	  the	  pre	  and	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	  VEGF	  
measured	  in	  the	  malignant	  patients	  across	  the	  0-­‐39	  age	  group.	  	  
	  
Figure	  5-­‐21	  Boxplot	  summarizing	  the	  pre	  and	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	  PDGF-­‐
BB	  measured	  in	  the	  malignant	  patients	  across	  the	  0-­‐39	  age	  group.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	   5-­‐22	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	  
Follistatin	   measured	   in	   the	   malignant	   patients	   across	   the	   0-­‐39	   age	   group.	   Asterisk	   (*)	   indicates	  
statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Pre-­‐	   vs.	   post-­‐operative	   angiogenesis	   factors	   level	   comparison	   (age	   group	  
40-­‐69	  years)	  	  Similarly,	  the	  levels	  of	  angiogenesis	  factors	  between	  the	  pre-­‐	  and	  post-­‐operative	  samples	   for	   the	   age	   group	   40-­‐69	   years	  were	   analysed	   to	   check	   for	   statistical	  difference.	   The	   results	   from	   the	   Student’s	   paired	   t-­‐test	   for	   this	   age	   group	   are	  shown	  on	  the	  seventh	  row	  of	  Table	  5-­‐2	  and	  Figure	  5-­‐23,	  Figure	  5-­‐24	  and	  Figure	  5-­‐25.	  Based	   on	   these	   results,	   the	   levels	   of	   all	   three	   angiogenesis	   factors	   in	   this	   age	  group	  were	  significantly	  different	   (P<0.001)	  on	  patients	  prior	   to	  and	  after	   the	  operation.	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Figure	  5-­‐23	  Boxplot	   summarizing	   the	  pre	  and	  post-­‐operative	  serum	  concentration	   (pg/ml)	  of	  VEGF	  
measured	   in	   the	   malignant	   patients	   across	   the	   40-­‐69	   age	   group.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  	  
	  
Figure	  5-­‐24	  Boxplot	  summarizing	  the	  pre	  and	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	  PDGF-­‐
BB	  measured	  in	  the	  malignant	  patients	  across	  the	  40-­‐69	  age	  group.	  Asterisk	  (*)	  indicates	  statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  	  
	  
Figure	   5-­‐25	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	  
Follistatin	   measured	   in	   the	   malignant	   patients	   across	   the	   40-­‐69	   age	   group.	   Asterisk	   (*)	   indicates	  
statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Pre-­‐	   vs.	   post-­‐operative	   angiogenesis	   factors	   level	   comparison	   (age	   group	  
70-­‐100	  years)	  	  The	   last	   age	   group	   to	   be	   tested	   for	   any	   difference	   in	   the	   angiogenesis	   factor	  levels	   pre-­‐	   and	   post	   operatively	   was	   the	   70-­‐100	   years.	   The	   results	   from	   the	  Student’s	   paired	   t-­‐test	   are	   shown	   on	   the	   eighth	   row	   of	   Table	   5-­‐2	   and	   Figure	  5-­‐26,	  Figure	  5-­‐27	  and	  Figure	  5-­‐28.	  	  The	  analysis	  has	  shown	  that	   the	   levels	  of	  all	   three	  angiogenesis	   factors	   in	   this	  age	  group	  were	  significantly	  different	  (P<0.001)	  on	  patients	  prior	   to	  and	  after	  the	  operation.	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Figure	  5-­‐26	  Boxplot	   summarizing	   the	  pre	  and	  post-­‐operative	  serum	  concentration	   (pg/ml)	  of	  VEGF	  
measured	   in	   the	  malignant	   patients	   across	   the	   70-­‐100	   age	   group.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	  5-­‐27	  Boxplot	  summarizing	  the	  pre	  and	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	  PDGF-­‐
BB	  measured	  in	  the	  malignant	  patients	  across	  the	  70-­‐100	  age	  group.	  Asterisk	  (*)	  indicates	  statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	   5-­‐28	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	  
Follistatin	  measured	   in	   the	  malignant	   patients	   across	   the	   70-­‐100	   age	   group.	   Asterisk	   (*)	   indicates	  
statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Age	  group	  comparison	  within	  the	  pre-­‐	  and	  the	  post-­‐operation	  datasets	  	  	  In	  the	  above	  analysis	  it	  has	  been	  established	  whether	  there	  was	  any	  difference	  in	  the	  levels	  of	  angiogenesis	  factors	  tested	  between	  the	  pre-­‐	  and	  post-­‐operative	  samples	   and	   between	   the	   Controls	   and	   the	   pre-­‐operation	   patients	   for	   the	  different	  age	  groups.	  	  	  The	   next	   thing	   to	   look	   into	   is	   whether	   age	   plays	   a	   role	   on	   the	   levels	   of	   the	  angiogenesis	  factors	  pre-­‐	  and	  post-­‐operatively	  as	  well	  as	  in	  the	  Controls.	  Using	  the	   Student’s	   paired	   t-­‐test	   the	   levels	   of	   angiogenesis	   factors	   were	   compared	  between	   the	   three	   age	   groups	   in	   the	   pre-­‐	   or	   post-­‐operatively	   datasets.	   The	  results	  are	  shown	  in	  Table	  5-­‐3,	  Table	  5-­‐4,	  Table	  5-­‐5	  and	  Table	  5-­‐6	  respectively.	  	  Overall	  no	  significant	  difference	  on	  the	  levels	  of	  the	  tested	  angiogenesis	  factors	  was	  observed	  between	   the	  different	  age	  groups	   for	  either	   the	  Controls,	  or	   the	  patients	   prior	   to	   or	   after	   the	   operation	   (α=0.05).	   The	   only	   exception	  was	   the	  comparison	   between	   the	   age	   groups	   40-­‐69	   years	   and	   70-­‐100	   years	   post-­‐operatively	  as	  the	  two	  age	  groups	  appeared	  to	  have	  significantly	  different	  levels	  for	  both	  VEGF	  and	  Follistatin	  (P<0.05).	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Table	  5-­‐3	  Comparison	  of	  the	  levels	  of	  the	  angiogenesis	  factors	  between	  the	  different	  age	  groups	  in	  the	  
Control	  pre-­‐operation	  datasets	  (p-­‐values	  as	  determined	  by	  the	  Student’s	  paired	  t-­‐test).	  	   0-­‐39	  vs.	  40-­‐69	   0-­‐39	  vs.	  70-­‐100	   40-­‐69	  vs.	  70-­‐100	  Control	  VEGF	  (Pre-­‐op)	   0.775 0.463 0.175 Control	  PDGF-­‐BB	  (Pre-­‐op)	   0.688 0.866 0.519 	  Control	  Follistatin	  (Pre-­‐op)	   0.097 0.341 0.155 	  
Table	  5-­‐4	  Comparison	  of	  the	  VEGF	  levels	  between	  the	  different	  age	  groups.	  	  VEGF	  (Pre)	   0-­‐39	   40-­‐69	   70-­‐100	   VEGF	  (Post)	  0-­‐39	   	   0.3787	   0.1598	   0-­‐39	  40-­‐69	   0.4235	   	   <0.05	   40-­‐69	  70-­‐100	   0.3975	   0.9078	   	   70-­‐100	  
p-­‐values	  as	  determined	  by	  the	  Student’s	  paired	  t-­‐test.	  Significant	  values	  are	  shown	  
in	  bold.	  White	   cells	   represent	  preoperative	  p	  values;	   light	  grey	   cells	   represent	  postoperative	  values.	  	  
Table	  5-­‐5	  Comparison	  of	  the	  PDGF-­‐BB	  levels	  between	  the	  different	  age	  groups.	  	  PDGF-­‐BB	  (Pre)	   0-­‐39	   40-­‐69	   70-­‐100	   PDGF-­‐BB	  (Post)	  0-­‐39	   	   0.6605	   0.8527	   0-­‐39	  40-­‐69	   0.8237	   	   0.2722	   40-­‐69	  70-­‐100	   0.4933	   0.2265	   	   70-­‐100	  
p-­‐values	   as	   determined	   by	   the	   Student’s	   paired	   t-­‐test.	   White	   cells	   represent	  preoperative	  p	  values;	  light	  grey	  cells	  represent	  postoperative	  values.	  
	  
Table	  5-­‐6	  Comparison	  of	  the	  Follistatin	  levels	  between	  the	  different	  age	  groups.	  	  Follistatin	  (Pre)	   0-­‐39	   40-­‐69	   70-­‐100	   Follistatin	  (Post)	  0-­‐39	   	   0.4412	   0.9576	   0-­‐39	  40-­‐69	   0.1006	   	   <0.05	   40-­‐69	  70-­‐100	   0.978	   0.1709	   	   70-­‐100	  
p-­‐values	  as	  determined	  by	  the	  Student’s	  paired	  t-­‐test.	  Significant	  values	  are	  shown	  
in	  bold.	  White	   cells	   represent	  preoperative	  p	  values;	   light	  grey	   cells	   represent	  postoperative	  values.	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Effect	  of	  gender	  on	  angiogenesis	  factors	  levels	  pre-­‐	  and	  post-­‐operatively	  	  Finally,	   it	   was	   investigated	   whether	   gender	   had	   an	   effect	   on	   the	   levels	   of	  angiogenesis	   factors	  pre-­‐	   and	  post-­‐operatively	  as	  well	   as	  between	   the	   tumour	  patients	  and	  the	  Controls.	  This	  was	  achieved	  by	  grouping	  the	  patients	  based	  on	  their	   gender.	   The	   levels	   of	   the	   angiogenesis	   factors	   between	   the	   different	  gender	  groups	  were	  compared	  using	  the	  Student’s	  paired	  t-­‐test.	  The	  results	  of	  the	   analysis	   are	   shown	   in	   Table	   5-­‐7	   and	   statistically	   significant	   results	   are	  shown	   in	   Figure	   5-­‐29,	   Figure	   5-­‐30,	   Figure	   5-­‐31,	   Figure	   5-­‐32,	   Figure	   5-­‐33	   and	  Figure	  5-­‐34.	  	  
	   205	  
Table	  5-­‐7	   Comparison	  of	  pre-­‐	  and	  post-­‐operative	   levels	  of	  angiogenesis	   factors	  VEGF,	  PDGF-­‐BB	  and	  
Follistatin	  and	  gender	  (p-­‐values	  as	  determined	  by	  the	  Student’s	  paired	  t-­‐test).	  Significant	  values	  are	  
shown	  in	  bold.	  
	   	   Angiogenesis	  factors	  	   	   VEGF	   PDGF-­‐BB	   Follistatin	  All	  data	  vs.	  Male	   Pre-­‐op	   0.955	   0.720	   0.895	  	   Post-­‐op	   0.306	   0.734	   0.403	  All	  data	  vs.	  Female	   Pre-­‐op	   0.947	   0.672	   0.828	  	   Post-­‐op	   0.301	   0.702	   0.416	  Female	  vs.	  Male	   Pre-­‐op	   0.917	   0.504	   0.762	  	   Post-­‐op	   0.086	   0.535	   0.170	  Pre-­‐op	  vs.	  Post-­‐op	   All	  Male	   <0.001	   <0.001	   <0.001	  Pre-­‐op	  vs.	  Post-­‐op	   All	  Female	   0.001	   <0.001	   <0.001	  Male	  Control	  vs.	  Male	  Patient	   Pre-­‐op	   0.825	   <0.001	   <0.001	  Female	  Control	  vs.	  Female	  Patient	   Pre-­‐op	   0.361	   <0.001	   <0.001	  Male	  Control	  vs.	  Female	  Control	   Pre-­‐op	   0.398	   0.719	   0.411	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Figure	  5-­‐29	  Boxplot	   summarizing	   the	  pre	  and	  post-­‐operative	  serum	  concentration	   (pg/ml)	  of	  VEGF	  
measured	   in	   the	   male	   malignant	   patients	   across	   all	   age	   groups.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	  5-­‐30	  Boxplot	  summarizing	  the	  pre	  and	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	  PDGF-­‐
BB	  measured	  in	  the	  male	  malignant	  patients	  across	  all	  age	  groups.	  Asterisk	  (*)	   indicates	  statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  
	  
Figure	   5-­‐31	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	  
Follistatin	   measured	   in	   the	   male	   malignant	   patients	   across	   all	   age	   groups.	   Asterisk	   (*)	   indicates	  
statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Figure	  5-­‐32	  Boxplot	   summarizing	   the	  pre	  and	  post-­‐operative	  serum	  concentration	   (pg/ml)	  of	  VEGF	  
measured	   in	   the	   female	  malignant	   patients	   across	   all	   age	   groups.	   Asterisk	   (*)	   indicates	   statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  	  
	  
Figure	  5-­‐33	  Boxplot	  summarizing	  the	  pre	  and	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	  PDGF-­‐
BB	  measured	  in	  the	  female	  malignant	  patients	  across	  all	  age	  groups.	  Asterisk	  (*)	  indicates	  statistical	  
difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	  	  
	  
Figure	   5-­‐34	   Boxplot	   summarizing	   the	   pre	   and	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	  
Follistatin	  measured	   in	   the	   female	  malignant	   patients	   across	   all	   age	   groups.	   Asterisk	   (*)	   indicates	  
statistical	  difference	  between	  datasets.	  P	  value	  shown	  in	  parenthesis.	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Figure	  5-­‐35	  Boxplot	  summarizing	  the	  preoperative	  serum	  concentration	  (pg/ml)	  of	  VEGF	  measured	  
in	  the	  male	  and	  female	  malignant	  patients	  across	  all	  age	  groups	  	  
	  
Figure	   5-­‐36	   Boxplot	   summarizing	   the	   preoperative	   serum	   concentration	   (pg/ml)	   of	   PDGF-­‐BB	  
measured	  in	  the	  male	  and	  female	  malignant	  patients	  across	  all	  age	  groups.	  	  
	  
Figure	   5-­‐37	   Boxplot	   summarizing	   the	   pre-­‐operative	   serum	   concentration	   (pg/ml)	   of	   Follistatin	  
measured	  in	  the	  male	  and	  female	  malignant	  patients	  across	  all	  age	  groups.	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Figure	  5-­‐38	  Boxplot	  summarizing	  the	  post-­‐operative	  serum	  concentration	  (pg/ml)	  of	  VEGF	  measured	  
in	  the	  male	  and	  female	  malignant	  patients	  across	  all	  age	  groups.	  
	  
Figure	   5-­‐39	   Boxplot	   summarizing	   the	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   PDGF-­‐BB	  
measured	  in	  the	  male	  and	  female	  malignant	  patients	  across	  all	  age	  groups.	  
	  
Figure	   5-­‐40	   Boxplot	   summarizing	   the	   post-­‐operative	   serum	   concentration	   (pg/ml)	   of	   Follistatin	  
measured	  in	  the	  male	  and	  female	  malignant	  patients	  across	  all	  age	  groups.	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Figure	   5-­‐41	   Boxplot	   summarizing	   the	   serum	   concentration	   (pg/ml)	   of	   VEGF	  measured	   in	   the	  male	  
and	  female	  controls	  across	  all	  age	  groups.	  
	  
	  
Figure	  5-­‐42	  Boxplot	  summarizing	  the	  serum	  concentration	  (pg/ml)	  of	  PDGF-­‐BB	  measured	  in	  the	  male	  
and	  female	  controls	  across	  all	  age	  groups.	  	  
	  
Figure	   5-­‐43	   Boxplot	   summarizing	   the	   serum	   concentration	   (pg/ml)	   of	   Follistatin	  measured	   in	   the	  
male	  and	  female	  controls	  across	  all	  age	  groups.	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According	  to	  these	  results,	  neither	  the	  male	  nor	  the	  female	  group	  had	  displayed	  any	  significant	  difference	  against	  the	  combined	  dataset	  (males	  and	  females)	  as	  well	   as	   against	   the	   opposite	   gender	   (α=0.05)	   suggesting	   that	   gender	   doesn’t	  seem	   to	   play	   a	   significant	   role	   for	   patients	   with	   glioblastoma	   tumour.	   These	  observations	   held	   true	   for	   both	   gender	   groups	   regardless	   of	   their	   operative	  stage	  (pre-­‐	  vs.	  post-­‐)	  (Figure	  5-­‐35,	  Figure	  5-­‐36,	  Figure	  5-­‐37,	  Figure	  5-­‐38,	  Figure	  5-­‐39	   and	   Figure	   5-­‐40).	   On	   the	   contrary,	   when	   the	   operative	   stages	   were	  compared	   against	   each	   other	   for	   each	   gender	   group,	   both	   male	   and	   female	  groups	  had	  shown	  highly	  significant	  difference	  (P<0.001).	  	  	  Similarly	   to	   the	   results	   above,	   gender	   didn’t	   seem	   to	   have	   an	   effect	   in	   the	  preoperative	   Controls	   either	   (α=0.05)	   (see	   Male	   Control	   vs.	   Female	   Control	   in	  
Table	  5.7	  as	  well	  as	  Figure	  5-­‐41,	  Figure	  5-­‐42	  and	  Figure	  5-­‐43).	  However,	  male	  and	  female	  Controls	  had	  significantly	  different	  levels	  only	  for	  the	  PDGF-­‐BB	  and	  Follistatin	  when	  they	  were	  compared	  to	  their	  equivalent	  patient	  samples	  (Males	  P<0.001,	  Females	  P<0.001).	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5.5 Discussion	  	  The	   serum	   concentrations	   of	   three	   angiogenesis	   factors	  were	  measured	   from	  patients	   with	   malignant	   brain	   tumours	   as	   well	   as	   from	   controls	   affected	   by	  degenerative	  spinal	  disease.	  Out	  of	  these	  three	  factors,	  PDGF-­‐BB	  and	  Follistatin	  were	   found	   to	   be	   lower	   in	   the	   controls	   compared	   to	   the	   preop	   patients.	   In	  addition,	   the	  preoperative	   levels	   of	   all	   three	   angiogenesis	   factors	  were	  higher	  than	  those	  observed	  postoperatively.	  Age	  and	  gender	  did	  not	  play	  a	  role	  on	  the	  angiogenesis	  factor	  concentrations.	  	  	  There	   is	   a	   clear	   need	   for	   biomarkers	   to	   aid	   the	   management	   of	   malignant	  gliomas.	   VEGF	   and	   PDGF-­‐BB	   have	   been	   previously	   proposed	   as	   potential	  candidates	   [214-­‐219].	   In	   agreement	  with	   the	   literature,	   both	   these	  molecules	  along	   with	   Follistatin	   have	   shown	   significant	   correlation	   with	   malignant	  gliomas	   in	   this	   present	   study.	   More	   specifically,	   the	   average	   concentrations	  found	  in	  the	  healthy	  population	  were	  for	  VEGF	  61	  (±37)	  pg/ml,	  for	  PDGF	  2316	  (±696)	   pg/ml	   and	   for	   Follistatin	   335	   (±93)	   pg/ml.	   These	   concentrations	   for	  VEGF	   and	   PDGF-­‐BB	   are	   within	   the	   same	   range	   with	   those	   reported	   in	   the	  literature	   [233,	   258].	   This	   comparison	   bears	   the	   assumption	   that	   these	  concentrations	  are	  directly	  comparable	  and	  the	  assay	  used	  to	  measure	  them	  (i.e.	  Bio-­‐Plex	   vs.	   ELISA)	   did	   not	   affect	   their	   values.	   There	   is	   evidence	   that	  angiogenesis	  factors	  (VEGF	  and	  PDGF)	  have	  a	  role	  in	  inducing	  the	  spontaneous	  resorption	   of	   the	   herniated	   disc	   disease	   [273,	   274].	   Given	   the	   fact	   that	   the	  healthy	  participants	  in	  this	  study	  were	  affected	  from	  benign	  spinal	  disease,	  the	  measured	  concentrations	  were	  expected	  to	  be	  higher	  than	  the	  reported	  normal	  average	   values.	   As	   it	   is	   unclear	   what	   was	   the	   past	   medical	   history	   of	   the	  participants	   used	   as	   controls	   in	   the	   aforementioned	   studies,	   it	   is	   difficult	   to	  draw	  any	  comparative	  conclusions.	  	  	  Interestingly,	  Follistatin	  concentrations	  of	  the	  controls	  in	  this	  study	  were	  almost	  three	   times	   lower	   than	   the	   lowest	   concentrations	   reported	   in	   the	   literature	  [267].	  This	   comes	  as	   a	   surprise	  as	   the	   controls	  were	  affected	  by	  degenerative	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spinal	   disease	   and	   there	   is	   evidence	   to	   support	   that	   serum	   Follistatin	  concentrations	   reflect	   the	   severity	   of	   joint	   damage	   in	   osteoarthritis	   [275].	   A	  possible	  explanation	  for	  this	  discrepancy	  might	  be	  that	  these	  concentrations	  are	  not	   directly	   comparable	   as	   the	  methodology	   used	   to	   measure	   them	   could	   be	  different.	   However,	   the	   BioRad	   assay	   used	   in	   the	   present	   study	   has	   clearly	  identified	   differences	   in	   the	   Follistatin	   concentrations	  measured	   between	   the	  two	   populations.	   This	   suggests	   that	   Follistatin	   does	   indeed	   differ	   between	  healthy	   controls	   and	   tumour	   patients	   and	   that	   this	  methodology	   is	   a	   reliable	  way	   for	   measuring	   that.	   The	   Bio-­‐Plex	   assay	   was	   proven	   to	   be	   a	   suitable	  technique	  as	  it	  measures	  levels	  of	  multiple	  angiogenesis	  factors	  simultaneously	  from	  several	  samples	  within	  three	  to	  four	  hours.	  Furthermore,	  it	  is	  using	  a	  small	  quantity	   of	   sample,	   has	   low	   variability	   and	   high	   reproducibility	   making	   it	  appropriate	  for	  use	  in	  clinical	  practice.	  	  	  Patients	   affected	   by	  malignant	   gliomas	   in	   this	   study	   had	   higher	   pre-­‐operative	  concentrations	   for	  all	   three	  angiogenesis	   factors	   than	   the	  healthy	  participants.	  This	   is	   due	   to	   the	   fact	   that	   the	   tumour	   produces	   angiogenesis	   factors	   in	  response	   to	  hypoxia	  and	   in	  order	   to	  promote	   its	  neoangiogenesis	  and	  growth.	  Similar	   observations	   have	   also	   been	   reported	   in	   the	   literature	   [276-­‐281].	  Interestingly,	  the	  patients	  in	  this	  present	  study	  were	  taking	  Dexamethasone	  in	  high	  dose	  (16	  mg/day),	  which	  is	  widely	  known	  to	  down	  regulate	  the	  production	  of	   VEGF,	   IL-­‐6,	   Follistatin	   and	   PDGF-­‐BB	   [276-­‐281].	   Despite	   this,	   significant	  difference	   between	   the	   two	   groups	  was	   observed.	   One	   could	   speculate	   that	   if	  the	   patients	   were	   not	   taking	   Dexamethasone,	   the	   measured	   concentrations	  would	  be	  even	  higher.	  Another	  possibility	  is	  that	  Dexamethasone	  did	  not	  down-­‐regulate	   the	   production	   of	   angiogenesis	   factors	   in	   the	   tumor	   cells	   of	   these	  patients.	  	  To	   summarise,	   patients	   affected	   by	   brain	   tumours	   have	   significantly	   higher	  concentrations	  of	  the	  three	  angiogenesis	  factors	  than	  the	  controls.	  Such	  finding	  supports	  the	  hypothesis	  that	  these	  molecules	  are	  suitable	  candidates	  to	  be	  used	  as	  biomarkers	  for	  the	  diagnosis	  of	  malignant	  gliomas.	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The	   next	   thing	   investigated	   was	   the	   comparison	   of	   the	   angiogenesis	   factor	  concentrations	   between	   the	   patients	   affected	   by	   malignant	   glioma	   pre-­‐	   and	  postoperatively.	  No	  studies	  have	  been	   found	   in	   the	   literature	   investigating	   the	  above.	   Angiogenesis	   factors	   that	   are	   related	   to	   the	   presence	   of	   the	   tumour	  would	   be	   expected	   to	   have	   their	   levels	   reduced	   following	   its	   removal.	   In	   the	  present	  study,	  a	  significant	  reduction	  of	   the	  concentrations	  of	  all	   three	   factors	  was	   observed	   postoperatively.	   A	   decrease	   of	   78%	   (from	   18	   to	   4	   pg/ml)	   for	  VEGF,	   77%	   (from	   1950	   to	   450	   pg/ml)	   for	   PDGF	   and	   90%	   (from	   295	   to	   30	  pg/ml)	   for	  Follistatin	  was	  noted.	  The	  effect	  of	  debulking	  surgery	   is	  one	  of	   the	  possible	  explanatory	  factors	  for	  this	  observation.	  As	  tumour	  cells	  constitutively	  produce	   angiogenesis	   factors,	   cell	   removal	   by	   the	   operation	   would	   lead	   to	   a	  reduced	  production	  of	  these	  factors.	  Another	  cause	  for	  such	  drop	  could	  be	  the	  reduced	  hypoxic	  drive	  of	  the	  tumour	  following	  the	  operation.	  Hypoxia	  is	  known	  to	   stimulate	   angiogenesis	   factor	  production	  by	   tumour	   cells	   [214].	  As	   surgery	  reduces	  the	  hypoxic	  area	  of	  the	  tumour,	  the	  stimulus	  for	  such	  production	  is	  also	  reduced.	  	  	  	  Age	   did	   not	   influence	   the	   angiogenesis	   factor	   concentrations	   in	   any	   of	   the	  comparisons	   performed	   as	   all	   age	   groups	   tested	   yielded	   the	   same	   result.	   The	  sample	  size	  of	  the	  0-­‐39	  years	  age	  group	  was	  small	  (less	  than	  4)	  and	  this	  might	  explain	   the	   lack	   of	   significance	   between	   some	   of	   the	   compared	   datasets	   (see	  Table	  5-­‐2).	  Larger	  cohort	  of	  patients	   in	   this	  age	  group	   in	   future	  studies	  would	  strengthen	   the	   statistical	   significance	   of	   these	   findings.	   Moreover	   no	  significance	  was	  found	  between	  the	  age	  group	  comparisons	  within	  each	  dataset.	  No	   published	   reports	   on	   the	   effect	   of	   age	   on	   the	   angiogenesis	   factor	  concentrations	  of	  patients	  with	  malignant	  gliomas	  have	  been	  found.	  However,	  a	  study	   on	   healthy	   controls	   has	   reported	   similar	   findings	   to	   this	   current	   study	  [249].	  	  	  According	  to	  the	  results	  of	  this	  study,	  gender	  similarly	  to	  age	  did	  not	  influence	  the	  concentrations	  of	  the	  angiogenesis	  factors	  tested	  in	  any	  of	  the	  datasets.	  As	  there	   are	   no	   previous	   reports	   on	   the	   patients	   with	   malignant	   gliomas	   this	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finding	   is	  novel.	  However,	   studies	  on	  healthy	   individuals	   revealed	   that	  gender	  influenced	  VEGF	  levels	  [249]	  whereas	  Follistatin	  levels	  were	  unaffected	  [270].	  	  This	  work	  demonstrates	   that	  all	   three	   tested	  angiogenesis	   factors	  are	  suitable	  candidates	  to	  use	  as	  biomarkers	  for	  malignant	  gliomas.	  Such	  biomarkers	  would	  allow	  clinicians	  to	  follow	  up	  patients	  during	  the	  course	  of	  their	  disease	  in	  terms	  of	   monitoring	   response	   to	   treatment	   as	   well	   as	   early	   detection	   of	   disease	  recurrence.	  While	  VEGF	  and	  PDGF-­‐BB	  have	  already	  been	  proposed	  for	  this	  role,	  Follistatin	  is	  a	  novel	  biomarker	  for	  this	  disease.	  Another	  novelty	  of	  this	  work	  is	  that	  there	  are	  no	  previous	  studies	  investigating	  the	  pre	  vs.	  postoperative	  levels	  of	   angiogenesis	   factors	   in	  patients	  with	  malignant	   gliomas.	  As	   such,	   this	  work	  offers	   a	   significant	   contribution	   towards	   a	   better	   understanding	   of	   these	  molecules	   and	   their	   role	   in	   this	   disease.	   Further	   studies	  with	   larger	   cohort	   of	  healthy	  controls	  and	  patients	  would	   increase	  the	  reliability	  of	   the	  use	  of	   these	  molecules	  as	  biomarkers	  for	  malignant	  gliomas	  while	  it	  would	  allow	  novel	  ones	  to	  be	  discovered.	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6 GENERAL	  DISCUSSION	  	  Chemosensitivity	   testing	  was	   performed	   on	   twelve	   primary	  malignant	   glioma	  cultures	   at	   passage	   0.	   The	   drugs	   tested	   are	   commonly	   administered	  chemotherapeutic	   drugs	   in	   clinical	   practice	   in	   our	   Unit.	   The	   results	   revealed	  that	  cultures	  derived	  from	  females	  or	  from	  patients	  under	  65	  years	  of	  age	  were	  more	   responsive	   to	   chemosensitivity	   testing.	   More	   importantly,	   the	   in	   vitro	  results	  showed	  correlation	  with	  the	  overall	  survival	  following	  chemotherapy	  of	  the	  donor	  patients.	  During	  chemosensitivity	  testing	  Temozolomide	  was	  found	  to	  have	  poor	  in	  vitro	  effect.	  Increased	  frequency	  of	  application	  as	  well	  as	  cell	  cycle	  synchronisation	  of	  glioma	  cell	  lines	  were	  found	  to	  improve	  the	  kill	  efficiency	  of	  Temozolomide.	  	  	  Six	  molecules	  were	  considered	  as	  potential	  biomarkers.	  All	  of	  them	  were	  found	  to	   be	   effective	   at	   predicting	   the	   presence	   of	   malignant	   gliomas.	   With	   the	  exception	   of	   VEGF	   and	  PDGF-­‐BB,	   this	   is	   the	   first	   report	   of	   these	  molecules	   as	  biomarkers	   for	  malignant	   gliomas.	  Overall	   age	   and	   gender	   of	   patients	   did	   not	  affect	  the	  biomarker	  results.	  	  	  Glioblastoma	  is	  the	  most	  malignant	  tumor	  of	  central	  nervous	  system	  neoplasms	  with	   poor	   overall	   survival.	   Early	   detection	   and	   treatment	   of	   glioblastoma	   is	  challenging	  and	  little	  progress	  has	  been	  made	  so	  far.	  This	  imposes	  a	  clear	  need	  for	  improving	  the	  diagnosis	  and	  management	  of	  malignant	  gliomas.	  This	  study	  aimed	  to	  address	  both	  challenges	  and	  proposed	  ways	  of	  improvement.	  	  	  	  The	  novelty	  of	  this	  study	  lies	  in	  the	  use	  of	  primary	  glioma	  cultures	  at	  passage	  0	  as	   opposed	   to	   short-­‐term	  glioma	   cultures	   (passages	  1-­‐19)	  or	   glioma	   cell	   lines	  (20	   passages	   or	  more).	   This	   type	   of	   culture	   at	   passage	   0	   is	  more	   suitable	   for	  chemosensitivity	  studies	  as	  it	  is	  more	  representative	  of	  the	  considerable	  genetic	  heterogeneity	  of	  malignant	  gliomas	  between	  patients.	  On	   the	   contrary,	   glioma	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cell	  lines	  carry	  a	  more	  homogenous	  genetic	  load,	  as	  with	  every	  passage	  there	  is	  clonal	  selection	  of	  rapidly	  dividing	  cells.	  Such	  genetic	  misrepresentation	  in	  cell	  lines	  poses	  a	  limit	  as	  to	  their	  usefulness	  in	  research	  and	  clinical	  studies.	  	  Another	   advantage	   of	   the	   present	  work	   is	   the	   availability	   of	   clinical	   data	   that	  enabled	   a	   retrospective	   evaluation	   of	   the	   chemosensitivity	   results.	   There	  was	  good	  correlation	  between	   in	  vivo	  and	   in	  vitro	  results	  for	  nine	  out	  of	  the	  twelve	  patients	   tested.	   In	   vitro	   chemosensitivity	   testing	   allowed	   the	   identification	   of	  the	   most	   suitable	   drug	   for	   each	   patient.	   This	   challenges	   the	   current	   clinical	  practice	   of	   administering	   Temozolomide	   to	   all	   patients	   regardless	   of	   their	  sensitivity	   to	   this	   drug.	   Introducing	   chemosensitivity	   testing	   for	   all	   patients	  undergoing	   chemotherapy	   treatment	   could	   potentially	   influence	   their	   clinical	  outcome.	  	  Yet	   this	  hypothesis	  has	   to	  be	  validated	  by	  more	  chemosensitivity	  studies	  with	  larger	  patient	  numbers.	  	  	  	  Molecular	   biomarkers	   are	   important	   in	   clinical	   practice	   as	   they	   can	   have	  diagnostic,	   predictive	   and	   prognostic	   potential	   in	   Glioblastomas.	   This	   work	  demonstrates	   that	   all	   six	   tested	   molecules	   are	   suitable	   candidates	   to	   use	   as	  biomarkers	   for	  malignant	   gliomas.	   Such	   biomarkers	  would	   allow	   clinicians	   to	  diagnose	   as	   well	   as	   follow	   up	   patients	   during	   the	   course	   of	   their	   disease	   in	  terms	   of	   monitoring	   response	   to	   treatment	   and	   early	   detection	   of	   disease	  recurrence.	  	  	  Further	   studies	   would	   allow	   the	   discovery	   of	   even	   more	   biomarkers	   using	  similar	   high	   throughput	   screening	   assays.	   Association	   between	   those	   and	  chemosensitivity	   status	   could	   further	   enhance	   the	   management	   of	   malignant	  gliomas.	  	  	  Reflecting	   on	   the	   learnings	   of	   this	   study	   a	   number	   of	   improvements	   could	   be	  proposed.	   Firstly,	   a	   greater	   number	   of	   specimens	   at	   different	   stages	   of	   the	  patients’	  disease	  would	  greatly	  reinforce	  the	  findings.	  Better	  coordination	  of	  the	  resources	   as	   well	   as	   more	   specialised	   personnel	   could	   facilitate	   this	   process.	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Secondly,	  optimisation	  of	   the	  experimental	  design	   including	   frequency	  of	  drug	  administration,	   length	   of	   drug	   exposure	   and	   incubation,	   number	   of	   replicates	  and	  prevention	  of	  culture	  contamination	  would	  improve	  the	  efficiency	  and	  the	  sensitivity	  of	  the	  assay.	  	  	  Patients’	  recruitment	  is	  a	  difficult	  and	  lengthy	  process.	  Moreover,	  availability	  of	  clinical	   data	   for	   research	   is	   not	   straightforward	   and	   their	   collection	   is	   not	  research	   oriented.	   Because	   of	   these	   two	   reasons	   prospective	   studies	  may	   run	  for	   many	   years.	   An	   alternative	   approach	   would	   be	   to	   use	   material	   already	  available	   in	   tumour	   banks	   and	   their	   readily	   accessible	   clinical	   data.	  Retrospective	   molecular	   analysis	   of	   these	   specimens	   using	   high	   throughput	  methods	  would	  allow	  the	  identification	  of	  the	  underlying	  genetic	  causes	  of	  the	  disease.	   Their	   subsequent	   correlation	   with	   clinical	   data	   could	   accelerate	   the	  translation	  of	  these	  findings	  to	  clinical	  practice.	  	  	  Brain	  tumours	  represent	  2%	  of	  all	  cancers	  in	  the	  UK.	  There	  is	  a	  growing	  interest	  in	   the	   scientific	   community	   and	   the	   charities	   towards	   research	   in	   brain	  tumours.	  The	  present	  work	  contributes	  to	   this	  effort.	  Scientific	  resources	  such	  as	   brain	   tumour	   tissue	   banks	   and	   clinical	   databases	   are	   invaluable	   assets	   in	  such	   research.	   Moreover,	   relevant	   online	   resources	   such	   as	   Brain	   Tumour	  Research	  continue	  raising	  awareness	  and	  attracting	  more	  funding.	  Coordination	  of	  these	  activities	  will	  lead	  to	  significant	  developments	  in	  this	  area	  in	  the	  years	  to	  come.	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Appendices	  
Appendix	  1	  	  Consent	  forms	  and	  information	  sheets	  for	  patients	  and	  relatives	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Appendix	  2	  Cell	  culture	  media	  constituents	  Cell	  Culture	  Media	  Constituents	  (Sigma	  –	  Aldrich)	  	   DMEM*	   HAM’s	  F-­‐12	  Contents	   g/l	   g/l	  L-­‐Arginine	  HCL	   0.084	   0.211	  L-­‐cysteine	  2	  HCL	   0.0626	   0.035	  L-­‐Glutamine	   0.584	   0.146	  G;ycine	   0.03	   0.00751	  L-­‐Histidine	  HCL	   0.042	   0.02096	  L-­‐isoleucine	   0.105	   0.00394	  L-­‐leucine	   0.105	   0.0131	  L-­‐lysine	  HCL	   0.146	   0.0365	  L-­‐methionine	   0.03	   0.00448	  L-­‐phenylalanine	   0.066	   0.00496	  L-­‐Proline	   -­‐	   0.0345	  L-­‐serine	   0.042	   0.0105	  L-­‐threonine	   0.095	   0.0119	  L-­‐tryptophan	   0.016	   0.00204	  L-­‐tyrosine	   0.1038	   0.00778	  L-­‐valine	   0.094	   0.0117	  L-­‐biotin	   -­‐	   0.0000073	  Choline	  chloride	   0.004	   0.01396	  Folic	  acid	   0.004	   0.00132	  Myo-­‐inositol	   0.0072	   0.018	  Niacinamide	   0.004	   0.000037	  D=pantothenic	  acid	   0.004	   0.00048	  Pyridoxal-­‐HCL	   0.004	   0.000062	  Riboflavin	   0.0004	   0.000038	  Thiamine-­‐HCL	   0.004	   0.00034	  Calcium	  chloride	   0.2	   0.0333	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Cupric	  sulphate	   -­‐	   0.0000025	  Ferrous	  sulphate	   -­‐	   0.000834	  Ferric	  nitrate	   0.0001	   -­‐	  Magnesium	  sulphate	   0.098	   -­‐	  Magnesium	  chloride	   -­‐	   0.0576	  Potassium	  chloride	   0.4	   0.224	  Sodium	  chloride	   6.4	   7.599	  Sodium	  phosphate	   0.109	   0.14204	  Glucose	   4.5	   1.802	  Phenol	  red-­‐Na	   0.0159	   0.0013	  Vitamin	  B12	   -­‐	   0.00136	  Hypoxanthine	   -­‐	   0.00408	  Linoleic	  acid	   -­‐	   0.000084	  Putrescien	  di	  HCL	   -­‐	   0.000161	  Pyruvic	  acid-­‐Na	   -­‐	   0.11	  Thymidine	   -­‐	   0.00073	  *DMEM-­‐	  Dulbeco’s	  Modified	  Eagle’s	  Medium	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Appendix	  3	  Number	  of	  patients	  in	  the	  cytokines	  and	  angiogenesis	  factors	  analysis	  	   Age	   IL-­‐6	   IL-­‐8	   IL-­‐10	  Control	   0-­‐100	   20	   20	   21	  	   0-­‐39	   3	   4	   3	  	   40-­‐69	   11	   11	   12	  	   70-­‐100	   6	   5	   6	  Pt	  preop	   0-­‐100	   26	   32	   27	  	   0-­‐39	   2	   4	   2	  	   40-­‐69	   13	   14	   14	  	   70-­‐100	   11	   14	   11	  Pt	  Postop	   0-­‐100	   29	   31	   28	  	   0-­‐39	   4	   3	   3	  	   40-­‐69	   11	   15	   13	  	   70-­‐100	   14	   13	   12	  Table	  1:	  Summary	  of	  number	  of	  patients	  included	  in	  the	  analysis	  for	  each	  of	  the	  datasets	  grouped	  by	  age.	  	  	  	   Control	   Pt	  Preop	   Pt	  Postop	  Female	   	   	   	  IL-­‐6	   8	   10	   11	  IL-­‐8	   7	   13	   12	  IL-­‐10	   9	   9	   8	  Male	   	   	   	  Il-­‐6	   12	   16	   18	  IL-­‐8	   13	   19	   19	  IL-­‐10	   12	   18	   20	  Table	  2:	  Summary	  of	  number	  of	  patients	  included	  in	  the	  analysis	  for	  each	  of	  the	  datasets	  grouped	  by	  gender.	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   Age	   VEGF	   PDGF-­‐BB	   Follistatin	  Controls	   0-­‐100	   27	   23	   23	  	   0-­‐39	   4	   2	   2	  	   40-­‐69	   16	   14	   14	  	   70-­‐100	   7	   7	   7	  Pt	  preop	   0-­‐100	   31	   29	   29	  	   0-­‐39	   3	   3	   4	  	   40-­‐69	   15	   13	   13	  	   70-­‐100	   13	   13	   12	  Pt	  postop	   0-­‐100	   28	   19	   30	  	   0-­‐39	   3	   3	   3	  	   40-­‐69	   15	   14	   14	  	   70-­‐100	   9	   11	   13	  Table	  3:	  Summary	  of	  number	  of	  patients	  included	  in	  the	  analysis	  for	  each	  of	  the	  datasets	  grouped	  by	  age.	  	  	  	  	  	  	  	   Control	   Pt	  Preop	   Pt	  Postop	  Female	   	   	   	  VEGF	   10	   13	   12	  PDGF-­‐BB	   9	   12	   13	  Follistatin	   10	   13	   12	  Male	   	   	   	  VEGF	   17	   18	   16	  PDGF-­‐BB	   14	   17	   16	  Follistatin	   14	   18	   17	  Table	  4:	  Summary	  of	  number	  of	  patients	  included	  in	  the	  analysis	  for	  each	  of	  the	  datasets	  grouped	  by	  gender.	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   Age	   IL-­‐6	   IL-­‐8	   IL-­‐10	  Control	   0-­‐100	   20	   20	   21	  	   0-­‐39	   3	   4	   3	  	   40-­‐69	   11	   11	   12	  	   70-­‐100	   6	   5	   6	  Pt	  preop	   0-­‐100	   26	   32	   27	  	   0-­‐39	   2	   4	   2	  	   40-­‐69	   13	   14	   14	  	   70-­‐100	   11	   14	   11	  Pt	  Postop	   0-­‐100	   29	   31	   28	  	   0-­‐39	   4	   3	   3	  	   40-­‐69	   11	   15	   13	  	   70-­‐100	   14	   13	   12	  Table	  5:	  Summary	  of	  number	  of	  patients	  included	  in	  the	  analysis	  for	  each	  of	  the	  datasets	  grouped	  by	  age.	  	  	   Control	   Pt	  Preop	   Pt	  Postop	  Female	   	   	   	  IL-­‐6	   8	   10	   11	  IL-­‐8	   7	   13	   12	  IL-­‐10	   9	   9	   8	  Male	   	   	   	  Il-­‐6	   12	   16	   18	  IL-­‐8	   13	   19	   19	  IL-­‐10	   12	   18	   20	  Table	  6:	  Summary	  of	  number	  of	  patients	  included	  in	  the	  analysis	  for	  each	  of	  the	  datasets	  grouped	  by	  gender.	  	  	  	   Age	   VEGF	   PDGF-­‐BB	   Follistatin	  Controls	   0-­‐100	   27	   23	   23	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   0-­‐39	   4	   2	   2	  	   40-­‐69	   16	   14	   14	  	   70-­‐100	   7	   7	   7	  Pt	  preop	   0-­‐100	   31	   29	   29	  	   0-­‐39	   3	   3	   4	  	   40-­‐69	   15	   13	   13	  	   70-­‐100	   13	   13	   12	  Pt	  postop	   0-­‐100	   28	   19	   30	  	   0-­‐39	   3	   3	   3	  	   40-­‐69	   15	   14	   14	  	   70-­‐100	   9	   11	   13	  Table	  7:	  Summary	  of	  number	  of	  patients	  included	  in	  the	  analysis	  for	  each	  of	  the	  datasets	  grouped	  by	  age.	  	  	   Control	   Pt	  Preop	   Pt	  Postop	  Female	   	   	   	  VEGF	   10	   13	   12	  PDGF-­‐BB	   9	   12	   13	  Follistatin	   10	   13	   12	  Male	   	   	   	  VEGF	   17	   18	   16	  PDGF-­‐BB	   14	   17	   16	  Follistatin	   14	   18	   17	  Table	  8:	  Summary	  of	  number	  of	  patients	  included	  in	  the	  analysis	  for	  each	  of	  the	  datasets	  grouped	  by	  gender.	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Appendix	  4	  	  Tables	  with	  raw	  data.	  Highlighted	  values	  indicate	  outliers.	  Appendix	  Table	  1	  
	  	   	  
	   	   	   	   pre	   Post	  Age	  Group	   Cytokine	   Age	   Sex	   IL-­‐6	   IL-­‐6	  446	   30	   M	   15.32	   10.73	  375	   35	   F	   0	   29.26	  438	   39	   F	   0	   14.87	  0-­‐39	   532	   39	   F	   70.62	   1.82	  641	   44	   M	   0	   10.38	  665	   46	   M	   0	   9	  378	   46	   F	   0	   6.86	  443	   46	   M	   1.24	   44.32	  550	   50	   F	   0	   16.93	  423	   51	   M	   22.22	   18.28	  455	   53	   M	   0	   555.92	  545	   58	   M	   0	   51.11	  536	   63	   F	   6.3	   2.11	  555	   63	   F	   0	   1.44	  413	   63	   M	   0	   8.66	  516	   66	   M	   0	   177.44	  511	   67	   M	   0	   4.47	  405	   67	   M	   0	   29.13	  534	   67	   M	   0	   26.18	  40-­‐69	   440	   69	   F	   0	   195.05	  548	   70	   M	   0	   29.65	  437	   70	   F	   0	   12.13	  402	   70	   M	   0.7	   7.08	  605	   72	   M	   10.74	   27.71	  501	   73	   F	   0	   4.26	  628	   73	   M	   8.57	   12.25	  459	   73	   F	   13.66	   8.77	  434	   74	   M	   0	   19.39	  523	   75	   M	   0	   8.21	  385	   76	   F	   0	   11.66	  403	   76	   M	   1.94	   10.61	  373	   76	   M	   0	   3.53	  471	   76	   M	   0	   20.5	  391	   80	   M	   0	   2.91	  70-­‐100	   415	   80	   F	   0	   55.93	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Appendix	  Table	  2	  	   	   	   	   pre	   post	  Age	  Group	   Cytokine	   Age	   Sex	   IL-­‐8	   IL-­‐8	  446	   30	   M	   4.92	   3.47	  375	   35	   F	   1.46	   1042.11	  438	   39	   F	   1.57	   4.17	  0-­‐39	   532	   39	   F	   5.34	   29.84	  641	   44	   M	   3.43	   15.57	  665	   46	   M	   1.23	   1.48	  378	   46	   F	   1.68	   19.99	  443	   46	   M	   1.01	   5.12	  550	   50	   F	   1.68	   18.32	  423	   51	   M	   35.58	   24.31	  455	   53	   M	   3.43	   75.14	  545	   58	   M	   3.21	   9.14	  536	   63	   F	   6.61	   12.35	  555	   63	   F	   2.45	   16.41	  413	   63	   M	   2.12	   5.23	  516	   66	   M	   3.64	   29.24	  511	   67	   M	   4.92	   17.84	  405	   67	   M	   11.89	   12.47	  534	   67	   M	   2.78	   11.52	  40-­‐69	   440	   69	   F	   0.78	   38.52	  548	   70	   M	   7.02	   27.43	  437	   70	   F	   4.28	   9.5	  402	   70	   M	   1.9	   1746.77	  605	   72	   M	   4.71	   15.69	  501	   73	   F	   2.89	   3.35	  628	   73	   M	   1.35	   9.02	  459	   73	   F	   1.46	   6.65	  434	   74	   M	   19.55	   23.47	  523	   75	   M	   4.5	   16.88	  385	   76	   F	   0.78	   9.26	  403	   76	   M	   2.34	   1850.29	  373	   76	   M	   7.23	   7.24	  471	   76	   M	   5.13	   11.64	  391	   80	   M	   2.34	   6.3	  70-­‐100	   415	   80	   F	   4.5	   15.45	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Appendix	  Table	  3	  	   	   	   	   pre	   post	  Age	  Group	   Cytokine	   Age	   Sex	   IL-­‐10	   IL-­‐10	  446	   30	   M	   7.3	   6	  375	   35	   F	   0	   25.34	  438	   39	   F	   1.53	   6.37	  0-­‐39	   532	   39	   F	   110.02	   5.91	  641	   44	   M	   0	   5.17	  665	   46	   M	   0.43	   2.91	  378	   46	   F	   0.47	   25.46	  443	   46	   M	   0	   5.08	  550	   50	   F	   0	   3.73	  423	   51	   M	   620.79	   10.26	  455	   53	   M	   0.34	   121.89	  545	   58	   M	   2.11	   12.94	  536	   63	   F	   5.69	   8.58	  555	   63	   F	   0	   2.53	  413	   63	   M	   1.43	   4.44	  516	   66	   M	   0	   3.38	  511	   67	   M	   1.62	   8.87	  405	   67	   M	   0	   3.34	  534	   67	   M	   0	   10.41	  40-­‐69	   440	   69	   F	   0	   19.66	  548	   70	   M	   0.3	   14.03	  437	   70	   F	   5.16	   6	  402	   70	   M	   0.09	   9.51	  605	   72	   M	   154.54	   7.85	  501	   73	   F	   1.1	   8.29	  628	   73	   M	   11.3	   4.89	  459	   73	   F	   65.53	   2.33	  434	   74	   M	   2.7	   6.51	  523	   75	   M	   0	   4.99	  385	   76	   F	   1.57	   23.06	  403	   76	   M	   0	   16.92	  373	   76	   M	   0	   7.9	  471	   76	   M	   0	   4.18	  391	   80	   M	   0.02	   5.72	  70-­‐100	   415	   80	   F	   2.9	   19.07	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Appendix	  Table	  4	  	   	   	   	   pre	   post	  Age	  Group	   Angio	   Age	   Sex	   VEGF	   VEGF	  0-­‐39	   374	   35	   F	   61.76	   42.32	  	   427	   35	   F	   12.8	   30.2	  	   436	   39	   F	   218.24	   77.52	  	   428	   39	   F	   73.96	   15.08	  40-­‐69	   640	   44	   M	   138.88	   32.4	  	   660	   46	   M	   47.16	   20.56	  	   472	   46	   F	   55.8	   23.56	  	   442	   46	   M	   22.96	   9.12	  	   418	   50	   F	   121.56	   32.88	  	   421	   51	   M	   88.24	   23.56	  	   453	   53	   M	   64.52	   15.44	  	   545	   58	   M	   76.08	   18.16	  	   535	   63	   F	   106.2	   21.32	  	   552	   63	   F	   86.36	   38.64	  	   411	   63	   M	   33.8	   7.44	  	   515	   66	   M	   127.2	   30.44	  	   510	   67	   M	   44.96	   14.36	  	   404	   67	   M	   52.24	   3.96	  	   533	   67	   M	   73.96	   20.24	  	   439	   69	   F	   27.6	   13.32	  70-­‐100	   544	   70	   M	   111.72	   54	  	   435	   70	   F	   111.96	   71.72	  	   396	   70	   M	   134.56	   87.6	  	   597	   72	   M	   37.16	   6.4	  	   500	   73	   F	   40.76	   6	  	   626	   73	   M	   61.2	   8.88	  	   458	   73	   F	   47.72	   11.88	  	   522	   75	   M	   57.24	   15.64	  	   382	   76	   F	   93.4	   24	  	   397	   76	   M	   84.44	   102.92	  	   371	   76	   M	   21.4	   4.64	  	   390	   80	   M	   83.84	   20.44	  	   410	   80	   F	   25.96	   14.6	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  5	  	   	   	   	   pre	   post	  Age	  Group	   Angio	   Age	   Sex	   PDGF-­‐BB	   PDGF-­‐BB	  0-­‐39	   374	   35	   F	   9501.12	   2626.32	  	   427	   35	   F	   151.16	   5972.6	  	   436	   39	   F	   5371.12	   1270.16	  	   428	   39	   F	   12126.6	   1022.4	  40-­‐69	   640	   44	   M	   8902.96	   2451.92	  	   660	   46	   M	   5604.36	   1906.12	  	   472	   46	   F	   5968.44	   1280.32	  	   442	   46	   M	   792.32	   938.24	  	   418	   50	   F	   9943.4	   1184.44	  	   421	   51	   M	   12122.2	   2918.08	  	   453	   53	   M	   7178.92	   1514	  	   545	   58	   M	   9067.88	   1711.16	  	   535	   63	   F	   11056.48	   2553.64	  	   552	   63	   F	   6887.76	   3257.12	  	   411	   63	   M	   9153.32	   2426.04	  	   515	   66	   M	   12364.32	   2633.48	  	   510	   67	   M	   5536.68	   1798.12	  	   404	   67	   M	   6533.12	   478.04	  	   533	   67	   M	   19516.56	   6269.56	  	   439	   69	   F	   806.16	   1506.56	  70-­‐100	   544	   70	   M	   9025.88	   3455.48	  	   435	   70	   F	   7925.64	   2598.76	  	   396	   70	   M	   10711.64	   2216.72	  	   597	   72	   M	   6913.32	   825.72	  	   500	   73	   F	   5741.4	   661.04	  	   626	   73	   M	   7216.28	   1461.76	  	   458	   73	   F	   7958.52	   1332.72	  	   522	   75	   M	   4202.08	   1064.12	  	   382	   76	   F	   5951.04	   1217.12	  	   397	   76	   M	   8689.08	   4306.4	  	   371	   76	   M	   11260.8	   4228.92	  	   390	   80	   M	   6480.04	   1334.72	  	   410	   80	   F	   3371.08	   618.8	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  6	  	   	   	   	   pre	   post	  Age	  Group	   Angio	   Age	   Sex	   Follistatin	   Follistatin	  0-­‐39	   374	   35	   F	   1318.44	   228.76	  	   427	   35	   F	   1201.72	   102.68	  	   436	   39	   F	   1221.84	   168.88	  	   428	   39	   F	   1094.72	   39.76	  40-­‐69	   640	   44	   M	   857.96	   57.64	  	   660	   46	   M	   854.56	   60.6	  	   472	   46	   F	   630.52	   91.24	  	   442	   46	   M	   799.44	   35.28	  	   418	   50	   F	   1119.28	   49.88	  	   421	   51	   M	   915.84	   67.32	  	   453	   53	   M	   1715.24	   73.92	  	   545	   58	   M	   1270.6	   48.32	  	   535	   63	   F	   2245.88	   125.64	  	   552	   63	   F	   784.88	   82.12	  	   411	   63	   M	   1120.44	   52.4	  	   515	   66	   M	   1120.44	   259.48	  	   510	   67	   M	   1911.88	   143.52	  	   404	   67	   M	   893.08	   22.36	  	   533	   67	   M	   1459.88	   213.56	  	   439	   69	   F	   2370.68	   43.08	  70-­‐100	   544	   70	   M	   1255.12	   127.28	  	   435	   70	   F	   1261.08	   133.12	  	   396	   70	   M	   1670.36	   69.88	  	   597	   72	   M	   1131	   140.28	  	   500	   73	   F	   1189.88	   77.08	  	   626	   73	   M	   1182.8	   74.68	  	   458	   73	   F	   978.8	   45.76	  	   522	   75	   M	   1503.84	   47.64	  	   382	   76	   F	   1448.92	   137.4	  	   397	   76	   M	   572.08	   94.96	  	   371	   76	   M	   1262.28	   126.36	  	   390	   80	   M	   1022.64	   46.56	  	   410	   80	   F	   2113.24	   197.96	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  7	  BTNW	   Age	   Gender	   Control-­‐IL-­‐6	   Control-­‐IL-­‐8	   Control-­‐IL-­‐10	  574	   26	   F	   2.31	   2.74	   1.71	  575	   68	   F	   1.83	   3.17	   0	  579	   100	   F	   0.26	   3.17	   2.34	  580	   81	   F	   0.42	   4.12	   0.01	  582	   75	   F	   0.18	   5.42	   0	  583	   39	   M	   8.92	   3.88	   14.66	  585	   35	   M	   18.85	   2.74	   17	  586	   61	   M	   0.34	   8.59	   0	  587	   65	   F	   0.11	   4.64	   0	  589	   45	   M	   3.31	   13.05	   3.42	  591	   85	   M	   0.42	   3.68	   0.11	  592	   68	   F	   0.73	   9.92	   1.34	  593	   84	   M	   1.51	   5.07	   0.91	  594	   57	   M	   1564.01	   4.95	   1617.42	  595	   39	   M	   2.31	   3.7	   6.26	  600	   68	   M	   1.67	   6.03	   4	  601	   61	   M	   0.26	   1.72	   0.34	  603	   87	   M	   0.26	   24.55	   0.08	  606	   37	   M	   3.43	   111.39	   4.32	  607	   56	   F	   7.26	   19.85	   6.21	  608	   48	   F	   3.56	   32.16	   3.37	  609	   60	   M	   2.56	   12.67	   3.14	  610	   58	   M	   3.5	   15.94	   2.21	  616	   65	   M	   1.35	   3	   0.18	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  8	  BTNW	   Age	   Gender	   Control-­‐VEGF	   Control-­‐PDGF-­‐BB	   Control-­‐Folistatin	  574	   26	   F	   39.19	   1904.01	   258.05	  575	   68	   F	   56.26	   898.63	   229.42	  576	   81	   M	   62.08	   2771.63	   372.83	  579	   100	   F	   22	   3086.74	   330.21	  580	   81	   F	   33.64	   2787.47	   293.01	  582	   75	   F	   46.99	   2084.97	   243.84	  583	   39	   M	   122.33	   3112.12	   384.49	  585	   35	   M	   40.87	   4495.45	   799.46	  586	   61	   M	   72.82	   3776.26	   246.61	  587	   65	   F	   122.52	   2655.5	   417.97	  589	   45	   M	   22.02	   1901.94	   518.29	  591	   85	   M	   14	   1587	   308.62	  592	   68	   F	   13.36	   2135.63	   229.56	  593	   84	   M	   36.64	   1405.69	   308.62	  594	   57	   M	   117.62	   2538.24	   721.99	  595	   39	   M	   30.48	   2231.73	   185.36	  598	   68	   F	   79.85	   2488.33	   363.86	  599	   62	   M	   59.17	   2415.75	   431.11	  600	   68	   M	   116.22	   2938.14	   317.06	  601	   61	   M	   22.54	   1727.2	   470.77	  603	   87	   M	   104.39	   1576.6	   357.91	  606	   37	   M	   74.7	   1773.37	   242.79	  607	   56	   F	   88.47	   3423.29	   884.87	  608	   48	   F	   26.82	   4592.99	   468.93	  609	   60	   M	   74.88	   6965.25	   812.88	  610	   58	   M	   25.33	   2051.71	   266.63	  616	   65	   M	   112.88	   4579.94	   457.51	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BTNW	  No	   Gender	   Age	   Cis100	   Cis10	   Cis1	   Detergent	   Medium	  BTNW338	   M	   72	   87453	   124216	   149778	   965	   155303	  	   	   	   73264	   119370	   108605	   805	   121672	  	   	   	   79451	   124115	   88722	   615	   96024	  	   	   	   70217	   104853	   122550	   545	   138431	  BTNW370	   F	   66	   41626	   108291	   158080	   990	   149317	  	   	   	   47978	   118016	   153151	   940	   161532	  	   	   	   46352	   127616	   147273	   710	   160378	  	   	   	   47376	   119873	   152918	   690	   163942	  BTNW377	   F	   45	   27314	   33118	   56360	   605	   77854	  	   	   	   23907	   30902	   51459	   415	   56712	  	   	   	   30150	   39827	   52122	   485	   50877	  	   	   	   27214	   53196	   50275	   405	   54040	  BTNW382	   F	   75	   63	   13	   353	   193	   43337	  	   	   	   113	   123	   35192	   143	   46950	  	   	   	   253	   213	   263	   123	   47472	  	   	   	   193	   243	   313	   73	   52452	  BTNW500	   F	   73	   75658	   140386	   140426	   713	   206563	  	   	   	   97597	   118171	   193408	   1063	   171810	  	   	   	   133957	   147304	   144391	   1303	   212774	  	   	   	   114629	   118999	   198404	   1413	   200009	  BTNW533	   M	   67	   170492	   168749	   255330	   1233	   301016	  	   	   	   184861	   169935	   325798	   1423	   281332	  	   	   	   190717	   142904	   281475	   933	   265587	  	   	   	   211432	   113478	   260912	   873	   303710	  BTNW544	   M	   68	   13487	   174842	   110505	   350	   47710	  	   	   	   22109	   159419	   106904	   400	   49156	  	   	   	   19905	   107751	   137258	   460	   52590	  	   	   	   16320	   83709	   112089	   240	   57773	  BTNW546	   F	   50	   34670	   60196	   108690	   1173	   156783	  	   	   	   55143	   98254	   127232	   993	   178935	  	   	   	   38140	   77490	   129182	   1283	   187823	  	   	   	   59242	   110435	   158595	   1313	   163396	  BTNW590	   M	   50	   34338	   104188	   88348	   1048	   107298	  	   	   	   27258	   107298	   129878	   778	   126408	  	   	   	   37898	   103498	   122228	   1018	   117618	  	   	   	   16088	   98328	   124328	   1448	   120438	  BTNW597	   M	   71	   20073	   24583	   59923	   753	   65103	  	   	   	   12443	   25023	   71513	   573	   66923	  	   	   	   9583	   30293	   66793	   683	   77783	  	   	   	   22083	   35383	   81663	   343	   70023	  BTNW365	   F	   42	   47634	   217799	   1687281	   3265	   344995	  	   	   	   55787	   803650	   1043007	   4265	   427367	  	   	   	   53196	   790107	   759881	   4775	   434793	  	   	   	   61895	   768147	   1182408	   4035	   450891	  BTNW374	   F	   34	   80459	   774029	   740398	   4665	   471293	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   94737	   904611	   1114796	   4425	   443414	  	   	   	   80922	   935356	   1361128	   4075	   485276	  	   	   	   98727	   840775	   899099	   3715	   465588	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BTNW	  No	   Gender	   Age	   Carmu100	   Carmu10	   Carmu1	   Detergent	   Medium	  BTNW338	   M	   72	   145155	   98513	   102152	   965	   155303	  	   	   	   106971	   94584	   87352	   805	   121672	  	   	   	   100075	   91693	   96619	   615	   96024	  	   	   	   63954	   96196	   101214	   545	   138431	  BTNW370	   F	   66	   122053	   132101	   141227	   990	   149317	  	   	   	   133051	   167781	   133738	   940	   161532	  	   	   	   120720	   144320	   139518	   710	   160378	  	   	   	   120125	   154001	   147142	   690	   163942	  BTNW377	   F	   45	   49040	   39536	   58038	   605	   77854	  	   	   	   57566	   49501	   53779	   415	   56712	  	   	   	   55757	   50104	   59886	   485	   50877	  	   	   	   49180	   60499	   56330	   405	   54040	  BTNW382	   F	   75	   233	   73	   103	   193	   43337	  	   	   	   33	   203	   42093	   143	   46950	  	   	   	   203	   36856	   243	   123	   47472	  	   	   	   233	   143	   223	   73	   52452	  BTNW500	   F	   73	   126642	   138516	   150886	   713	   206563	  	   	   	   203880	   217961	   194443	   1063	   171810	  	   	   	   193611	   194149	   214035	   1303	   212774	  	   	   	   194250	   230785	   194941	   1413	   200009	  BTNW533	   M	   67	   218226	   213354	   303075	   1233	   301016	  	   	   	   286618	   163339	   202376	   1423	   281332	  	   	   	   302604	   119039	   203961	   933	   265587	  	   	   	   257830	   115830	   157313	   873	   303710	  BTNW544	   M	   68	   163298	   167736	   159479	   350	   47710	  	   	   	   131285	   114915	   139877	   400	   49156	  	   	   	   101993	   151845	   133144	   460	   52590	  	   	   	   97034	   119265	   108336	   240	   57773	  BTNW546	   F	   50	   73436	   102871	   120194	   1173	   156783	  	   	   	   105876	   45735	   135852	   993	   178935	  	   	   	   117327	   47311	   129091	   1283	   187823	  	   	   	   105412	   54701	   142676	   1313	   163396	  BTNW590	   M	   50	   113778	   139358	   113918	   1048	   107298	  	   	   	   123818	   145538	   139428	   778	   126408	  	   	   	   101438	   122828	   102248	   1018	   117618	  	   	   	   119988	   128508	   130118	   1448	   120438	  BTNW597	   M	   71	   54293	   56733	   65573	   753	   65103	  	   	   	   41583	   57653	   74323	   573	   66923	  	   	   	   45613	   74423	   81303	   683	   77783	  	   	   	   58023	   66593	   79363	   343	   70023	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BTNW365	   F	   42	   1273045	   898788	   919218	   3265	   344995	  	   	   	   1302636	   1089416	   850353	   4265	   427367	  	   	   	   1535082	   1088992	   1191591	   4775	   434793	  	   	   	   1166676	   657111	   947435	   4035	   450891	  BTNW374	   F	   34	   1016996	   1140836	   788789	   4665	   471293	  	   	   	   1209152	   798829	   741679	   4425	   443414	  	   	   	   1437931	   886668	   922794	   4075	   485276	  	   	   	   1033439	   848120	   1080043	   3715	   465588	  	  Appendix	  Table	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BTNW	  No	   Gender	   Age	   Temo100	   Temo10	   Temo1	   Detergent	   Medium	  BTNW338	   M	   72	   110531	   91874	   91451	   965	   155303	  	   	   	   108131	   95259	   90605	   805	   121672	  	   	   	   94080	   110692	   97102	   615	   96024	  	   	   	   57805	   68769	   88540	   545	   138431	  BTNW370	   F	   66	   101839	   144189	   147071	   990	   149317	  	   	   	   120852	   158495	   152149	   940	   161532	  	   	   	   106940	   149519	   140731	   710	   160378	  	   	   	   114555	   161674	   140418	   690	   163942	  BTNW377	   F	   45	   51439	   59947	   47444	   605	   77854	  	   	   	   61404	   54281	   53066	   415	   56712	  	   	   	   70250	   54080	   44684	   485	   50877	  	   	   	   56441	   49582	   50686	   405	   54040	  BTNW382	   F	   75	   233	   203	   203	   193	   43337	  	   	   	   27482	   26470	   34620	   143	   46950	  	   	   	   26470	   43227	   12359	   123	   47472	  	   	   	   243	   40136	   263	   73	   52452	  BTNW500	   F	   73	   187063	   142823	   18897	   713	   206563	  	   	   	   179302	   178450	   37739	   1063	   171810	  	   	   	   224168	   102798	   57031	   1303	   212774	  	   	   	   161374	   66094	   47983	   1413	   200009	  BTNW533	   M	   67	   208819	   56277	   63079	   1233	   301016	  	   	   	   142156	   54921	   51035	   1423	   281332	  	   	   	   136160	   80950	   171394	   933	   265587	  	   	   	   106095	   73053	   40758	   873	   303710	  BTNW544	   M	   68	   129516	   138805	   175573	   350	   47710	  	   	   	   204538	   123769	   161920	   400	   49156	  	   	   	   131113	   150813	   181293	   460	   52590	  	   	   	   132922	   143103	   159905	   240	   57773	  BTNW546	   F	   50	   75780	   126313	   95705	   1173	   156783	  	   	   	   84566	   145074	   112927	   993	   178935	  	   	   	   174554	   169263	   120264	   1283	   187823	  	   	   	   134790	   165463	   156803	   1313	   163396	  BTNW590	   M	   50	   119818	   119108	   120578	   1048	   107298	  	   	   	   120358	   136958	   126168	   778	   126408	  	   	   	   106678	   127638	   115678	   1018	   117618	  	   	   	   38568	   118948	   113398	   1448	   120438	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BTNW597	   M	   71	   52353	   61523	   46903	   753	   65103	  	   	   	   58753	   72813	   66203	   573	   66923	  	   	   	   60633	   84093	   71583	   683	   77783	  	   	   	   64553	   79153	   81493	   343	   70023	  BTNW365	   F	   42	   360559	   983599	   854295	   3265	   344995	  	   	   	   898295	   830734	   1324120	   4265	   427367	  	   	   	   191205	   1285150	   1297188	   4775	   434793	  	   	   	   240687	   1218980	   874623	   4035	   450891	  BTNW374	   F	   34	   215277	   1386554	   1047744	   4665	   471293	  	   	   	   482566	   1309978	   789767	   4425	   443414	  	   	   	   336573	   863691	   1250950	   4075	   485276	  	   	   	   208728	   873489	   641070	   3715	   465588	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   plate	  T	  once	   	   	   	  	   Day	  -­‐4	   Day	  0	   Day	  1	   Day	  2	   Day	  3	   Day	  4	  1321N1	  once	   2000	   2600	   4800	   5800	   12200	   12800	  	   2000	   2200	   4600	   5400	   12000	   13200	  	   2000	   2400	   4400	   6000	   12400	   13000	  	   2000	   5200	   8800	   17600	   24000	   28800	  	   2000	   5200	   7800	   14400	   19200	   26200	  	   2000	   4800	   7200	   14800	   15600	   26800	  	   2000	   2400	   4600	   4400	   12200	   12400	  	   2000	   2200	   4000	   5800	   12800	   12800	  	   2000	   2400	   4000	   5800	   13200	   13200	  IN077	  once	   2000	   7000	   9400	   9600	   17200	   17200	  	   2000	   5200	   10400	   10000	   19000	   16800	  	   2000	   6400	   11000	   11000	   17400	   16000	  	   2000	   2400	   3600	   2600	   5800	   7600	  	   2000	   2800	   4200	   4800	   5600	   7200	  	   2000	   3000	   3600	   3400	   5600	   7000	  	   2000	   2200	   2200	   3600	   5600	   11400	  	   2000	   2000	   2400	   3000	   5400	   8600	  	   2000	   2600	   3000	   3200	   6200	   11400	  IN859	  once	   2000	   3200	   3200	   3200	   9200	   10200	  	   2000	   2600	   3600	   2800	   8000	   9800	  	   2000	   2400	   3800	   2000	   8200	   11000	  	   2000	   4000	   3800	   3600	   4200	   2400	  	   2000	   2400	   3800	   4200	   3400	   2800	  	   2000	   2600	   4000	   4000	   3000	   2400	  	   2000	   1400	   5600	   5000	   6200	   8000	  	   2000	   3600	   4200	   4400	   3600	   6600	  	   2000	   2200	   5200	   3800	   3200	   7600	  IN1265	  once	   2000	   8200	   14600	   11200	   15000	   22800	  	   2000	   6800	   13800	   14400	   15200	   21800	  	   2000	   7800	   12600	   13000	   14600	   19400	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   2000	   3400	   7000	   5000	   3200	   6800	  	   2000	   2800	   4800	   6600	   4000	   7600	  	   2000	   3000	   3800	   4200	   4800	   8000	  	   2000	   4000	   2200	   4800	   4200	   5800	  	   2000	   3600	   2200	   5200	   5600	   5200	  	   2000	   3600	   3200	   4200	   3000	   5000	  U257	  once	   2000	   14800	   55800	   27600	   40000	   16400	  	   2000	   10400	   55400	   28200	   44600	   14200	  	   2000	   11400	   54400	   29800	   38200	   15200	  	   2000	   5800	   3800	   13800	   14800	   8600	  	   2000	   5000	   5200	   6000	   15000	   12200	  	   2000	   5000	   5600	   8200	   12200	   9600	  	   2000	   8400	   21800	   12200	   12600	   8400	  	   2000	   5000	   1800	   7400	   10200	   10200	  	   2000	   6800	   3000	   10800	   9200	   10800	  U373	  once	   2000	   3800	   8400	   7000	   12200	   13400	  	   2000	   5600	   9400	   7600	   11600	   11200	  	   2000	   4800	   8600	   9600	   12000	   11000	  	   2000	   2000	   3800	   10000	   4200	   4400	  	   2000	   2000	   3800	   7800	   4400	   5400	  	   2000	   3400	   3200	   8600	   5200	   5400	  	   2000	   2200	   3000	   3400	   3600	   4400	  	   2000	   3600	   3600	   3600	   4400	   4800	  	   2000	   4000	   4000	   4400	   5000	   5600	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   plate	  T"s"	  once	   	   	  	   Day	  -­‐4	   Day	  0	   Day	  1	   Day	  2	   Day	  3	   Day	  4	  1321N1	  once	   2000	   2600	   4400	   5400	   7000	   13800	  	   2000	   2200	   3400	   5400	   7600	   12800	  	   2000	   2400	   3600	   5600	   7800	   13200	  	   2000	   5200	   9800	   6600	   14000	   18600	  	   2000	   5200	   8200	   8400	   13000	   19600	  	   2000	   4800	   9000	   9200	   13400	   22800	  	   2000	   2400	   4800	   8200	   12000	   14200	  	   2000	   2200	   4400	   7200	   12000	   14800	  	   2000	   2400	   4200	   7200	   12400	   15000	  IN077	  once	   2000	   7000	   8200	   10000	   15600	   17200	  	   2000	   5200	   7600	   9600	   17200	   18000	  	   2000	   6400	   8800	   8800	   16600	   18200	  	   2000	   2400	   3600	   4200	   5200	   9200	  	   2000	   2800	   2400	   3200	   6400	   11800	  	   2000	   3000	   1800	   4400	   7600	   13600	  	   2000	   2200	   3400	   3000	   7000	   4800	  	   2000	   2000	   3400	   3800	   4800	   6800	  	   2000	   2600	   3400	   2400	   7000	   5600	  IN859	  once	   2000	   3200	   3000	   3200	   5400	   7800	  	   2000	   2600	   2600	   2400	   5200	   6200	  	   2000	   2400	   2800	   2000	   6000	   8000	  	   2000	   4000	   2800	   3400	   3000	   2600	  	   2000	   2400	   2000	   4600	   3200	   2400	  	   2000	   2600	   1600	   3800	   2400	   2800	  	   2000	   1400	   5000	   3000	   4200	   3000	  	   2000	   3600	   3600	   4000	   2800	   2400	  	   2000	   2200	   3800	   2800	   3000	   2200	  IN1265	  once	   2000	   8200	   13000	   13800	   15600	   22400	  	   2000	   6800	   14200	   16000	   15800	   25000	  	   2000	   7800	   11600	   15400	   14000	   25200	  	   2000	   3400	   11000	   6000	   6800	   6200	  	   2000	   2800	   4800	   5800	   5200	   5800	  	   2000	   3000	   3800	   6200	   5000	   6800	  	   2000	   4000	   6400	   4600	   3200	   4200	  	   2000	   3600	   5400	   5200	   5600	   4000	  	   2000	   3600	   3600	   3800	   4000	   3600	  U257	  once	   2000	   14800	   21800	   23600	   40000	   24000	  	   2000	   10400	   24800	   25800	   39800	   24200	  	   2000	   11400	   22000	   26400	   41000	   24400	  	   2000	   5800	   16200	   17600	   14200	   10400	  	   2000	   5000	   13000	   8800	   11000	   7600	  	   2000	   5000	   13200	   7600	   14600	   8000	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   2000	   8400	   26800	   8600	   10200	   8800	  	   2000	   5000	   4200	   8400	   9200	   9600	  	   2000	   6800	   4000	   7600	   8800	   8800	  U373	  once	   2000	   3800	   3000	   5000	   4000	   3000	  	   2000	   5600	   3400	   5400	   3600	   3000	  	   2000	   4800	   3400	   4800	   3200	   2600	  	   2000	   2000	   3000	   5000	   4000	   3000	  	   2000	   2000	   3400	   5400	   3600	   3000	  	   2000	   3400	   3400	   4800	   3200	   2600	  	   2000	   2200	   3000	   4200	   4000	   4600	  	   2000	   3600	   3400	   4400	   3800	   4200	  	   2000	   4000	   3400	   2800	   4200	   5400	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   plate	  cis	  once	   	   	  	   Day	  -­‐4	   Day	  0	   Day	  1	   Day	  2	   Day	  3	   Day	  4	  1321N1	  once	   2000	   2600	   3400	   2400	   2200	   1600	  	   2000	   2200	   2800	   2400	   2000	   1600	  	   2000	   2400	   3200	   2800	   2400	   1800	  	   2000	   5200	   12800	   3000	   2000	   1200	  	   2000	   5200	   11200	   2000	   1800	   1400	  	   2000	   4800	   9000	   3600	   2300	   2000	  	   2000	   2400	   2600	   2000	   1800	   1200	  	   2000	   2200	   3000	   1200	   1800	   1000	  	   2000	   2400	   3200	   1800	   1600	   1000	  IN077	  once	   2000	   7000	   7200	   4000	   2000	   3000	  	   2000	   5200	   8600	   4600	   3200	   2800	  	   2000	   6400	   8800	   3200	   2400	   2400	  	   2000	   2400	   1800	   1200	   1400	   2800	  	   2000	   2800	   1400	   1400	   2200	   2000	  	   2000	   3000	   1200	   1000	   1600	   2400	  	   2000	   2200	   1600	   1000	   600	   3000	  	   2000	   2000	   2200	   1400	   800	   2800	  	   2000	   2600	   1600	   800	   1600	   2200	  IN859	  once	   2000	   3200	   3400	   2000	   2000	   2000	  	   2000	   2600	   2000	   4400	   2800	   1200	  	   2000	   2400	   2000	   2800	   2200	   1000	  	   2000	   4000	   3600	   3600	   2600	   600	  	   2000	   2400	   2200	   2400	   3000	   800	  	   2000	   2600	   3200	   3600	   2800	   800	  	   2000	   1400	   2400	   2000	   1200	   800	  	   2000	   3600	   2200	   1400	   1800	   600	  	   2000	   2200	   2600	   1200	   1600	   600	  IN1265	  once	   2000	   8200	   7800	   7400	   5200	   6000	  	   2000	   6800	   7800	   7400	   7600	   6800	  	   2000	   7800	   7400	   7200	   7600	   6600	  	   2000	   3400	   10000	   5600	   1800	   1600	  	   2000	   2800	   6000	   5600	   2000	   1600	  	   2000	   3000	   5800	   5200	   2600	   1000	  	   2000	   4000	   5200	   2800	   5400	   4800	  	   2000	   3600	   3600	   1800	   5000	   2000	  	   2000	   3600	   4800	   2000	   3400	   4200	  U257	  once	   2000	   14800	   15600	   11200	   13200	   18600	  	   2000	   10400	   16800	   13200	   13200	   20400	  	   2000	   11400	   15000	   14000	   13000	   17600	  	   2000	   5800	   15000	   9200	   10000	   4800	  	   2000	   5000	   12200	   5400	   4200	   4000	  	   2000	   5000	   11400	   4600	   4800	   5400	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   2000	   8400	   16000	   8600	   4600	   2800	  	   2000	   5000	   2800	   5800	   6000	   3200	  	   2000	   6800	   3800	   7200	   4800	   4800	  U373	  once	   2000	   3800	   10600	   4800	   9600	   6000	  	   2000	   5600	   8400	   4000	   11000	   5400	  	   2000	   4800	   8200	   4600	   10200	   6000	  	   2000	   2000	   3800	   1600	   2200	   1200	  	   2000	   2000	   4400	   4000	   3000	   1000	  	   2000	   3400	   3400	   2800	   2800	   1400	  	   2000	   2200	   3200	   2800	   2000	   1200	  	   2000	   3600	   3800	   2400	   1800	   1200	  	   2000	   4000	   3200	   3000	   2600	   1800	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   plate	  Car	  once	   	   	  	   Day	  -­‐4	   Day	  0	   Day	  1	   Day	  2	   Day	  3	   Day	  4	  1321N1	  once	   2000	   2600	   4800	   5200	   12800	   23800	  	   2000	   2200	   4800	   5600	   12800	   23880	  	   2000	   2400	   4600	   5600	   12400	   24020	  	   2000	   5200	   4600	   6400	   19000	   22000	  	   2000	   5200	   6600	   4800	   14600	   24600	  	   2000	   4800	   7200	   8400	   15600	   22800	  	   2000	   2400	   3200	   4000	   13200	   25200	  	   2000	   2200	   3800	   5200	   13800	   26000	  	   2000	   2400	   3200	   4800	   13600	   25800	  IN077	  once	   2000	   7000	   12800	   10200	   11000	   13000	  	   2000	   5200	   11800	   12200	   9200	   12000	  	   2000	   6400	   10000	   10800	   9800	   12800	  	   2000	   2400	   1200	   7400	   3600	   8400	  	   2000	   2800	   1400	   5600	   5000	   7400	  	   2000	   3000	   1600	   3400	   6800	   7800	  	   2000	   2200	   1800	   3200	   7400	   8000	  	   2000	   2000	   1600	   2800	   5600	   9000	  	   2000	   2600	   2600	   1800	   4800	   7400	  IN859	  once	   2000	   3200	   2800	   9200	   13200	   15000	  	   2000	   2600	   4400	   7800	   14000	   17000	  	   2000	   2400	   3400	   8600	   12200	   18200	  	   2000	   4000	   3800	   4800	   3600	   7000	  	   2000	   2400	   3800	   4800	   4600	   5400	  	   2000	   2600	   4400	   4000	   3400	   4400	  	   2000	   1400	   5600	   5600	   5800	   7400	  	   2000	   3600	   7200	   6000	   3600	   8200	  	   2000	   2200	   7400	   5800	   4200	   7800	  IN1265	  once	   2000	   8200	   11800	   14000	   18000	   22000	  	   2000	   6800	   13800	   17800	   17800	   23800	  	   2000	   7800	   12800	   15400	   19000	   21000	  	   2000	   3400	   13600	   4600	   7600	   4400	  	   2000	   2800	   4400	   1200	   5800	   5000	  	   2000	   3000	   6000	   2200	   5000	   6400	  	   2000	   4000	   7200	   8800	   5000	   8200	  	   2000	   3600	   7800	   5200	   6000	   6600	  	   2000	   3600	   7200	   5200	   5600	   6400	  U257	  once	   2000	   14800	   31800	   47400	   53000	   60200	  	   2000	   10400	   28600	   46800	   55600	   59800	  	   2000	   11400	   26000	   45800	   54200	   61000	  	   2000	   5800	   6000	   38000	   51600	   24600	  	   2000	   5000	   5800	   27000	   53000	   23600	  	   2000	   5000	   5800	   39400	   43200	   20600	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   2000	   8400	   14800	   10000	   11000	   38600	  	   2000	   5000	   4000	   9000	   11000	   30800	  	   2000	   6800	   3400	   9200	   10600	   32600	  U373	  once	   2000	   3800	   8600	   7000	   13000	   15000	  	   2000	   5600	   8800	   9000	   12800	   14800	  	   2000	   4800	   9200	   9000	   14000	   16000	  	   2000	   2000	   1800	   4200	   5000	   4800	  	   2000	   2000	   1800	   3800	   5800	   4400	  	   2000	   3400	   1000	   4000	   5800	   4000	  	   2000	   2200	   3200	   4000	   5200	   6200	  	   2000	   3600	   4000	   4800	   5800	   6000	  	   2000	   4000	   3000	   5000	   4800	   7000	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Plate	  Medium	  	   Day	  -­‐4	   Day	  0	   Day	  4	  1321N1	  once	   2000	   2600	   24800	  	   2000	   2200	   23600	  	   2000	   2400	   24400	  	   2000	   5200	   36400	  	   2000	   5200	   31200	  	   2000	   4800	   29600	  	   2000	   2400	   22800	  	   2000	   2200	   23200	  	   2000	   2400	   24000	  IN077	  once	   2000	   7000	   15000	  	   2000	   5200	   14600	  	   2000	   6400	   16400	  	   2000	   2400	   7000	  	   2000	   2800	   8200	  	   2000	   3000	   7000	  	   2000	   2200	   7000	  	   2000	   2000	   10000	  	   2000	   2600	   8200	  IN859	  once	   2000	   3200	   26600	  	   2000	   2600	   28000	  	   2000	   2400	   25400	  	   2000	   4000	   7200	  	   2000	   2400	   9600	  	   2000	   2600	   9200	  	   2000	   1400	   11800	  	   2000	   3600	   10000	  	   2000	   2200	   9800	  IN1265	  once	   2000	   8200	   24400	  	   2000	   6800	   25600	  	   2000	   7800	   24600	  	   2000	   3400	   9400	  	   2000	   2800	   8200	  	   2000	   3000	   7400	  	   2000	   4000	   7600	  	   2000	   3600	   9000	  	   2000	   3600	   8200	  U257	  once	   2000	   14800	   64000	  	   2000	   10400	   64200	  	   2000	   11400	   64200	  	   2000	   5800	   24200	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   2000	   5000	   18800	  	   2000	   5000	   19600	  	   2000	   8400	   40200	  	   2000	   5000	   42200	  	   2000	   6800	   38400	  U373	  once	   2000	   3800	   14800	  	   2000	   5600	   15200	  	   2000	   4800	   15600	  	   2000	   2000	   8600	  	   2000	   2000	   8400	  	   2000	   3400	   7800	  	   2000	   2200	   8600	  	   2000	   3600	   8800	  	   2000	   4000	   9000	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Appendix	  Table	  17	  
	   	   	   plate	  T	  Daily	   	   	   	  	   Day	  -­‐4	   Day	  0	   Day	  1	   Day	  2	   Day	  3	   Day	  4	  1321N1	  daily	   2000	   3400	   6800	   15000	   21000	   15000	  	   2000	   4800	   9000	   9000	   15200	   14400	  	   2000	   6000	   8000	   7800	   17400	   16200	  	   2000	   1200	   1000	   3200	   1800	   2400	  	   2000	   2400	   800	   2600	   2800	   3200	  	   2000	   2000	   1800	   3200	   2200	   1800	  	   2000	   2600	   2800	   6400	   3000	   3400	  	   2000	   2600	   3800	   5800	   2600	   6400	  	   2000	   3200	   3200	   5600	   2200	   5000	  IN077	  daily	   2000	   7000	   3000	   4600	   5600	   8800	  	   2000	   5200	   2800	   3800	   6800	   7800	  	   2000	   6400	   2400	   4600	   5400	   8000	  	   2000	   2400	   2200	   4200	   5400	   7800	  	   2000	   2800	   3600	   3600	   5400	   8400	  	   2000	   3000	   2400	   3600	   5400	   9200	  	   2000	   2200	   5400	   5200	   7200	   10800	  	   2000	   2000	   3800	   3800	   7800	   8200	  	   2000	   2600	   4400	   4400	   6000	   8800	  IN859	  daily	   2000	   3000	   2800	   5600	   9800	   10400	  	   2000	   2200	   3600	   5000	   10200	   10000	  	   2000	   2600	   4000	   7200	   11000	   10800	  	   2000	   5000	   3800	   3000	   1400	   2800	  	   2000	   4000	   5000	   3800	   1400	   1200	  	   2000	   3400	   4600	   2600	   2200	   3000	  	   2000	   2000	   5200	   4800	   2200	   2600	  	   2000	   3200	   3800	   4600	   1600	   2400	  	   2000	   2400	   4200	   5400	   2400	   3000	  IN1265	  daily	   2000	   2600	   3400	   2000	   4600	   4800	  	   2000	   2200	   3600	   2800	   4800	   4200	  	   2000	   3800	   4200	   3200	   5400	   6000	  	   2000	   4600	   4600	   2800	   3800	   5200	  	   2000	   5200	   4200	   1000	   3800	   4800	  	   2000	   5200	   3800	   2800	   4800	   4600	  	   2000	   1800	   2400	   5400	   3200	   4400	  	   2000	   2200	   4200	   7800	   4600	   3600	  	   2000	   3600	   2800	   6000	   5000	   5400	  U257	  daily	   2000	   6800	   19800	   15600	   22200	   21600	  	   2000	   9800	   22200	   11800	   21600	   20800	  	   2000	   9600	   19600	   11000	   18000	   26800	  	   2000	   5000	   13000	   6800	   8400	   13600	  	   2000	   7600	   4000	   5800	   10200	   8800	  	   2000	   5200	   4000	   5400	   10400	   10800	  	   2000	   5200	   3600	   3200	   10400	   14800	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   2000	   3200	   4400	   5000	   10800	   15000	  	   2000	   3600	   4000	   4400	   9600	   16200	  U373	  daily	   2000	   2000	   1600	   2600	   2800	   2600	  	   2000	   2000	   1600	   2800	   3600	   2400	  	   2000	   3400	   1200	   2400	   2400	   2400	  	   2000	   2200	   2600	   3000	   2600	   2200	  	   2000	   3000	   2800	   3200	   2200	   1800	  	   2000	   2600	   3200	   3800	   2800	   1800	  	   2000	   4000	   3000	   3400	   3000	   1800	  	   2000	   2200	   2600	   4400	   3800	   1800	  	   2000	   3600	   4000	   3400	   4000	   2800	  	  	  	  
	   275	  
Appendix	  Table	  18	  
	   	   	   plate	  T"s"	  Daily	   	   	  	   Day	  -­‐4	   Day	  0	   Day	  1	   Day	  2	   Day	  3	   Day	  4	  1321N1	  daily	   2000	   3400	   8800	   19200	   20000	   21600	  	   2000	   4800	   10600	   11400	   15600	   21800	  	   2000	   6000	   9600	   10600	   16400	   23800	  	   2000	   1200	   600	   2800	   180	   2200	  	   2000	   2400	   1200	   4000	   800	   2000	  	   2000	   2000	   1200	   2400	   600	   2400	  	   2000	   2600	   2200	   3400	   2800	   1800	  	   2000	   2600	   1600	   2000	   2400	   1600	  	   2000	   3200	   2000	   2400	   2400	   1400	  IN077	  daily	   2000	   3000	   4600	   4400	   4400	   7800	  	   2000	   3600	   4000	   3200	   3800	   6800	  	   2000	   3400	   3000	   4800	   3200	   8000	  	   2000	   4000	   3200	   4800	   2800	   9200	  	   2000	   3400	   5800	   3200	   2400	   9600	  	   2000	   3400	   4600	   5000	   5600	   8800	  	   2000	   4800	   7200	   3600	   4000	   6800	  	   2000	   3000	   9200	   4200	   5000	   9200	  	   2000	   2800	   8000	   5000	   7400	   9600	  IN859	  daily	   2000	   3000	   2800	   5000	   6200	   6800	  	   2000	   2200	   2600	   4800	   6800	   7200	  	   2000	   2600	   3200	   5200	   7000	   8000	  	   2000	   5000	   3200	   4600	   2200	   4000	  	   2000	   4000	   3400	   3600	   2400	   1600	  	   2000	   3400	   2400	   3200	   2200	   3200	  	   2000	   2000	   3200	   2800	   2600	   4600	  	   2000	   3200	   3200	   3000	   3200	   3600	  	   2000	   2400	   3200	   3200	   2200	   4400	  IN1265	  daily	   2000	   2600	   10200	   5400	   4000	   3800	  	   2000	   2200	   2000	   10000	   3800	   3600	  	   2000	   3800	   2200	   9200	   3200	   4400	  	   2000	   4600	   2400	   8800	   2600	   4800	  	   2000	   5200	   1200	   7400	   1400	   4000	  	   2000	   5200	   1600	   8000	   1200	   4200	  	   2000	   1800	   6600	   4000	   3600	   1200	  	   2000	   2200	   5200	   4200	   5200	   2800	  	   2000	   3600	   6400	   5200	   4000	   3400	  U257	  daily	   2000	   6800	   11600	   13400	   17000	   21800	  	   2000	   9800	   12600	   6800	   16600	   20800	  	   2000	   9600	   10800	   4600	   14000	   20800	  	   2000	   5000	   13800	   4400	   6800	   10200	  	   2000	   7600	   4400	   3800	   7200	   9600	  	   2000	   5200	   1200	   4600	   8000	   11000	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   2000	   5200	   3000	   2800	   6800	   11800	  	   2000	   3200	   3200	   3000	   9000	   12200	  	   2000	   3600	   3600	   2400	   7200	   13000	  U373	  daily	   2000	   2000	   1400	   2000	   2200	   2600	  	   2000	   2000	   1000	   2200	   2800	   2000	  	   2000	   3400	   1400	   2800	   2600	   2600	  	   2000	   2200	   2200	   3200	   3000	   2400	  	   2000	   3000	   2800	   3600	   3800	   1800	  	   2000	   2600	   3400	   4200	   2800	   2400	  	   2000	   4000	   2200	   3400	   3000	   1800	  	   2000	   2200	   1800	   4400	   3600	   3000	  	   2000	   3600	   2200	   3200	   3400	   3600	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Appendix	  Table	  19	  
	   	   	   plate	  cis	  Daily	   	   	  	   Day	  -­‐4	   Day	  0	   Day	  1	   Day	  2	   Day	  3	   Day	  4	  1321N1	  daily	   2000	   3400	   6400	   11800	   1800	   2000	  	   2000	   4800	   6400	   4400	   2400	   2400	  	   2000	   6000	   6400	   2200	   1800	   1000	  	   2000	   1200	   1000	   3000	   1800	   2000	  	   2000	   2400	   600	   1400	   600	   1800	  	   2000	   2000	   200	   1800	   1800	   1600	  	   2000	   2600	   1800	   2200	   1200	   1000	  	   2000	   2600	   2000	   2400	   1200	   800	  	   2000	   3200	   2800	   2400	   1200	   1600	  IN077	  daily	   2000	   3000	   5200	   5000	   1000	   800	  	   2000	   3600	   4400	   4000	   600	   3000	  	   2000	   3400	   3400	   5400	   1800	   1000	  	   2000	   4000	   4200	   3600	   2600	   1600	  	   2000	   3400	   3400	   3200	   1200	   1800	  	   2000	   3400	   3600	   3200	   2600	   1600	  	   2000	   4800	   8200	   8800	   1000	   1000	  	   2000	   3000	   5400	   9000	   800	   1600	  	   2000	   2800	   5800	   8200	   1200	   1400	  IN859	  daily	   2000	   3000	   3400	   2200	   2600	   1800	  	   2000	   2200	   4600	   2800	   2200	   1200	  	   2000	   2600	   4000	   2200	   2400	   1400	  	   2000	   5000	   2400	   2000	   4400	   1400	  	   2000	   4000	   3200	   1000	   2600	   2600	  	   2000	   3400	   2400	   1200	   4000	   2200	  	   2000	   2000	   4000	   7400	   2400	   2600	  	   2000	   3200	   3800	   5200	   2200	   3800	  	   2000	   2400	   4400	   4400	   1400	   2600	  IN1265	  daily	   2000	   2600	   9400	   2800	   5400	   3800	  	   2000	   2200	   3800	   3800	   6000	   5000	  	   2000	   3800	   2200	   3800	   4800	   4200	  	   2000	   4600	   1800	   3800	   3000	   3400	  	   2000	   5200	   1200	   3400	   1800	   3000	  	   2000	   5200	   2600	   3400	   2000	   2200	  	   2000	   1800	   5600	   3000	   2400	   3800	  	   2000	   2200	   4800	   3600	   1800	   2000	  	   2000	   3600	   4000	   2400	   3200	   1200	  U257	  daily	   2000	   6800	   10800	   10200	   8600	   4200	  	   2000	   9800	   9200	   4200	   4000	   4600	  	   2000	   9600	   9000	   3400	   5000	   4600	  	   2000	   5000	   18800	   6800	   4000	   3600	  	   2000	   7600	   4200	   6200	   2800	   3600	  	   2000	   5200	   3400	   4800	   3000	   3400	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   2000	   5200	   1600	   2200	   3600	   4000	  	   2000	   3200	   2200	   1800	   2600	   2500	  	   2000	   3600	   2000	   1800	   2400	   2200	  U373	  daily	   2000	   2000	   4400	   1600	   2200	   1200	  	   2000	   2000	   3800	   4000	   3000	   1000	  	   2000	   3400	   3400	   2800	   2800	   1400	  	   2000	   2200	   2800	   2400	   1800	   1600	  	   2000	   3000	   2000	   2600	   1600	   1200	  	   2000	   2600	   3000	   1800	   2200	   1800	  	   2000	   4000	   3200	   2400	   2000	   6000	  	   2000	   2200	   3400	   2200	   1400	   4600	  	   2000	   3600	   3800	   2800	   1000	   4400	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Appendix	  Table	  20	  
	   	   	   plate	  Car	  Daily	   	   	  	   Day	  -­‐4	   Day	  0	   Day	  1	   Day	  2	   Day	  3	   Day	  4	  1321N1	  daily	   2000	   3400	   7400	   13000	   11200	   20000	  	   2000	   4800	   7400	   7000	   14400	   21000	  	   2000	   6000	   7400	   5400	   12600	   23400	  	   2000	   1200	   800	   1200	   2400	   3200	  	   2000	   2400	   800	   1800	   2800	   4000	  	   2000	   2000	   800	   2000	   2400	   5200	  	   2000	   2600	   4200	   13200	   4600	   2600	  	   2000	   2600	   4600	   12200	   3200	   4400	  	   2000	   3200	   3000	   13800	   2600	   3200	  IN077	  daily	   2000	   3000	   5000	   5000	   4800	   7000	  	   2000	   3600	   4400	   4000	   6200	   8800	  	   2000	   3400	   4600	   4600	   2800	   7000	  	   2000	   4000	   5600	   4200	   1200	   9000	  	   2000	   3400	   4600	   5000	   1600	   8600	  	   2000	   3400	   4200	   3200	   1200	   7800	  	   2000	   4800	   5400	   6400	   3800	   9200	  	   2000	   3000	   5400	   3800	   3200	   6400	  	   2000	   2800	   4800	   3800	   3200	   7200	  IN859	  daily	   2000	   3000	   4000	   12000	   10800	   14000	  	   2000	   2200	   4600	   9800	   12200	   15200	  	   2000	   2600	   5400	   10800	   14000	   15800	  	   2000	   5000	   6000	   5800	   5600	   6200	  	   2000	   4000	   5800	   6000	   7000	   4800	  	   2000	   3400	   7600	   5800	   6000	   5600	  	   2000	   2000	   4400	   8000	   5000	   3600	  	   2000	   3200	   5200	   5200	   4800	   4400	  	   2000	   2400	   4200	   8000	   3600	   4000	  IN1265	  daily	   2000	   2600	   10000	   5800	   5000	   7400	  	   2000	   2200	   1400	   5800	   5400	   4400	  	   2000	   3800	   1600	   4600	   5000	   8000	  	   2000	   4600	   2800	   4600	   5400	   15200	  	   2000	   5200	   2200	   3800	   3200	   14600	  	   2000	   5200	   3800	   3600	   5200	   11000	  	   2000	   1800	   2200	   5800	   9000	   6400	  	   2000	   2200	   3800	   5600	   5800	   10000	  	   2000	   3600	   2000	   5200	   10200	   8800	  U257	  daily	   2000	   6800	   14800	   8400	   10200	   40200	  	   2000	   9800	   14800	   3600	   11400	   40200	  	   2000	   9600	   13600	   4600	   9200	   42200	  	   2000	   5000	   18000	   15000	   13200	   24800	  	   2000	   7600	   3000	   15600	   12000	   31000	  	   2000	   5200	   2600	   10800	   9600	   30200	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   2000	   5200	   4600	   5800	   15200	   21000	  	   2000	   3200	   4000	   8600	   16000	   19800	  	   2000	   3600	   3400	   4400	   15800	   22000	  U373	  daily	   2000	   2000	   1800	   4000	   5000	   4800	  	   2000	   2000	   1800	   3800	   5800	   4400	  	   2000	   3400	   1000	   4200	   5800	   4000	  	   2000	   2200	   3000	   3800	   3800	   5800	  	   2000	   3000	   4000	   4600	   5200	   6000	  	   2000	   2600	   4200	   5000	   4800	   6600	  	   2000	   4000	   2800	   4200	   4800	   8400	  	   2000	   2200	   3000	   3800	   2800	   10400	  	   2000	   3600	   4000	   3000	   3200	   7000	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Appendix	  Table	  21	  
	   	   	   Plate	  Medium	  	   Day	  -­‐4	   Day	  0	   Day	  4	  1321N1	  daily	   2000	   3400	   27400	  	   2000	   4800	   29400	  	   2000	   6000	   29600	  	   2000	   1200	   22800	  	   2000	   2400	   22600	  	   2000	   2000	   22800	  	   2000	   2600	   28200	  	   2000	   2600	   29400	  	   2000	   3200	   27600	  IN077	  daily	   2000	   3000	   9800	  	   2000	   3600	   8800	  	   2000	   3400	   9600	  	   2000	   4000	   8400	  	   2000	   3400	   8600	  	   2000	   3400	   9200	  	   2000	   4800	   9600	  	   2000	   3000	   11000	  	   2000	   2800	   9600	  IN859	  daily	   2000	   3000	   28000	  	   2000	   2200	   26800	  	   2000	   2600	   29200	  	   2000	   5000	   8600	  	   2000	   4000	   6400	  	   2000	   3400	   6400	  	   2000	   2000	   7200	  	   2000	   3200	   7000	  	   2000	   2400	   7200	  IN1265	  daily	   2000	   2600	   7000	  	   2000	   2200	   8200	  	   2000	   3800	   12600	  	   2000	   4600	   10200	  	   2000	   5200	   13200	  	   2000	   5200	   10800	  	   2000	   1800	   15400	  	   2000	   2200	   18200	  	   2000	   3600	   16800	  U257	  daily	   2000	   6800	   58800	  	   2000	   9800	   57400	  	   2000	   9600	   57800	  	   2000	   5000	   39800	  	   2000	   7600	   42600	  	   2000	   5200	   43800	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   2000	   5200	   42000	  	   2000	   3200	   40000	  	   2000	   3600	   39200	  U373	  daily	   2000	   2000	   8600	  	   2000	   2000	   8400	  	   2000	   3400	   7800	  	   2000	   2200	   6800	  	   2000	   3000	   8000	  	   2000	   2600	   7800	  	   2000	   4000	   6800	  	   2000	   2200	   8200	  	   2000	   3600	   6800	  
	  	  
